Germany	O
Heidelberg	O
Germany	O
Prostate	O
bed	O
irradiation	O
with	O
alternative	O
radio	O
-	O
oncological	O
approaches	O
(	O
PAROS	O
)	O
-a	O
prospective	B-study_type
,	I-study_type
multicenter	I-study_type
and	I-study_type
randomized	I-study_type
phase	I-study_type
III	I-study_type
trial	I-study_type
27	O
September	O
2018	O
.	O
27	O
September	O
2018	O
.	O
27	O
September	O
2018	O
.	O
10.1186	O
/	O
s13014	O
-	O
019	O
-	O
1325-x	O
Received	O
:	O
21	O
February	O
2019	O
Accepted	O
:	O
26	O
June	O
2019	O

The	O
primary	O
endpoint	O
is	O
defined	O
as	O
the	O
change	O
in	O
the	O
bowel	O
-	O
score	O
according	O
to	O
EORTC	O
QLQ	O
-	O
PR25	O
from	O
baseline	O
to	O
12	O
weeks	O
after	O
start	O
of	O
proton	B-arm_description
therapy	I-arm_description
compared	O
to	O
photon	B-arm_description
irradiation	I-arm_description
.	O

The	O
trial	O
is	O
a	O
prospective	B-study_type
,	I-study_type
multicenter	I-study_type
,	I-study_type
randomized	I-study_type
phase	I-study_type
III	I-study_type
trial	I-study_type
of	O
patients	O
with	O
operated	O
prostate	O
carcinoma	O
and	O
is	O
planned	O
to	O
enroll	O
897	O
patients	O
with	O
localized	O
prostate	O
cancer	O
after	O
prostatectomy	O
.	O
Patients	O
will	O
be	O
randomized	O
to	O
one	O
of	O
the	O
three	O
arms	O
:	O
nRT	B-arm_description
with	I-arm_description
photons	I-arm_description
,	O
hRT	O
with	O
photons	O
or	O
hRT	O
with	O
protons	O
.	O
Total	O
dose	O
is	O
70.0	B-arm_dosage
Gy	I-arm_dosage
in	I-arm_dosage
35	I-arm_dosage
fractions	I-arm_dosage
for	O
nRT	B-arm_description
with	I-arm_description
photons	I-arm_description
(	O
arm	O
1	O
)	O
,	O
57.0	B-arm_dosage
Gy	I-arm_dosage
in	I-arm_dosage
19	I-arm_dosage
fractions	I-arm_dosage
for	O
hRT	B-arm_description
with	I-arm_description
photons	I-arm_description
(	O
arm	O
2	O
)	O
and	O
57.0	B-arm_dosage
Gy	I-arm_dosage
relative	O
biological	O
effectiveness	O
(	O
RBE	O
)	O
in	B-arm_dosage
19	I-arm_dosage
fractions	I-arm_dosage
for	O
hRT	B-arm_description
with	I-arm_description
protons	I-arm_description
(	O
arm	O
3	O
)	O
,	O
respectively	O
(	O
Fig	O
.	O
1	O
)	O
.	O
The	O
study	O
was	O
designed	O
as	O
a	O
multicenter	B-study_type
trial	I-study_type
in	O
at	O
least	O
seven	O
radio	O
oncological	O
centers	O
in	O
Germany	O
and	O
is	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
the	O
guidelines	O
of	O
Good	O
Clinical	O
Practice	O
in	O
their	O
current	O
versions	O
.	O
Before	O
trial	O
initiation	O
,	O
the	O
study	O
was	O
approved	O
by	O
the	O
local	O
institutional	O
review	O
board	O
and	O
the	O
expert	O
committee	O
of	O
the	O
German	O
Society	O
of	O
Radiation	O
Oncology	O
.	O
Written	O
informed	O
consent	O
will	O
be	O
obtained	O
from	O
all	O
patients	O
prior	O
to	O
inclusion	O
into	O
the	O
trial	O
.	O

Biochemical	O
failure	O
is	O
defined	O
as	O
two	O
consecutive	O
increases	O
of	O
PSA	O
from	O
nadir	O
according	O
to	O
national	O
guidelines	O
[	O
14][15][16][17	O
]	O
.	O
bPFS	O
is	O
defined	O
as	O
time	O
from	O
first	O
diagnosis	O
to	O
biochemical	O
failure	O
.	O
OS	O
is	O
defined	O
as	O
time	O
from	O
the	O
first	O
diagnosis	O
to	O
death	O
from	O
any	O
course	O
.	O
If	O
the	O
respective	O
event	O
has	O
been	O
observed	O
,	O
the	O
patient	O
is	O
censored	O
at	O
the	O
date	O
of	O
the	O
last	O
follow	O
-	O
up	O
examination	O
.	O

Here	O
,	O
we	O
considered	O
the	O
following	O
eligibility	O
criteria	O
for	O
patients	O
:	O
histologically	O
proven	O
peripheral	O
stage	O
I	O
NSCLC	O
,	O
diagnosed	O
in	O
line	O
with	O
TNM	O
Classification	O
of	O
the	O
Union	O
for	O
International	O
Cancer	O
Control	O
's	O
(	O
7th	O
Edition	O
)	O
;	O
inoperable	O
,	O
or	O
refusal	O
of	O
surgery	O
;	O
a	O
measurable	O
tumor	O
;	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
's	O
scale	O
performance	O
status	O
between	O
0	O
and	O
2	O
.	O
The	O
following	O
were	O
set	O
as	O
exclusion	O
criteria	O
:	O
a	O
previous	O
history	O
of	O
radiotherapy	O
anywhere	O
near	O
the	O
target	O
volume	O
;	O
chemotherapy	O
within	O
the	O
month	O
prior	O
to	O
C	B-arm_description
-	I-arm_description
ion	I-arm_description
RT	I-arm_description
;	O
a	O
life	O
expectancy	O
estimated	O
to	O
be	O
≤6	O
months	O
;	O
a	O
second	O
active	O
cancer	O
;	O
interstitial	O
pneumonitis	O
;	O
or	O
an	O
intractable	O
infectious	O
disease	O
in	O
the	O
region	O
of	O
the	O
target	O
volume	O
.	O
Each	O
patient	O
's	O
eligibility	O
was	O
confirmed	O
at	O
a	O
joint	O
conference	O
involving	O
medical	O
oncologists	O
,	O
thoracic	O
surgeons	O
,	O
and	O
radiation	O
oncologists	O
.	O

Depending	O
on	O
the	O
tumor	O
location	O
,	O
the	O
patient	O
was	O
immobilized	O
in	O
the	O
supine	O
or	O
prone	O
position	O
using	O
a	O
thermoplastic	O
shell	O
(	O
Shellfitter	O
;	O
Sanyo	O
Polymer	O
Industrial	O
)	O
with	O
a	O
pillow	O
made	O
of	O
water	O
-	O
sclerogenic	O
polymers	O
(	O
Moldcare	O
;	O
ALCARE	O
)	O
.	O
To	O
achieve	O
a	O
suitable	O
posture	O
for	O
oblique	O
beam	O
irradiation	O
,	O
the	O
patient	O
was	O
rotated	O
±	O
15	O
°	O
to	O
the	O
superior	O
-	O
inferior	O
axis	O
.	O
Subsequently	O
,	O
computed	O
tomography	O
(	O
CT	O
)	O
was	O
run	O
in	O
2-mm	O
slices	O
with	O
two	O
different	O
body	O
positions	O
.	O
A	O
respiratory	O
-	O
gated	O
CT	O
image	O
was	O
obtained	O
after	O
exhaling	O
.	O
This	O
was	O
followed	O
by	O
a	O
four	O
-	O
dimensional	O
CT	O
scan	O
to	O
account	O
for	O
respiratory	O
motion	O
,	O
reconstructing	O
four	O
-	O
dimensional	O
images	O
for	O
each	O
phase	O
of	O
respiration	O
.	O

We	O
calculated	O
local	O
control	O
rates	O
or	O
survival	O
times	O
starting	O
with	O
the	O
first	O
day	O
of	O
C	B-arm_description
-	I-arm_description
ion	I-arm_description
RT	I-arm_description
administration	O
.	O
The	O
Kaplan	O
-	O
Meier	O
method	O
was	O
applied	O
to	O
determine	O
the	O
defined	O
endpoints	O
(	O
local	O
control	O
rate	O
,	O
OS	O
rate	O
,	O
and	O
PFS	B-arm_efficacy_metric
rate	I-arm_efficacy_metric
)	O
.	O
For	O
purposes	O
of	O
sample	O
size	O
calculation	O
,	O
we	O
hypothesized	O
that	O
the	O
2-year	O
local	O
control	O
rate	O
of	O
stage	O
I	O
NSCLC	O
would	O
be	O
60	O
%	O
by	O
conventionally	O
fractionated	O
radiation	O
therapy	O
with	O
photons	O
and	O
90	O
%	O
by	O
C	B-arm_description
-	I-arm_description
ion	I-arm_description
RT	I-arm_description
.	O
Using	O
the	O
normal	O
approximation	O
,	O
we	O
calculated	O
that	O
35	O
patients	O
would	O
be	O
needed	O
for	O
80	O
%	O
power	O
and	O
95	O
%	O
confidence	O
.	O
In	O
the	O
univariate	O
analyses	O
,	O
we	O
applied	O
log	O
-	O
rank	O
tests	O
to	O
evaluate	O
the	O
effects	O
of	O
age	O
group	O
,	O
sex	O
,	O
histological	O
type	O
,	O
performance	O
status	O
,	O
T	O
stage	O
of	O
TNM	O
classification	O
,	O
operability	O
,	O
and	O
smoking	O
history	O
on	O
the	O
study	O
's	O
endpoints	O
.	O
P	O
-	O
values	O
of	O
lower	O
than	O
0.05	O
were	O
considered	O
as	O
statistically	O
significant	O
.	O
All	O
tests	O
were	O
performed	O
two	O
-	O
tailed	O
with	O
JMP	O
version	O
12.2.0	O
(	O
SAS	O
Institute	O
Inc	O
)	O
.	O

30	O
Duke	O
Medicine	O
Circle	O
,	O
Room	O
#	O
0050	O
,	O
Durham	O
Box	O
3216	O
27705	O
NC	O
USA	O
HerbertIHurwitz	B-authors
Genentech	O
,	O
Inc	O
94080	O
South	O
San	O
Francisco	O
CA	O
USA	O

HTG	O
Molecular	O
Diagnostics	O
,	O
Leadiant	O
Biosciences	O
,	O
MedPacto	O
Inc.	O
,	O
Novartis	O
,	O
Seattle	O
Genetics	O
,	O
and	O
Tracon	O
Pharma	O
.	O
Dr.	B-authors
Strickler	I-authors
discloses	O
receiving	O
research	O
funding	O
from	O
Seattle	O
Genetics	O
,	O
Exelixis	O
,	O
Amgen	O
,	O
AbbVie	O
,	O
Genentech	O
/	O
Roche	O
,	O
and	O
Sanofi	O
Genzyme	O
.	O
Additionally	O
,	O
Dr.	B-authors
Strickler	I-authors
performs	O
consulting	O
and	O
honoraria	O
work	O
for	O
Amgen	O

Of	O
the	O
63	O
patients	O
that	O
accrued	O
to	O
the	O
study	O
,	O
a	O
total	O
of	O
31	O
tumor	O
samples	O
yielded	O
sufficient	O
RNA	O
for	O
reverse	O
-	O
transcription	O
.	O
Expression	O
levels	O
of	O
VEGF	O
-	O
A	O
,	O
VEGF	O
-	O
C	O
,	O
VEGF	O
-	O
D	O
,	O
PlGF	O
,	O
NRP1	O
,	O
and	O
NRP2	O
were	O
quantified	O
using	O
preformulated	O
TaqMan	O
real	O
-	O
time	O
PCR	O
assays	O
and	O
TaqMan	O
Gene	O
Expression	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
in	O
10	O
μl	O
reactions	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O
All	O
assays	O
were	O
run	O
in	O
duplicate	O
.	O
If	O
the	O
standard	O
deviation	O
(	O
SD	O
)	O
in	O
cycle	O
thresholds	O
(	O
CT	O
)	O
between	O
replicate	O
wells	O
was	O
>	O
0.5	O
then	O
the	O
reaction	O
was	O
rerun	O
.	O
If	O
the	O
rerun	O
data	O
improved	O
replicate	O
consistency	O
(	O
SD	O
<	O
0.5	O
)	O
,	O
then	O
the	O
rerun	O
data	O
was	O
used	O
.	O
Gene	O
expressions	O
levels	O
were	O
normalized	O
to	O
β	O
-	O
actin	O
using	O
the	O
ΔCT	O
method	O
.	O
Gene	O
-	O
specific	O
assays	O
are	O
listed	O
in	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
.	O

Within	O
the	O
expansion	O
cohort	O
,	O
forty	O
-	O
five	O
patients	O
(	O
90	O
%	O
)	O
had	O
experienced	O
disease	O
progression	O
on	O
bevacizumab	O
prior	O
to	O
enrollment	O
.	O
One	O
patient	O
had	O
received	O
ziv	O
-	O
aflibercept	O
prior	O
to	O
enrollment	O
(	O
in	O
combination	O
with	O
FOLFIRI	O
)	O
,	O
and	O
this	O
patient	O
experienced	O
disease	O
progression	O
.	O

Endpoints	O
included	O
PFS	B-arm_efficacy_metric
,	O
OS	O
,	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
,	O
improvement	O
in	O
hematologic	O
parameters	O
,	O
patient	O
-	O
reported	O
outcomes	O
,	O
and	O
safety	O
.	O
Long	O
-	O
term	O
PD	O
and	O
response	O
were	O
assessed	O
by	O
the	O
investigator	O
per	O
2008	O
International	O
Workshop	O
on	O
CLL	O
(	O
iwCLL	O
)	O
criteria	O
[	O
12	O
]	O
.	O
Long	O
-	O
term	O
safety	O
data	O
are	O
reported	O
for	O
patients	O
who	O
were	O
initially	O
randomized	O
to	O
ibrutinib	B-arm_description
.	O
Nonhematologic	O
adverse	O
events	O
(	O
AEs	O
)	O
were	O
graded	O
using	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
,	O
v4.03	O
[	O
13	O
]	O
.	O
Hematologic	O
AEs	O
were	O
graded	O
using	O
iwCLL	O
criteria	O
[	O
12	O
]	O
.	O

With	O
a	O
median	O
follow	O
-	O
up	O
of	O
5	O
years	O
(	O
up	O
to	O
66	O
months	O
)	O
,	O
the	O
ORR	O
including	O
partial	O
response	O
with	O
lymphocytosis	O
was	O
92	O
%	O
for	O
patients	O
treated	O
with	O
ibrutinib	B-arm_description
compared	O
with	O
37	O
%	O

Treatment	O
discontinuations	O
decreased	O
over	O
time	O
on	O
ibrutinib	B-arm_description
,	O
with	O
7	O
%	O
of	O
patients	O
discontinuing	O
because	O
of	O
AEs	O
in	O
years	O
0	O
-	O
1	O
,	O
6	O
%	O
in	O
years	O
1	O
-	O
2	O
,	O
5	O
%	O
in	O
years	O
2	O
-	O
3	O
,	O
6	O
%	O
in	O
years	O
3	O
-	O
4	O
,	O
and	O
1	O
%	O
in	O
years	O
4	O
-	O
5	O
(	O
Supplementary	O
Fig	O
.	O
6	O
)	O
.	O
Thirtyeight	O
patients	O
experienced	O
AEs	O
leading	O
to	O
discontinuation	O
of	O
ibrutinib	B-arm_description
;	O
those	O
reported	O
in	O
≥2	O
patients	O
were	O
atrial	O
fibrillation	O
(	O
n	O
=	O
4	O
)	O
,	O
and	O
palpitations	O
,	O
pneumonia	O
,	O
and	O
worsening	O
CLL	O
(	O
n	O
=	O
2	O
each	O
)	O
,	O
in	O
addition	O
to	O
2	O
deaths	O
with	O
unknown	O
cause	O
.	O

At	O
the	O
time	O
of	O
data	O
cutoff	O
,	O
23	O
patients	O
randomized	O
to	O
ibrutinib	B-arm_description
died	O
(	O
8	O
while	O
on	O
treatment	O
)	O
;	O
4	O
due	O
to	O
PD	O
(	O
all	O
were	O
aged	O
≥70	O
years	O
)	O
.	O
One	O
AE	O
of	O
pneumonia	O
was	O
considered	O
possibly	O
related	O
to	O
ibrutinib	O
.	O
There	O
were	O
six	O
patients	O
for	O
whom	O
cause	O
of	O
death	O
was	O
unknown	O
,	O
and	O
of	O
the	O
remaining	O
,	O
there	O
were	O
two	O
infections	O
,	O
three	O
second	O
malignancies	O
,	O
and	O
one	O
each	O
reported	O
as	O
multiorgan	O
failure	O
,	O
heart	O
attack	O
,	O
sudden	O
death	O
,	O
heart	O
failure	O
,	O
sepsis	O
,	O
pulmonary	O
fibrosis	O
,	O
and	O
septic	O
shock	O
(	O
Supplementary	O
Fig	O
.	O
7	O
)	O
.	O

Randomised	B-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type
of	O
mFOLFOX6	B-arm_description
plus	I-arm_description
bevacizumab	I-arm_description
versus	O
mFOLFOX6	B-arm_description
plus	I-arm_description
cetuximab	I-arm_description
as	O
first	O
-	O
line	O
treatment	O
for	O
colorectal	O
liver	O
metastasis	O
(	O
ATOM	O
trial	O
)	O
EijiOki	B-authors
okieiji@surg2.med.kyushu-u.ac.jp	O

Japan	O
Fukuoka	O
Japan	O
Randomised	B-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type
of	O
mFOLFOX6	B-arm_description
plus	I-arm_description
bevacizumab	I-arm_description
versus	O
mFOLFOX6	B-arm_description
plus	I-arm_description
cetuximab	I-arm_description
as	O
first	O
-	O
line	O
treatment	O
for	O
colorectal	O
liver	O
metastasis	O
(	O
ATOM	O
trial	O
)	O
9	O
July	O
2019	O
9	O
July	O
2019	O
9	O
July	O
2019	O
10.1038	O
/	O
s41416	O
-	O
019	O
-	O
0518	O
-	O
2	O
Received	O
:	O
16	O
March	O
2019	O
Revised	O
:	O
12	O
June	O
2019	O
Accepted	O
:	O
20	O
June	O
2019	O

Patients	O
received	O
either	O
mFOLFOX6	B-arm_description
plus	I-arm_description
BEV	I-arm_description
(	B-arm_dosage
BEV	I-arm_dosage
5	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
kg	I-arm_dosage
,	I-arm_dosage
followed	I-arm_dosage
by	I-arm_dosage
oxaliplatin	B-arm_dosage
85	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
,	I-arm_dosage
l	I-arm_dosage
-	I-arm_dosage
leucovorin	I-arm_dosage
200	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
and	I-arm_dosage
bolus	I-arm_dosage
infusion	I-arm_dosage
of	I-arm_dosage
fluorouracil	I-arm_dosage
400	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
on	I-arm_dosage
Day	I-arm_dosage
1	I-arm_dosage
and	I-arm_dosage
continuous	I-arm_dosage
fluorouracil	I-arm_dosage
infusion	I-arm_dosage
2400	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
on	I-arm_dosage
Day	I-arm_dosage
1	I-arm_dosage
through	I-arm_dosage
Day	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
or	O
mFOLFOX6	B-arm_description
plus	O
CET	B-arm_description
(	O
CET	O
400	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
as	I-arm_dosage
the	I-arm_dosage
initial	I-arm_dosage
dose	I-arm_dosage
and	I-arm_dosage
250	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
as	I-arm_dosage
the	I-arm_dosage
subsequent	I-arm_dosage
doses	I-arm_dosage
on	I-arm_dosage
Days	I-arm_dosage
1	I-arm_dosage
and	I-arm_dosage
8	I-arm_dosage
,	O
followed	O
by	O
mFOLFOX6	O
)	O
,	O
no	B-arm_dosage
later	I-arm_dosage
than	I-arm_dosage
2	I-arm_dosage
weeks	I-arm_dosage
after	I-arm_dosage
enrolment	I-arm_dosage
in	I-arm_dosage
the	I-arm_dosage
study	I-arm_dosage
.	O
Study	O
treatments	O
were	O
continued	O
in	O
2-week	O
cycles	O
until	O
disease	O
progression	O
.	O
In	O
accordance	O
with	O
the	O
Response	O
Evaluation	O
Criteria	O
In	O
Solid	O
Tumours	O
version	O
1.1	O
,	O
the	O
same	O
methods	O
were	O
used	O
to	O
perform	O
tumour	O
assessment	O
at	O
baseline	O
and	O
every	O
subsequent	O
8	O
weeks	O
using	O
torso	O
contrast	O
-	O
enhanced	O
computed	O
tomography	O
(	O
CT	O
)	O
,	O
liver	O
contrast	O
-	O
enhanced	O
magnetic	O
resonance	O
imaging	O
,	O
or	O
whole	O
-	O
body	O
non	O
-	O
contrast	O
CT	O
.	O
The	O
tumour	O
histopathological	O
response	O
rate	O
was	O
defined	O
as	O
the	O
proportion	O
of	O
patients	O
with	O
grade	O
≥Ib	O
in	O
accordance	O
with	O
the	O
following	O
definition	O
:	O
grade	O
0	O
,	O
no	O
necrosis	O
in	O
the	O
tumour	O
;	O
grade	O
1a	O
,	O
necrosis	O
in	O
<	O
33.3	O
%	O
of	O
the	O
tumour	O
;	O
grade	O
1b	O
,	O
necrosis	O
in	O
33.3	O
-	O
66.6	O
%	O
of	O
the	O
tumour	O
;	O
grade	O
2	O
,	O
necrosis	O
in	O
66.6-<100	O
%	O
of	O
the	O
tumour	O
;	O
and	O
grade	O
3	O
,	O
necrosis	O
in	O
100	O
%	O
of	O
the	O
tumour	O
.	O

The	O
primary	O
endpoint	O
was	O
PFS	B-arm_efficacy_metric
,	O
as	O
assessed	O
by	O
the	O
Independent	O
Central	O
Review	O
Committee	O
(	O
IRC	O
)	O
.	O
The	O
cases	O
were	O
not	O
censored	O
at	O
the	O
time	O
of	O
liver	O
resection	O
.	O
Recurrence	O
was	O
considered	O
to	O
be	O
a	O
PFS	B-arm_efficacy_metric
event	O
in	O
patients	O
who	O
underwent	O
liver	O
resection	O
after	O
protocol	O
treatment	O
.	O
Secondary	O
endpoints	O
included	O
response	O
rate	O
,	O
tumour	O
shrinkage	O
at	O
week	O
8	O
,	O
liver	O
resection	O
rate	O
,	O
time	O
to	O
treatment	O
failure	O
,	O
OS	O
,	O
quality	O
of	O
life	O
,	O
and	O
adverse	O
events	O
(	O
AEs	O
)	O
.	O

Phase	B-study_type
II	I-study_type
trial	I-study_type
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
PIK3CA	B-arm_description
or	I-arm_description
AKT	I-arm_description
mutations	I-arm_description
,	O
and/or	O
PTEN	B-arm_description
loss	I-arm_description
/	I-arm_description
PTEN	I-arm_description
mutation	I-arm_description
Phase	B-study_type
II	I-study_type
trial	I-study_type
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
PIK3CA	B-arm_description
or	I-arm_description
AKT	I-arm_description
mutations	I-arm_description
,	O
and/or	O
PTEN	B-arm_description
loss	I-arm_description
/	I-arm_description
PTEN	I-arm_description
mutation	I-arm_description
YanXing	B-authors

The	O
Sheikh	O
Khalifa	O
Bin	O
Zayed	O
Al	O
Nahyan	O
Institute	O
for	O
Personalized	O
Cancer	O
Therapy	O
,	O
The	O
University	O
of	O
Texas	O
MD	O
Anderson	O
Cancer	O
Center	O
77030	O
Houston	O
TX	O
USA	O
Breast	O
Surgical	O
Oncology	O

Phase	B-study_type
II	I-study_type
trial	I-study_type
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
PIK3CA	B-arm_description
or	I-arm_description
AKT	I-arm_description
mutations	I-arm_description
,	O
and/or	O
PTEN	B-arm_description
loss	I-arm_description
/	I-arm_description
PTEN	I-arm_description
mutation	I-arm_description

Deaconess	O
Medical	O
Center	O
and	O
Dana	O
Farber	O
Harvard	O
Cancer	O
Center	O
02215	O
Beth	O
,	O
Boston	O
MA	O
Israel	O
,	O
USA	O
LewisCCantley	B-authors
Cornell	O
University	O
14850	O
Ithaca	O
NY	O
USA	O
GordonBMills	B-authors
Systems	O
Biology	O

The	O
Sheikh	O
Khalifa	O
Bin	O
Zayed	O
Al	O
Nahyan	O
Institute	O
for	O
Personalized	O
Cancer	O
Therapy	O
,	O
The	O
University	O
of	O
Texas	O
MD	O
Anderson	O
Cancer	O
Center	O
77030	O
Houston	O
TX	O
USA	O
Breast	O
Surgical	O
Oncology	O

Phase	B-study_type
II	I-study_type
trial	I-study_type
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
PIK3CA	B-arm_description
or	I-arm_description
AKT	I-arm_description
mutations	I-arm_description
,	O
and/or	O
PTEN	B-arm_description
loss	I-arm_description
/	I-arm_description
PTEN	I-arm_description
mutation	I-arm_description

The	O
Sheikh	O
Khalifa	O
Bin	O
Zayed	O
Al	O
Nahyan	O
Institute	O
for	O
Personalized	O
Cancer	O
Therapy	O
,	O
The	O
University	O
of	O
Texas	O
MD	O
Anderson	O
Cancer	O
Center	O
77030	O
Houston	O
TX	O
USA	O
Breast	O
Surgical	O
Oncology	O

The	O
Sheikh	O
Khalifa	O
Bin	O
Zayed	O
Al	O
Nahyan	O
Institute	O
for	O
Personalized	O
Cancer	O
Therapy	O
,	O
The	O
University	O
of	O
Texas	O
MD	O
Anderson	O
Cancer	O
Center	O
77030	O
Houston	O
TX	O
USA	O
Breast	O
Surgical	O
Oncology	O

We	O
present	O
here	O
the	O
results	O
of	O
a	O
biomarker	B-study_type
-	I-study_type
selected	I-study_type
phase	I-study_type
II	I-study_type
breast	I-study_type
cancer	I-study_type
trial	I-study_type
of	O
MK-2206	O
.	O
Further	O
,	O
we	O
present	O
results	O
of	O
correlative	O
studies	O
including	O
assessment	O
of	O
pathway	O
inhibition	O
in	O
circulating	O
biomarkers	O
and	O
pre	O
-	O
treatment	O
and	O
on	O
-	O
treatment	O
biopsies	O
,	O
as	O
well	O
as	O
in	O
-	O
depth	O
characterization	O
of	O
a	O
patient	O
with	O
response	O
to	O
MK-2206	O
.	O

"	O
Phase	B-study_type
II	I-study_type
Trial	I-study_type
of	O
AKT	O
Inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
a	O
PIK3CA	B-arm_description
mutation	I-arm_description
,	I-arm_description
or	I-arm_description
an	I-arm_description
AKT	I-arm_description
mutation	I-arm_description
,	O
and/or	O
PTEN	B-arm_description
loss	I-arm_description
/	I-arm_description
PTEN	I-arm_description
mutation	I-arm_description
"	O
(	O
NCT01277757	O
)	O
was	O
a	O
phase	O
II	O
trial	O
sponsored	O
by	O
The	O
Cancer	O
Therapy	O
Evaluation	O
Program	O
and	O
conducted	O
by	O
the	O
American	O
Academy	O
of	O
Cancer	O
Research	O
Stand	O
Up	O
to	O
Cancer	O
PI3	O
K	O
Dream	O
Team	O
.	O
This	O
multicenter	B-study_type
trial	I-study_type
accrued	O
in	O
five	O
centers	O
:	O
MD	O
Anderson	O
Cancer	O
Center	O
(	O
lead	O
organization	O
)	O
,	O
Dana	O
-	O
Farber	O
Cancer	O
Institute	O
,	O
Beth	O
Israel	O
Deaconess	O
Medical	O
Center	O
,	O
Columbia	O
University	O
Medical	O
Center	O
,	O
and	O
Vanderbilt	O
-	O
Ingram	O
Cancer	O
Center	O
.	O

Secondary	O
objectives	O
included	O
(	O
1	O
)	O
determining	O
the	O
6-month	B-arm_efficacy_metric
progression	I-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
(	O
PFS	B-arm_efficacy_metric
)	O
,	O
(	O
2	O
)	O
determining	O
baseline	O
molecular	O
markers	O
that	O
may	O
predict	O
clinical	O
outcome	O
,	O
(	O
3	O
)	O
establishing	O
pharmacodynamic	O
markers	O
in	O
blood	O
and	O
tumor	O
tissue	O
that	O
may	O
predict	O
outcome	O
,	O
and	O
(	O
4	O
)	O
determining	O
safety	O
and	O
tolerability	O
of	O
MK-2206	O
in	O
previously	O
treated	O
patients	O
with	O
advanced	O
breast	O
cancer	O
.	O

Tumor	O
biopsies	O
(	O
core	O
biopsies	O
and	O
fine	O
needle	O
aspirates	O
)	O
were	O
obtained	O
pretreatment	O
and	O
on	O
day	O
16	O
(	O
1	O
day	O
after	O
third	O
weekly	O
treatment	O
)	O
.	O
IHC	O
was	O
performed	O
on	O
core	O
biopsies	O
.	O
PTEN	B-arm_description
IHC	O
was	O
performed	O
in	O
the	O
MD	O
Anderson	O
CLIA	O
clinical	O
laboratory	O
.	O
PTEN	B-arm_description
IHC	O
was	O
performed	O
using	O
monoclonal	O
mouse	O
anti	O
-	O
Human	O
PTEN	B-arm_description
antibody	O
Clone	O
6H2.1	O
from	O
Dako	O
at	O
1:100	O
dilution	O
.	O
In	O
previous	O
studies	O
,	O
we	O
had	O
already	O
demonstrated	O
that	O
PTEN	B-arm_description
loss	I-arm_description
by	O
IHC	O
is	O
associated	O
with	O
PI3	O
K	O
pathway	O
activation	O
[	O
7	O
]	O
.	O
PTEN	B-arm_description
staining	O
was	O
evaluated	O
by	O
assessing	O
both	O
intensity	O
and	O
percent	O
positivity	O
of	O
staining	O
.	O
Both	O
nuclear	O
and	O
cytoplasmic	O
staining	O
were	O
evaluated	O
.	O
Staining	O
of	O
normal	O
cells	O
such	O
as	O
benign	O
breast	O
epithelium	O
,	O
stromal	O
cells	O
and/or	O
endothelial	O
cells	O
was	O
evaluated	O
as	O
an	O
internal	O
control	O
.	O
Any	O
tumor	O
nuclear	O
or	O
cytoplasmic	O
staining	O
showing	O
similar	O
intensity	O
with	O
internal	O
control	O
cells	O
was	O
considered	O
positive	O
staining	O
(	O
no	O
PTEN	B-arm_description
loss	I-arm_description
)	O
.	O
Complete	O
lack	O
of	O
staining	O
or	O
faint	O
staining	O
(	O
cytoplasmic	O
or	O
nuclear	O
)	O
in	O
up	O
to	O
50	O
%	O
of	O
tumor	O
cells	O
was	O
considered	O
as	O
PTEN	B-arm_description
loss	I-arm_description
.	O
If	O
there	O
was	O
no	O
staining	O
in	O
internal	O
control	O
cells	O
,	O
the	O
staining	O
was	O
considered	O
to	O
be	O
inconclusive	O
.	O

Pre	O
-	O
treatment	O
and	O
on	O
-	O
treatment	O
core	O
biopsies	O
were	O
also	O
assessed	O
for	O
pAKT	O
Ser473	O
(	O
1:50	O
)	O
,	O
pS6	O
Ser235/236	O
(	O
1:50	O
)	O
,	O
and	O
pS6	O
Ser240/244	O
(	O
1:200	O
;	O
all	O
from	O
Cell	O
Signaling	O
,	O
Danvers	O
,	O
MA	O
)	O
as	O
previously	O
described	O
[	O
7	O
]	O
.	O
The	O
Refine	O
Polymer	O
Detection	O
kit	O
was	O
used	O
for	O
immunostaining	O
,	O
with	O
3,3-diaminobenzidine	O
serving	O
as	O
chromagen	O
.	O
Slides	O
were	O
counterstained	O
with	O
Mayer	O
's	O
hematoxylin	O
.	O
Antibodies	O
were	O
evaluated	O
with	O
known	O
positive	O
and	O
negative	O
tissue	O
controls	O
.	O

Samples	O
were	O
evaluated	O
by	O
reverse	O
phase	O
protein	O
arrays	O
(	O
RPPA	O
)	O
to	O
assess	O
PI3	O
K	O
activation	O
status	O
as	O
previously	O
described	O
[	O
7][8][9	O
]	O
.	O
Fine	O
-	O
needle	O
aspiration	O
biopsy	O
samples	O
were	O
obtained	O
at	O
pre	O
-	O
and	O
post	O
-	O
treatment	O
from	O
patients	O
and	O
were	O
frozen	O
immediately	O
.	O
Among	O
24	O
patients	O
who	O
had	O
biopsies	O
,	O
one	O
patient	O
was	O
excluded	O
because	O
there	O
was	O
no	O
tumor	O
in	O
samples	O
for	O
H&E	O
analysis	O
of	O
core	O
biopsies	O
.	O
Fifteen	O
patients	O
had	O
paired	O
pre	O
-	O
and	O
post	O
-	O
treatment	O
samples	O
available	O
,	O
while	O
eight	O
patients	O
had	O
pre	O
-	O
treatment	O
samples	O
only	O
.	O
Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
and	O
platelet	O
enriched	O
plasma	O
(	O
PRP	O
)	O
were	O
evaluated	O
by	O
RPPA	O
at	O
the	O
following	O
time	O
points	O
:	O
at	O
screening	O
,	O
C1-D1	O
(	O
pretreatment	O
)	O
,	O
C1-D1	O
(	O
post	O
-	O
treatment	O
)	O
,	O
and	O
C1-D2	O
.	O

The	O
RPPA	O
raw	O
data	O
were	O
normalized	O
by	O
loading	O
control	O
by	O
the	O
RPPA	O
core	O
and	O
log2	O
transformed	O
.	O
A	O
linear	O
mixed	O
effects	O
(	O
LME	O
)	O
model	O
was	O
used	O
to	O
assess	O
the	O
differences	O
in	O
protein	O
expression	O
between	O
time	O
points	O
on	O
a	O
protein	O
-	O
by	O
-	O
protein	O
basis	O
.	O
The	O
LME	O
model	O
includes	O
the	O
fixed	O
effect	O
of	O
time	O
point	O
(	O
two	O
pre	O
-	O
treatment	O
:	O
early	O
,	O
C1D1	O
:	O
pre	O
-	O
treatment	O
;	O
two	O
post	O
-	O
treatment	O
:	O
C1D1	O
:	O
post	O
-	O
treatment	O
,	O
C1D2	O
)	O
and	O
random	O
effect	O
of	O
the	O
patient	O
.	O
To	O
account	O
for	O
multiple	O
testing	O
,	O
we	O
estimated	O
the	O
false	O
discovery	O
rates	O
(	O
FDR	O
)	O
of	O
the	O
overall	O
test	O
of	O
the	O
model	O
using	O
the	O
Benjamini	O
-	O
Hochberg	O
method	O
[	O
10	O
]	O
.	O
The	O
modified	O
Z	O
-	O
scores	O
of	O
9	O
important	O
PI3	O
K	O
pathway	O
biomarkers	O
were	O
calculated	O
and	O
used	O
to	O
compute	O
the	O
composite	O
PI3	O
K	O
pathway	O
activity	O
score	O
.	O
The	O
modified	O
Z	O
-	O
score	O
proposed	O
by	O
Iglewicz	O
and	O
Hoaglin	O
[	O
11	O
]	O
was	O
calculated	O
based	O
on	O
the	O
median	O
of	O
expression	O
and	O
absolute	O
deviation	O
about	O
the	O
median	O
.	O
We	O
defined	O
the	O
patient	O
's	O
composite	O
PI3	O
K	O
pathway	O
activity	O
score	O
as	O
the	O
sum	O
of	O
the	O
modified	O
Z	O
-	O
scores	O
of	O
phospho	O
-	O
protein	O
of	O
pAKT	O
,	O
4E	O
-	O
BP1	O
,	O
S6	O
K	O
,	O
and	O
S6	O
(	O
i.e.	O
,	O
PI3	O
K	O
score	O
=	O
pS6	O
S240/244	O
+	O
pS6	O
S235/236	O
+	O
pS6	O
K	O
T389	O
+	O
p4E	O
-	O
BP1	O
S65	O
+	O
p4E	O
-	O
BP1	O
T37/46	O
+	O
p	O
-	O
mTOR	O
S2448	O
+	O
pPRAS40	O
T246	O
+	O
pAKT	O
S473	O
+	O
pAKT	O
T308	O
)	O
.	O
The	O
LME	O
model	O
described	O
above	O
was	O
used	O
to	O
compare	O
the	O
PI3	O
K	O
activity	O
scores	O
between	O
pre	O
-	O
and	O
post	O
-	O
treatment	O
.	O

CLIA	O
DNA	O
analysis	O
was	O
performed	O
initially	O
using	O
the	O
Sanger	O
sequencing	O
,	O
and	O
then	O
transitioned	O
to	O
mass	O
spectroscopy	O
-	O
based	O
multiplex	O
assay	O
to	O
assess	O
the	O
mutational	O
status	O
of	O
hotspot	O
regions	O
in	O
11	O
genes	O
(	O
Sequenom	O
)	O
or	O
with	O
next	O
-	O
generation	O
sequencing	O
using	O
the	O
Ion	O
Ampliseq	O
46	O
Gene	O
Cancer	O
Panel	O
(	O
Life	O
Technologies	O
)	O
to	O
assess	O
hotspot	O
mutations	O
in	O
PIK3CA	B-arm_description
and	I-arm_description
AKT1	I-arm_description
genes	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O
Through	O
the	O
course	O
of	O
the	O
trial	O
,	O
genomic	O
testing	O
became	O
more	O
comprehensive	O
and	O
frequently	O
performed	O
at	O
individual	O
institutions	O
.	O
Testing	O
performed	O
on	O
alternate	O
CLIA	O
platforms	O
was	O
allowed	O
.	O
Genomic	O
testing	O
was	O
performed	O
on	O
available	O
archival	O
tissue	O
;	O
testing	O
on	O
either	O
primary	O
tumors	O
or	O
metastatic	O
biopsies	O
was	O
allowed	O
,	O
but	O
testing	O
on	O
most	O
recent	O
samples	O
was	O
encouraged	O
.	O

1	O
×	O
10	O
7	O
ZR75	O
-	O
1	O
breast	O
cancer	O
cells	O
were	O
inoculated	O
in	O
the	O
mammary	O
fat	O
pads	O
of	O
female	O
nu	O
/	O
nu	O
mice	O
(	O
Department	O
of	O
Experimental	O
Oncology	O
,	O
MD	O
Anderson	O
)	O
.	O
Mice	O
were	O
subcutaneously	O
implanted	O
with	O
17β	O
-	O
estradiol	O
pellets	O
(	O
Innovative	O
Research	O
of	O
America	O
)	O
.	O
Mice	O
bearing	O
ZR75	O
-	O
1	O
xenografts	O
were	O
randomized	O
into	O
3	O
groups	O
(	O
vehicle	O
,	O
MK-2206	O
240	O
mg	O
/	O
kg	O
,	O
or	O
480	O
mg	O
/	O
kg	O
,	O
n	O
=	O
5	O
-	O
6	O
)	O
.	O
Tumor	O
measurements	O
were	O
followed	O
to	O
assess	O
antitumor	O
efficacy	O
,	O
and	O
RPPA	O
was	O
utilized	O
to	O
assess	O
the	O
effect	O
on	O
cell	O
signaling	O
as	O
described	O
above	O
.	O
All	O
animal	O
experiments	O
were	O
approved	O
by	O
the	O
MD	O
Anderson	O
Cancer	O
Center	O
Animal	O
Care	O
and	O
Use	O
Committee	O
.	O
Table	O
1	O
summarizes	O
patient	O
characteristics	O
.	O
The	O
median	O
age	O
was	O
51	O
years	O
(	O
range	O
30	O
-	O
73	O
years	O
)	O
.	O
Fifteen	O
patients	O
had	O
ER	O
or	O
PR	O
-	O
positive	O
disease	O
(	O
HR	O
-	O
positive	O
)	O
,	O
three	O
had	O
HER2-positive	O
disease	O
,	O
and	O
nine	O
had	O
triple	O
-	O
negative	O
breast	O
cancer	O
(	O
TNBC	O
)	O
.	O
A	O
median	O
number	O
of	O
previous	O
lines	O
of	O
therapy	O
was	O
six	O
(	O
range	O
2	O
-	O
9	O
)	O
.	O
Four	O
patients	O
had	O
previously	O
received	O
everolimus	O
.	O

Twenty	O
-	O
seven	O
patients	O
received	O
MK-2206	B-arm_description
treatment	O
:	O
18	O
patients	O
were	O
treated	O
on	O
the	O
PIK3CA	B-arm_description
/	I-arm_description
AKT1	I-arm_description
mutation	I-arm_description
arm	I-arm_description
(	O
cohort	O
A)-13	O
had	O
PIK3CA	B-arm_description
mutations	O
,	O
4	O
had	O
AKT1	B-arm_description
mutations	O
,	O
and	O
one	O
had	O
a	O
PIK3CA	B-arm_description
mutation	O
as	O
well	O
as	O
PTEN	O
loss	O
.	O
Nine	O
patients	O
were	O
enrolled	O
on	O
the	O
PTEN	B-arm_description
mutation	I-arm_description
/	I-arm_description
loss	I-arm_description
arm	I-arm_description
(	O
cohort	O
B	O
)	O
:	O
4	O
with	O
PTEN	B-arm_description
mutations	I-arm_description
and	O
5	O
with	O
PTEN	B-arm_description
loss	I-arm_description
by	O
IHC	O
.	O

PI3	O
K	O
pathway	O
activation	O
was	O
also	O
assessed	O
by	O
IHC	O
for	O
pAKT	O
S473	O
,	O
pS6	O
S235/236	O
,	O
pS6	O
S240/244	O
,	O
and	O
p4EBP1	O
T70	O
(	O
Fig	O
.	O
3	O
)	O
.	O
Overall	O
in	O
the	O
study	O
,	O
no	O
difference	O
in	O
IRS	O
score	O
was	O
observed	O
between	O
paired	O
baseline	O
and	O
ontreatment	O
samples	O
based	O
on	O
Wilcoxon	O
signed	O
-	O
rank	O
tests	O
(	O
Fig	O
.	O
3a	O
)	O
.	O
Notably	O
,	O
IHC	O
did	O
reveal	O
pathway	O
inhibition	O
in	O
the	O
two	O
patients	O
who	O
evidenced	O
clinical	O
benefit	O
(	O
Fig	O
.	O
3b	O
)	O
.	O

The	O
primary	O
endpoint	O
is	O
the	O
ORR	O
.	O
The	O
secondary	O
endpoints	O
are	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
(	O
PFS	B-arm_efficacy_metric
)	O
,	O
duration	O
of	O
response	O
,	O
proportion	O
of	O
disease	O
control	O
,	O
and	O
safety	O
.	O

12	O
.	O
No	O
interstitial	O
pneumonia	O
or	O
history	O
of	O
interstitial	O
pneumonia	O
13	O
.	O
Patients	O
or	O
their	O
family	O
members	O
who	O
signed	O
the	O
informed	O
consent	O
14	O
.	O
Female	O
patients	O
of	O
childbearing	O
age	O
who	O
agreed	O
to	O
use	O
contraceptives	O
(	O
such	O
as	O
intrauterine	O
devices	O
,	O
birth	O
control	O
pills	O
,	O
or	O
condoms	O
)	O
in	O
the	O
study	O
period	O
and	O
for	O
six	O
months	O
after	O
the	O
end	O
of	O
the	O
drug	O
treatment	O
;	O
the	O
serum	O
or	O
urine	O
test	O
indicated	O
no	O
pregnancy	O
in	O
the	O
seven	O
days	O
prior	O
to	O
the	O
study	O
,	O
and	O
patients	O
who	O
were	O
not	O
lactating	O
;	O
male	O
patients	O
who	O
agreed	O
to	O
use	O
contraception	O
during	O
the	O
study	O
period	O
and	O
for	O
six	O
months	O
after	O
the	O
end	O
of	O
the	O
study	O
period	O
.	O

1	O
.	O
Previously	O
used	O
anlotinib	B-arm_description
or	O
S-1	B-arm_description
2	O
.	O
Small	O
-	O
cell	O
lung	O
cancer	O
(	O
including	O
small	O
-	O
cell	O
carcinoma	O
and	O
non	O
-	O
small	O
-	O
cell	O
carcinoma	O
mixed	O
lung	O
cancer	O
)	O

Adverse	O
events	O
were	O
recorded	O
in	O
accordance	O
with	O
the	O
requirements	O
of	O
Medical	O
Dictionary	O
for	O
Regulatory	O
Activities	O
(	O
Med	O
DRA	O
)	O
.	O
The	O
severity	O
of	O
adverse	O
events	O
was	O
graded	O
according	O
to	O
the	O
National	O
Cancer	O
Institute	O
Common	O
Terminology	O
Criteria(NCI	O
-	O
CTC	O
)	O
.	O
The	O
toxicity	O
of	O
the	O
treatment	O
,	O
including	O
acute	O
and	O
chronic	O
toxicity	O
,	O
was	O
evaluated	O
during	O
treatment	O
and	O
follow	O
-	O
up	O
(	O
Table	O
1).Any	O
serious	O
adverse	O
drug	O
reaction	O
was	O
promptly	O
reported	O
to	O
the	O
hospital	O
ethics	O
committee	O
.	O
PFS	O
was	O
defined	O
as	O
the	O
date	O
from	O
randomization	O
to	O
tumor	O
progression	O
or	O
death	O
.	O
Duration	O
of	O
response	O
was	O
assessed	O
in	O
patients	O
who	O
achieved	O
a	O
response	O
and	O
was	O
defined	O
as	O
the	O
time	O
from	O
the	O
date	O
of	O
the	O
first	O
documented	O
response	O
to	O
the	O
date	O
of	O
the	O
documented	O
progression	O
or	O
death	O
from	O
any	O
cause	O
.	O
Disease	O
control	O
was	O
defined	O
as	O
the	O
proportion	O
of	O
patients	O
who	O
achieved	O
a	O
CR	O
,	O
PR	O
,	O
or	O
SD	O
.	O

A	O
phase	B-study_type
2	I-study_type
study	I-study_type
of	O
an	O
oral	O
mTORC1	B-arm_description
/	I-arm_description
mTORC2	I-arm_description
kinase	I-arm_description
inhibitor	I-arm_description
(	O
CC-223	O
)	O
for	O
non	O
-	O
pancreatic	O
neuroendocrine	O
tumors	O
with	O
or	O
without	O
carcinoid	O
symptoms	O

Tumors	O
were	O
restaged	O
by	O
the	O
principal	O
investigator	O
at	O
each	O
site	O
using	O
computed	O
tomography	O
(	O
CT	O
)	O
,	O
positron	O
emission	O
tomography	O
(	O
PET)-CT	O
,	O
or	O
magnetic	O
resonance	O
imaging	O
scans	O
after	O
every	O
2	O
cycles	O
through	O
cycle	O
6	O
,	O
and	O
every	O
3	O
cycles	O
thereafter	O
,	O
using	O
Response	O
Evaluation	O
Criteria	O
In	O
Solid	O
Tumors	O
(	O
RECIST	O
)	O
version	O
1.1	O
criteria	O
for	O
response	O
[	O
14	O
]	O
.	O

Blood	O
for	O
PK	O
analysis	O
was	O
drawn	O
on	O
day	O
1	O
pre	O
-	O
dose	O
and	O
for	O
up	O
to	O
48	O
hours	O
post	O
-	O
dose	O
,	O
and	O
then	O
on	O
day	O
15	O
up	O
to	O
8	O
hours	O
post	O
-	O
dose	O
.	O
Urine	O
on	O
day	O
1	O
was	O
collected	O
within	O
30	O
minutes	O
prior	O
to	O
dosing	O
and	O
at	O
intervals	O
up	O
to	O
24	O
hours	O
post	O
-	O
dose	O
.	O
Samples	O
were	O
assayed	O
for	O
CC-223	B-arm_description
and	O
the	O
principal	O
active	O
metabolite	O
(	O
M1	O
)	O
using	O
validated	O
chiral	O
liquid	O
chromatography	O
mass	O
spectrometry	O
.	O
CC-223	B-arm_description
PK	O
parameters	O
were	O
calculated	O
using	O
dosing	O
and	O
sample	O
collection	O
times	O
.	O
Noncompartmental	O
PK	O
analysis	O
was	O
performed	O
used	O
WinNonlin	O
Enterprise	O
version	O
5.2	O
Model	O
200	O
and	O
Model	O
210	O
(	O
Certara	O
,	O
Princeton	O
,	O
NJ	O
)	O
.	O

This	O
phase	B-study_type
1/2	I-study_type
study	I-study_type
was	O
not	O
powered	O
for	O
inferential	O
statistics	O
and	O
mostly	O
descriptive	O
statistics	O
were	O
used	O
.	O
All	O
patients	O
dosed	O
with	O
CC-223	B-arm_description
were	O
included	O
in	O
the	O
safety	O
analysis	O
.	O
The	O
efficacy	O
analysis	O
included	O
all	O
patients	O
completing	O
at	O
least	O
one	O
cycle	O
of	O
drug	O
who	O
had	O
both	O
baseline	O
and	O
one	O
post	O
-	O
baseline	O
tumor	O
efficacy	O
assessment	O
,	O
unless	O
otherwise	O
specified	O
.	O
Categorical	O
baseline	O
variables	O
including	O
tumor	O
type	O
-	O
specific	O
characteristics	O
were	O
summarized	O
using	O
frequency	O
counts	O
and	O
percentage	O
.	O
Continuous	O
demographic	O
and	O
baseline	O
characteristic	O
variables	O
were	O
summarized	O
by	O
descriptive	O
statistics	O
.	O
A	O
Wilcoxon	O
signed	O
rank	O
test	O
was	O
used	O
to	O
analyse	O
change	O
from	O
baseline	O
in	O
serum	O
hormone	O
levels	O
at	O
selected	O
scheduled	O
visits	O
.	O

Relationship	O
between	O
PFS	B-arm_efficacy_metric
and	O
NET	O
-	O
specific	O
assessments	O
such	O
as	O
serum	O
hormone	O
levels	O
and	O
carcinoid	O
symptoms	O
were	O
investigated	O
.	O
The	O
Kaplan	O
-	O
Meier	O
estimate	O
of	O
median	B-arm_efficacy_metric
PFS	B-arm_efficacy_metric
with	O
its	O
two	O
-	O
sided	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
was	O
provided	O
for	O
each	O
baseline	O
category	O
of	O
the	O
selected	O
biomarkers	O
.	O
Kaplan	O
-	O
Meier	O
plots	O
of	O
PFS	O
were	O
created	O
by	O
category	O
.	O
The	O
raw	O
P	O
value	O
of	O
the	O
log	O
rank	O
test	O
comparing	O
survival	O
distribution	O
of	O
PFS	O
between	O
categories	O
was	O
also	O
provided	O
.	O

Of	O
the	O
47	O
patients	O
,	O
41	O
completed	O
at	O
least	O
one	O
cycle	O
of	O
CC-223	B-arm_description
,	O
had	O
at	O
least	O
one	O
restaging	O
,	O
and	O
were	O
thus	O
evaluable	O
for	O
efficacy	O
.	O
By	O
investigator	O
assessment	O
,	O
no	O
patient	O
had	O
a	O
complete	O
response	O
(	O
CR	O
)	O
,	O
3	O
patients	O
(	O
7.3	O
%	O
)	O
had	O
a	O
partial	O
response	O
(	O
PR	O
)	O
,	O
34	O
(	O
82.9	O
%	O
)	O
showed	O
stable	O
disease	O
(	O
SD	O
)	O
,	O
1	O
(	O
2.4	O
%	O
)	O
had	O
progressive	O
disease	O
(	O
PD	O
)	O
,	O
and	O
for	O
3	O
(	O
7.3	O
%	O
)	O
the	O
assessment	O
was	O
not	O
done	O
.	O
Thus	O
,	O
the	O
objective	O
response	O
rate	O
(	O
CR+PR	O
)	O
was	O
7.3	O
%	O
(	O
95	O
%	O
CI	O
1.5	O
-	O
19.9	O
%	O
)	O
and	O
the	O
disease	O
control	O
rate	O
(	O
CR+PR+SD	O
)	O
was	O
90.2	O
%	O
(	O
95	O
%	O
CI	O
76.9	O
-	O
97.3	O
%	O
)	O
.	O
It	O
is	O
noteworthy	O
that	O
tumor	O
shrinkage	O
of	O
any	O
magnitude	O
relative	O
to	O
baseline	O
was	O
observed	O
in	O
73.2	O
%	O
patients	O
(	O
95	O
%	O
CI	O
57.1	O
-	O
85.8	O
%	O
)	O
(	O
Fig	O
2	O
)	O
.	O
Duration	O
of	O
response	O
for	O
the	O
three	O
patients	O
with	O
PR	O
was	O
125	O
,	O
253	O
+	O
(	O
no	O
PD	O
reported	O
)	O
,	O
and	O
401	O
days	O
.	O
The	O
median	O
duration	O
of	O
SD	O
was	O
long	O
and	O
lasted	O
297	O
days	O
(	O
min	O
50	O
days	O
,	O
max	O
1519	O
days	O
)	O
.	O
Duration	O
of	O
SD	O
was	O
longer	O
than	O
a	O
year	O
in	O
17	O
patients	O
.	O
Median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
for	O
the	O
treated	O
population	O
was	O
19.5	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
10.4	I-arm_efficacy_results
-	I-arm_efficacy_results
28.5	I-arm_efficacy_results
months	I-arm_efficacy_results
)	I-arm_efficacy_results
with	O
rates	B-arm_efficacy_results
at	I-arm_efficacy_results
6	I-arm_efficacy_results
and	I-arm_efficacy_results
10	I-arm_efficacy_results
months	I-arm_efficacy_results
of	I-arm_efficacy_results
85	I-arm_efficacy_results
%	I-arm_efficacy_results
and	I-arm_efficacy_results
64	I-arm_efficacy_results
%	I-arm_efficacy_results
,	O
respectively	O
;	O
median	O
OS	O
was	O
not	O
assessable	O
(	O
OS	O
rate	O
at	O
48	O
weeks	O
was	O
0.97	O
)	O
(	O
Fig	O
3	O
)	O
.	O

Impact	O
of	O
circulating	O
tumor	O
DNA	O
mutant	O
allele	O
fraction	O
on	O
prognosis	O
in	O
RAS	O
-	O
mutant	O
metastatic	O
colorectal	O
cancer	O
Impact	O
of	O
circulating	O
tumor	O
DNA	O
mutant	O
allele	O
fraction	O
on	O
prognosis	O
in	O
RAS	O
-	O
mutant	O
metastatic	O
colorectal	O
cancer	O
ElenaElez	B-authors

Spain	O
Cellex	O
Building	O
,	O
C/	O
Natzaret	O
115	O
-	O
117	O
08035	O
Barcelona	O
Spain	O
Impact	O
of	O
circulating	O
tumor	O
DNA	O
mutant	O
allele	O
fraction	O
on	O
prognosis	O
in	O
RAS	O
-	O
mutant	O
metastatic	O
colorectal	O
cancer	O
10.1002/1878	O
-	O
0261.12547	O
Received	O
21	O
October	O
2018	O
,	O
revised	O
11	O
May	O
2019	O
,	O
accepted	O
15	O
July	O
2019	O
,	O
available	O
online	O
31	O
July	O
2019	O

This	O
multicentric	O
study	O
included	O
both	O
retrospective	O
and	O
prospective	O
patients	O
:	O
Retrospective	O
patients	O
were	O
recruited	O
from	O
two	O
Spanish	O
hospitals	O
(	O
Vall	O
d'Hebron	O
University	O
Hospital	O
and	O
Catalan	O
Institute	O
of	O
Oncology	O
,	O
Duran	O
I	O
Reynals	O
)	O
;	O
prospective	O
patients	O
were	O
recruited	O
from	O
the	O
Vall	O
d'Hebron	O
University	O
Hospital	O
only	O
.	O
Additionally	O
,	O
an	O
independent	O
cohort	O
of	O
first	O
-	O
line	O
patients	O
derived	O
from	O
the	O
CAPRI	B-study_type
-	I-study_type
GOIM	I-study_type
trial	I-study_type
(	O
registration	O
number	O
:	O
2009	O
-	O
014041	O
-	O
81	O
)	O
were	O
also	O
included	O
.	O
The	O
study	O
was	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
all	O
hospitals	O
,	O
and	O
all	O
patients	O
signed	O
written	O
informed	O
consent	O
.	O
This	O
study	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
Good	O
Clinical	O
Practice	O
guidelines	O
.	O

Blood	O
samples	O
(	O
4	O
mL	O
)	O
were	O
collected	O
in	O
CellSaveÒ	O
Preservative	O
Tubes	O
(	O
Menarini	O
-	O
Silicon	O
Biosystems	O
,	O
Bologna	O
,	O
Italy	O
)	O
,	O
and	O
plasma	O
was	O
isolated	O
within	O
48	O
h.	O
For	O
nontrial	O
patients	O
,	O
10	O
mL	O
of	O
blood	O
was	O
collected	O
in	O
EDTA	O
tubes	O
and	O
plasma	O
was	O
isolated	O
within	O
1	O
h.	O
A	O
two	O
-	O
step	O
centrifugation	O
was	O
performed	O
with	O
blood	O
initially	O
centrifuged	O
for	O
10	O
min	O
at	O
1600	O
g	O
at	O
room	O
temperature	O
.	O
Supernatant	O
was	O
collected	O
,	O
avoiding	O
the	O
buffy	O
coat	O
,	O
and	O
then	O
centrifuged	O
again	O
for	O
10	O
min	O
at	O
room	O
temperature	O
at	O
3000	O
g	O
to	O
remove	O
remaining	O
cells	O
.	O
Plasma	O
supernatant	O
was	O
transferred	O
into	O
a	O
1.5-mL	O
tube	O
and	O
stored	O
at	O
À80	O
°	O
C	O
until	O
use	O
.	O

In	O
the	O
first	O
-	O
line	O
setting	O
,	O
using	O
an	O
optimized	O
MAF	O
cutoff	O
of	O
5.8	O
%	O
,	O
PFS	B-arm_efficacy_metric
was	O
not	O
significantly	O
better	O
in	O
samples	B-arm_description
with	I-arm_description
MAF	I-arm_description
<	I-arm_description
5.8	I-arm_description
%	I-arm_description
(	O
Fig	O
.	O
2A	O
)	O
;	O
however	O
,	O
a	O
trend	O
toward	O
lower	O
PFS	B-arm_efficacy_metric
was	O
observed	O
in	O
samples	B-arm_description
with	I-arm_description
a	I-arm_description
higher	I-arm_description
MAF	I-arm_description
.	O
The	O
difference	O
in	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
between	O
patients	O
with	O
RAS	B-arm_description
-	I-arm_description
mutant	I-arm_description
samples	I-arm_description
with	I-arm_description
MAF	I-arm_description
<	I-arm_description
5.8	I-arm_description
%	I-arm_description
(	O
N	O
=	O
10	O
)	O
and	O
those	B-arm_description
with	I-arm_description
MAF	I-arm_description
≥	I-arm_description
5.8	I-arm_description
%	I-arm_description
was	O
10.7	B-arm_efficacy_results
months	I-arm_efficacy_results
vs	O
7.0	B-arm_efficacy_results
months	I-arm_efficacy_results
with	O
an	O
HR	B-arm_efficacy_results
of	I-arm_efficacy_results
2.2	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
:	I-arm_efficacy_results
0.94	I-arm_efficacy_results
-	I-arm_efficacy_results
7.20	I-arm_efficacy_results
;	I-arm_efficacy_results
P	I-arm_efficacy_results
=	I-arm_efficacy_results
0.06	I-arm_efficacy_results
)	I-arm_efficacy_results
.	O

Our	O
data	O
strongly	O
support	O
that	O
RAS	O
MAFs	O
have	O
independent	O
prognostic	O
value	O
for	O
CRC	O
survival	O
and	O
that	O
,	O
along	O
with	O
tumor	O
and	O
patient	O
characteristics	O
,	O
could	O
provide	O
a	O
useful	O
noninvasive	O
decision	O
-	O
making	O
tool	O
in	O
the	O
first	O
-	O
line	O
setting	O
.	O
After	O
demonstrating	O
the	O
feasibility	O
for	O
implementing	O
liquid	O
biopsies	O
in	O
routine	O
care	O
(	O
Grasselli	O
et	O
al	O
.	O
,	O
2017	O
)	O
,	O
we	O
propose	O
RAS	O
MAFs	O
as	O
a	O
novel	O
independent	O
prognostic	O
biomarker	O
for	O
mCRC	O
.	O
AIRC	O
(	O
Associazione	O
Italiana	O
per	O
la	O
Ricerca	O
sul	O
cancro	O
)	O
.	O
This	O
research	O
project	O
was	O
supported	O
by	O
ESMO	O
[	O
Translational	O
Research	O
Fellowship	O
]	O
with	O
the	O
aid	O
of	O
a	O
grant	O
from	O
Amgen	O
.	O
Any	O
views	O
,	O
opinions	O
,	O
findings	O
,	O
conclusions	O
,	O
or	O
recommendations	O
expressed	O
in	O
this	O
material	O
are	O
those	O
solely	O
of	O
the	O
author(s	O
)	O
and	O
do	O
not	O
necessarily	O
reflect	O
those	O
of	O
ESMO	O
or	O
Amgen	O
.	O
This	O
work	O
was	O
supported	O
partially	O
by	O
the	O
Instituto	O
de	O
Salud	O
Carlos	O
III	O
(	O
Ministerio	O
de	O
Econom	O
ıa	O
y	O
Competitividad	O
)	O
and	O
'	O
Fondo	O
Europeo	O
de	O
Desarrollo	O
Regional	O
(	O
FEDER	O
)	O
,	O
una	O
manera	O
de	O
hacer	O
Europa	O
'	O
grants	O
[	O
FIS	O
PI12	O
-	O
01589	O
to	O
RS	O
]	O
and	O
RETICC	O
Cancer	O
.	O
The	O
funders	O
had	O
no	O
role	O
in	O
study	O
design	O
,	O
data	O
collection	O
and	O
analysis	O
,	O
decision	O
to	O
publish	O
,	O
or	O
preparation	O
of	O
the	O
manuscript	O
.	O

JT	B-authors
has	O
served	O
in	O
a	O
consulting	O
or	O
advisory	O
role	O
for	O
Amgen	O
,	O
Boehringer	O
Ingelheim	O
,	O
Celgene	O
,	O
Chugai	O
,	O
ImClone	O
,	O
Lilly	O
,	O
Merck	O
,	O
S.L.	O
,	O
Madrid	O
,	O
Merck	O
Serono	O
,	O
Millennium	O
Pharmaceuticals	O
,	O
Inc.	O
,	O
Novartis	O
,	O
Roche	O
,	O
Sanofi	O
,	O
and	O
Taiho	O
.	O
RS	B-authors
has	O
served	O
in	O
a	O
consulting	O
or	O
advisory	O
role	O
for	O
Amgen	O
,	O
Merck	O
,	O
S.L.	O
,	O
Madrid	O
,	O
and	O
Roche	O
Dx	O
and	O
obtained	O
research	O
funding	O
from	O
Roche	O
Dx	O
.	O
AV	B-authors
has	O
served	O
in	O
a	O
consulting	O
or	O
advisory	O
role	O
for	O
Merck	O
,	O
S.L.	O
,	O
Madrid	O
,	O
Merck	O
Serono	O
,	O
and	O
Sysmex	O
.	O
All	O
remaining	O
authors	O
have	O
declared	O
no	O
conflicts	O
of	O
interest	O
.	O

The	O
Christie	O
NHS	O
Foundation	O
Trust	O
Manchester	O
UK	O
PhDMargheritaCarucci	B-authors
DrRobertHJones	B-authors
robert.hugh.jones@wales.nhs.uk	O
CatrinCox	B-authors
RachelButler	B-authors
FouadAlchami	B-authors
Tracie	B-authors
-	I-authors
AnnMadden	I-authors
CatherineBale	B-authors
PavelBezecny	B-authors
JohnathanJoffe	B-authors
SarahMoon	B-authors
ChrisTwelves	B-authors
RamachandranVenkitaraman	B-authors
SimonWaters	B-authors
AndrewFoxley	B-authors
Joffe	B-authors
FRCP	O
)	O

robert.hugh.jones@wales.nhs.uk	O
DrRobertHJones	B-authors
Dr	B-authors
Robert	I-authors
H	I-authors
Jones	I-authors
robert.hugh.jones@wales.nhs.uk	O
CatrinCox	B-authors
CatrinCox	B-authors
Catrin	B-authors
Cox	I-authors
RachelButler	B-authors
RachelButler	B-authors
Rachel	B-authors
Butler	I-authors
FouadAlchami	B-authors
FouadAlchami	B-authors
Fouad	B-authors
Alchami	I-authors
Tracie	B-authors
-	I-authors
AnnMadden	I-authors
Tracie	B-authors
-	I-authors
AnnMadden	I-authors
Tracie	B-authors
-	I-authors
Ann	I-authors
Madden	I-authors
CatherineBale	B-authors
CatherineBale	B-authors
Catherine	B-authors
Bale	I-authors
PavelBezecny	B-authors
PavelBezecny	B-authors
Pavel	B-authors
Bezecny	I-authors
JohnathanJoffe	B-authors
JohnathanJoffe	B-authors
Johnathan	B-authors
Joffe	I-authors
SarahMoon	B-authors
SarahMoon	B-authors
Sarah	B-authors
Moon	I-authors
ChrisTwelves	B-authors
ChrisTwelves	B-authors
Chris	B-authors
Twelves	I-authors
RamachandranVenkitaraman	B-authors
RamachandranVenkitaraman	B-authors
Ramachandran	B-authors
Venkitaraman	I-authors
SimonWaters	B-authors
SimonWaters	B-authors
Simon	B-authors
Waters	I-authors
AndrewFoxley	B-authors
Joffe	B-authors
FRCP	O
)	O

Capivasertib	O
(	O
AZD5363	O
)	O
is	O
a	O
potent	O
and	O
selective	O
inhibitor	O
of	O
the	O
three	O
AKT	O
isoforms	O
.	O
Preclinical	O
data	O
show	O
synergistic	O
activity	O
with	O
fulvestrant	O
in	O
both	O
endocrinesensitive	O
and	O
endocrineresistant	O
models	O
of	O
oestrogen	O
receptorpositive	O
breast	O
cancer	O
.	O
12	O
Preliminary	O
clinical	O
activity	O
was	O
seen	O
with	O
capivasertib	O
monotherapy	O
in	O
heavily	O
pretreated	O
patients	O
with	O
AKT1mutant	O
solid	O
cancers	O
,	O
including	O
oestrogen	O
receptorpositive	O
breast	O
cancer	O
,	O
but	O
very	O
low	O
singleagent	O
activity	O
in	O
patients	O
with	O
PIK3CAmutant	O
breast	O
and	O
gynaeco	O
logical	O
cancers	O
.	O
13,14	O
In	O
the	O
phase	O
2	O
BEECH	O
trial	O
,	O
capivasertib	O
did	O
not	O
enhance	O
the	O
efficacy	O
of	O
paclitaxel	O
in	O
oestrogen	O
receptorpositive	O
advanced	O
breast	O
cancer	O
,	O
although	O
endocrine	O
therapy	O
was	O
not	O
permitted	O
in	O
this	O
study	O
as	O
is	O
standard	O
practice	O
.	O
15	O
In	O
a	O
phase	O
1b	O
study	O
,	O
we	O
determined	O
the	O
capivasertib	O
dose	O
to	O
be	O
used	O
in	O
combination	O
with	O
fulvestrant	O
was	O
400	O
mg	O
twice	O
daily	O
for	O
4	O
days	O
then	O
3	O
days	O
off	O
in	O
a	O
weekly	O
schedule	O
.	O
16	O
In	O
the	O
phase	B-study_type
2	I-study_type
FAKTION	O
trial	B-study_type
,	O
we	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
capivasertib	B-arm_description
plus	B-arm_description
fulvestrant	I-arm_description
in	O
post	O
menopausal	O
women	O
with	O
aromatase	O
inhibitorresistant	O
,	O
oestrogen	O
receptorpositive	O
,	O
HER2negative	O
advanced	O
or	O
metastatic	O
breast	O
cancer	O
.	O
Furthermore	O
,	O
the	O
relative	O
efficacy	O
of	O
the	O
treatment	O
combination	O
in	O
participants	O
with	O
and	O
without	O
alteration	O
of	O
the	O
PI3	O
K	O
pathway	O
was	O
assessed	O
.	O

Baseline	O
PTEN	O
status	O
was	O
assessed	O
centrally	O
at	O
the	O
University	O
Hospital	O
Wales	O
Cellular	O
Pathology	O
Department	O
(	O
Cardiff	O
,	O
UK	O
)	O
.	O
Freshly	O
cut	O
sections	O
(	O
5	O
µm	O
thick	O
)	O
were	O
taken	O
from	O
each	O
formalinfixed	O
paraffin	O
embedded	O
tumour	O
block	O
.	O
The	O
first	O
section	O
was	O
stained	O
with	O
haematoxylin	O
and	O
eosin	O
to	O
identify	O
the	O
area	O
of	O
greatest	O
tumour	O
density	O
and	O
tumour	O
percentage	O
,	O
and	O
the	O
rest	O
was	O
made	O
available	O
for	O
DNA	O
extraction	O
and	O
whole	O
section	O
immunohistochemistry	O
.	O
Immunohistochemistry	O
was	O
prepared	O
using	O
DAKO	O
(	O
Ely	O
,	O
UK	O
)	O
PTEN	O
Monoclonal	O
Mouse	O
AntiHumanClone	O
(	O
code	O
M3627	O
)	O
,	O
with	O
antigen	O
retrieval	O
done	O
with	O
high	O
pH	O
DAKO	O
Target	O
Retrieval	O
Solution	O
and	O
the	O
DAKO	O
Autostainer	O
Link	O
48	O
automated	O
strainer	O
with	O
a	O
predetection	O
dilution	O
of	O
1:100	O
.	O
The	O
validation	O
study	O
and	O
full	O
protocol	O
for	O
the	O
PTEN	O
immunohistochemistry	O
detection	O
have	O
been	O
published	O
previously	O
.	O
18	O
The	O
PTEN	O
protein	O
expression	O
was	O
docu	O
mented	O
using	O
a	O
numeric	O
intensity	O
score	O
of	O
the	O
cyto	O
plasmic	O
staining	O
in	O
comparison	O
with	O
the	O
surrounding	O
stroma	O
and	O
macrophages	O
(	O
0	O
:	O
null	O
;	O
1	O
:	O
weak	O
;	O
2	O
:	O
moderate	O
;	O
and	O
3	O
:	O
strong	O
)	O
.	O
The	O
protocol	O
definition	O
of	O
PTEN	O
loss	O
,	O
for	O
inclusion	O
of	O
a	O
patient	O
in	O
the	O
altered	O
pathway	O
subgroup	O
,	O
was	O
either	O
immunohistochemistry	O
0	O
or	O
weak	O
PTEN	O
staining	O
in	O
less	O
than	O
10	O
%	O
of	O
cancer	O
cells	O
.	O

The	O
protocol	O
specified	O
that	O
pathway	O
alteration	O
was	O
defined	O
as	O
either	O
a	O
hotspot	O
mutation	O
detected	O
by	O
digital	O
droplet	O
PCR	O
(	O
ddPCR	O
)	O
on	O
PIK3CA	O
exons	O
9	O
or	O
20	O
in	O
tumour	O
tissue	O
or	O
blood	O
or	O
an	O
immuno	O
histochemistry	O
null	O
status	O
for	O
PTEN	O
in	O
tumour	O
tissue	O
(	O
primary	O
tumour	O
or	O
metastatic	O
biopsy	O
)	O
.	O
The	O
method	O
of	O
mutational	O
analysis	O
changed	O
from	O
pyrosequencing	O
to	O
ddPCR	O
during	O
the	O
trial	O
(	O
from	O
Nov	O
9	O
,	O
2016	O
)	O
,	O
which	O
provided	O
greater	O
sensitivity	O
to	O
detect	O
mutations	O
.	O
14	O
patients	O
who	O
were	O
categorised	O
as	O
nonaltered	O
on	O
the	O
basis	O
of	O
pyrosequencing	O
analysis	O
had	O
insufficient	O
material	O
to	O
carry	O
out	O
a	O
repeat	O
ddPCR	O
analysis	O
.	O
Tissue	O
DNA	O
and	O
cellfree	O
DNA	O
were	O
analysed	O
by	O
ddPCR	O
using	O
the	O
BioRad	O
(	O
Watford	O
,	O
UK	O
)	O
QX	O
200	O
system	O
.	O
Samples	O
were	O
analysed	O
for	O
the	O
common	O
PIK3CA	O
exon	O
9	O
and	O
20	O
mutations	O
(	O
reference	O
sequence	O
NM_006218.2	O
)	O
.	O

Between	O
March	O
16	O
,	O
2015	O
,	O
and	O
March	O
6	O
,	O
2018	O
,	O
183	O
patients	O
were	O
screened	O
for	O
eligibility	O
and	O
140	O
were	O
randomly	O
assigned	O
to	O
receive	O
fulvestrant	B-arm_description
plus	O
capivasertib	B-arm_description
(	O
n=69	O
[	O
49	O
%	O
]	O
)	O
or	O
fulvestrant	B-arm_description
plus	O
placebo	B-arm_description
(	O
n=71	O
[	O
51	O
%	O
]	O
;	O
figure	O
1	O
)	O
.	O
All	O
randomly	O
assigned	O
participants	O
were	O
included	O
in	O
primary	O
efficacy	O
and	O
safety	O
analyses	O
.	O
Participants	O
were	O
followed	O
up	O
until	O
all	O
had	O
had	O
at	O
least	O
6	O
months	O
followup	O
and	O
the	O
minimum	O
98	O
disease	O
progression	O
events	O
required	O
for	O
analysis	O
were	O
confirmed	O
.	O
Median	B-arm_efficacy_metric
progressionfree	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
followup	O
was	O
4•9	O
months	O
(	O
IQR	O
1•6	O
-	O
11•6	O
)	O
.	O
Treatment	O
groups	O
were	O
well	O
balanced	O
for	O
baseline	O
characteristics	O
(	O
table	O
1	O
)	O
.	O

RHJ	B-authors
,	O
SJH	B-authors
,	O
AC	B-authors
,	O
and	O
AF	B-authors
were	O
responsible	O
for	O
study	O
design	O
,	O
and	O
RHJ	B-authors
,	O
SJH	B-authors
,	O
AC	B-authors
,	O
and	O
MC	B-authors
for	O
writing	O
of	O
the	O
manuscript	O
.	O
MC	B-authors
and	O
TAM	B-authors
were	O
responsible	O
for	O
trial	O
management	O
,	O
coordination	O
,	O
and	O
conduct	O
.	O
RHJ	B-authors
,	O
SJH	B-authors
,	O
CB	B-authors
,	O
PB	B-authors
,	O
JJ	B-authors
,	O
SM	B-authors
,	O
CT	B-authors
,	O
RV	B-authors
,	O
and	O
SW	B-authors
were	O
responsible	O
for	O
patient	O
accrual	O
,	O
trial	O
conduct	O
,	O
and	O
obtaining	O
the	O
data	O
.	O
RB	B-authors
and	O
FA	B-authors
were	O
responsible	O
for	O
the	O
analysis	O
of	O
biological	O
samples	O
.	O
AC	B-authors
,	O
RHJ	B-authors
,	O
and	O
SJH	B-authors
wrote	O
the	O
statistical	O
analysis	O
plan	O
.	O
CC	B-authors
and	O
AC	B-authors
analysed	O
the	O
data	O
and	O
produced	O
the	O
results	O
and	O
figures	O
.	O
All	O
authors	O
interpreted	O
the	O
data	O
and	O
reviewed	O
the	O
draft	O
and	O
final	O
versions	O
of	O
the	O
manuscript	O
.	O

Therapy	O
of	O
nodal	O
Follicular	O
Lymphoma	O
(	O
WHO	O
grade	O
1/2	O
)	O
in	O
clinical	O
stage	O
I	O
/	O
II	O
using	O
response	O
adapted	O
Involved	B-arm_description
Site	I-arm_description
Radiotherapy	I-arm_description
in	O
combination	O
with	O
Obinutuzumab	B-arm_description
(	I-arm_description
Gazyvaro	I-arm_description
)	I-arm_description
-GAZAI	O
Trial	O
(	O
GAZyvaro	O
and	O
response	O
adapted	O
Involvedsite	O
Radiotherapy	O
)	O
:	O
a	O
study	B-study_type
protocol	I-study_type
for	I-study_type
a	I-study_type
single	I-study_type
-	I-study_type
arm	I-study_type
,	I-study_type
non	I-study_type
-	I-study_type
randomized	I-study_type
,	I-study_type
open	I-study_type
,	I-study_type
national	I-study_type
,	I-study_type
multi	I-study_type
-	I-study_type
center	I-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type

Also	O
,	O
rituximab	O
may	O
enhance	O
radiosensitivity	O
of	O
lymphoma	O
cells	O
and	O
thus	O
may	O
improve	O
the	O
efficacy	O
of	O
RT	O
[	O
20	O
]	O
.	O
Additionally	O
,	O
rituximab	O
maintenance	O
has	O
been	O
shown	O
to	O
prolong	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
after	O
first	O
-	O
line	O
therapy	O
of	O
advanced	O
stage	O
FL	O
[	O
21	O
]	O
and	O
therefore	O
may	O
contribute	O
to	O
the	O
elimination	O
of	O
minimal	O
disease	O
that	O
is	O
not	O
covered	O
by	O
the	O
radiation	O
field	O
.	O

MRD	O
will	O
be	O
analyzed	O
initially	O
,	O
at	O
week	O
18	O
,	O
and	O
at	O
months	O
6	O
,	O
12	O
,	O
18	O
,	O
and	O
24	O
using	O
the	O
markers	O
t(14:18	O
)	O
PCR	O
for	O
MBR	O
,	O
3′mbr	O
,	O
5′mcr	O
,	O
and	O
MCR	O
;	O
clonal	O
IGH	O
rearrangements	O
(	O
FR1	O
-	O
3	O
)	O
;	O
and	O
clonal	O
IGL	O
rearrangements	O
(	O
IGK	O
and	O
Kappa	O
-	O
KDE	O
)	O
.	O

Calculation	O
of	O
the	O
number	O
of	O
patients	O
to	O
be	O
recruited	O
is	O
based	O
on	O
the	O
ITT	O
population	O
.	O
The	O
primary	O
endpoint	O
is	O
the	O
rate	O
of	O
metabolic	O
CR	O
in	O
week	O
18	O
in	O
patients	O
with	O
initially	O
remaining	O
lymphoma	O
after	O
the	O
diagnostic	O
surgery	O
as	O
judged	O
by	O
FDG	O
-	O
PET	O
/	O
CT	O
.	O
Given	O
the	O
morphologic	O
CR	O
rate	O
of	O
37%-84	O
%	O
after	O
LDRT	O
documented	O
in	O
the	O
literature	O
and	O
a	O
lack	O
of	O
data	O
for	O
metabolic	O
CR	O
after	O
LDRT	O
,	O
a	O
CR	O
rate	O
of	O
60	O
%	O
is	O
assumed	O
.	O
If	O
50	O
patients	O
enter	O
the	O
FDG	O
-	O
PET	O
/	O
CT	O
and	O
the	O
observed	O
metabolic	O
CR	O
rate	O
amounts	O
to	O
60	O
%	O
,	O
the	O
half	O
width	O
of	O
the	O
asymptotic	O
twosided	O
95	O
%	O
confidence	O
interval	O
amounts	O
to	O
about	O
±13.5	O
%	O
.	O
Based	O
on	O
the	O
experience	O
of	O
the	O
MIR	O
trial	O
,	O
a	O
general	O
dropout	O
rate	O
of	O
10	O
%	O
is	O
assumed	O
,	O
and	O
about	O
30	O
%	O
of	O
the	O
included	O
patients	O
will	O
not	O
have	O
remaining	O
lymphoma	O
after	O
initial	O
surgery	O
.	O
In	O
addition	O
,	O
owing	O
to	O
stage	O
shifting	O
to	O
stage	O
III	O
/	O
IV	O
disease	O
,	O
a	O
dropout	O
rate	O
of	O
about	O
15	O
%	O
after	O
the	O
initial	O
FDG	O
-	O
PET	O
/	O
CT	O
is	O
expected	O
.	O

A	O
clinical	B-study_type
study	I-study_type
of	O
traditional	O
Chinese	O
medicine	O
prolonging	O
the	O
survival	O
of	O
advanced	O
gastric	O
cancer	O
patients	O
by	O
regulating	O
the	O
immunosuppressive	O
cell	O
population	O
A	O
study	O
protocol	O
for	O
a	O
multicenter	B-study_type
,	I-study_type
randomized	I-study_type
controlled	I-study_type
trail	I-study_type
A	O
clinical	B-study_type
study	I-study_type
of	O
traditional	O
Chinese	O
medicine	O
prolonging	O
the	O
survival	O
of	O
advanced	O
gastric	O
cancer	O
patients	O
by	O
regulating	O
the	O
immunosuppressive	O
cell	O
population	O
A	O
study	O
protocol	O
for	O
a	O
multicenter	B-study_type
,	I-study_type
randomized	I-study_type
controlled	I-study_type
trail	I-study_type
BSXiaotingPan	B-authors

Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Zhangjiagang	O
,	O
d	O
Changzhou	O
TCM	O
Hospital	O
,	O
e	O
Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Kunshan	O
,	O
f	O
Jiangsu	O
Cancer	O
Hospital	O
,	O
g	O
Nanjing	O
Drum	O
Tower	O
Hospital	O
China	O
MSShenlinLiu	B-authors

Nanjing	O
MSQingminSun	B-authors
MS	O
Qingmin	B-authors
Sun	I-authors
sunqingminnjmu@163.com	O
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O

Gastric	O
cancer	O
(	O
GC	O
)	O
is	O
an	O
important	O
disease	O
with	O
high	O
morbidity	O
and	O
mortality	O
globally	O
,	O
which	O
ranks	O
the	O
fifth	O
most	O
frequently	O
diagnosed	O
cancer	O
and	O
the	O
third	O
leading	O
cause	O
of	O
cancer	O
death	O
.	O
In	O
2018	O
,	O
over	O
1,000,000	O
new	O
cases	O
were	O
diagnosed	O
with	O
GC	O
and	O
approximately	O
783,000	O
deaths	O
(	O
equating	O
to	O
1	O
in	O
12	O
deaths	O
worldwide	O
)	O
.	O
[	O
1	O
]	O
Most	O
patients	O
(	O
>	O
70	O
%	O
)	O
with	O
GC	O
are	O
diagnosed	O
at	O
the	O
advanced	O
stage	O
,	O
[	O
2	O
]	O
as	O
a	O
consequence	O
,	O
it	O
shows	O
a	O
disappointing	O
result	O
.	O
[	O
3,4	O
]	O
Accumulating	O
evidence	O
shows	O
that	O
only	O
5	O
%	O
of	O
patients	O
with	O
metastatic	O
cancer	O
are	O
still	O
alive	O
5	O
years	O
after	O
diagnosis	O
.	O
[	O
5	O
]	O
In	O
recent	O
years	O
,	O
immune	O
microenvironment	O
has	O
been	O
increasingly	O
valued	O
for	O
its	O
crucial	O
role	O
in	O
the	O
process	O
of	O
GC	O
onset	O
and	O
progression	O
.	O
[	O
6][7][8	O
]	O
Although	O
surgical	O
resection	O
,	O
chemotherapy	O
,	O
radiotherapy	O
,	O
biologic	O
therapeutic	O
agents	O
,	O
and	O
other	O
measures	O
have	O
been	O
used	O
to	O
improve	O
the	O
therapeutic	O
efficacy	O
of	O
GC	O
,	O
[	O
9	O
]	O
the	O
prognosis	O
is	O
still	O
dismal	O
.	O
[	O
10	O
]	O
Thus	O
,	O
it	O
is	O
important	O
to	O
explore	O
new	O
strategies	O
to	O
prolong	O
the	O
survival	O
,	O
improve	O
the	O
quality	O
of	O
life	O
of	O
the	O
advanced	O
GC	O
patients	O
.	O
Fortunately	O
,	O
traditional	O
Chinese	O
medicine	O
(	O
TCM	O
)	O
has	O
its	O
unique	O
advantages	O
in	O
preventing	O
and	O
treating	O
GC	O
[	O
11,12	O
]	O
and	O
it	O
also	O
has	O
an	O
efficacy	O
in	O
improving	O
immune	O
function	O
.	O
[	O
13	O
]	O
The	O
JPYZXZ	O
decoction	O
is	O
a	O
traditional	O
Chinese	O
herbal	O
formulation	O
created	O
by	O
Professor	O
Shenlin	O
Liu	O
,	O
the	O
national	O
famous	O
Chinese	O
Physician	O
.	O
JPYZXZ	O
decoction	O
is	O
composed	O
of	O
12	O
kinds	O
of	O
Chinese	O
herbal	O
medicine	O
,	O
as	O
is	O
shown	O
in	O
Table	O
1	O
.	O
Our	O

The	O
datasets	O
generated	O
during	O
and/or	O
analyzed	O
during	O
the	O
current	O
study	O
are	O
not	O
publicly	O
available	O
,	O
but	O
are	O
available	O
from	O
the	O
corresponding	O
author	O
on	O
reasonable	O
request	O
.	O

A	O
total	O
of	O
210	O
patients	O
with	O
advanced	O
GC	O
will	O
be	O
recruited	O
in	O
this	O
clinical	O
trail	O
.	O
The	O
purpose	O
,	O
benefits	O
and	O
potential	O
risks	O
of	O
this	O
trail	O
and	O
other	O
information	O
will	O
be	O
informed	O
to	O
the	O
patients	O
in	O
detail	O
.	O
All	O
the	O
patients	O
participating	O
in	O
this	O
trail	O
are	O
entirely	O
voluntary	O
,	O
and	O
they	O
can	O
also	O
withdraw	O
at	O
any	O
time	O
during	O
the	O
whole	O
trail	O
without	O
any	O
consequence	O
.	O
Written	O
consent	O
will	O
be	O
obtained	O
from	O
each	O
eligibility	O
patient	O
before	O
them	O
participating	O
in	O
the	O
study	O
.	O
(	O
1	O
)	O
Patients	O
who	O
is	O
unable	O
to	O
swallow	O
oral	O
medications	O
including	O
with	O
digestive	O
tract	O
obstruction	O
and	O
jejunostomy	O
;	O
(	O
2	O
)	O
Patients	O
with	O
symptomatic	O
brain	O
metastasis	O
or	O
mental	O
disorder	O
;	O
(	O
3	O
)	O
Patients	O
with	O
severe	O
cardiovascular	O
disease	O
,	O
chronic	O
liver	O
disease	O
,	O
kidney	O
disease	O
or	O
blood	O
disease	O
;	O
(	O
4	O
)	O
Patients	O
whose	O
laboratory	O
examination	O
before	O
enrollment	O
is	O
abnormal	O
according	O
to	O
the	O
following	O
criteria	O
:	O
Blood	O
routine	O
examination	O
:	O
ANC	O
<	O
2.0	O
Â	O
10	O
9	O
/L	O
,	O
Hb	O
<	O
90	O
g	O
/	O
L	O
,	O
PLT	O
<	O
80	O
Â	O
10	O
9	O
/L	O
,	O
Renal	O
function	O
:	O
Cr	O
>	O
1.5	O
Â	O
upper	O
normal	O
limit	O
(	O
UNL	O
)	O
;	O
2.5.2	O
.	O
The	O
treatment	O
group	O
.	O
Total	O
of	O
140	O
patients	O
in	O
the	O
treatment	O
group	O
will	O
be	O
treated	O
with	O
chemotherapy	B-arm_description
combined	O
with	O
JPYZXZ	B-arm_description
decoction	O
.	O
The	O
chemotherapy	B-arm_description
regimens	O
will	O
be	O
the	O
same	O
as	O
the	O
control	B-arm_description
group	I-arm_description
and	O
the	O
JPYZXZ	B-arm_description
decoction	O
,	O
available	O
in	O
the	O
forms	O
of	O
granules	O
,	O
should	O
be	O
taken	O
at	B-arm_dosage
least	I-arm_dosage
6	B-arm_dosage
months	I-arm_dosage
,	O
per	O
bag	O
twice	B-arm_dosage
daily	I-arm_dosage
,	O
add	O
boiled	O
water	O
in	O
it	O
and	O
mix	O
up	O
it	O
,	O
150	B-arm_dosage
ml	I-arm_dosage
each	I-arm_dosage
time	I-arm_dosage
.	O

The	O
time	O
-	O
points	O
of	O
assessment	O
is	O
listed	O
in	O
Table	O
2	O
.	O
2.6.1	O
.	O
Primary	O
outcomes	O
.	O
The	O
primary	O
outcomes	O
include	O
1year	O
survival	O
rate	O
,	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
One	O
-	O
year	O
survival	O
rate	O
=	O
(	O
the	O
number	O
of	O
patients	O
still	O
alive	O
after	O
1	O
year	O
of	O
follow	O
-	O
up	O
/	O
the	O
total	O
number	O
of	O
patients	O
followed	O
up	O
)	O
Â	O
100	O
%	O
.	O
Progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
means	O
the	O
time	O
from	O
the	O
start	O
of	O
treatment	O
to	O
recurrence	O
or	O
death	O
due	O
to	O
any	O
causes	O
.	O
OS	O
is	O
the	O
time	O
from	O
the	O
beginning	O
of	O
diagnosis	O
to	O
death	O
for	O
any	O
causes	O
.	O
All	O
of	O
the	O
indicators	O
will	O
be	O
calculated	O
at	O
the	O
end	O
of	O
the	O
trail	O
.	O

Considering	O
20	O
%	O
of	O
the	O
drop	O
rate	O
,	O
allocating	O
patients	O
at	O
a	O
ratio	O
of	O
2:1	O
,	O
the	O
total	O
sample	O
size	O
is	O
210	O
(	O
140	O
in	O
chemotherapy	B-arm_description
plus	O
JPYZXZ	B-arm_description
group	O
and	O
70	O
in	O
chemotherapy	B-arm_description
alone	I-arm_description
group	O
)	O
.	O

Avelumab	B-arm_description
monotherapy	O
as	O
first	O
-	O
line	O
or	O
second	O
-	O
line	O
treatment	O
in	O
patients	O
with	O
metastatic	O
renal	O
cell	O
carcinoma	O
:	O
phase	B-study_type
Ib	I-study_type
results	I-study_type
from	O
the	O
JAVELIN	O
Solid	O
Tumor	O
trial	O
Avelumab	B-arm_description
monotherapy	O
as	O
first	O
-	O
line	O
or	O
second	O
-	O
line	O
treatment	O
in	O
patients	O
with	O
metastatic	O
renal	O
cell	O
carcinoma	O
:	O
phase	B-study_type
Ib	I-study_type
results	I-study_type
from	O
the	O
JAVELIN	O
Solid	O
Tumor	O
trial	O
UlkaVaishampayan	B-authors

Avelumab	B-arm_description
monotherapy	O
as	O
first	O
-	O
line	O
or	O
second	O
-	O
line	O
treatment	O
in	O
patients	O
with	O
metastatic	O
renal	O
cell	O
carcinoma	O
:	O
phase	B-study_type
Ib	I-study_type
results	I-study_type
from	O
the	O
JAVELIN	O
Solid	O
Tumor	O
trial	O

4100	O
John	O
R.	O
Street	O
48201	O
Detroit	O
MI	O
USA	O
PatrickSchöffski	B-authors
General	O
Medical	O
Oncology	O
Leuven	O
Cancer	O
Institute	O
University	O
Hospitals	O
Leuven	O
Leuven	O
Belgium	O
AlainRavaud	B-authors
Medical	O
Oncology	O
Bordeaux	O
University	O
Hospital	O
Bordeaux	O
France	O
ChristianBorel	B-authors
Medical	O
Oncology	O

4100	O
John	O
R.	O
Street	O
48201	O
Detroit	O
MI	O
USA	O
PatrickSchöffski	B-authors
General	O
Medical	O
Oncology	O
Leuven	O
Cancer	O
Institute	O
University	O
Hospitals	O
Leuven	O
Leuven	O
Belgium	O
AlainRavaud	B-authors
Medical	O
Oncology	O
Bordeaux	O
University	O
Hospital	O
Bordeaux	O
France	O
ChristianBorel	B-authors
Medical	O
Oncology	O

Horovice	O
Oncology	O
Clinic	O
,	O
Nemocnice	O
Rudolfa	O
a	O
Stefanie	O
Benešov	O
,	O
a.	O
s	O
,	O
Benešov	O
,	O
Czech	O
Republic	O
.	O
10	O
Merck	O
Serono	O
Pharmaceutical	O
R&D	O
Co	O
Beijing	O
China	O
DongliZhou	B-authors
SilkeGuenther	B-authors
Merck	O
KGaA	O
Darmstadt	O
Germany	O
MarcisBajars	B-authors

Horovice	O
Oncology	O
Clinic	O
,	O
Nemocnice	O
Rudolfa	O
a	O
Stefanie	O
Benešov	O
,	O
a.	O
s	O
,	O
Benešov	O
,	O
Czech	O
Republic	O
.	O
10	O
Merck	O
Serono	O
Pharmaceutical	O
R&D	O
Co	O
Beijing	O

In	O
the	O
1	B-arm_description
L	I-arm_description
and	O
2	B-arm_description
L	I-arm_description
subgroups	O
,	O
respectively	O
,	O
the	O
ORR	O
was	O
16.1	O
%	O
(	O
CR	O
,	O
n	O
=	O
1	O
[	O
1.6	O
%	O
]	O
;	O
PR	O
,	O
n	O
=	O
9	O
[	O
14.5	O
%	O
]	O
)	O
and	O
10.0	O
%	O
(	O
PR	O
,	O
n	O
=	O
2	O
)	O
(	O
seven	O
patients	O
(	O
35.0	O
%	O
)	O
had	O
serious	O
AEs	O
,	O
which	O
were	O
related	O
to	O
treatment	O
in	O
two	O
patients	O
(	O
3.2	O
%	O
)	O
in	O
the	O
1	O
L	O
subgroup	O
(	O
grade	O
3	O
colitis	O
and	O
grade	O
2	O
hyperthermia	O
,	O
both	O
n	O
=	O
1	O
)	O
.	O
Four	O
patients	O
(	O
6.5	O
%	O
)	O
in	O
the	O
1	B-arm_description
L	I-arm_description
subgroup	O
and	O
two	O
patients	O
(	O
10.0	O
%	O
)	O
in	O
the	O
2	B-arm_description
L	I-arm_description
subgroup	O
had	O
an	O
AE	O
leading	O
to	O
death	O
(	O
none	O
treatment	O
related	O
)	O
.	O

and	O
Pfizer	O
,	O
outside	O
the	O
submitted	O
work	O
;	O
personal	O
fees	O
from	O
Novartis	O
,	O
Millennium	O
Pharmaceuticals	O
,	O
Takeda	O
,	O
Veridex	O
and	O
the	O
Institute	O
of	O
Cancer	O
Research	O
(	O
ICR	O
)	O
,	O
outside	O
the	O
submitted	O
work	O
;	O
grants	O
from	O
AstraZeneca	O
,	O
Arno	O
Therapeutics	O
,	O
Innocrin	O
Pharma	O
and	O
Veridex	O
,	O
outside	O
the	O
submitted	O
work	O
;	O
received	O
a	O
share	O
of	O
this	O
income	O
through	O
the	O
ICR	O
's	O
Rewards	O
to	O
Discoverers	O
Scheme	O
.	O
SC	B-authors
reports	O
personal	O
fees	O
from	O
Janssen	O
Pharmaceutical	O
,	O
outside	O
the	O
submitted	O
work	O
.	O
WC	B-authors
reports	O
personal	O
fees	O
from	O
Janssen	O
and	O
other	O
from	O
Bayer	O
outside	O
the	O
submitted	O
work	O
.	O
DPD	B-authors
reports	O
other	O
from	O
UK	O
NWClarke	B-authors
noel.clarke@christie.nhs.uk	O
Department	O
of	O
Urology	O

All	O
procedures	O
relating	O
to	O
administration	O
and	O
reporting	O
of	O
docetaxel	O
as	O
a	O
research	O
treatment	O
have	O
been	O
reported	O
previously	O
[	O
1	O
]	O
.	O
In	O
brief	O
,	O
patients	O
were	O
randomised	O
to	O
lifelong	O
ADT	B-arm_description
with	O
or	O
without	O
six	B-arm_dosage
cycles	I-arm_dosage
of	O
docetaxel	B-arm_description
(	B-arm_dosage
75	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
given	O
3-weekly	B-arm_dosage
with	O
prednisolone	O
5	B-arm_dosage
mg	I-arm_dosage
twice	I-arm_dosage
daily	I-arm_dosage
during	I-arm_dosage
the	I-arm_dosage
18-week	I-arm_dosage
period	I-arm_dosage
of	I-arm_dosage
therapy	I-arm_dosage
.	O

A	O
sensitivity	O
analysis	O
was	O
undertaken	O
without	O
the	O
M1	O
patients	O
retrospectively	O
found	O
not	O
to	O
have	O
met	O
all	O
of	O
the	O
strict	O
protocol	O
eligibility	O
criteria	O
,	O
mostly	O
concerning	O
a	O
review	O
of	O
baseline	O
blood	O
pressure	O
measurements	O
.	O
Removing	O
these	O
120	O
patients	O
(	O
11	O
%	O
)	O
did	O
not	O
change	O
the	O
primary	O
outcome	O
measure	O
results	O
HR	O
¼	O
0.81	O
(	O
95	O
%	O
CI	O
0.68	O
-	O
0.96	O
;	O
P	O
¼	O
0.013	O
)	O
.	O

Apatinib	B-arm_description
in	O
patients	O
with	O
extensive	O
-	O
stage	O
small	O
-	O
cell	O
lung	O
cancer	O
after	O
second	O
-	O
line	O
or	O
third	O
-	O
line	O
chemotherapy	O
:	O
a	O
phase	B-study_type
II	I-study_type
,	I-study_type
singlearm	I-study_type
,	I-study_type
multicentre	I-study_type
,	I-study_type
prospective	I-study_type
study	I-study_type
YanjunXu	B-authors

The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
relevant	O
institutional	O
review	O
board	O
or	O
ethics	O
committee	O
at	O
each	O
medical	O
centre	O
,	O
and	O
it	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
Good	O
Clinical	O
Practice	O
guidelines	O
,	O
as	O
defined	O
by	O
the	O
International	O
Conference	O
on	O
Harmonisation	O
.	O
All	O
enrolled	O
patients	O
provided	O
written	O
informed	O
consent	O
before	O
any	O
study	O
-	O
specific	O
procedures	O
were	O
performed	O
.	O

The	O
following	O
three	O
populations	O
were	O
analysed	O
:	O
the	O
full	O
analysis	O
set	O
(	O
FAS	O
)	O
,	O
the	O
per	O
-	O
protocol	O
set	O
(	O
PPS	O
)	O
and	O
the	O
safety	O
analysis	O
set	O
(	O
SAS	O
)	O
.	O
The	O
FAS	O
consisted	O
of	O
all	O
enrolled	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
medication	O
according	O
to	O
the	O
intention	O
-	O
totreat	O
(	O
ITT	O
)	O
principle	O
.	O
The	O
PPS	O
referred	O
to	O
a	O
subset	O
of	O
the	O
patients	O
in	O
the	O
FAS	O
who	O
were	O
compliant	O
with	O
the	O
protocol	O
and	O
without	O
any	O
major	O
protocol	O
violations	O
(	O
including	O
violation	O
of	O
study	O
entry	O
criteria	O
)	O
.	O
The	O
SAS	O
included	O
all	O
enrolled	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
the	O
study	O
medication	O
,	O
though	O
not	O
those	O
without	O
any	O
safety	O
data	O
.	O
Patients	O
'	O
baseline	O
characteristics	O
were	O
summarised	O
for	O
the	O
ITT	O
population	O
.	O
The	O
efficacy	O
analysis	O
was	O
performed	O
in	O
both	O
the	O
ITT	O
and	O
PPS	O
populations	O
.	O
Safety	O
data	O
were	O
explored	O
in	O
the	O
SAS	O
.	O

Objective	O
response	O
and	O
disease	O
control	O
rate	O
were	O
evaluated	O
via	O
the	O
binomial	O
response	O
rate	O
and	O
the	O
corresponding	O
two	O
-	O
sided	O
95	O
%	O
exact	O
confidence	O
intervals	O
(	O
CIs	O
)	O
,	O
using	O
the	O
Clopper	O
-	O
Pearson	O
method	O
.	O
The	O
Kaplan	O
-	O
Meier	O
method	O
was	O
used	O
to	O
estimate	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
and	O
overall	O
survival	O
,	O
and	O
median	O
values	O
were	O
estimated	O
with	O
two	O
-	O
sided	O
95	O
%	O
CIs	O
by	O
using	O
the	O
Brookmeyer	O
-	O
Crowley	O
method	O
.	O
Cox	O
proportional	O
-	O
hazards	O
regression	O
models	O
were	O
used	O
for	O
univariate	O
and	O
multivariate	O
analysis	O
to	O
identify	O
the	O
potential	O
factors	O
associated	O
with	O
clinical	O
outcomes	O
.	O
A	O
p	O
-	O
value	O
(	O
two	O
-	O
sided	O
)	O
<	O
0.05	O
was	O
considered	O
statistically	O
significant	O
.	O
All	O
analyses	O
were	O
performed	O
with	O
SPSS	O
®	O
22.0	O
.	O
The	O
study	O
was	O
registered	O
with	O
ClinicalTrials.gov	O
(	O
NCT02945852	O
)	O
.	O

The	O
SAS	O
included	O
the	O
entire	O
40	O
patients	O
,	O
and	O
all	O
experienced	O
AEs	O
related	O
to	O
apatinib	O
treatment	O
.	O
AEs	O
of	O
clinical	O
significance	O
,	O
as	O
selected	O
by	O
the	O
investigators	O
,	O
are	O
summarised	O
in	O
Table	O
3	O
.	O
The	O
most	O
commonly	O
observed	O
grade	O
3	O
or	O
greater	O
AEs	O
were	O
hypertension	O
(	O
25	O
%	O
;	O
10/40	O
)	O
,	O
hand	O
-	O
foot	O
syndrome	O
(	O
10	O
%	O
;	O
4/40	O
)	O
,	O
increased	O
Lgamma	O
glutamyltransferase	O
(	O
10	O
%	O
;	O
4/40	O
)	O
,	O
increased	O
aspartate	O
transaminase	O
(	O
7.5	O
%	O
;	O
3/40	O
)	O
and	O
thrombocytopenia	O
(	O
7.5	O
%	O
;	O
3/40	O
)	O
.	O
In	O
addition	O
,	O
one	O
patient	O
required	O
hospitalisation	O
for	O
the	O
management	O
of	O
grade	O
4	O
neutropenia	O
.	O
No	O
grade	O
5	O
AEs	O
were	O
reported	O
,	O
and	O
no	O
unexpected	O
AEs	O
were	O
observed	O
during	O
the	O
study	O
.	O

Dosage	O
reduction	O
of	O
apatinib	O
was	O
required	O
in	O
15	O
patients	O
(	O
37.5	O
%	O
)	O
during	O
the	O
therapy	O
with	O
following	O
reasons	O
:	O
11	O
cases	O
(	O
73.3	O
%	O
)	O
of	O
hand	O
-	O
foot	O
syndrome	O
,	O
10	O
(	O
66.7	O
%	O
)	O
cases	O
of	O
hypertension	O
,	O
one	O
(	O
6.7	O
%	O
)	O
case	O
of	O
proteinuria	O
one	O
(	O
6.7	O
%	O
)	O
case	O
of	O
mucositis	O
,	O
one	O
(	O
6.7	O
%	O
)	O
case	O
of	O
thrombocytopenia	O
and	O
one	O
(	O
6.7	O
%	O
)	O
case	O
of	O
impaired	O
liver	O
function	O
.	O
Of	O
note	O
,	O
10	O
of	O
the	O
15	O
patients	O
(	O
66.7	O
%	O
)	O
needed	O
dosage	O
reduction	O
due	O
to	O
two	O
(	O
60	O
%	O
;	O
n	O
=	O
9	O
)	O
or	O
three	O
(	O
6.7	O
%	O
;	O
n	O
=	O
1	O
)	O
toxic	O
reactions	O
.	O
Treatment	O
had	O
to	O
be	O
stopped	O
due	O
to	O
intolerable	O
toxic	O
reactions	O
for	O
four	O
patients	O
,	O
one	O
for	O
fatigue	O
,	O
two	O
cases	O
for	O
hand	O
-	O
foot	O
syndrome	O
and	O
one	O
case	O
for	O
proteinuria	O
.	O
The	O
reasons	O
for	O
apatinib	B-arm_description
dose	O
reduction	O
are	O
summarised	O
in	O
Supplementary	O
Table	O
1	O
.	O

Cediranib	O
(	O
AstraZeneca	O
,	O
Cheshire	O
,	O
United	O
Kingdom	O
)	O
,	O
an	O
oral	O
tyrosine	O
kinase	O
inhibitor	O
of	O
VEGFR	O
1,2,3	O
and	O
PDGFR	O
has	O
been	O
evaluated	O
in	O
mesothelioma	O
as	O
monotherapy	O
and	O
in	O
combination	O
with	O
chemotherapy	O
.	O
Southwest	O
Oncology	O
Group	O
trial	O
SWOG	O
0509	O
reported	O
a	O
9	O
%	O
response	O
rate	O
and	O
34	O
%	O
disease	O
stabilization	O
with	O
cediranib	O
in	O
patients	O
with	O
previously	O
treated	O
mesothelioma	O
.	O
10	O
We	O
theorized	O
that	O
targeting	O
VEGFR	O
and	O
PDGFR	O
would	O
enhance	O
chemotherapy	O
efficacy	O
and	O
potentially	O
bypass	O
resistance	O
mechanisms	O
of	O
high	O
VEGF	O
ligand	O
secretion	O
.	O
11	O
SWOG	O
0905	O
was	O
thus	O
designed	O
as	O
a	O
phase	O
I	O
and	O
II	O
front	O
-	O
line	O
trial	O
.	O
The	O
phase	O
I	O
trial	O
established	O
the	O
maximum	O
tolerated	O
dose	O
of	O
cediranib	O
at	O
20	O
mg	O
per	O
day	O
when	O
combined	O
with	O
cisplatin	O
-	O
pemetrexed	O
.	O
12	O
Median	O
RECIST	O
v1.1	O
PFS	O
was	O
12.8	O
months	O
,	O
median	O
modified	O
RECIST	O
(	O
mRECIST	O
)	O
PFS	O
was	O
8.6	O
months	O
,	O
and	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
16.2	O
months	O
.	O
12	O
Here	O
,	O
we	O
report	O
the	O
results	O
of	O
the	O
randomized	B-study_type
phase	I-study_type
II	I-study_type
SWOG	I-study_type
0905	I-study_type
trial	I-study_type
.	O

Patients	O
were	O
randomly	O
assigned	O
with	O
equal	O
probability	O
(	O
1:1	O
)	O
between	O
cisplatin	B-arm_description
-	O
pemetrexed	B-arm_description
with	O
cediranib	B-arm_description
versus	O
placebo	B-arm_description
.	O
Randomization	O
was	O
stratified	O
by	O
PS	O
(	O
0	O
to	O
1	O
v	O
2	O
)	O
and	O
histology	O
(	O
epithelioid	O
v	O
biphasic	O
or	O
sarcomatoid	O
)	O
using	O
a	O
dynamic	O
balancing	O
algorithm	O
.	O
15	O
Patients	O
were	O
enrolled	O
via	O
a	O
Web	O
-	O
based	O
application	O
and	O
simultaneous	O
randomization	O
was	O
performed	O
by	O
a	O
computer	O
program	O
.	O
Patients	O
and	O
investigators	O
were	O
blinded	O
to	O
the	O
treatment	O
arm	O
.	O

Patients	O
in	O
the	O
cediranib	B-arm_description
arm	I-arm_description
received	O
fewer	O
cycles	O
of	O
chemotherapy	O
(	O
median	O
,	O
four	O
v	O
six	O
;	O
P	O
=	O
.41	O
)	O
and	O
fewer	O
days	O
of	O
cediranib	O
/	O
placebo	O
use	O
(	O
median	O
,	O
80	O
days	O
v	O
124	O
days	O
;	O
P	O
=	O
.31	O
;	O
Appendix	O
Table	O
A1	O
,	O
The	O
addition	B-arm_description
of	I-arm_description
cediranib	I-arm_description
to	I-arm_description
chemotherapy	I-arm_description
led	O
to	O
a	O
higher	O
rate	O
of	O
treatment	O
-	O
related	O
adverse	O
events	O
compared	O
with	O
placebo	B-arm_description
(	O
100	O
%	O
v	O
91	O
%	O
;	O
P	O
=	O
.06	O
)	O
.	O
Toxicities	O
(	O
any	O
grade	O
;	O
Table	O
3	O
)	O
that	O
were	O
higher	O
in	O
the	O
cediranib	B-arm_description
arm	I-arm_description
were	O
anorexia	O
(	O
21	O
%	O
)	O
,	O
and	O
myelosuppression	O
(	O
44	O
%	O
v	O
30	O
%	O
)	O
.	O
There	O
were	O
two	O
cases	O
of	O
sinus	O
bradycardia	O
and	O
one	O
of	O
supraventricular	O
tachycardia	O
in	O
the	O
cediranib	B-arm_description
arm	I-arm_description
compared	O
with	O
none	O
in	O
the	O
placebo	B-arm_description
arm	I-arm_description
.	O
The	O
cediranib	B-arm_description
arm	I-arm_description
was	O
associated	O
with	O
69	O
%	O
grade	O
3	O
and	O
4	O
toxicities	O
compared	O
with	O
57	O
%	O
in	O
the	O
placebo	B-arm_description
arm	I-arm_description
(	O
P	O
=	O
.13	O
)	O
.	O
Four	O
deaths	O
occurred	O
:	O
two	O
in	O
the	O
cediranib	B-arm_description
and	O
one	O
in	O
the	O
placebo	B-arm_description
arm	I-arm_description
from	O
respiratory	O
failure	O
,	O
and	O
one	O
sudden	O
death	O
in	O
the	O
placebo	B-arm_description
arm	I-arm_description
.	O

South	O
Korea	O
81	O
,	O
Irwon	O
-	O
ro	O
,	O
Gangnam	O
-	O
gu	O
06351	O
Seoul	O
South	O
Korea	O
Division	O
of	O
Hematology	O
and	O
Oncology	O
Department	O
of	O
Medicine	O
Samsung	O
Medical	O
Center	O

South	O
Korea	O
Division	O
of	O
Hematology	O
and	O
Oncology	O
Department	O
of	O
Medicine	O
Samsung	O
Medical	O
Center	O
Sungkyunkwan	O
University	O
School	O
of	O
Medicine	O
81	O
,	O
Irwon	O
-	O
ro	O
,	O
Gangnam	O
-	O
gu	O
06351	O
Seoul	O

South	O
Korea	O
Division	O
of	O
Hematology	O
and	O
Oncology	O
Department	O
of	O
Medicine	O
Samsung	O
Medical	O
Center	O
Sungkyunkwan	O
University	O
School	O
of	O
Medicine	O
81	O
,	O
Irwon	O
-	O
ro	O
,	O
Gangnam	O
-	O
gu	O
06351	O
Seoul	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV)-positive	O
,	O
diffuse	O
large	O
B	O
cell	O
lymphoma	O
(	O
DLBCL	O
)	O
is	O
an	O
EBV	O
-	O
positive	O
,	O
monoclonal	O
,	O
large	O
B	O
cell	O
lymphoproliferative	O
disorder	O
mainly	O
seen	O
in	O
individuals	O
older	O
than	O
50	O
years	O
of	O
age	O
[	O
1,2	O
]	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
EBV	O
-	O
positive	O
DLBCL	O
is	O
mainly	O
correlated	O
with	O
high	O
-	O
intermediate	O
/	O
high	O
International	O
Prognostic	O
Index	O
(	O
IPI	O
)	O
scores	O
,	O
advanced	O
disease	O
stage	O
(	O
III	O
/	O
IV	O
)	O
at	O
diagnosis	O
,	O
and	O
inferior	O
outcomes	O
in	O
comparison	O
with	O
EBV	O
-	O
negative	O
DLBCL	O
[	O
3,4	O
]	O
.	O

This	O
study	O
was	O
an	O
open	B-study_type
-	I-study_type
label	I-study_type
,	I-study_type
single	I-study_type
-	I-study_type
arm	I-study_type
,	I-study_type
prospective	I-study_type
multicenter	I-study_type
clinical	I-study_type
trial	I-study_type
for	O
evaluating	O
the	O
efficacy	O
and	O
toxicity	O
of	O
I	O
-	O
RCHOP	B-arm_description
in	O
subjects	O
with	O
newly	O
diagnosed	O
,	O
chemotherapy	O
-	O
naïve	O
,	O
EBV	O
-	O
positive	O
DLBCL	O
.	O
We	O
defined	O
EBV	O
positivity	O
as	O
a	O
finding	O
of	O
20	O
%	O
or	O
more	O
of	O
EBV	O
-	O
encoded	O
RNA	O
in	O
situ	O
hybridization	O
-	O
positive	O
tumor	O
cells	O
among	O
total	O
tumor	O
cells	O
during	O
pathology	O
evaluation	O
[	O
2	O
]	O
.	O
Ibrutinib	B-arm_description
(	O
560	B-arm_dosage
mg/	I-arm_dosage
day	I-arm_dosage
)	O
was	O
administrated	O
orally	B-arm_dosage
and	O
RCHOP	B-arm_description
(	O
rituximab	B-arm_description
375	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
,	I-arm_dosage
cyclophosphamide	B-arm_description
750	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
,	I-arm_dosage
doxorubicin	B-arm_description
50	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
,	I-arm_dosage
vincristine	B-arm_description
1.4	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
(	I-arm_dosage
maximum	I-arm_dosage
total	I-arm_dosage
of	I-arm_dosage
2	I-arm_dosage
mg	I-arm_dosage
)	I-arm_dosage
on	I-arm_dosage
day	I-arm_dosage
1	I-arm_dosage
and	I-arm_dosage
oral	I-arm_dosage
prednisone	B-arm_description
100	I-arm_dosage
mg	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
-	I-arm_dosage
5	I-arm_dosage
)	O
therapy	O
was	O
administered	O
intravenously	B-arm_dosage
every	I-arm_dosage
21	I-arm_dosage
days	I-arm_dosage
,	O
respectively	O
,	O
until	O
the	O
end	O
of	O
6	B-arm_dosage
cycles	I-arm_dosage
or	O
progression	O
or	O
unacceptable	O
toxicity	O
were	O
observed	O
.	O

Patients	O
had	O
to	O
fulfill	O
the	O
following	O
criteria	O
to	O
be	O
included	O
in	O
this	O
research	O
:	O
(	O
1	O
)	O
histologically	O
confirmed	O
EBV	O
-	O
positive	O
DLBCL	O
without	O
central	O
nervous	O
system	O
involvement	O
;	O
(	O
2	O
)	O
aged	O
19	O
years	O
or	O
older	O
;	O
(	O
3	O
)	O
no	O
previous	O
treatment	O
for	O
DLBCL	O
,	O
although	O
we	O
allowed	O
the	O
usage	O
of	O
prednisolone	B-arm_description
100	O
mg	O
or	O
equivalent	O
dosage	O
of	O
any	O
type	O
of	O
steroid	O
(	O
for	O
a	O
maximum	O
of	O
7	O
days	O
)	O
and	O
radiation	O
for	O
reducing	O
symptoms	O
related	O
with	O
mass	O
effect	O
;	O
(	O
4	O
)	O
one	O
or	O
more	O
measurable	O
lesions	O
;	O
(	O
5	O
)	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
of	O
0	O
to	O
2	O
;	O
and	O
(	O
6	O
)	O
adequate	O
organ	O
function	O
.	O
The	O
exclusion	O
criteria	O
included	O
any	O
life	O
-	O
threatening	O
illness	O
,	O
medical	O
condition	O
,	O
or	O
organ	O
system	O
dysfunction	O
that	O
could	O
compromise	O
the	O
subject	O
's	O
safety	O
,	O
according	O
to	O
the	O
investigator	O
's	O
opinion	O
.	O
Written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
patient	O
prior	O
to	O
study	O
enrollment	O
.	O
This	O
study	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
of	O
each	O
institution	O
and	O
conducted	O
in	O
accordance	O
with	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O
This	O
trial	O
was	O
registered	O
at	O
www.ClinicalTrials.gov	O
as	O
NCT02670616	O
.	O

The	O
primary	O
endpoint	O
of	O
this	O
research	O
was	O
the	O
objective	O
response	O
rate	O
(	O
ORR	O
)	O
based	O
on	O
the	O
proportion	O
of	O
complete	O
response	O
(	O
CR	O
)	O
and	O
partial	O
response	O
(	O
PR	O
)	O
.	O
Secondary	O
endpoints	O
included	O
toxicity	O
,	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
(	O
PFS	B-arm_efficacy_metric
)	O
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
Adverse	O
events	O
(	O
AEs	O
)	O
were	O
assessed	O
according	O
to	O
the	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
version	O
4.0	O
.	O

Between	O
September	O
2016	O
and	O
August	O
2019	O
,	O
24	O
patients	O
were	O
enrolled	O
from	O
10	O
institutes	O
.	O
The	O
cutoff	O
date	O
for	O
analysis	O
was	O
March	O
2019	O
,	O
and	O
the	O
median	O
follow	O
-	O
up	O
period	O
was	O
7.9	O
months	O
,	O
with	O
six	O
death	O
events	O
(	O
25	O
%	O
)	O
.	O
Sixteen	O
patients	O
(	O
67	O
%	O
)	O
finished	O
6	O
cycles	O
of	O
chemotherapy	O
.	O
In	O
the	O
48	O
patients	O
who	O
were	O
confirmed	O
to	O
have	O
EBV	O
-	O
positive	O
DLBCL	O
at	O
Samsung	O
Medical	O
Center	O
for	O
the	O
purpose	O
of	O
the	O
matched	O
case	O
-	O
control	O
study	O
,	O
baseline	O
clinical	O
characteristics	O
were	O
balanced	O
comparatively	O
among	O
both	O
the	O
I	O
-	O
RCHOP	B-arm_description
(	O
n	O
=	O
24	O
)	O
and	O
RCHOP	B-arm_description
(	O
n	O
=	O
24	O
)	O
groups	O
(	O
Table	O
1	O
)	O
.	O
The	O
median	O
ages	O
were	O
58	O
years	O
(	O
range	O
,	O

Median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
(	O
20.6	B-arm_efficacy_results
months	I-arm_efficacy_results
,	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
non	I-arm_efficacy_results
-	I-arm_efficacy_results
evaluable	I-arm_efficacy_results
vs.	O
35.3	B-arm_efficacy_results
months	I-arm_efficacy_results
,	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
0.0	I-arm_efficacy_results
-	I-arm_efficacy_results
86.9	I-arm_efficacy_results
;	I-arm_efficacy_results
p	I-arm_efficacy_results
=	I-arm_efficacy_results
0.46	I-arm_efficacy_results
)	O
and	O
median	O
OS	O
(	O
20.9	O
months	O
,	O
95	O
%	O
CI	O
0.6	O
-	O
41.2	O
vs.	O
48.1	O
months	O
,	O
95	O
%	O
CI	O
NR	O
;	O
p	O
=	O
0.72	O
)	O
according	O
to	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
and	O
RCHOP	B-arm_description
were	O
not	O
significantly	O
different	O
(	O
Fig	O
.	O
2a	O
and	O
b	O
)	O
.	O
Based	O
on	O
the	O
one	O
-	O
year	O
survival	O
analysis	O
,	O
one	O
-	O
year	O
OS	O
(	O
33.3	O
%	O
vs.	O
58.3	O
%	O
;	O
p	O
=	O
0.15	O
)	O
and	O
PFS	B-arm_efficacy_metric
(	O
29.2	B-arm_efficacy_results
%	I-arm_efficacy_results
vs.	O
36.8	B-arm_efficacy_results
%	I-arm_efficacy_results
,	I-arm_efficacy_results
p	I-arm_efficacy_results
=	I-arm_efficacy_results
0.24	I-arm_efficacy_results
)	O
were	O
not	O
correlated	O
with	O
more	O
favorable	O
outcomes	O
in	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
than	O
in	O
RCHOP	B-arm_description
among	O
all	O
patients	O
.	O
In	O
line	O
with	O
age	O
-	O
based	O
case	O
-	O
control	O
comparisons	O
,	O
in	O
patients	O
aged	O
younger	O
than	O
65	O
years	O
,	O
the	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
(	O
NR	B-arm_efficacy_results
vs.	O
92.2	B-arm_efficacy_results
months	I-arm_efficacy_results
,	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
9.8	I-arm_efficacy_results
-	I-arm_efficacy_results
176.0	I-arm_efficacy_results
;	I-arm_efficacy_results
p	I-arm_efficacy_results
=	I-arm_efficacy_results
0.68	I-arm_efficacy_results
)	O
and	O
OS	O
(	O
NR	O
vs.	O
NR	O
;	O
p	O
=	O
0.45	O
)	O
showed	O
a	O
superior	O
tendency	O
in	O
the	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
group	O
(	O
Fig	O
.	O
2c	O
and	O
d	O
)	O
.	O
In	O
patients	O
aged	O
older	O
than	O
65	O
years	O
,	O
the	O
survival	O
benefit	O
was	O
lower	O
in	O
the	O
I	O
-	O
RCHOP	O
group	O
because	O
of	O
the	O
large	O
number	O
of	O
patients	O
terminated	O
during	O
the	O
initial	O
treatment	O
(	O
Figs	O
.	O
2e	O
,	O
f	O
,	O
and	O
3	O
)	O
.	O

Weekly	O
platinum	O
-	O
based	O
chemotherapy	O
versus	O
3-weekly	O
platinum	O
-	O
based	O
chemotherapy	O
for	O
newly	O
diagnosed	O
ovarian	O
cancer	O
(	O
ICON8	O
)	O
:	O
quality	O
-	O
of	O
-	O
life	O
results	O
of	O
a	O
phase	B-study_type
3	I-study_type
,	I-study_type
randomised	I-study_type
,	I-study_type
controlled	I-study_type
trial	I-study_type
Weekly	O
platinum	O
-	O
based	O
chemotherapy	O
versus	O
3-weekly	O
platinum	O
-	O
based	O
chemotherapy	O
for	O
newly	O
diagnosed	O
ovarian	O
cancer	O
(	O
ICON8	O
)	O
:	O
quality	O
-	O
of	O
-	O
life	O
results	O
of	O
a	O
phase	B-study_type
3	I-study_type
,	I-study_type
randomised	I-study_type
,	I-study_type
controlled	I-study_type
trial	I-study_type
21	O
July	O
2020	O
21	O
July	O
2020	O
MScAdrianDCook	B-authors

Weekly	O
platinum	O
-	O
based	O
chemotherapy	O
versus	O
3-weekly	O
platinum	O
-	O
based	O
chemotherapy	O
for	O
newly	O
diagnosed	O
ovarian	O
cancer	O
(	O
ICON8	O
)	O
:	O
quality	O
-	O
of	O
-	O
life	O
results	O
of	O
a	O
phase	B-study_type
3	I-study_type
,	I-study_type
randomised	I-study_type
,	I-study_type
controlled	I-study_type
trial	I-study_type

Jane	B-authors
Hook	I-authors
,	O
Elizabeth	B-authors
C	I-authors
James	I-authors
,	O
Ian	B-authors
R	I-authors
White	I-authors
,	O
Timothy	B-authors
Perren	I-authors
,	O
Rosemary	B-authors
Lord	I-authors
,	O
Graham	O
Dark	O
,	O
Helena	B-authors
M	I-authors
Earl	I-authors
,	O
Marcia	B-authors
Hall	I-authors
,	O
Richard	B-authors
Kaplan	I-authors
,	O
Jonathan	B-authors
A	I-authors
Ledermann	I-authors
Andrew	B-authors
R	I-authors
Clamp	I-authors

Weekly	O
platinum	O
-	O
based	O
chemotherapy	O
versus	O
3-weekly	O
platinum	O
-	O
based	O
chemotherapy	O
for	O
newly	O
diagnosed	O
ovarian	O
cancer	O
(	O
ICON8	O
)	O
:	O
quality	O
-	O
of	O
-	O
life	O
results	O
of	O
a	O
phase	B-study_type
3	I-study_type
,	I-study_type
randomised	I-study_type
,	I-study_type
controlled	I-study_type
trial	I-study_type
MScAdrianDCook	B-authors
MScAdrianDCook	B-authors
MSc	B-authors
Adrian	I-authors
D	I-authors
Cook	I-authors
MScECJames	B-authors
MScECJames	B-authors
MSc	O
E	B-authors
C	I-authors
James	I-authors
ProfIRWhite	B-authors
ProfIRWhite	B-authors
Prof	O
I	B-authors
R	I-authors
White	I-authors
JHook	B-authors
JHook	B-authors
J	B-authors
Hook	I-authors
MBBchir	B-authors
MBBchir	B-authors
M	O
B	B-authors
Bchir	I-authors
DrSarahPBlagden	B-authors
sarah.blagden@oncology.ox.ac.uk	O

Prof	O
C	O
Poole	O
MB	O
BChir	O
)	O
;	O
Maggie	O
Keswick	O
Jencks	O
Cancer	O
Caring	O
Centres	O
Trust	O
,	O
London	O
,	O
UK	O
(	O
L	O
Howells	O
M	O
App	O
Sci	O
)	O
;	O
Ovarian	O
Cancer	O
Action	O
Research	O
Centre	O
University	O
Hospital	O
Coventry	O
Imperial	O
College	O
London	O
Perth	O

Prof	O
C	O
Poole	O
MB	O
BChir	O
)	O
;	O
Maggie	O
Keswick	O
Jencks	O
Cancer	O
Caring	O
Centres	O
Trust	O
,	O
London	O
,	O
UK	O
(	O
L	O
Howells	O
M	O
App	O
Sci	O
)	O
;	O
Ovarian	O
Cancer	O
Action	O
Research	O
Centre	O
University	O
Hospital	O
Coventry	O
Imperial	O
College	O
London	O
Perth	O

UK	O
Prof	O
T	B-authors
Perren	I-authors
MD	O
)	O
Department	O
of	O
Oncology	O
,	O
Clatterbridge	O
Cancer	O
Centre	O
Department	O
of	O
Oncology	O
Department	O
of	O
Medical	O
Oncology	O
(	O
Prof	O
M	B-authors
Hall	I-authors
PhD	O
)	O
;	O
UCL	O
Cancer	O
Centre	O
Institute	O
G	B-authors
Dark	I-authors
MBBS	O
)	O
;	O
NIHR	O
Cambridge	O
Biomedical	O
Research	O
Centre	O
,	O
Cambridge	O
,	O
UK	O
(	O
Prof	O
H	B-authors
M	I-authors
Earl	I-authors
PhD	O
Newcastle	O
University	O
Mount	O
Vernon	O
Cancer	O
Centre	O
Newcastle	O

UK	O
OX3	O
7LE	O
Oxford	O
UK	O
Weekly	O
platinum	O
-	O
based	O
chemotherapy	O
versus	O
3-weekly	O
platinum	O
-	O
based	O
chemotherapy	O
for	O
newly	O
diagnosed	O
ovarian	O
cancer	O
(	O
ICON8	O
)	O
:	O
quality	O
-	O
of	O
-	O
life	O
results	O
of	O
a	O
phase	B-study_type
3	I-study_type
,	I-study_type
randomised	I-study_type
,	I-study_type
controlled	I-study_type
trial	I-study_type
21	O
July	O
2020	O
21	O
July	O
2020	O
21	O
July	O
2020	O

To	O
our	O
knowledge	O
,	O
ICON8	O
is	O
the	O
largest	O
study	O
to	O
date	O
of	O
weekly	O
treatment	O
for	O
primary	O
ovarian	O
cancer	O
.	O
The	O
study	O
showed	O
no	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
advantage	O
for	O
patients	O
receiving	O
dosedense	O
paclitaxel	O
-	O
containing	O
chemotherapy	O
compared	O
with	O
3-weekly	O
carboplatin	O
and	O
paclitaxel	O
.	O
The	O
quality	O
-	O
of	O
-	O
life	O
results	O
show	O
that	O
,	O
although	O
the	O
global	O
quality	O
of	O
life	O
of	O
patients	O
was	O
similar	O
between	O
the	O
three	O
treatment	O
groups	O
at	O
9	O
months	O
,	O
those	O
receiving	O
dose	O
-	O
dense	O
paclitaxel	O
had	O
poorer	O
quality	O
of	O
life	O
during	O
chemotherapy	O
treatment	O
,	O
with	O
more	O
severe	O
peripheral	O
neuropathy	O
that	O
lasted	O
for	O
up	O
to	O
18	O
months	O
.	O

In	O
the	O
UK	O
,	O
ethical	O
approval	O
was	O
granted	O
by	O
the	O
London	O
-	O
Chelsea	O
research	O
ethics	O
committee	O
.	O
The	O
trial	O
also	O
received	O
ethical	O
approval	O
from	O
appropriate	O
national	O
or	O
local	O
institutional	O
review	O
boards	O
in	O
other	O
jurisdictions	O
.	O
The	O
protocol	O
can	O
be	O
found	O
online	O
.	O

The	O
sample	O
size	O
of	O
ICON8	O
was	O
determined	O
to	O
detect	O
a	O
hazard	O
ratio	O
of	O
0•75	O
in	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
between	O
groups	B-arm_description
1	I-arm_description
and	O
2	B-arm_description
,	O
and	O
groups	B-arm_description
1	I-arm_description
and	O
3	B-arm_description
,	O
with	O
two	O
-	O
sided	O
2•5	O
%	O
significance	O
and	O
90	O
%	O
power	O
.	O
For	O
quality	O
of	O
life	O
,	O
a	O
retrospective	O
power	O
calculation	O
showed	O
that	O
the	O
study	O
had	O
90	O
%	O
power	O
to	O
detect	O
a	O
difference	O
between	O
groups	O
of	O
5	O
points	O
in	O
global	O
quality	O
of	O
life	O
using	O
the	O
SD	O
observed	O
in	O
group	B-arm_description
1	I-arm_description
.	O
The	O
quality	O
-	O
of	O
-	O
life	O
study	O
adhered	O
to	O
the	O
null	O
hypothesis	O
of	O
the	O
main	O
ICON8	O
study	O
-	O
no	O
expected	O
difference	O
in	O
quality	O
of	O
life	O
between	O
the	O
three	O
randomised	O
treatment	O
groups	O
.	O
A	O
quality	O
-	O
of	O
-	O
life	O
expert	O
panel	O
(	O
comprised	O
of	O
LH	O
,	O
CP	O
,	O
SPB	O
,	O
and	O
RK	O
)	O
,	O
invited	O
by	O
the	O
trial	O
management	O
group	O
,	O
convened	O
on	O
June	O
9	O
,	O
2016	O
,	O
to	O
define	O
the	O
primary	O
,	O
secondary	O
,	O
and	O
exploratory	O
endpoints	O
.	O

It	O
is	O
also	O
the	O
timepoint	O
in	O
ICON8	O
at	O
which	O
follow	O
-	O
up	O
,	O
and	O
hence	O
data	O
collection	O
,	O
changed	O
from	O
6-weekly	O
to	O
3-monthly	O
.	O
The	O
co	O
-	O
primary	O
endpoints	O
of	O
cross	O
-	O
sectional	O
and	O
longitudinal	O
changes	O
in	O
global	O
health	O
score	O
are	O
complementary	O
-	O
longitudinal	O
analysis	O
compares	O
patient	O
experience	O
across	O
the	O
whole	O
9-month	O
period	O
and	O
crosssectional	O
analysis	O
compares	O
scores	O
at	O
the	O
9-month	O
timepoint	O
.	O
Thus	O
,	O
longitudinal	O
analysis	O
makes	O
better	O
use	O
of	O
the	O
data	O
and	O
is	O
the	O
preferred	O
method	O
,	O
whereas	O
crosssectional	O
analysis	O
provides	O
a	O
post	O
-	O
treatment	O
snapshot	O
.	O

We	O
assessed	O
the	O
potential	O
effect	O
of	O
missing	O
data	O
on	O
the	O
co	O
-	O
primary	O
outcome	O
using	O
imputation	O
to	O
model	O
the	O
following	O
scenarios	O
:	O
scenario	O
1	O
,	O
a	O
global	O
score	O
of	O
0	O
was	O
imputed	O
for	O
patients	O
who	O
died	O
within	O
9	O
months	O
of	O
enrolment	O
;	O
scenarios	O
2	O
-	O
4	O
,	O
all	O
patients	O
alive	O
and	O
without	O
progression	O
at	O
9	O
months	O
but	O
missing	O
quality	O
-	O
of	O
-	O
life	O
data	O
were	O
assigned	O
a	O
score	O
,	O
starting	O
respectively	O
with	O
the	O
mean	O
9-month	O
score	O
,	O
then	O
the	O
mean	O
score	O
minus	O
10	O
points	O
,	O
then	O
mean	O
minus	O
20	O
;	O
scenario	O
5	O
,	O
a	O
global	O
score	O
of	O
0	O
was	O
imputed	O
for	O
patients	O
who	O
died	O
within	O
9	O
months	O
,	O
all	O
other	O
patients	O
(	O
including	O
those	O
with	O
disease	O
progression	O
)	O
with	O
a	O
baseline	O
global	O
quality	O
-	O
of	O
-	O
life	O
score	O
but	O
missing	O
their	O
9-month	O
global	O
quality	O
-	O
of	O
-	O
life	O
score	O
were	O
assigned	O
the	O
mean	O
9-month	O
score	O
.	O
The	O
rationale	O
for	O
scenarios	O
2	O
-	O
4	O
was	O
that	O
patients	O
might	O
have	O
missed	O
submitting	O
their	O
questionnaires	O
due	O
to	O
illness	O
,	O
in	O
which	O
case	O
a	O
lower	O
quality	O
of	O
life	O
would	O
be	O
expected	O
.	O
All	O
analyses	O
were	O
done	O
on	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
with	O
Stata	O
version	O
15.0	O
.	O
The	O
trial	O
is	O
registered	O
on	O
ClinicalTrials.gov	O
,	O
NCT01654146	O
and	O
ISRCTN	O
Registry	O
,	O
ISRCTN10356387	O
.	O

We	O
observed	O
evidence	O
of	O
better	O
emotional	O
functioning	O
(	O
QLQ	O
-	O
C30	O
)	O
with	O
weekly	O
treatment	O
(	O
group	B-arm_description
3	I-arm_description
)	O
than	O
with	O
3-weekly	O
treatment	O
(	O
group	B-arm_description
1	I-arm_description
)	O
using	O
cross	O
-	O
sectional	O
analysis	O
;	O
however	O
,	O
it	O
did	O
not	O
meet	O
the	O
threshold	O
for	O
clinical	O
significance	O
(	O
table	O
3	O
;	O
figure	O
2	O
)	O
.	O
Longitudinal	O
analysis	O
revealed	O
no	O
significant	O
differences	O
in	O
emotional	O
functioning	O
between	O
study	O
groups	O
(	O
table	O
3	O
;	O
figure	O
2	O
)	O
.	O
We	O
found	O
no	O
difference	O
in	O
social	O
functioning	O
(	O
QLQ	O
-	O
C30	O
)	O
between	O
treatment	O
groups	O
using	O
either	O
cross	O
-	O
sectional	O
or	O
longitudinal	O
analyses	O
(	O
table	O
3	O
;	O
figure	O
2	O
)	O
.	O
We	O
observed	O
no	O
difference	O
in	O
fatigue	O
(	O
QLQ	O
-	O
C30	O
)	O
between	O
groups	O
by	O
cross	O
-	O
sectional	O
analysis	O
;	O
although	O
fatigue	O
scores	O
were	O
significantly	O
different	O
between	O
the	O
weekly	O
(	O
group	B-arm_description
2	I-arm_description
)	O
and	O
3-weekly	O
(	O
group	B-arm_description
1	I-arm_description
)	O
treatment	O
groups	O
by	O
longitudinal	O
analysis	O
,	O
they	O
did	O
not	O
meet	O
the	O
threshold	O
for	O
clinical	O
signifi	O
cance	O
(	O
table	O
3	O
;	O
figure	O
2	O
)	O
.	O
By	O
cross	O
-	O
sectional	O
analysis	O
,	O
peripheral	O
neuropathy	O
scores	O
(	O
QLQ	O
-	O
OV28	O
)	O
were	O
statisti	O
cally	O
and	O
clinically	O
significantly	O
different	O
between	O
group	B-arm_description
2	I-arm_description
and	O
group	B-arm_description
1	I-arm_description
;	O
however	O
,	O
there	O
was	O
no	O
difference	O
by	O
longitudinal	O
analysis	O
(	O
table	O
3	O
;	O
figure	O
2	O
)	O
.	O
Data	O
are	O
n	O
(	O
%	O
)	O
,	O
mean	O
(	O
SD	O
)	O
,	O
or	O
mean	O
(	O
95	O
%	O
CI	O
)	O
,	O
unless	O
otherwise	O
indicated	O
.	O
Group	B-arm_description
1	I-arm_description
=	O
standard	O
three	O
-	O
weekly	O
carboplatin	O
and	O
paclitaxel	O
.	O
Group	B-arm_description
2	I-arm_description
=	O
three	O
-	O
weekly	O
carboplatin	O
and	O
weekly	O
dose	O
-	O
dense	O
paclitaxel	O
.	O
Group	B-arm_description
3	I-arm_description
=	O
weekly	O
carboplatin	O
and	O
weekly	O
dose	O
-	O
dense	O
paclitaxel	O
.	O
*	O
From	O
area	O
under	O
the	O
curve	O
,	O
calculated	O
from	O
mixed	O
effects	O
regression	O
model	O
.	O
†Adjusted	O
for	O
baseline	O
.	O

We	O
did	O
a	O
post	O
-	O
hoc	O
analysis	O
to	O
assess	O
concordance	O
between	O
self	O
-	O
reported	O
peripheral	O
neuropathy	O
from	O
the	O
quality	O
-	O
of	O
-	O
life	O
questionnaires	O
and	O
clinician	O
-	O
assessed	O
peripheral	O
neuropathy	O
reported	O
during	O
the	O
treatment	O
period	O
;	O
there	O
was	O
good	O
agreement	O
between	O
the	O
measures	O
(	O
appendix	O
p	O
12	O
)	O
.	O
Sensitivity	O
analyses	O
to	O
assess	O
the	O
potential	O
effect	O
of	O
missing	O
data	O
did	O
not	O
alter	O
our	O
interpretation	O
of	O
the	O
data	O
(	O
appendix	O
p	O
13	O
)	O
.	O

Adjuvant	O
intensity	O
modulated	O
wholeabdominal	B-arm_description
radiation	I-arm_description
therapy	I-arm_description
for	O
high	O
-	O
risk	O
patients	O
with	O
ovarian	O
cancer	O
FIGO	O
stage	O
III	O
:	O
final	O
results	B-study_type
of	I-study_type
a	I-study_type
prospective	I-study_type
phase	I-study_type
2	I-study_type
study	I-study_type

Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Klinikum	O
Hanau	O
,	O
Academic	O
Teaching	O
Hospital	O
of	O
the	O
Medical	O
Faculty	O
of	O
the	O
Goethe	O
University	O
of	O
Frankfurt	O
/	O
Main	O
Hanau	O
Germany	O
SonjaKatayama	B-authors
2,3,6,7	O

Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Klinikum	O
Hanau	O
,	O
Academic	O
Teaching	O
Hospital	O
of	O
the	O
Medical	O
Faculty	O
of	O
the	O
Goethe	O
University	O
of	O
Frankfurt	O
/	O
Main	O
Hanau	O
Germany	O
SonjaKatayama	B-authors
2,3,6,7	O

Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Klinikum	O
Hanau	O
,	O
Academic	O
Teaching	O
Hospital	O
of	O
the	O
Medical	O
Faculty	O
of	O
the	O
Goethe	O
University	O
of	O
Frankfurt	O
/	O
Main	O
Hanau	O

Germany	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Klinikum	O
Hanau	O
,	O
Academic	O
Teaching	O
Hospital	O
of	O
the	O
Medical	O
Faculty	O
of	O
the	O
Goethe	O
University	O
of	O
Frankfurt	O
/	O
Main	O
Hanau	O

First	O
-	O
line	O
treatment	O
of	O
advanced	O
ovarian	O
cancer	O
patients	O
consists	O
of	O
radical	O
cytoreductive	O
surgery	O
(	O
"	O
no	O
residual	O
tumor	O
"	O
)	O
and	O
a	O
platinum	O
-	O
and	O
taxane	O
-	O
based	O
chemotherapy	O
(	O
6	O
cycles	O
of	O
platinum	O
-	O
based	O
chemotherapy	O
in	O
combination	O
with	O
paclitaxel	O
175	O
mg	O
/	O
m	O
2	O
)	O
[	O
5][6][7][8][9][10][11][12][13][14][15][16][17][18	O
]	O
.	O
Simultaneous	O
followed	O
by	O
consolidative	O
administration	O
of	O
bevacizumab	O
for	O
12	O
-	O
15	O
months	O
can	O
be	O
considered	O
in	O
stage	O
IIIB	O
-	O
IV	O
patients	O
with	O
high	O
risk	O
for	O
recurrence	O
,	O
accepting	O
reduced	O
quality	O
of	O
life	O
[	O
19][20][21	O
]	O
.	O

We	O
enrolled	O
15	O
patients	O
with	O
GBM	O
or	O
variants	O
in	O
Stage	O
1	O
(	O
Table	O
1	O
)	O
between	O
July	O
2015	O
and	O
June	O
2017	O
.	O
Median	O
age	O
was	O
61	O
(	O
range	O
27	O
-	O
74	O
)	O
and	O
median	O
KPS	O
was	O
80	O
(	O
range	O
70	O
-	O
90	O
)	O
.	O
The	O
median	O
number	O
of	O
prior	O
therapies	O
was	O
2	O
(	O
range	O
2	O
-	O
4	O
)	O
and	O
the	O
median	O
time	O
between	O
last	O
bevacizumab	O
dose	O
and	O
first	O
ponatinib	B-arm_description
dose	O
was	O
34	O
days	O
(	O
range	O
20	O
-	O
92	O
)	O
.	O
At	O
the	O
time	O
of	O
study	O
enrollment	O
,	O
GBM	O
with	O
oligodendroglial	O
features	O
(	O
GBMO	O
)	O
was	O
a	O
recognized	O
GBM	O
variant	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
Classification	O
of	O
Tumors	O
.	O
Upon	O
central	O
review	O
,	O
one	O
patient	O
had	O
a	O
GBMO	O
with	O
1p/19q	O
loss	O
(	O
which	O
would	O
be	O
classified	O
as	O
an	O
anaplastic	O
oligodendroglioma	O
by	O
updated	O
WHO	O
2016	O
criteria	O
15	O
)	O
.	O

As	O
none	O
of	O
the	O
patients	O
achieved	O
PFS3	B-arm_efficacy_metric
,	O
the	O
study	O
was	O
permanently	O
closed	O
after	O
the	O
first	O
stage	O
(	O
Table	O
2	O
)	O
.	O
The	O
longest	O
time	O
to	O
progression	O
observed	O
was	O
84	O
days	O
.	O
Median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
was	O
28	B-arm_efficacy_results
days	I-arm_efficacy_results
[	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
27	I-arm_efficacy_results
,	I-arm_efficacy_results
30	I-arm_efficacy_results
]	I-arm_efficacy_results
and	O
median	O
OS	O
was	O
98	O
days	O
[	O
95	O
%	O
CI	O
56	O
,	O
257	O
]	O
.	O
There	O
were	O
no	O
complete	O
or	O
partial	O
responses	O
seen	O
and	O
SD	O
was	O
the	O
best	O
response	O
in	O
two	O
patients	O
(	O
13.7	O
%	O
)	O
.	O
Toxicities	O
on	O
study	O
were	O
as	O
expected	O
for	O
ponatinib	B-arm_description
with	O
fatigue	O
,	O
increased	O
lipase	O
,	O
and	O
hypertension	O
as	O
the	O
most	O
common	O
AEs	O
(	O
Table	O
3	O
)	O
.	O
Two	O
patients	O
were	O
dose	O
reduced	O
,	O
one	O
due	O
to	O
grade	O
3	O
lipase	O
and	O
the	O
other	O
due	O
to	O
recurrent	O
grade	O
2	O
diarrhea	O
.	O
One	O
patient	O
was	O
taken	O
off	O
study	O
due	O
to	O
unacceptable	O
toxicity	O
(	O
grade	O
3	O
bullous	O
dermatitis	O
occurring	O
during	O
the	O
first	O
cycle	O
)	O
.	O
Another	O
patient	O
withdrew	O
consent	O
from	O
study	O
participation	O
,	O
also	O
during	O
the	O
first	O
cycle	O
of	O
treatment	O
.	O

LEE	B-authors
Et	O
aL	O
comparative	O
genomic	O
hybridization	O
harbored	O
evidence	O
of	O
FGFR	O
-	O
TACC	O
fusions	O
.	O
In	O
summary	O
,	O
ponatinib	B-arm_description
has	O
limited	O
efficacy	O
in	O
patients	O
with	O
bevacizumab	O
-	O
resistant	O
GBM	O
.	O
The	O
circulating	O
biomarker	O
data	O
suggest	O
that	O
immunomodulation	O
may	O
have	O
played	O
a	O
role	O
in	O
resistance	O
to	O
treatment	O
,	O
although	O
further	O
studies	O
are	O
needed	O
to	O
clarify	O
the	O
interplay	O
between	O
angiogenesis	O
and	O
these	O
immune	O
cytokines	O
.	O
It	O
is	O
unclear	O
if	O
ponatinib	O
could	O
be	O
beneficial	O
in	O
bevacizumab	O
-	O
naïve	O
patients	O
or	O
in	O
patients	O
whose	O
GBM	O
harbors	O
a	O
FGFR	O
-	O
TACC	O
fusion	O
as	O
neither	O
of	O
these	O
populations	O
were	O
examined	O
in	O
this	O
study	O
.	O
Given	O
ponatinib	B-arm_description
's	O
cumulative	O
cardiovascular	O
toxicity	O
,	O
potentially	O
limited	O
penetration	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
and	O
the	O
recent	O
drug	O
development	O
of	O
selective	O
brain	O
penetrant	O
FGFR	O
inhibitors	O
,	O
further	O
evaluation	O
of	O
ponatinib	B-arm_description
in	O
GBMs	O
with	O
FGFR	O
-	O
TACC	O
fusion	O
is	O
not	O
recommended	O
.	O

Daratumumab	O
plus	O
bortezomib	O
,	O
melphalan	O
,	O
and	O
prednisone	O
in	O
East	O
Asian	O
patients	O
with	O
non	O
-	O
transplant	O
multiple	O
myeloma	O
:	O
subanalysis	O
of	O
the	O
randomized	B-study_type
phase	I-study_type
3	I-study_type
ALCYONE	I-study_type
trial	I-study_type
Daratumumab	O
plus	O
bortezomib	O
,	O
melphalan	O
,	O
and	O
prednisone	O
in	O
East	O
Asian	O
patients	O
with	O
non	O
-	O
transplant	O
multiple	O
myeloma	O
:	O
subanalysis	O
of	O
the	O
randomized	B-study_type
phase	I-study_type
3	I-study_type
ALCYONE	I-study_type
trial	I-study_type
16	O
October	O
2019	O
16	O
October	O
2019	O
TomoakiFujisaki	B-authors

Daratumumab	O
plus	O
bortezomib	O
,	O
melphalan	O
,	O
and	O
prednisone	O
in	O
East	O
Asian	O
patients	O
with	O
non	O
-	O
transplant	O
multiple	O
myeloma	O
:	O
subanalysis	O
of	O
the	O
randomized	B-study_type
phase	I-study_type
3	I-study_type
ALCYONE	I-study_type
trial	I-study_type
16	O
October	O
2019	O

Japan	O
67	O
Asahi	O
-	O
machi	O
830	O
-	O
0011	O
Kurume	O
Japan	O
Daratumumab	O
plus	O
bortezomib	O
,	O
melphalan	O
,	O
and	O
prednisone	O
in	O
East	O
Asian	O
patients	O
with	O
non	O
-	O
transplant	O
multiple	O
myeloma	O
:	O
subanalysis	O
of	O
the	O
randomized	B-study_type
phase	I-study_type
3	I-study_type
ALCYONE	I-study_type
trial	I-study_type
16	O
October	O
2019	O
16	O
October	O
2019	O
16	O
October	O
2019	O
10.1007	O
/	O
s00277	O
-	O
019	O
-	O
03794	O
-	O
9	O
Received	O
:	O
19	O
August	O
2019	O
/	O
Accepted	O
:	O
29	O
August	O
2019	O
#	O
The	O
Author(s	O
)	O
2019	O

Bortezomib	O
,	O
melphalan	O
,	O
and	O
prednisone	O
(	O
VMP	O
)	O
was	O
approved	O
based	O
on	O
the	O
VISTA	O
trial	O
in	O
non	O
-	O
transplant	O
newly	O
diagnosed	O
multiple	O
myeloma	O
(	O
NDMM	O
)	O
patients	O
and	O
remains	O
as	O
one	O
of	O
several	O
standard	O
-	O
of	O
-	O
care	O
regimens	O
for	O
non	O
-	O
transplant	O
NDMM	O
[	O
14	O
]	O
.	O
The	O
randomized	O
,	O
open	O
-	O
label	O
,	O
phase	O
3	O
ALCYONE	O
study	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
daratumumab	O
in	O
combination	O
with	O
VMP	O
(	O
D	O
-	O
VMP	O
)	O
versus	O
VMP	O
alone	O
in	O
patients	O
with	O
NDMM	O
who	O
were	O
considered	O
ineligible	O
for	O
autologous	O
stem	O
cell	O
transplantation	O
(	O
ASCT	O
)	O
[	O
15	O
]	O
.	O
Interim	O
results	O
that	O
were	O
reported	O
after	O
a	O
median	O
follow	O
-	O
up	O
of	O
16.5	O
months	O
showed	O
a	O
significant	O
improvement	O
in	O
the	O
primary	O
endpoint	O
of	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
with	O
D	O
-	O
VMP	O
versus	O
VMP	O
,	O
along	O
with	O
significant	O
improvements	O
in	O
response	O
and	O
minimal	O
residual	O
disease	O
(	O
MRD)-negativity	O
rates	O
at	O
a	O
10	O
−5	O
sensitivity	O
threshold	O
.	O
Overall	O
,	O
D	O
-	O
VMP	O
was	O
associated	O
with	O
a	O
toxicity	O
profile	O
similar	O
to	O
that	O
of	O
VMP	O
;	O
while	O
grade	O
3	O
and	O
4	O
infections	O
were	O
more	O
commonly	O
seen	O
with	O
D	O
-	O
VMP	O
relative	O
to	O
VMP	O
alone	O
,	O
rates	O
of	O
discontinuations	O
due	O
to	O
infection	O
were	O
comparable	O
(	O
0.9	O
%	O
vs	O
1.4	O
%	O
for	O
D	O
-	O
VMP	O
and	O
VMP	O
,	O
respectively	O
)	O
.	O
Based	O
on	O
these	O
results	O
,	O
D	O
-	O
VMP	O
has	O
been	O
approved	O
in	O
the	O
USA	O
,	O
European	O
Union	O
,	O
and	O
Brazil	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
NDMM	O
who	O
are	O
ineligible	O
for	O
ASCT	O
[	O
12	O
]	O
.	O

Analysis	O
populations	O
in	O
ALCYONE	O
included	O
intent	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
and	O
safety	O
populations	O
.	O
The	O
ITT	O
population	O
was	O
defined	O
as	O
all	O
patients	O
randomized	O
into	O
the	O
study	O
.	O
This	O
population	O
was	O
used	O
for	O
all	O
primary	O
efficacy	O
endpoints	O
,	O
key	O
secondary	O
endpoints	O
,	O
and	O
all	O
analyses	O
of	O
disposition	O
,	O
demographic	O
,	O
and	O
baseline	O
disease	O
characteristics	O
.	O
The	O
safety	O
population	O
included	O
all	O
treated	O
patients	O
who	O
had	O
at	O
least	O
1	O
administration	O
of	O
study	O
drug	O
and	O
was	O
used	O
for	O
all	O
safety	O
analyses	O
and	O
all	O
analyses	O
of	O
treatment	O
compliance	O
and	O
exposure	O
.	O
East	O
Asian	O
patients	O
from	O
the	O
ITT	O
and	O
safety	O
populations	O
of	O
ALCYONE	O
were	O
used	O
for	O
this	O
report	O
.	O

Lung	O
cancer	O
is	O
the	O
most	O
common	O
type	O
of	O
cancer	O
and	O
the	O
leading	O
cause	O
of	O
cancer	O
death	O
.	O
[	O
1	O
]	O
Non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
accounts	O
for	O
75	O
%	O
to80	O
%	O
of	O
lung	O
cancer	O
,	O
and	O
the	O
5-year	O
survival	O
rate	O
is	O
about	O
15	O
%	O
.	O
[	O
2	O
]	O
The	O
main	O
pathological	O
types	O
of	O
NSCLC	O
are	O
adenocarcinoma	O
(	O
32	O
%	O
-40	O
%	O
)	O
,	O
squamous	O
cell	O
carcinoma	O
(	O
25	O
%	O
-30	O
%	O
)	O
,	O
and	O
large	O
cell	O
carcinoma	O
(	O
8	O
%	O
-16	O
%	O
)	O
.	O
[	O
3	O
]	O
About	O
70	O
%	O
of	O
lung	O
cancer	O
patients	O
are	O
at	O
an	O
advanced	O
stage	O
when	O
they	O
are	O
first	O
diagnosed	O
,	O
and	O
surgery	O
therapy	O
is	O
n't	O
available	O
for	O
which	O
.	O
Chemotherapy	O
,	O
radiotherapy	O
,	O
targeted	O
therapy	O
,	O
and	O
immunotherapy	O
can	O
be	O
selected	O
as	O
treatments	O
for	O
stage	O
IIIB	O
/	O
IV	O
NSCLC	O
,	O
platinum	O
-	O
based	O
doublets	O
chemotherapy	O
is	O
the	O
main	O
option	O
among	O
which	O
.	O
However	O
,	O
the	O
effective	O
rate	O
of	O
each	O
chemotherapy	O
regimen	O
varies	O
from	O
20	O
%	O
to	O
30	O
%	O
,	O
and	O
progress	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
is	O
only	O
a	O
few	O
months	O
.	O
[	O
4][5][6	O
]	O
Also	O
,	O
adverse	O
events	O
such	O
as	O
marrow	O
suppression	O
,	O
nausea	O
,	O
vomiting	O
can	O
decrease	O
the	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
of	O
patients	O
.	O
[	O
7	O
]	O
It	O
is	O
necessary	O
to	O
find	O
an	O
effective	O
and	O
safe	O
treatment	O
for	O
advanced	O
NSCLC	O
.	O

Initially	O
,	O
many	O
elderly	O
patients	O
with	O
advanced	O
lung	O
cancer	O
chose	O
Cancer	O
Green	O
Therapy	O
(	O
cryoablation	O
combined	O
with	O
TCM	O
)	O
for	O
better	O
QOL	O
.	O
However	O
,	O
we	O
found	O
that	O
the	O
survival	O
was	O
longer	O
than	O
that	O
we	O
had	O
expected	O
during	O
the	O
follow	O
-	O
up	O
visit	O
.	O
Later	O
,	O
we	O
conducted	O
a	O
retrospective	O
analysis	O
and	O
screened	O
186	O
patients	O
who	O
underwent	O
cryoablation	O
plus	O
TCM	O
in	O
our	O
department	O
between	O
2005	O
and	O
2013	O
.	O
119	O
cases	O
were	O
followed	O
up	O
in	O
2014	O
.	O
Among	O
them	O
,	O
82	O
cases	O
were	O
advanced	O
NSCLC	O
patients	O
,	O
the	O
average	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
them	O
is	O
18	O
months	O
,	O
almost	O
double	O
as	O
that	O
in	O
NCCN	O
guidelines	O
(	O
8	O
-	O
10	O
months	O
)	O
.	O
[	O
19,20	O
]	O
The	O
present	O
multi	B-study_type
-	I-study_type
center	I-study_type
,	I-study_type
prospective	I-study_type
,	I-study_type
randomized	I-study_type
controlled	I-study_type
trial	I-study_type
is	O
designed	O
to	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
Cancer	O
Green	O
Therapy	O
(	O
cryoablation	B-arm_description
combined	I-arm_description
with	I-arm_description
TCM	I-arm_description
)	O
,	O
setting	O
chemotherapy	B-arm_description
as	I-arm_description
the	I-arm_description
control	I-arm_description
treatment	I-arm_description
.	O
We	O
hope	O
that	O
,	O
through	O
this	O
rigorously	O
designed	O
study	O
,	O
we	O
can	O
provide	O
scientific	O
and	O
objective	O
assessments	O
for	O
the	O
efficacy	O
and	O
safety	O
of	O
cryoablation	B-arm_description
combined	I-arm_description
with	I-arm_description
TCM	I-arm_description
for	O
stage	O
IIIB	O
/	O
IV	O
NSCLC	O
patients	O
and	O
possibly	O
offer	O
the	O
world	O
an	O
alternative	O
treatment	O
.	O

The	O
trial	O
is	O
a	O
multi	B-study_type
-	I-study_type
center	I-study_type
,	I-study_type
prospective	I-study_type
,	I-study_type
randomized	I-study_type
controlled	I-study_type
trial	I-study_type
.	O
The	O
flowchart	O
of	O
the	O
study	O
is	O
presented	O
in	O
Figure	O
1	O
.	O

(	O
2	O
)	O
Objective	O
remission	O
rate	O
(	O
ORR	O
)	O
:	O
Enhanced	O
CT	O
of	O
the	O
chest	O
will	O
be	O
performed	O
at	O
the	O
baseline	O
period	O
and	O
the	O
end	O
of	O
therapy	O
.	O
The	O
therapeutic	O
effect	O
will	O
be	O
evaluated	O
as	O
complete	O
response	O
(	O
CR	O
)	O
,	O
partial	O
response	O
(	O
PR	O
)	O
,	O
stability	O
disease	O
(	O
SD	O
)	O
,	O
and	O
progressive	O
disease	O
(	O
PD	O
)	O
according	O
to	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
(	O
RECIST	O
)	O
.	O
ORR	O
will	O
be	O
defined	O
as	O
the	O
percentage	O
of	O
CR	O
and	O
PR	O
cases	O
in	O
patients	O
.	O
(	O
3	O
)	O
QOL	O
:	O
QOL	O
will	O
refer	O
to	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
Life	O
Questionnaire	O
Core	O
30	O
scale	O
and	O
lung	O
cancer	O
-	O
specific	O
LC13	O
scale	O
.	O

David	O
Geffen	O
School	O
of	O
Medicine	O
at	O
UCLA	O
Los	O
Angeles	O
CA	O
USA	O
JorgeMouro	B-authors
Celgene	O
Corporation	O
Summit	O
NJ	O
USA	O
WilliamEPierceall	B-authors
Celgene	O
Corporation	O
Summit	O
NJ	O
USA	O
FaizaZafar	B-authors
Celgene	O
Corporation	O
Summit	O
NJ	O
USA	O
WeiyuanChung	B-authors
Celgene	O
Corporation	O
Summit	O
NJ	O
USA	O
ShankarSrinivasan	B-authors
Celgene	O
Corporation	O
Summit	O
NJ	O
USA	O
AmitAgarwal	B-authors
Celgene	O
Corporation	O
Summit	O
NJ	O
USA	O
NizarJBahlis	B-authors
University	O
of	O
Calgary	O
Calgary	O
AB	O
Canada	O
JohnTheurer	O

Patients	O
received	O
pomalidomide	B-arm_description
plus	O
low	B-arm_description
-	I-arm_description
dose	I-arm_description
dexamethasone	I-arm_description
in	O
28-day	O
cycles	O
until	O
PD	O
or	O
unacceptable	O
toxicity	O
.	O
Pomalidomide	B-arm_description
at	O
a	O
dose	O
of	O
4	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
day	I-arm_dosage
was	I-arm_dosage
given	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
to	I-arm_dosage
21	I-arm_dosage
of	I-arm_dosage
each	I-arm_dosage
28-day	I-arm_dosage
cycle	I-arm_dosage
.	O
Dexamethasone	B-arm_description
at	O
a	O
dose	O
of	O
40	B-arm_dosage
mg/	I-arm_dosage
day	I-arm_dosage
(	O
20	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
day	I-arm_dosage
for	O
patients	B-arm_description
>	I-arm_description
75	I-arm_description
years	I-arm_description
of	I-arm_description
age	I-arm_description
)	O
was	O
given	O
on	O
days	B-arm_dosage
1	I-arm_dosage
,	I-arm_dosage
8	I-arm_dosage
,	I-arm_dosage
15	I-arm_dosage
and	I-arm_dosage
22	I-arm_dosage
of	I-arm_dosage
each	I-arm_dosage
28-day	I-arm_dosage
cycle	I-arm_dosage
.	O
Both	O
agents	O
were	O
administered	O
orally	O
.	O
Dose	O
interruptions	O
and	O
reductions	O
were	O
permitted	O
throughout	O
the	O
study	O
.	O

Safety	O
monitoring	O
included	O
pregnancy	O
testing	O
and	O
counselling	O
,	O
physical	O
examination	O
,	O
clinical	O
laboratory	O
evaluations	O
,	O
venous	O
thromboembolism	O
monitoring	O
and	O
electrocardiograms	O
.	O
AEs	O
were	O
coded	O
according	O
to	O
the	O
Medical	O
Dictionary	O
for	O
Regulatory	O
Activities	O
(	O
version	O
20.0	O
;	O
https://www.meddra	O
.	O
org/	O
)	O
and	O
graded	O
according	O
to	O
the	O
National	O
Cancer	O
Institute	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
,	O
version	O
4.03	O
(	O
https://www.eortc.be/services/doc/ctc/CTCAE_4.03	O
_	O
2010-06-14_QuickReference_5x7.pdf	O
)	O
.	O
If	O
a	O
patient	O
experienced	O
the	O
same	O
AE	O
multiple	O
times	O
,	O
only	O
the	O
event	O
with	O
the	O
worst	O
severity	O
was	O
counted	O
.	O
SPMs	O
were	O
monitored	O
as	O
events	O
of	O
interest	O
.	O

Median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
was	O
12Á2	B-arm_efficacy_results
months	I-arm_efficacy_results
in	O
the	O
ITT	B-arm_description
population	I-arm_description
(	O
Fig	O
4	O
)	O
.	O
The	O
1-and	B-arm_efficacy_metric
2-year	I-arm_efficacy_metric
PFS	I-arm_efficacy_metric
rates	I-arm_efficacy_metric
were	O
50Á2	B-arm_efficacy_results
%	I-arm_efficacy_results
and	I-arm_efficacy_results
29Á8	I-arm_efficacy_results
%	I-arm_efficacy_results
,	O
respectively	O
.	O
Median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
in	O
the	O
efficacy	B-arm_description
-	I-arm_description
evaluable	I-arm_description
(	I-arm_description
EE	I-arm_description
)	I-arm_description
population	I-arm_description
was	O
also	O
12Á2	B-arm_efficacy_results
months	I-arm_efficacy_results
,	O
and	O
1-and	B-arm_efficacy_metric
2-year	I-arm_efficacy_metric
PFS	I-arm_efficacy_metric
rates	I-arm_efficacy_metric
for	O
the	O
EE	B-arm_description
population	I-arm_description
were	O
similar	O
to	O
those	O
in	O
the	O
ITT	O
population	O
(	O
52Á1	B-arm_efficacy_results
%	I-arm_efficacy_results
and	I-arm_efficacy_results
30Á9	I-arm_efficacy_results
%	I-arm_efficacy_results
,	O
respectively	O
)	O
.	O
Median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
in	O
patients	O
who	O
achieved	O
MR	O
and	O
≥PR	O
was	O
13Á9	O
and	O
28Á5	O
months	O
,	O
respectively	O
.	O
In	O
the	O
prior	O
-	O
bortezomib	O
subgroup	O
,	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
was	O
7Á9	O
months	O
.	O
In	O
both	O
the	O
ITT	O
and	O
EE	B-arm_description
populations	I-arm_description
,	O
median	O
TTP	O
was	O
13Á8	O
months	O
.	O
Median	O
TTP	O
was	O
8Á7	O
months	O
in	O
the	O
prior	O
-	O
bortezomib	O
subgroup	O
.	O
Follow	O
-	O
up	O
for	O
OS	O
is	O
ongoing	O
.	O
At	O
the	O
time	O
of	O
data	O
cut	O
-	O
off	O
,	O
median	O
OS	O
was	O
41Á7	O
months	O
in	O
both	O
the	O
ITT	O
and	O
EE	B-arm_description
populations	I-arm_description
.	O
The	O
1-and	O
2-year	O
OS	O
rates	O
were	O
89Á3	O
%	O
and	O
76Á6	O
%	O
,	O
respectively	O
,	O
in	O
the	O
ITT	O
population	O
,	O
and	O
92Á5	O
%	O
and	O
79Á1	O
%	O
,	O
respectively	O
,	O
in	O
the	O
EE	B-arm_description
population	I-arm_description
.	O
In	O
the	O
prior	O
-	O
bortezomib	O
subgroup	O
,	O
median	O
OS	O
was	O
38Á6	O
months	O
.	O

Oral	O
S-1	O
with	O
24-h	O
Infusion	O
of	O
Irinotecan	O
plus	O
Bevacizumab	O
versus	O
FOLFIRI	B-arm_description
plus	O
Bevacizumab	O
as	O
First	O
-	O
Line	O
Chemotherapy	O
for	O
Metastatic	O
Colorectal	O
Cancer	O
:	O
An	O
Open	B-study_type
-	I-study_type
Label	I-study_type
Randomized	I-study_type
Phase	I-study_type
II	I-study_type
Trial	I-study_type
Oral	O
S-1	O
with	O
24-h	O
Infusion	O
of	O
Irinotecan	O
plus	O
Bevacizumab	O
versus	O
FOLFIRI	B-arm_description
plus	O
Bevacizumab	O
as	O
First	O
-	O
Line	O
Chemotherapy	O
for	O
Metastatic	O
Colorectal	O
Cancer	O
:	O
An	O
Open	B-study_type
-	I-study_type
Label	I-study_type
Randomized	I-study_type
Phase	I-study_type
II	I-study_type
Trial	I-study_type
May	O
29	O
,	O
2020	O
May	O
29	O
,	O
2020	O
MDSotaroSadahiro	B-authors

Bevacizumab	B-arm_description
was	O
given	O
to	O
patients	O
who	O
had	O
grade	O
2	O
or	O
lower	O
hypertension	O
,	O
proteinuria	O
(	O
protein	O
≤1	O
+	O
or	O
<	O
2	O
g	O
of	O
protein	O
per	O
24-h	O
urine	O
collection	O
)	O
,	O
and	O
grade	O
1	O
or	O
lower	O
bleeding	O
,	O
with	O
no	O
evidence	O
of	O
thrombosis	O
or	O
embolism	O
.	O
Treatment	O
was	O
discontinued	O
in	O
patients	O
who	O
had	O
any	O
of	O
the	O
following	O
conditions	O
:	O
gastrointestinal	O
perforation	O
,	O
grade	O
3	O
or	O
higher	O
hypertension	O
,	O
bleeding	O
,	O
thrombosis	O
or	O
embolism	O
,	O
hypersensitivity	O
,	O
and	O
grade	O
4	O
or	O
higher	O
proteinuria	O
.	O
Treatment	O
was	O
delayed	O
for	O
up	O
to	O
1	O
week	O
if	O
any	O
of	O
these	O
requirements	O
was	O
not	O
satisfied	O
.	O

Randomized	B-study_type
phase	I-study_type
III	I-study_type
study	I-study_type
(	O
ADMYRE	O
)	O
of	O
plitidepsin	B-arm_description
in	O
combination	B-arm_description
with	I-arm_description
dexamethasone	I-arm_description
vs.	O
dexamethasone	B-arm_description
alone	I-arm_description
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
Randomized	B-study_type
phase	I-study_type
III	I-study_type
study	I-study_type
(	O
ADMYRE	O
)	O
of	O
plitidepsin	B-arm_description
in	O
combination	B-arm_description
with	I-arm_description
dexamethasone	I-arm_description
vs.	O
dexamethasone	B-arm_description
alone	I-arm_description
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O
25	O
June	O
2019	O
IvanSpicka	B-authors

Randomized	B-study_type
phase	I-study_type
III	I-study_type
study	I-study_type
(	O
ADMYRE	O
)	O
of	O
plitidepsin	B-arm_description
in	O
combination	B-arm_description
with	I-arm_description
dexamethasone	I-arm_description
vs.	O
dexamethasone	B-arm_description
alone	I-arm_description
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O

Randomized	B-study_type
phase	I-study_type
III	I-study_type
study	I-study_type
(	O
ADMYRE	O
)	O
of	O
plitidepsin	B-arm_description
in	O
combination	O
with	O
dexamethasone	B-arm_description
vs.	O
dexamethasone	B-arm_description
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
IvanSpicka	B-authors
Department	O
of	O
Medicine	O
Faculty	O
of	O
Medicine	O

The	O
prognosis	O
for	O
patients	O
with	O
multiple	O
myeloma	O
(	O
MM	O
)	O
who	O
are	O
refractory	O
to	O
both	O
proteasome	O
inhibitors	O
(	O
PIs	O
)	O
and	O
immunomodulatory	O
drugs	O
(	O
IMiDs	O
)	O
is	O
poor	O
:	O
with	O
further	O
treatment	O
,	O
the	O
median	O
survival	O
is	O
9	O
months	O
and	O
3	O
months	O
in	O
patients	O
without	O
further	O
treatment	O
[	O
1	O
]	O
.	O
Furthermore	O
,	O
treatment	O
options	O
for	O
MM	O
decrease	O
with	O
each	O
relapse	O
and	O
outcomes	O
with	O
subsequent	O
treatment	O
using	O
standard	O
therapies	O
are	O
characterized	O
by	O
short	O
duration	O
of	O
response	O
and	O
increasing	O
drug	O
resistance	O
[	O
2	O
]	O
.	O
Therefore	O
,	O
there	O
is	O
a	O
need	O
for	O
alternative	O
antimyeloma	O
treatments	O
for	O
patients	O
with	O
advanced	O
illness	O
following	O
refractory/	O
multiply	O
relapsed	O
disease	O
.	O

Safety	O
was	O
evaluated	O
in	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
the	O
study	O
treatment	O
by	O
assessment	O
of	O
adverse	O
events	O
(	O
AEs	O
)	O
,	O
clinical	O
laboratory	O
test	O
results	O
,	O
physical	O
examinations	O
,	O
and	O
vital	O
signs	O
.	O
AEs	O
were	O
recorded	O
and	O
coded	O
with	O
the	O
Medical	O
Dictionary	O
for	O
Regulatory	O
Activities	O
(	O
MedDRA	O
)	O
v.16.0	O
.	O
AEs	O
and	O
laboratory	O
values	O
were	O
graded	O
according	O
to	O
the	O
National	O
Cancer	O
Institute	O
-	O
Common	O
Toxicity	O
Criteria	O
for	O
Adverse	O
Events	O
(	O
NCI	O
-	O
CTCAE	O
)	O
v.4	O
.	O
All	O
patients	O
were	O
followed	O
until	O
recovery	O
from	O
any	O
treatment	O
-	O
related	O
AE	O
.	O
Follow	O
-	O
up	O
was	O
longer	O
in	O
arm	B-arm_description
A	I-arm_description
partly	O
because	O
it	O
included	O
patients	O
that	O
had	O
crossed	O
over	O
from	O
arm	B-arm_description
B.	I-arm_description

All	O
treated	O
patients	O
were	O
evaluable	O
for	O
safety	O
.	O
The	O
median	O
(	O
range	O
)	O
of	O
cycles	O
received	O
was	O
3	O
(	O
1	O
-	O
33	O
)	O
in	O
arm	B-arm_description
A	I-arm_description
(	O
plitidepsin	B-arm_description
plus	B-arm_description
DXM	I-arm_description
;	O
total	O
cycles	O
=	O
842	O
)	O
and	O
2	O
(	O
1	O
-	O
21	O
)	O
in	O
arm	B-arm_description
B	I-arm_description
(	O
DXM	B-arm_description
;	O
total	O
cycles	O
=	O
251	O
)	O
.	O
Median	O
time	O
on	O
treatment	O
was	O
12.3	O
weeks	O
(	O
1.3	O
-	O
137.1	O
weeks	O
)	O
in	O
arm	B-arm_description
A	I-arm_description
and	O
8.3	O
weeks	O
(	O
1.4	O
-	O
85.3	O
weeks	O
)	O
in	O
arm	B-arm_description
B.	I-arm_description
Fifteen	O
patients	O
(	O
9.0	O
%	O
)	O
discontinued	O
treatment	O
because	O
of	O
treatment	O
-	O
related	O
AEs	O
in	O
arm	B-arm_description
A	I-arm_description
and	O
eight	O
patients	O
(	O
9.6	O
%	O
)	O
in	O
arm	B-arm_description
B.	I-arm_description

In	O
arm	B-arm_description
A	I-arm_description
(	O
plitidepsin	B-arm_description
plus	B-arm_description
DXM	I-arm_description
)	O
,	O
the	O
most	O
common	O
AEs	O
(	O
all	O
grades	O
)	O
related	O
to	O
the	O
study	O
treatment	O
(	O
or	O
with	O
unknown	O
causality	O
)	O
were	O
nausea	O
(	O
37.1	O
%	O
of	O
patients	O
)	O
,	O
fatigue	O
(	O
36.5	O
%	O
)	O
,	O
vomiting	O
(	O
16.8	O
%	O
)	O
,	O
diarrhea	O
(	O
14.4	O
%	O
)	O
,	O
myalgia	O
(	O
14.4	O
%	O
)	O
,	O
peripheral	O
edema	O
(	O
12.0	O
%	O
)	O
,	O
decreased	O
appetite	O
(	O
12.6	O
%	O
)	O
,	O
and	O
Table	O
2	O
)	O
.	O
Other	O
grade	O
3/4	O
AEs	O
of	O
specific	O
interest	O
were	O
as	O
follows	O
:	O
creatine	O
phosphokinase	O
(	O
CPK	O
)	O
increase	O
(	O
20.0	O
%	O
)	O
,	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
increase	O
(	O
14.5	O
%	O
)	O
,	O
peripheral	O
sensory	O
neuropathy	O
(	O
0.6	O
%	O
)	O
,	O
and	O
infection	O
/	O
pneumonia	O
(	O
2.4	O
%	O
)	O
.	O
One	O
patient	O
died	O
following	O
a	O
treatment	O
-	O
related	O
AE	O
(	O
grade	O
4	O
myopathy	O
)	O
after	O
having	O
received	O
one	O
cycle	O
(	O
n	O
=	O
1/167	O
patients	O
;	O
0.6	O
%	O
)	O
.	O

Here	O
,	O
we	O
report	O
long	O
-	O
term	O
data	O
from	O
the	O
trial	O
,	O
including	O
efficacy	O
outcomes	O
and	O
late	O
toxicity	O
.	O
In	O
addition	O
,	O
the	O
role	O
of	O
early	O
marker	O
decline	O
for	O
predicting	O
long	O
-	O
term	O
outcomes	O
is	O
considered	O
.	O

Estimated	O
3-year	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
was	O
higher	O
in	O
the	O
group	O
with	O
unfavourable	O
marker	O
decline	O
compared	O
with	O
those	O
with	O
favourable	O
decline	O
,	O
though	O
this	O
trend	O
was	O
non	O
-	O
significant	O
(	B-arm_efficacy_results
51.7	I-arm_efficacy_results
%	I-arm_efficacy_results
vs	I-arm_efficacy_results
41.0	I-arm_efficacy_results
%	I-arm_efficacy_results
,	I-arm_efficacy_results
HR	I-arm_efficacy_results
Z	I-arm_efficacy_results
0.82	I-arm_efficacy_results
,	I-arm_efficacy_results
p	I-arm_efficacy_results
Z	I-arm_efficacy_results
0.54	I-arm_efficacy_results
)	I-arm_efficacy_results
.	O
Results	O
were	O
similar	O
in	O
the	O
subgroup	O
who	O
did	O
not	O
receive	O
stabilising	O
chemotherapy	O
and	O
in	O
the	O
subgroup	O
of	O
BEP	B-arm_description
patients	O
.	O

Results	O
for	O
univariate	O
and	O
multivariable	O
models	O
for	O
OS	O
were	O
similar	O
to	O
those	O
for	O
PFS	B-arm_efficacy_metric
e	O
the	O
only	O
significant	O
associations	O
were	O
for	O
receipt	O
of	O
stabilising	O
chemotherapy	O
and	O
mediastinal	O
primary	O
tumours	O
(	O
appendix	O
C	O
)	O
.	O
Treatment	O
effect	O
remained	O
similar	O
after	O
adjustment	O
for	O
these	O
factors	O
.	O

Thirty	O
-	O
five	O
patients	O
relapsed	O
or	O
their	O
disease	O
progressed	O
during	O
the	O
trial	O
(	O
22	O
BEP	B-arm_description
,	O
13	O
CBOP	B-arm_description
/	I-arm_description
BEP	I-arm_description
)	O
,	O
including	O
all	O
patients	O
with	O
a	O
treatment	O
failure	O
.	O
Thirty	O
patients	O
(	O
20	O
BEP	B-arm_description
,	O
10	O
CBOP	B-arm_description
/	I-arm_description
BEP	I-arm_description
)	O
received	O
treatment	O
for	O
relapse	O
.	O
Of	O
the	O
remaining	O
five	O
,	O
three	O
died	O
around	O
the	O
time	O
of	O
diagnosis	O
of	O
relapse	O
/	O
progression	O
;	O
one	O
was	O
felt	O
not	O
to	O
be	O
fit	O
enough	O
for	O
salvage	O
treatment	O
and	O
died	O
two	O
months	O
later	O
;	O
and	O
the	O
remaining	O
patient	O
did	O
not	O
require	O
further	O
treatment	O
and	O
remained	O
alive	O
at	O
the	O
end	O
of	O
the	O
followup	O
.	O
Of	O
those	O
treated	O
,	O
all	O
but	O
5	O
received	O
combination	O
chemotherapy	O
(	O
sometimes	O
alongside	O
radiotherapy	O
or	O
surgery	O
)	O
,	O
most	O
commonly	O
paclitaxel	O
,	O
ifosfamide	O
and	O
cisplatin	O
(	O
TIP	O
)	O
(	O
13	O
patients	O
)	O
,	O
but	O
a	O
range	O
of	O
other	O
regimens	O
were	O
used	O
.	O
Only	O
1	O
patient	O
(	O
BEP	B-arm_description
arm	I-arm_description
)	O
had	O
a	O
complete	O
response	O
and	O
9	O
(	O
7	O
BEP	B-arm_description
,	O
2	O
CBOP	B-arm_description
/	I-arm_description
BEP	I-arm_description
)	O
had	O
a	O
partial	O
response	O
with	O
negative	O
markers	O
.	O

Morphologic	O
response	O
to	O
chemotherapy	O
containing	O
bevacizumab	B-arm_description
in	O
patients	O
with	O
colorectal	O
liver	O
metastases	O
A	O
post	B-study_type
hoc	I-study_type
analysis	I-study_type
of	O
the	O
WJOG4407	O
G	O
phase	B-study_type
III	I-study_type
study	I-study_type
Morphologic	O
response	O
to	O
chemotherapy	O
containing	O
bevacizumab	B-arm_description
in	O
patients	O
with	O
colorectal	O
liver	O
metastases	O
A	O
post	B-study_type
hoc	I-study_type
analysis	I-study_type
of	O
the	O
WJOG4407	O
G	O
phase	B-study_type
III	I-study_type
study	I-study_type
MDAyumuHosokawa	B-authors

morphologic	O
response	O
was	O
not	O
associated	O
with	O
PFS	B-arm_efficacy_metric
or	O
OS	O
,	O
whereas	O
RECIST	O
response	O
was	O
significantly	O
associated	O
with	O
both	O
PFS	B-arm_efficacy_metric
and	O
OS	O
,	O
with	O
ETS	O
and	O
DpR	O
being	O
associated	O
with	O
significantly	O
longer	O
PFS	B-arm_efficacy_metric
.	O

Länsi	O
-	O
Pohja	O
Central	O
Hospital	O
Kemi	O
Finland	O
AnuRäsänen	B-authors
Department	O
of	O
Medicine	O
Kymenlaakso	O
Central	O
Hospital	O
Kotka	O
Finland	O
Department	O
of	O
Medicine	O
Kymenlaakso	O
Central	O
Hospital	O
Kotka	O
Finland	O
AnuSikiö	B-authors
Department	O
of	O
Medicine	O

Helsinki	O
University	O
Hospital	O
and	O
University	O
of	O
Helsinki	O
Helsinki	O
Finland	O
TuomasSelander	B-authors
Science	O
Service	O
Center	O
Kuopio	O
University	O
Hospital	O
Kuopio	O
Finland	O
Science	O
Service	O
Center	O
Kuopio	O
University	O
Hospital	O
Kuopio	O
Finland	O
Tarja	B-authors
-	I-authors
TerttuPelliniemi	I-authors
Fimlab	O
Laboratories	O
Ltd	O
Tampere	O
Finland	O
Fimlab	O
Laboratories	O
Ltd	O
Tampere	O
Finland	O
SorellaIlveskero	B-authors

RVD	O
induction	O
and	O
autologous	O
stem	O
cell	O
transplantation	O
followed	O
by	O
lenalidomide	B-arm_description
maintenance	I-arm_description
in	O
newly	O
diagnosed	O
multiple	O
myeloma	O
:	O
a	O
phase	B-study_type
2	I-study_type
study	I-study_type
of	O
the	O
Finnish	O
Myeloma	O
Group	O
SiniLuoma	B-authors
Comprehensive	O
Cancer	O
Center	O
Department	O
of	O
Hematology	O

Lenalidomide	O
maintenance	O
after	O
ASCT	O
prolongs	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
[	O
2][3][4	O
]	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
[	O
3	O
]	O
and	O
is	O
approved	O
by	O
EMA	O
and	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
for	O
NDMM	O
patients	O
after	O
ASCT	O
until	O
progression	O
.	O
The	O
three	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
evaluating	O
lenalidomide	O
maintenance	O
were	O
included	O
in	O
a	O
meta	O
-	O
analysis	O
[	O
5	O
]	O
which	O
demonstrated	O
a	O
significant	O
PFS	O
and	O
OS	O
benefit	O
with	O
lenalidomide	O
maintenance	O
after	O
ASCT	O
when	O
compared	O
with	O
placebo	O
or	O
observation	O
.	O
The	O
optimal	O
duration	O
of	O
lenalidomide	O
maintenance	O
is	O
a	O
matter	O
of	O
debate	O
.	O
In	O
Cancer	O
and	O
Leukemia	O
Group	O
B	O
(	O
CALGB	O
)	O
[	O
3	O
]	O
and	O
Intergroupe	O
Francophone	O
du	O
Myelome	O
(	O
IFM	O
)	O
[	O
2	O
]	O
trials	O
,	O
patients	O
received	O
post	O
-	O
ASCT	O
placebo	O
or	O
continuous	O
lenalidomide	O
10	O
mg	O
for	O
3	O
months	O
escalated	O
then	O
to	O
15	O
mg	O
,	O
until	O
disease	O
progression	O
,	O
intolerable	O
side	O
effects	O
,	O
or	O
death	O
.	O
The	O
IFM	O
group	O
decided	O
to	O
stop	O
the	O
treatment	O
in	O
the	O
lenalidomide	O
arm	O
due	O
to	O
the	O
noticed	O
risk	O
of	O
secondary	O
primary	O
malignancies	O
(	O
SPMs	O
)	O
in	O
opposite	O
to	O
the	O
CALGB	O
trial	O
where	O
patients	O
continued	O
maintenance	O
until	O
progression	O
.	O
Based	O
on	O
the	O
meta	O
-	O
analysis	O
,	O
the	O
risk	O
of	O
death	O
due	O
to	O
SPM	O
was	O
similar	O
between	O
lenalidomide	O
and	O
placebo	O
or	O
observation	O
groups	O
but	O
there	O
was	O
a	O
34	O
%	O
reduction	O
in	O
risk	O
to	O
die	O
of	O
multiple	O
myeloma	O
(	O
MM	O
)	O
in	O
lenalidomide	O
maintenance	O
arm	O
[	O
5	O
]	O
.	O

Mian	O
et	O
al	O
.	O
showed	O
in	O
their	O
retrospective	O
analysis	O
a	O
positive	O
correlation	O
between	O
the	O
duration	O
of	O
lenalidomide	O
maintenance	O
and	O
OS	O
[	O
6	O
]	O
.	O
In	O
the	O
study	O
by	O
Goldschmidt	O
et	O
al	O
.	O
,	O
the	O
patients	O
were	O
randomized	O
to	O
receive	O
lenalidomide	O
maintenance	O
for	O
2	O
years	O
or	O
until	O
CR	O
.	O
In	O
patients	O
receiving	O
lenalidomide	O
for	O
2	O
years	O
,	O
OS	O
was	O
higher	O
[	O
7	O
]	O
.	O

The	O
impact	O
of	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
negativity	O
for	O
PFS	O
and	O
OS	O
has	O
been	O
demonstrated	O
in	O
several	O
trials	O
[	O
9][10][11][12][13][14	O
]	O
and	O
it	O
is	O
also	O
recommended	O
for	O
one	O
of	O
the	O
primary	O
endpoints	O
for	O
evaluating	O
the	O
approval	O
of	O
new	O
drugs	O
for	O
MM	O
[	O
9,15	O
]	O
.	O

Patients	O
were	O
initially	O
treated	O
with	O
RVD	B-arm_description
induction	O
comprising	O
three	B-arm_dosage
21-day	I-arm_dosage
cycles	I-arm_dosage
of	I-arm_dosage
lenalidomide	B-arm_description
25	I-arm_dosage
mg	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
-	I-arm_dosage
14	I-arm_dosage
;	I-arm_dosage
bortezomib	B-arm_description
1.3	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
,	I-arm_dosage
4	I-arm_dosage
,	I-arm_dosage
8	I-arm_dosage
,	I-arm_dosage
and	I-arm_dosage
11	I-arm_dosage
subcutaneously	I-arm_dosage
;	I-arm_dosage
and	I-arm_dosage
dexamethasone	B-arm_description
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
day	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
-	I-arm_dosage
2	I-arm_dosage
,	I-arm_dosage
4	I-arm_dosage
-	I-arm_dosage
5	I-arm_dosage
,	I-arm_dosage
8	I-arm_dosage
-	I-arm_dosage
9	I-arm_dosage
,	I-arm_dosage
and	I-arm_dosage
11	I-arm_dosage
-	I-arm_dosage
12	I-arm_dosage
.	O
Acyclovir	O
and	O
enoxaparin	O
prophylaxis	O
were	O
given	O
during	O
induction	O
(	O
Online	O
Resources	O
4	O
-	O
5	O
)	O
.	O
The	O
mobilization	B-arm_description
in	O
arm	B-arm_description
A	I-arm_description
was	O
CY	B-arm_dosage
2	I-arm_dosage
g	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
on	I-arm_dosage
day	I-arm_dosage
+	I-arm_dosage
1	I-arm_dosage
plus	I-arm_dosage
filgrastim	I-arm_dosage
5	I-arm_dosage
μg	I-arm_dosage
/	I-arm_dosage
kg	I-arm_dosage
starting	I-arm_dosage
on	I-arm_dosage
day	I-arm_dosage
+	I-arm_dosage
4	I-arm_dosage
,	O
and	O
in	O
arm	B-arm_description
B	I-arm_description
,	O
filgrastim	B-arm_dosage
10	I-arm_dosage
μg	I-arm_dosage
/	I-arm_dosage
kg	I-arm_dosage
alone	I-arm_dosage
starting	I-arm_dosage
on	I-arm_dosage
day	I-arm_dosage
+	I-arm_dosage
1	I-arm_dosage
.	O
The	O
goal	O
was	O
to	O
collect	O
at	O
least	O
3	O
×	O
10	O
6	O
/kg	O
CD34	O
+	O
cells	O
for	O
one	O
transplant	O
and	O
6	O
×	O
10	O
6	O
/kg	O
if	O
the	O
second	O
transplant	O
was	O
an	O
option	O
.	O
The	O
details	O
of	O
the	O
apheresis	O
procedure	O
and	O
guidelines	O
for	O
use	O
of	O
plerixafor	O
as	O
well	O
as	O
the	O
results	O
of	O
the	O
randomized	O
mobilization	O
study	O
have	O
been	O
published	O
previously	O
[	O
18	O
]	O
.	O
Patients	O
received	O
a	O
single	O
ASCT	B-arm_description
after	I-arm_description
melphalan	I-arm_description
200	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
.	O

With	O
a	O
median	O
follow	O
-	O
up	O
of	O
27	O
(	O
0	O
-	O
59	O
)	O
months	O
,	O
neither	O
median	O
PFS	B-arm_efficacy_metric
nor	O
OS	O
have	O
been	O
reached	O
.	O
The	O
PFS	B-arm_efficacy_metric
at	O
1	B-arm_efficacy_results
,	I-arm_efficacy_results
2	I-arm_efficacy_results
,	I-arm_efficacy_results
and	I-arm_efficacy_results
3	I-arm_efficacy_results
years	I-arm_efficacy_results
after	I-arm_efficacy_results
inclusion	I-arm_efficacy_results
was	I-arm_efficacy_results
78	I-arm_efficacy_results
%	I-arm_efficacy_results
,	I-arm_efficacy_results
67	I-arm_efficacy_results
%	I-arm_efficacy_results
,	I-arm_efficacy_results
and	I-arm_efficacy_results
52	I-arm_efficacy_results
%	I-arm_efficacy_results
,	O
and	O
OS	O
96	O
%	O
,	O
90	O
%	O
,	O
and	O
83	O
%	O
,	O
respectively	O
.	O
Median	O
EFS	O
was	O
24	O
months	O
(	O
95	O
%	O
CI	O
9	O
-	O
39	O
months	O
)	O
(	O
Fig	O
.	O
1	O
)	O
.	O
The	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
for	O
the	O
Revised	O
Multiple	O
Myeloma	O
International	O
Staging	O
System	O
(	O
R	O
-	O
ISS	O
)	O
stage	O
3	O
group	O
was	O
only	O
eight	B-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
0	I-arm_efficacy_results
-	I-arm_efficacy_results
27	I-arm_efficacy_results
)	I-arm_efficacy_results
months	I-arm_efficacy_results
and	O
was	O
not	O
reached	O
for	O
the	O
other	O
groups	O
.	O
For	O
the	O
patients	O
who	O
started	O
maintenance	B-arm_description
(	O
N	O
=	O
54	O
)	O
,	O
PFS	B-arm_efficacy_metric
at	O
1	B-arm_efficacy_results
,	I-arm_efficacy_results
2	I-arm_efficacy_results
,	I-arm_efficacy_results
and	I-arm_efficacy_results
3	I-arm_efficacy_results
years	I-arm_efficacy_results
after	I-arm_efficacy_results
inclusion	I-arm_efficacy_results
was	I-arm_efficacy_results
94	I-arm_efficacy_results
%	I-arm_efficacy_results
,	I-arm_efficacy_results
80	I-arm_efficacy_results
%	I-arm_efficacy_results
,	I-arm_efficacy_results
and	I-arm_efficacy_results
65	I-arm_efficacy_results
%	I-arm_efficacy_results
and	O
OS	O
100	O
%	O
,	O
96	O
%	O
,	O
and	O
87	O
%	O
,	O
respectively	O
.	O

To	O
test	O
the	O
predictive	O
impact	O
of	O
different	O
variables	O
on	O
PFS	B-arm_efficacy_metric
,	O
gender	O
,	O
age	O
≤	O
or	O
>	O
65	O
years	O
,	O
study	O
arm	O
,	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
performance	O
status	O
,	O
IMWG	O
group	O
,	O
R	O
-	O
ISS	O
,	O
ISS	O
,	O
HR	O
cytogenetics	O
,	O
best	O
serological	O
response	O
(	O
sCR	O
vs.	O
CR	O
/	O
VGPR	O
vs.	O
PR	O
/	O
worse	O
)	O
,	O
and	O
achievement	O
of	O
flow	O
-	O
MRD	O
-	O
negativity	O
or	O
PCR	O
-	O
negativity	O
were	O
tested	O
with	O
multivariate	O
analyses	O
.	O
In	O
correlation	O
analysis	O
,	O
there	O
proved	O
to	O
be	O
high	O
pairwise	O
correlations	O
,	O
between	O
0.677	O
and	O
0.773	O
between	O
flow	O
-	O
MRD	O
-	O
negativity	O
,	O
PCRnegativity	O
,	O
and	O
serological	O
responses	O
,	O
and	O
due	O
to	O
this	O
multicollinearity	O
,	O
these	O
three	O
factors	O
competed	O
for	O
the	O
same	O
predictive	O
power	O
.	O
In	O
multivariate	O
analysis	O
,	O
only	O
one	O
of	O
them	O
,	O
achievement	O
of	O
flow	O
-	O
MRD	O
-	O
negativity	O
,	O
provided	O

Adverse	O
events	O
(	O
AEs	O
)	O
were	O
assessed	O
from	O
all	O
the	O
patients	O
(	O
N	O
=	O
78	O
)	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
trial	O
treatment	O
.	O
Lenalidomide	B-arm_description
maintenance	I-arm_description
AEs	O
were	O
separately	O
assessed	O
from	O
the	O
patients	O
(	O
N	O
=	O
54	O
)	O
who	O
received	O
at	O
least	O
one	O
dose	O
on	O
maintenance	B-arm_description
therapy	O
.	O

Canada	O
Division	O
of	O
Child	O
Neurology	O
Department	O
of	O
Pediatrics	O
CHU	O
Sainte	O
-	O
Justine	O
Université	O
de	O
Montréal	O
3175	O
Chemin	O
de	O
la	O
Côte	O
-	O
Sainte	O
-	O
Catherine	O
H3	O
T	O
1C5	O
Montreal	O
QC	O

Canada	O
Montreal	O
QC	O
Canada	O
A	O
phase	B-study_type
2	I-study_type
study	I-study_type
of	O
trametinib	O
for	O
patients	O
with	O
pediatric	O
glioma	O
or	O
plexiform	O
neurofibroma	O
with	O
refractory	O
tumor	O
and	O
activation	O
of	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
:	O
TRAM-01	O
10.1186	O
/	O
s12885	O
-	O
019	O
-	O
6442	O
-	O
2	O
Received	O
:	O
10	O
October	O
2019	O
Accepted	O
:	O
8	O
December	O
2019	O

Discussion	O
:	O
Trametinib	O
will	O
allow	O
us	O
to	O
target	O
directly	O
and	O
specifically	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
.	O
We	O
expect	O
to	O
observe	O
a	O
significant	O
response	O
in	O
most	O
patients	O
.	O
Following	O
our	O
study	O
,	O
trametinib	O
could	O
be	O
integrated	O
into	O
standard	O
treatment	O
of	O
PLGG	O
and	O
PN	O
.	O

Pediatric	O
low	O
-	O
grade	O
gliomas	O
Pediatric	O
low	O
grade	O
gliomas	O
(	O
PLGG	O
)	O
which	O
include	O
pilocytic	O
astrocytoma	O
(	O
PA	O
)	O
are	O
the	O
most	O
frequent	O
brain	O
tumors	O
and	O
represent	O
25	O
-	O
30	O
%	O
of	O
central	O
nervous	O
system	O
tumors	O
in	O
children	O
[	O
1	O
]	O
.	O
While	O
some	O
patients	O
can	O
be	O
cured	O
with	O
surgery	O
alone	O
,	O
more	O
than	O
70	O
%	O
need	O
complimentary	O
treatments	O
due	O
to	O
the	O
location	O
of	O
tumors	O
that	O
preclude	O
resection	O
[	O
2	O
]	O
.	O
Standard	O
therapy	O
for	O
PLGG	O
includes	O
chemotherapy	O
with	O
a	O
combination	O
of	O
intravenous	O
carboplatin	O
and	O
vincristine	O
,	O
or	O
weekly	O
vinblastine	O
for	O
70	O
weeks	O
.	O
Unfortunately	O
,	O
more	O
than	O
50	O
%	O
of	O
patients	O
will	O
have	O
progressive	O
disease	O
despite	O
conventional	O
treatment(s	O
)	O
[	O
3	O
]	O
[	O
4	O
]	O
.	O
Radiotherapy	O
remains	O
an	O
option	O
,	O
but	O
this	O
approach	O
has	O
significant	O
long	O
-	O
term	O
side	O
effects	O
including	O
cognitive	O
dysfunction	O
,	O
endocrinopathies	O
and	O
vasculopathies	O
[	O
5	O
]	O
.	O
Several	O
clinical	O
trials	O
have	O
focused	O
on	O
treatments	O
of	O
refractory	O
PLGG	O
but	O
have	O
failed	O
to	O
show	O
significant	O
efficacy	O
and	O
there	O
is	O
currently	O
no	O
standard	O
therapy	O
.	O

The	O
BRAF	O
V600E	O
mutation	O
lies	O
in	O
the	O
kinase	O
domain	O
and	O
results	O
in	O
a	O
constitutive	O
activation	O
of	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
.	O
The	O
V600E	O
mutation	O
is	O
positive	O
in	O
5	O
-	O
10	O
%	O
of	O
PA	O
usually	O
involving	O
the	O
brainstem	O
and	O
deep	O
gray	O
nuclei	O
[	O
11	O
]	O
[	O
12	O
]	O
.	O

Recently	O
,	O
phase	O
I	O
and	O
II	O
study	O
with	O
selumetinib	O
(	O
another	O
MEK	O
inhibitor	O
)	O
showed	O
promising	O
antitumor	O
activity	O
in	O
PLGG	O
[	O
22	O
]	O
[	O
23	O
]	O
and	O
Dombi	O
et	O
al	O
.	O
demonstrated	O
dramatic	O
responses	O
in	O
patients	O
with	O
PN	O
treated	O
with	O
selumetinib	O
[	O
24	O
]	O
.	O
However	O
,	O
this	O
agent	O
is	O
still	O
under	O
investigation	O
,	O
is	O
not	O
available	O
in	O
Canada	O
and	O
has	O
not	O
been	O
approved	O
yet	O
for	O
treatment	O
of	O
PN	O
or	O
PLGG	O
.	O

Total	O
leukocytes	O
≥3000	O
/	O
μL	O
Absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
≥	O
1000	O
/	O
μL	O
Hemoglobin	O
>	O
80	O
g	O
/	O
l	O
(	O
transfusion	O
independent	O
within	O
last	O
2	O
weeks	O
)	O
Platelet	O
count	O
≥100,000	O
/	O
μL	O
(	O
transfusion	O
independent	O
within	O
last	O
2	O
weeks	O
)	O
Total	O
bilirubin	O
≤1	O
.	O
5	O

To	O
document	O
the	O
quality	O
of	O
life	O
of	O
patients	O
,	O
the	O
PedsQL	O
Generic	O
scale	O
and	O
Brain	O
Tumor	O
module	O
[	O
32][33][34	O
]	O
.	O
The	O
measures	O
are	O
available	O
over	O
the	O
age	O
span	O
with	O
an	O
infant	O
scale	O
for	O
patients	O
under	O
2	O
years	O
will	O
be	O
used	O
to	O
assess	O
the	O
physical	O
,	O
mental	O
,	O
social	O
health	O
dimensions	O
,	O
as	O
well	O
as	O
the	O
cognitive	O
development	O
of	O
children	O
[	O
35	O
]	O
.	O
The	O
PedsQL	O
integrates	O
the	O
generic	O
and	O
disease	O
-	O
specific	O
approaches	O
with	O
child	O
selfreports	O
and	O
parent	O
proxy	O
-	O
reports	O
[	O
36	O
]	O
.	O
Thus	O
,	O
both	O
questionnaires	O
will	O
be	O
completed	O
by	O
the	O
patient	O
and	O
one	O
caregiver	O
.	O

An	O
independent	O
and	O
outside	O
ARO	O
(	O
academic	O
research	O
organization	O
)	O
,	O
Exactis	O
Innovation	O
,	O
has	O
been	O
assigned	O
for	O
the	O
management	O
of	O
this	O
study	O
.	O
Exactis	O
will	O
be	O
responsible	O
for	O
overseeing	O
the	O
regulatory	O
aspects	O
and	O
,	O
monitoring	O
of	O
sites	O
,	O
verify	O
compliance	O
and	O
conduct	O
site	O
visits	O
.	O

A	O
Data	O
Monitoring	O
Committee	O
(	O
DMC	O
)	O
will	O
receive	O
and	O
review	O
the	O
progress	O
and	O
accrual	O
data	O
of	O
this	O
trial	O
and	O
will	O
safeguard	O
the	O
interests	O
of	O
trial	O
participants	O
,	O
periodically	O
review	O
and	O
evaluate	O
the	O
accumulated	O
study	O
data	O
for	O
participant	O
safety	O
and	O
efficacy	O
and	O
monitor	O
the	O
progress	O
and	O
overall	O
conduct	O
of	O
the	O
clinical	O
trial	O
.	O
The	O
DMC	O
has	O
access	O
to	O
quarterly	O
study	O
reports	O
,	O
raw	O
study	O
data	O
so	O
that	O
they	O
can	O
see	O
any	O
emerging	O
risks	O
such	O
as	O
frequent	O
or	O
severe	O
adverse	O
events	O
.	O

Trifluridine	O
/	O
tipiracil	O
(	O
TAS-102	O
)	O
is	O
a	O
novel	O
,	O
oral	O
combination	O
comprising	O
the	O
thymidine	O
-	O
based	O
nucleoside	O
analog	O
trifluridine	O
and	O
tipiracil	O
hydrochloride	O
at	O
a	O
molar	O
ratio	O
of	O
1:0.5	O
.	O
Trifluridine	O
is	O
incorporated	O
into	O
DNA	O
after	O
phosphorylation	O
by	O
thymidine	O
kinase	O
1	O
(	O
TK1	O
)	O
.	O
We	O
previously	O
reported	O
results	O
from	O
a	O
randomized	O
phase	O
2	O
study	O
of	O
trifluridine	O
/	O
tipiracil	O
(	O
J003	O
-	O
10040030	O
)	O
,	O
and	O
this	O
therapy	O
was	O
first	O
approved	O
in	O
Japan	O
in	O
2014	O
[	O
8	O
]	O
.	O
More	O
recently	O
,	O
the	O
international	O
phase	O
3	O
RECOURSE	O
trial	O
has	O
demonstrated	O
a	O
more	O
significant	O
overall	O
survival	O
(	O
OS	O
)	O
benefit	O
of	O
trifluridine/	O
tipiracil	O
compared	O
with	O
placebo	O
,	O
with	O
acceptable	O
toxicity	O
,	O
in	O
patients	O
with	O
refractory	O
mCRC	O
[	O
7	O
]	O
.	O
In	O
addition	O
,	O
the	O
Asian	O
phase	O
3	O
TERRA	O
trial	O
has	O
reported	O
the	O
survival	O
benefit	O
and	O
safety	O
of	O
trifluridine	O
/	O
tipiracil	O
in	O
Asian	O
population	O
[	O
9	O
]	O
.	O
Based	O
on	O
these	O
findings	O
,	O
trifluridine	O
/	O
tipiracil	O
has	O
been	O
approved	O
by	O
many	O
countries	O
and	O
regions	O
including	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
and	O
European	O
Medicines	O
Agency	O
.	O

Clinical	O
data	O
of	O
patients	O
with	O
mCRC	O
who	O
received	O
trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
plus	O
bevacizumab	B-arm_description
or	O
trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
monotherapy	O
at	O
the	O
National	O
Cancer	O
Center	O
Hospital	O
East	O
was	O
retrospectively	B-study_type
collected	O
.	O
Study	O
protocol	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
.	O
Informed	O
consent	O
requirement	O
was	O
waived	O
due	O
to	O
the	O
study	O
's	O
observational	B-study_type
retrospective	I-study_type
design	I-study_type
,	O
with	O
an	O
opt	O
-	O
out	O
opportunity	O
provided	O
at	O
the	O
institution	O
's	O
website	O
.	O
Patient	O
follow	O
-	O
up	O
was	O
performed	O
until	O
December	O
2018	O
.	O

Trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
plus	O
bevacizumab	O
regimen	O
consisted	O
of	O
trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
35	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
of	I-arm_dosage
body	I-arm_dosage
surface	I-arm_dosage
area	I-arm_dosage
,	I-arm_dosage
given	I-arm_dosage
orally	I-arm_dosage
twice	I-arm_dosage
a	I-arm_dosage
day	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
-	I-arm_dosage
5	I-arm_dosage
and	I-arm_dosage
8	I-arm_dosage
-	I-arm_dosage
12	I-arm_dosage
in	I-arm_dosage
a	I-arm_dosage
28-day	I-arm_dosage
cycle	I-arm_dosage
,	O
and	O
bevacizumab	B-arm_description
5	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
kg	I-arm_dosage
of	I-arm_dosage
bodyweight	I-arm_dosage
,	O
administered	O
by	O
intravenous	O
infusion	O
every	B-arm_dosage
2	I-arm_dosage
weeks	I-arm_dosage
.	O
Trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
monotherapy	O
consisted	O
of	O
trifluridine/	B-arm_description
tipiracil	I-arm_description
35	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
of	I-arm_dosage
body	I-arm_dosage
surface	I-arm_dosage
area	I-arm_dosage
,	O
given	O
orally	O
twice	B-arm_dosage
a	I-arm_dosage
day	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
-	I-arm_dosage
5	I-arm_dosage
and	I-arm_dosage
8	I-arm_dosage
-	I-arm_dosage
12	I-arm_dosage
in	I-arm_dosage
a	I-arm_dosage
28-day	I-arm_dosage
cycle	I-arm_dosage
.	O

Median	O
OS	O
was	O
8.6	O
months	O
(	O
95	O
%	O
CI	O
6.9	O
-	O
10.3	O
months	O
)	O
for	O
trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
plus	O
bevacizumab	B-arm_description
and	O
8.0	O
months	O
(	O
95	O
%	O
CI	O
6.6	O
-	O
9.4	O
months	O
)	O
for	O
trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
monotherapy	O
(	O
Fig	O
.	O
1b	O
)	O
.	O
In	O
multivariate	O
analysis	O
,	O
an	O
OS	O
benefit	O
was	O
also	O
observed	O
for	O
trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
plus	O
bevacizumab	B-arm_description
compared	O
with	O
trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
monotherapy	O
,	O
but	O
without	O
statistical	O
significance	O
(	O
HR	O
0.74	O
;	O
95	O
%	O
CI	O
0.48	O
-	O
1.14	O
;	O
log	O
-	O
rank	O
p	O
=	O
0.164	O
)	O
.	O
Similarly	O
to	O
PFS	B-arm_efficacy_metric
,	O
longer	O
OS	O
was	O
observed	O
for	O
all	O
subgroups	O
,	O
except	O
ECOG	O
PS	O
.	O

Three	O
patients	O
in	O
the	O
trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
plus	O
bevacizumab	B-arm_description
group	I-arm_description
and	O
one	O
patient	O
in	O
the	O
trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
monotherapy	O
group	O
had	O
partial	O
response	O
,	O
resulting	O
in	O
a	O
5.0	O
and	O
1.5	O
%	O
ORR	O
for	O
each	O
group	O
,	O
respectively	O
(	O
p	O
=	O
0.35	O
)	O
.	O
Disease	O
control	O
was	O
achieved	O
in	O
32	O
patients	O
(	O
53.3	O
%	O
)	O
in	O
the	O
trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
plus	O
bevacizumab	B-arm_description
group	I-arm_description
and	O
in	O
30	O
patients	O
(	O
45.5	O
%	O
)	O
in	O
the	O
trifluridine	B-arm_description
/	I-arm_description
tipiracil	B-arm_description
monotherapy	O
group	O
(	O
p	O
=	O
0.48	O
)	O
(	O
Table	O
3	O
)	O
.	O
Additionally	O
,	O
proportion	O
of	O
patients	O
with	O
6	O
months	O
or	O
longer	O
of	O
disease	O
control	O
were	O
significantly	O
higher	O
in	O
the	O
trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
plus	O
bevacizumab	B-arm_description
group	I-arm_description
than	O
the	O
trifluridine	B-arm_description
/	I-arm_description
tipiracil	I-arm_description
monotherapy	O
group	O
(	O
26.7	O
%	O
vs.	O
12.1	O
%	O
,	O
p	O
=	O
0.04	O
)	O
.	O

Multicenter	B-study_type
,	I-study_type
randomised	I-study_type
,	I-study_type
open	I-study_type
-	I-study_type
label	I-study_type
,	I-study_type
non	I-study_type
-	I-study_type
comparative	I-study_type
phase	I-study_type
2	I-study_type
trial	I-study_type
on	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
combination	O
of	O
bevacizumab	B-arm_description
and	I-arm_description
trabectedin	I-arm_description
with	O
or	O
without	O
carboplatin	B-arm_efficacy_metric
in	O
women	O
with	O
partially	O
platinum	O
-	O
sensitive	O
recurrent	O
ovarian	O
cancer	O
20	O
September	O
2019	O

Secondary	O
objectives	O
of	O
the	O
study	O
were	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
(	O
PFS	B-arm_efficacy_metric
)	O
,	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
and	O
the	O
toxicity	O
profile	O
.	O
The	O
secondary	O
efficacy	O
endpoints	O
were	O
evaluated	O
in	O
the	O
PP	O
population	O
.	O
PFS	B-arm_efficacy_metric
was	O
defined	O
as	O
the	O
time	O
between	O
study	O
entry	O
and	O
progression	O
or	O
death	O
for	O
any	O
cause	O
.	O
Subjects	O
with	O
no	O
recurrence	O
or	O
who	O
died	O
while	O
on	O
study	O
were	O
censored	O
at	O
the	O
last	O
disease	O
assessment	O
date	O
.	O
OS	O
was	O
defined	O
as	O
the	O
time	O
between	O
the	O
study	O
entry	O
and	O
death	O
,	O
regardless	O
of	O
the	O
cause	O
of	O
death	O
.	O
Subjects	O
who	O
were	O
not	O
reported	O
as	O
having	O
died	O
at	O
the	O
time	O
of	O
the	O
analysis	O
were	O
censored	O
at	O
the	O
date	O
they	O
were	O
last	O
known	O
to	O
be	O
alive	O
.	O
Survival	O
curves	O
were	O
estimated	O
by	O
the	O
Kaplan	O
-	O
Meier	O
(	O
KM	O
)	O
method	O
.	O

From	O
July	O
2013	O
through	O
March	O
2016	O
,	O
21	O
patients	O
were	O
randomised	O
to	O
the	O
BT+C	B-arm_description
arm	I-arm_description
.	O
Figure	O
2	O
shows	O
the	O
flow	O
-	O
chart	O
and	O
the	O
populations	O
for	O
primary	O
and	O
secondary	O
analyses	O
.	O
Table	O
1	O
lists	O
the	O
clinical	O
characteristics	O
of	O
the	O
patients	O
with	O
no	O
major	O
violations	O
of	O
eligibility	O
criteria	O
.	O
Median	O
age	O
was	O
59.4	O
years	O
(	O
range	O
54.0	O
-	O
66.1	O
)	O
at	O
study	O
entry	O
;	O
17	O
(	O
85	O
%	O
)	O
patients	O
were	O
facing	O
their	O
first	O
progression	O
of	O
disease	O
and	O
the	O
other	O
3	O
(	O
15	O
%	O
)	O
the	O
second	O
.	O
The	O
median	O
platinumfree	O
interval	O
from	O
the	O
previous	O
platinum	O
-	O
based	O
therapy	O
was	O
8.2	O
months	O
(	O
IQR	O
:	O
6.6	O
-	O
10.7	O
;	O
range	O
6.1	O
-	O
12.8	O
)	O
.	O

In	O
the	O
PP	O
population	O
,	O
CR	O
was	O
observed	O
in	O
9	O
(	O
45	O
%	O
)	O
and	O
PR	O
in	O
8	O
(	O
40	O
%	O
)	O
patients	O
.	O
Three	O
patients	O
(	O
15	O
%	O
)	O
reached	O
SD	O
and	O
none	O
progressed	O
at	O
the	O
first	O
disease	O
assessment	O
.	O

Efficacy	O
and	O
safety	O
for	O
the	O
first	O
stage	O
are	O
illustrated	O
in	O
Table	O
2	O
.	O
The	O
BT+C	B-arm_description
arm	I-arm_description
was	O
not	O
expanded	O
to	O
second	O
stage	O
on	O
account	O
of	O
excessive	O
toxicity	O
.	O

Epithelial	O
tubo	O
-	O
ovarian	O
cancer	O
(	O
ETOC	O
)	O
is	O
the	O
deadliest	O
cancer	O
among	O
women	O
,	O
placing	O
with	O
fourth	O
place	O
of	O
all	O
the	O
fetal	O
diseases	O
among	O
women	O
and	O
ranking	O
seventh	O
of	O
most	O
common	O
cancers	O
in	O
women	O
's	O
cancer	O
and	O
women	O
's	O
cancer	O
-	O
related	O
deaths	O
in	O
Taiwan	O
and	O
globally	O
in	O
2018	O
[	O
1][2][3][4][5][6	O
]	O
.	O
Serous	O
-	O
type	O
is	O
the	O
most	O
common	O
subtype	O
among	O
EOCs	O
in	O
general	O
;	O
however	O
,	O
endometriosis	O
-	O
associated	O
EOCs	O
,	O
such	O
as	O
clear	O
cell	O
type	O
or	O
endometrioid	O
type	O
are	O
relatively	O
common	O
in	O
certain	O
populations	O
,	O
including	O
Taiwan	O
and	O
Japan	O
[	O
7][8][9][10][11	O
]	O
.	O
Clinically	O
,	O
the	O
serous	O
-	O
type	O
EOC	O
and	O
primary	O
peritoneal	O
serous	O
carcinoma	O
(	O
PPSC	O
)	O
and	O
primary	O
Fallopian	O
tube	O
cancer	O
(	O
PFTC	O
)	O
are	O
often	O
considered	O
the	O
same	O
group	O
disease	O
,	O
based	O
on	O
the	O
similar	O
clinical	O
behavior	O
and	O
possibly	O
sharing	O
the	O
similar	O
pathogenesis	O
[	O
12][13][14][15][16][17][18	O
]	O
.	O
In	O
1996	O
,	O
McGuire	O
and	O
colleagues	O
conducted	O
a	O
clinical	O
trial	O
to	O
set	O
up	O
the	O
standard	O
therapy	O
for	O
patients	O
with	O
ETOC	O
,	O
including	O
primary	O
debulking	O
surgery	O
(	O
PDS	O
)	O
,	O
also	O
called	O
primary	O
cytoreductive	O
surgery	O
(	O
PCS	O
)	O
plus	O
adjuvant	O
triweekly	O
paclitaxel	O
and	O
cisplatin	O
therapy	O
[	O
19	O
]	O
.	O
The	O
following	O
studies	O
have	O
confirmed	O
the	O
superiority	O
of	O
survival	O
benefits	O
using	O
paclitaxel	O
into	O
cisplatin	O
-	O
based	O
regimens	O
in	O
place	O
of	O
cyclophosphamide	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
ETOC	O
and	O
PPSC	O
[	O
20,21	O
]	O
.	O
Additionally	O
,	O
carboplatin	O
in	O
place	O
of	O
cisplatin	O
in	O
this	O
combination	O
has	O
statistically	O
significantly	O
reduced	O
the	O
cisplatin	O
-	O
related	O
potential	O
toxicity	O
of	O
neural	O
and	O
renal	O
systems	O
and	O
ameliorated	O
the	O
cisplatin	O
-	O
related	O
high	O
emetic	O
effects	O
[	O
22][23][24][25	O
]	O
.	O

Based	O
on	O
the	O
relative	O
worse	O
prognosis	O
of	O
advanced	O
-	O
stage	O
ETOC	O
and	O
PPSC	O
,	O
many	O
new	O
modalities	O
and	O
strategies	O
have	O
been	O
recently	O
developed	O
[	O
56][57][58][59	O
]	O
.	O
Although	O
some	O
of	O
them	O
have	O
been	O
already	O
recommended	O
by	O
updated	O
NCCN	O
guidelines	O
for	O
ETOC	O
and	O
PPSC	O
treatment	O
[	O
4,26	O
]	O
,	O
they	O
are	O
not	O
widely	O
used	O
in	O
the	O
routine	O
clinical	O
practice	O
[	O
60	O
]	O
.	O
Among	O
these	O
,	O
induction	O
chemotherapy	O
(	O
neoadjuvant	O
chemotherapy	O
-	O
NACT	O
)	O
using	O
either	O
standard	O
form	O
of	O
paclitaxel	O
and	O
carboplatin	O
or	O
its	O
modification	O
form	O
,	O
including	O
dose	O
-	O
dense	O
or	O
high	O
-	O
dose	O
chemotherapy	O
,	O
and	O
in	O
additional	O
adding	O
bevacizumab	O
,	O
has	O
become	O
more	O
and	O
more	O
popular	O
,	O
especially	O
for	O
those	O
patients	O
who	O
are	O
not	O
candidates	O
for	O
immediate	O
PCS	O
[	O
61][62][63][64][65][66][67][68][69	O
]	O
.	O

Therefore	O
,	O
the	O
application	O
of	O
a	O
combination	O
of	O
taxane	O
and	O
platinum	O
in	O
ETOC	O
has	O
been	O
conducted	O
.	O
In	O
the	O
management	O
of	O
all	O
chemosensitive	O
epithelial	O
cancers	O
,	O
combination	O
chemotherapy	O
treatment	O
has	O
provided	O
significant	O
survival	O
benefits	O
compared	O
to	O
single	O
agent	O
chemotherapy	O
when	O
applied	O
as	O
initial	O
therapy	O
,	O
and	O
there	O
is	O
no	O
doubt	O
that	O
the	O
treatment	O
of	O
ETOC	O
is	O
similar	O
in	O
this	O
regard	O
[	O
121	O
]	O
.	O
Studies	O
showed	O
that	O
combination	O
of	O
taxane	O
and	O
platinum	O
compound	O
appears	O
both	O
to	O
attenuate	O
the	O
toxicity	O
of	O
the	O
platinum	O
compound	O
and	O
to	O
facilitate	O
the	O
delivery	O
of	O
full	O
dose	O
on	O
schedule	O
and	O
this	O
full	O
dose	O
on	O
schedule	O
showed	O
the	O
strong	O
correlation	O
with	O
patient	O
outcomes	O
[	O
110	O
]	O
.	O
Since	O
both	O
platinum	O
and	O
paclitaxel	O
are	O
the	O
essential	O
cytotoxic	O
agents	O
in	O
ETOC	O
patients	O
after	O
PCS	O
,	O
either	O
any	O
one	O
or	O
both	O
can	O
be	O
administered	O
as	O
dose	O
-	O
dense	O
protocol	O
.	O
Furthermore	O
,	O
dose	O
-	O
dense	O
can	O
be	O
classified	O
according	O
to	O
the	O
types	O
,	O
including	O
semiweekly	O
dose	O
-	O
dense	O
,	O
in	O
which	O
paclitaxel	O
was	O
given	O
weekly	O
and	O
carboplatin	O
was	O
given	O
triweekly	O
,	O
and	O
weekly	O
dose	O
dense	O
,	O
in	O
which	O
both	O
paclitaxel	O
and	O
carboplatin	O
were	O
given	O
weekly	O
[	O
47	O
]	O
.	O
An	O
accumulation	O
dose	O
of	O
paclitaxel	O
is	O
240	O
-	O
270	O
mg	O
/	O
m	O
2	O
with	O
separating	O
into	O
80	O
-	O
90	O
mg	O
/	O
m	O
2	O
per	O
week	O
compared	O
to	O
a	O
single	O
use	O
of	O
175	O
-	O
180	O
mg	O
/	O
m	O
2	O
every	O
three	O
weeks	O
.	O
By	O
contrast	O
,	O
the	O
dosage	O
of	O
carboplatin	O
seems	O
to	O
be	O
consistent	O
with	O
accumulation	O
dose	O
as	O
AUC	O
5	O
-	O
7	O
,	O
regardless	O
of	O
administration	O
triweekly	O
(	O
a	O
single	O
use	O
of	O
AUC	O
5	O
-	O
7	O
)	O
or	O
weekly	O
(	O
AUC	O
2	O
)	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
effects	O
and	O
safety	O
of	O
dose	O
-	O
dense	O
of	O
paclitaxel	B-arm_description
combining	B-arm_description
with	O
either	O
cisplatin	O
or	O
carboplatin	B-arm_description
,	O
the	O
following	O
retrospective	B-study_type
study	I-study_type
was	O
conducted	O
.	O
Patients	O
with	O
FIGO	O
IIIC	O
serous	O
-	O
type	O
ETOC	O
and	O
PPSC	O
treated	O
either	O
with	O
triweekly	B-arm_dosage
cisplatin	B-arm_description
(	I-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
plus	B-arm_description
dose	I-arm_dosage
-	I-arm_dosage
dense	I-arm_dosage
weekly	I-arm_dosage
paclitaxel	B-arm_description
(	I-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
or	O
triweekly	B-arm_dosage
carboplatin	I-arm_dosage
(	I-arm_dosage
AUC	I-arm_dosage
5	I-arm_dosage
)	I-arm_dosage
plus	I-arm_dosage
dose	I-arm_dosage
-	I-arm_dosage
dense	I-arm_dosage
weekly	I-arm_dosage
paclitaxel	I-arm_dosage
(	I-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
as	O
postoperative	O
adjuvant	O
chemotherapy	O
after	O
PCS	O
were	O
retrospectively	O
reviewed	O
.	O
However	O
,	O
nearly	O
all	O
dose	O
-	O
dense	O
paclitaxel	B-arm_description
-	O
platinum	O
combination	O
chemotherapy	O
regimens	O
used	O
as	O
the	O
front	O
-	O
line	O
postoperative	O
adjuvant	O
therapy	O
are	O
focused	O
on	O
the	O
dose	O
-	O
dense	O
paclitaxel	B-arm_description
,	O
without	O
consideration	O
of	O
either	O
the	O
platinum	O
compounds	O
or	O
the	O
dose	O
-	O
dense	O
agents	O
.	O

All	O
patients	O
underwent	O
PCS	O
initially	O
and	O
then	O
were	O
treated	O
with	O
weekly	O
paclitaxel	B-arm_description
(	I-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
plus	B-arm_description
either	I-arm_dosage
triweekly	I-arm_dosage
cisplatin	B-arm_description
(	I-arm_dosage
20	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
or	O
triweekly	B-arm_dosage
carboplatin	B-arm_description
(	I-arm_dosage
AUC	I-arm_dosage
5	I-arm_dosage
)	I-arm_dosage
.	O
Paclitaxel	B-arm_description
was	I-arm_dosage
administered	I-arm_dosage
over	I-arm_dosage
2	I-arm_dosage
h	I-arm_dosage
intravenously	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
,	I-arm_dosage
8	I-arm_dosage
,	I-arm_dosage
and	I-arm_dosage
15	I-arm_dosage
,	O
and	B-arm_dosage
either	O
cisplatin	B-arm_description
for	I-arm_dosage
1	I-arm_dosage
h	I-arm_dosage
or	O
carboplatin	B-arm_description
for	I-arm_dosage
1	I-arm_dosage
h	I-arm_dosage
on	I-arm_dosage
day	I-arm_dosage
1	I-arm_dosage
was	I-arm_dosage
infused	I-arm_dosage
intravenously	I-arm_dosage
.	O
Premedication	O
including	O
dexamethasone	O
(	O
20	O
mg	O
)	O
,	O
2000	O
ml	O
of	O
normal	O
saline	O
,	O
and	O
palonosetron	O
(	O
250	O
ug	O
)	O
was	O
prescribed	O
intravenously	O
during	O
the	O
chemotherapy	O
therapy	O
day	O
.	O
When	O
grade	O
3/4	O
neutropenia	O
occurred	O
,	O
the	O
patients	O
were	O
treated	O
with	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
GCSF	O
)	O
for	O
three	O
days	O
before	O
chemotherapy	O
.	O
However	O
,	O
treatment	O
was	O
delayed	O
if	O
febrile	O
neutropenia	O
or	O
grade	O
3/4	O
neutropenia	O
without	O
correction	O
was	O
noted	O
.	O
If	O
a	O
three	O
-	O
fold	O
increase	O
in	O
liver	O
enzymes	O
of	O
patients	O
was	O
detected	O
,	O
paclitaxel	B-arm_description
(	I-arm_dosage
60	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
was	O
used	O
.	O
The	O
cisplatin	B-arm_description
dose	O
was	O
decreased	O
to	O
half	O
dosage	O
if	O
the	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
)	O
was	O
decreased	O
to	O
45	O
-	O
60	O
ml	O
/	O
min	O
,	O
which	O
was	O
calculated	O
using	O
the	O
Cockcroft	O
-	O
Gault	O
formula	O
[	O
122][123][124	O
]	O
.	O

During	O
the	O
whole	O
study	O
period	O
with	O
a	O
median	O
follow	O
-	O
up	O
time	O
of	O
55	O
months	O
(	O
at	O
the	O
time	O
of	O
the	O
data	O
cutoff	O
on	O
30	O
June	O
2019	O
)	O
,	O
disease	O
progression	O
and/or	O
disease	O
-	O
related	O
death	O
occurred	O
in	O
23	O
patients	O
(	O
57.5	O
%	O
)	O
.	O
As	O
was	O
presented	O
in	O
Figure	O
1	O
,	O
the	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
was	O
25.0	B-arm_efficacy_results
months	I-arm_efficacy_results
in	O
patients	O
treated	O
with	O
the	O
paclitaxel	B-arm_description
-	I-arm_description
carboplatin	I-arm_description
regimen	O
,	O
and	O
30.0	B-arm_efficacy_results
months	I-arm_efficacy_results
in	O
patients	O
treated	O
with	O
the	O
paclitaxel	B-arm_description
-	I-arm_description
cisplatin	I-arm_description
regimen	O
,	O
without	O
a	O
statistically	O
significant	O
difference	O
.	O
The	O
median	O
OS	O
was	O
55.0	O
months	O
and	O
58.5	O
months	O
in	O
patients	O
treated	O
with	O
paclitaxel	B-arm_description
-	I-arm_description
carboplatin	I-arm_description
and	O
paclitaxel	B-arm_description
-	I-arm_description
cisplatin	I-arm_description
regimens	O
,	O
respectively	O
(	O
Figure	O
2	O
)	O
.	O
There	O
was	O
also	O
no	O
statistically	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O
Table	O
2	O
.	O
Adverse	O
events	O
the	O
patients	O
with	O
FIGO	O
IIIC	O
serous	O
type	O
epithelial	O
tubo	O
-	O
ovarian	O
cancer	O
,	O
or	O
primary	O
peritoneal	O
carcinoma	O
treated	O
with	O
weekly	O
paclitaxel	B-arm_description
(	I-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
plus	O
either	O
carboplatin	B-arm_description
(	I-arm_dosage
AUC	I-arm_dosage
5	I-arm_dosage
)	I-arm_dosage
or	O
cisplatin	B-arm_description
(	I-arm_dosage
20mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
combination	O
chemotherapy	O
triweekly	B-arm_dosage
.	O

Addressing	O
Dose	O
-	O
Dense	O
therapy	O
:	O
Survival	O
Outcome	O
(	O
Table	O
5	O
)	O
Some	O
early	O
phase	O
studies	O
have	O
also	O
been	O
conducted	O
to	O
test	O
the	O
tolerability	O
and	O
efficacy	O
of	O
dose	O
-	O
dense	O
weekly	O
paclitaxel	B-arm_description
(	I-arm_dosage
80	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	I-arm_dosage
and	O
triweekly	O
carboplatin	B-arm_description
(	I-arm_dosage
AUC	I-arm_dosage
5	O
)	O
with	O
other	O
agents	O
[	O
132,133	O
]	O
.	O
For	O
example	O
,	O
one	O
phase	O
II	O
study	O
modified	O
a	O
dose	O
-	O
dense	O
paclitaxel	O
(	O
80	O
mg	O
/	O
m	O
2	O
)	O
and	O
carboplatin	O
(	O
AUC	O
5	O
)	O
every	O
four	O
weeks	O
for	O
the	O
treatment	O
of	O
advanced	O
-	O
stage	O
ETOC	O
patients	O
,	O
and	O
found	O
that	O
the	O
median	O
PFS	O
and	O
OS	O
were	O
22.5	O
and	O
31.5	O
months	O
,	O
respectively	O
[	O
132	O
]	O
.	O
Another	O
phase	O
II	O
study	O
adding	O
bevacizumab	O
in	O
dose	O
-	O
dense	O
chemotherapy	O
(	O
weekly	O
paclitaxel	O
80	O
mg	O
/	O
m	O
2	O
and	O
triweekly	O
carboplatin	O
AUC	O
5	O
)	O
showed	O
that	O
the	O
median	O
PFS	O
was	O
16.9	O
-	O
22.4	O
months	O
in	O
advanced	O
-	O
stage	O
ETOC	O
patients	O
[	O
133	O
]	O
.	O

Consistent	O
with	O
the	O
increased	O
toxicity	O
of	O
the	O
use	O
of	O
carboplatin	O
in	O
previous	O
studies	O
[	O
136	O
]	O
,	O
the	O
incidence	O
of	O
grade	O
3/4	O
neutropenia	O
was	O
significantly	O
lower	O
in	O
the	O
cisplatin	B-arm_description
-	I-arm_description
paclitaxel	I-arm_description
arm	O
than	O
in	O
that	O
of	O
the	O
carboplatin	B-arm_description
-	I-arm_description
paclitaxel	I-arm_description
arm	O
(	O
27.8	O
%	O
versus	O
77.3	O
%	O
,	O
p	O
=	O
0.002	O
)	O
in	O
our	O
study	O
.	O
In	O
addition	O
,	O
other	O
parameters	O
of	O
hematological	O
examination	O
,	O
including	O
grade	O
3/4	O
anemia	O
and	O
grade	O
3/4	O
thrombocytopenia	O
also	O
favored	O
the	O
cisplatin	B-arm_description
-	I-arm_description
paclitaxel	I-arm_description
regimen	O
with	O
incidence	O
of	O
5.6	O
%	O
and	O
none	O
,	O
respectively	O
,	O
compared	O
to	O
22.7	O
%	O
and	O
13.6	O
%	O
in	O
the	O
carboplatin	B-arm_description
-	I-arm_description
paclitaxel	I-arm_description
regimen	O
in	O
the	O
current	O
study	O
.	O
We	O
believe	O
that	O
this	O
carboplatin	B-arm_description
-	I-arm_description
paclitaxel	I-arm_description
combination	O
therapy	O
-	O
related	O
hematotoxicity	O
might	O
explain	O
why	O
more	O
patients	O
in	O
the	O
carboplatin	B-arm_description
-	I-arm_description
paclitaxel	I-arm_description
arm	O
had	O
a	O
prolongation	O
of	O
the	O
period	O
between	O
the	O
initial	O
first	O
dose	O
of	O
chemotherapy	O
and	O
the	O
final	O
dose	O
of	O
chemotherapy	O
(	O
six	O
cycles	O
of	O
chemotherapy	O
)	O
than	O
those	O
in	O
the	O
cisplatin	B-arm_description
-	I-arm_description
paclitaxel	I-arm_description
arm	O
(	O
45	O
%	O
versus	O
11.1	O
%	O
,	O
p	O
=	O
0.018	O
)	O
.	O
Further	O
survival	O
analysis	O
showed	O
that	O
this	O
prolongation	O
of	O
the	O
therapeutic	O
period	O
might	O
be	O
associated	O
with	O
a	O
worse	O
outcome	O
in	O
FIGO	O
IIIC	O
ETOC	O
and	O
PPSC	O
patients	O
.	O

The	O
current	O
study	O
has	O
the	O
following	O
strengths	O
:	O
All	O
patients	O
were	O
serous	O
-	O
type	O
ETOC	O
and	O
PPSC	O
with	O
FIGO	O
stage	O
IIIC	O
.	O
The	O
follow	O
-	O
up	O
period	O
was	O
long	O
enough	O
,	O
of	O
nearly	O
5	O
years	O
(	O
a	O
mean	O
follow	O
-	O
up	O
period	O
of	O
55	O
months	O
)	O
.	O
All	O
patients	O
were	O
treated	O
with	O
by	O
one	O
senior	O
doctor	O
(	O
P.-H.W	O
)	O
.	O
All	O
the	O
suggested	O
study	O
population	O
was	O
homogeneous	O
.	O

Squamous	O
cell	O
lung	O
cancer	O
(	O
SCC	O
)	O
accounts	O
for	O
approximately	O
20%-30	O
%	O
of	O
all	O
lung	O
cancers	O
.	O
However	O
,	O
in	O
contrast	O
to	O
the	O
notable	O
advances	O
in	O
the	O
treatment	O
of	O
metastatic	O
non	O
-	O
SCC	O
due	O
to	O
genetic	O
alterations	O
,	O
the	O
first	O
-	O
line	O
treatment	O
of	O
SCC	O
has	O
not	O
necessarily	O
been	O
established	O
.	O
Although	O
the	O
efficacy	O
of	O
immune	O
checkpoint	O
inhibitors	O
has	O
been	O
previously	O
demonstrated	O
,	O
platinum	O
-	O
based	O
cytotoxic	O
therapy	O
is	O
still	O
considered	O
a	O
cornerstone	O
of	O
the	O
treatment	O
of	O
SCC	O
.	O
1	O
In	O
clinical	O
practice	O
,	O
the	O
conventional	O
regimens	O
for	O
SCC	O
include	O
a	O
combination	O
of	O
cisplatin	O
or	O
carboplatin	O
with	O
taxanes	O
,	O
gemcitabine	O
,	O
and	O
S-1	O
based	O
chemotherapy	O
.	O
However	O
,	O
the	O
median	O
overall	O
survival	O
remains	O
approximately	O
12	O
-	O
17	O
months	O
,	O
regardless	O
of	O
the	O
occurrence	O
of	O
severe	O
adverse	O
events	O
.	O
[	O
2][3][4][5][6][7	O
]	O
Therefore	O
,	O
a	O
novel	O
combination	O
of	O
anticancer	O
agents	O
leading	O
to	O
fewer	O
severe	O
adverse	O
events	O
is	O
required	O
for	O
the	O
treatment	O
of	O
SCC	O
patients	O
.	O

This	O
study	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
.	O
The	O
study	O
protocol	O
was	O
reviewed	O
and	O
approved	O
by	O
the	O
institutional	O
review	O
boards	O
of	O
the	O
participating	O
institutions	O
,	O
and	O
a	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
patients	O
.	O
This	O
trial	O
was	O
registered	O
with	O
University	O
Hospital	O
Medical	O
Information	O
Network	O
(	O
UMIN000003282	O
)	O
.	O

All	O
patients	O
received	O
nedaplatin	B-arm_description
(	O
100	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	O
intravenously	B-arm_dosage
on	I-arm_dosage
day	I-arm_dosage
1	I-arm_dosage
and	O
amrubicin	B-arm_description
(	O
25	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	O
on	B-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
-	I-arm_dosage
3	I-arm_dosage
every	I-arm_dosage
4	I-arm_dosage
weeks	I-arm_dosage
.	O
Each	O
patient	O
received	O
a	O
minimum	B-arm_dosage
of	I-arm_dosage
three	I-arm_dosage
cycles	I-arm_dosage
until	O
the	O
onset	O
of	O
a	O
progressive	O
disease	O
or	O
unacceptable	O
toxicity	O
.	O
The	O
maximal	O
number	O
of	O
chemotherapy	O
cycles	O
was	O
six	O
;	O
however	O
,	O
the	O
patients	O
underwent	O
more	O
cycles	O
,	O
if	O
necessary	O
.	O

The	O
response	O
was	O
investigator	O
-	O
determined	O
according	O
to	O
RECIST	O
version	O
1.1	O
.	O
All	O
adverse	O
events	O
were	O
recorded	O
and	O
classified	O
by	O
grade	O
according	O
to	O
the	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
(	O
CTCAE	O
)	O
version	O
4.0	O
.	O

PRISM	O
protocol	O
:	O
a	O
randomised	B-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type
of	O
nivolumab	B-arm_description
in	O
combination	O
with	O
alternatively	O
scheduled	O
ipilimumab	B-arm_description
in	O
firstline	O
treatment	O
of	O
patients	O
with	O
advanced	O
or	O
metastatic	O
renal	O
cell	O
carcinoma	O

Leeds	O
Institute	O
of	O
Medical	O
Research	O
at	O
St	O
James	O
's	O
,	O
St.	O
James	O
's	O
University	O
Hospital	O
Beckett	O
Street	O
LS9	O
7TF	O
Leeds	O
UK	O
GalinaVelikova	B-authors
University	O
of	O
Leeds	O
LS9	O
7TF	O
Leeds	O
UK	O
TomWaddell	B-authors

UK	O
RosamondeEBanks	B-authors
Rosamonde	B-authors
E	I-authors
Banks	I-authors
Leeds	O
Institute	O
of	O
Medical	O
Research	O
at	O
St	O
James	O
's	O
,	O
St.	O
James	O
's	O
University	O
Hospital	O
Beckett	O
Street	O
LS9	O
7TF	O
Leeds	O

UK	O
Beckett	O
Street	O
LS9	O
7TF	O
Leeds	O
UK	O
Leeds	O
Institute	O
of	O
Medical	O
Research	O
at	O
St	O
James	O
's	O
,	O
St.	O
James	O
's	O
University	O
Hospital	O
Beckett	O
Street	O
LS9	O
7TF	O
Leeds	O

Kidney	O
cancer	O
is	O
the	O
14th	O
most	O
common	O
cancer	O
worldwide	O
with	O
an	O
estimated	O
400,000	O
new	O
cases	O
,	O
and	O
175,000	O
attributable	O
deaths	O
,	O
in	O
2018	O
[	O
1	O
]	O
.	O
The	O
majority	O
of	O
kidney	O
cancers	O
(	O
90	O
%	O
)	O
are	O
renal	O
cell	O
carcinomas	O
(	O
RCC	O
)	O
,	O
most	O
of	O
which	O
(	O
75	O
%	O
)	O
are	O
of	O
the	O
clear	O
cell	O
subtype	O
[	O
2	O
]	O
.	O

Studies	O
in	O
other	O
cancer	O
types	O
demonstrate	O
ipilimumab	O
dose	O
and	O
/	O
or	O
frequency	O
can	O
affect	O
the	O
toxicity	O
and	O
efficacy	O
of	O
treatment	O
.	O
In	O
advanced	O
melanoma	O
,	O
for	O
example	O
,	O
10	O
mg/	O
kg	O
ipilimumab	O
every	O
3	O
weeks	O
for	O
4	O
doses	O
was	O
associated	O
with	O
longer	O
median	O
OS	O
but	O
higher	O
rates	O
of	O
grade	O
3	O
or	O
4	O
toxicity	O
,	O
in	O
comparison	O
to	O
3	O
mg	O
/	O
kg	O
dosing	O
[	O
10	O
]	O
.	O
A	O
recently	O
reported	O
melanoma	O
trial	O
comparing	O
I3	O
+	O
N1	O
versus	O
I1	O
+	O
N3	O
again	O
showed	O
a	O
favourable	O
toxicity	O
profile	O
associated	O
with	O
a	O
lower	O
dose	O
of	O
ipilimumab	O
,	O
with	O
no	O
apparent	O
difference	O
in	O
efficacy	O
at	O
a	O
minimum	O
follow	O
-	O
up	O
of	O
12	O
months	O
[	O
11	O
]	O
.	O
Varying	O
doses	O
and	O
schedules	O
of	O
ipilimumab	O
plus	O
nivolumab	O
have	O
also	O
been	O
examined	O
amongst	O
8	O
cohorts	O
within	O
the	O
phase	O
Ib	O
CM012	O
study	O
in	O
patients	O
with	O
nonsmall	O
cell	O
lung	O
cancer	O
,	O
including	O
nivolumab	O
3	O
mg	O
/	O
kg	O
q2W	O
plus	O
ipilimumab	O
1	O
mg	O
/	O
kg	O
given	O
either	O
6-(n	O
=	O
39	O
)	O
or	O
12-(n	O
=	O
38	O
)	O
weekly	O
[	O
12	O
]	O
.	O
The	O
schedule	O
N3	O
(	O
2-weekly	O
)	O
+	O
I1	O
(	O
6weekly	O
)	O
was	O
selected	O
for	O
phase	O
III	O
evaluation	O
based	O
on	O
its	O
safety	O
and	O
efficacy	O
profile	O
[	O
13	O
]	O
.	O
Thus	O
,	O
formal	O
investigation	O
of	O
the	O
scheduling	O
of	O
ipilimumab	O
when	O
given	O
in	O
combination	O
with	O
nivolumab	O
in	O
patients	O
with	O
mRCC	O
is	O
warranted	O
.	O

The	O
primary	O
aim	O
of	O
the	O
PRISM	O
trial	O
is	O
to	O
assess	O
whether	O
the	O
proposed	O
alternative	O
scheduling	O
of	O
ipilimumab	B-arm_description
(	O
12-weekly	O
)	O
,	O
when	O
given	O
in	O
combination	O
with	O
nivolumab	B-arm_description
,	O
warrants	O
further	O
consideration	O
based	O
on	O
safety	O
and	O
efficacy	O
,	O
as	O
defined	O
by	O
the	O
proportion	O
of	O
participants	O
experiencing	O
a	O
grade	O
3	O
or	O
4	O
adverse	O
reaction	O
(	O
AR	O
)	O
within	O
12	O
months	O
and	O
12-month	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
(	O
PFS	B-arm_efficacy_metric
)	O
.	O

We	O
expect	O
approximately	O
40	O
%	O
of	O
participants	O
to	O
experience	O
a	O
grade	O
3	O
or	O
4	O
AR	O
within	O
the	O
initial	O
12	O
months	O
of	O
treatment	O
when	O
treated	O
with	O
the	O
standard	O
schedule	O
(	O
Arm	B-arm_description
B	I-arm_description
)	O
[	O
18	O
]	O
.	O
To	O
detect	O
a	O
clinically	O
relevant	O
reduction	O
to	O
22	O
%	O
with	O
the	O
modified	O
schedule	O
(	O
Arm	B-arm_description
A	I-arm_description
)	O
(	O
equivalent	O
to	O
a	O
45	O
%	O
relative	O
reduction	O
;	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
0.423	O
)	O
,	O
with	O
80	O
%	O
power	O
at	O
the	O
two	O
-	O
sided	O
10	O
%	O
significance	O
level	O
,	O
would	O
require	O
178	O
participants	O
,	O
allowing	O
for	O
5	O
%	O
attrition	O
.	O

Randomisation	O
will	O
be	O
performed	O
following	O
confirmation	O
of	O
eligibility	O
(	O
and	O
prior	O
to	O
any	O
trial	O
treatment	O
)	O
via	O
a	O
central	O
automated	O
24-h	O
system	O
(	O
provided	O
by	O
University	O
of	O
Leeds	O
)	O
to	O
either	O
the	O
modified	O
schedule	O
or	O
the	O
standard	O
schedule	O
on	O
a	O
2:1	O
allocation	O
ratio	O
in	O
favour	O
of	O
the	O
modified	O
schedule	O
.	O
A	O
computer	O
-	O
generated	O
minimisation	O
programme	O
incorporating	O
a	O
random	O
element	O
generated	O
by	O
the	O
independent	O
CTRU	O
Statisticians	O
will	O
be	O
used	O
to	O
ensure	O
treatment	O
groups	O
are	O
well	O
balanced	O
proportionately	O
with	O
respect	O
to	O
:	O
IMDC	O
prognostic	O
group	O
(	O
favourable	O
/	O
intermediate	O
/	O
poor	O
risk	O
)	O
;	O
nephrectomy	O
status	O
(	O
nephrectomy	O
/	O
no	O
nephrectomy	O
)	O
;	O
and	O
disease	O
type	O
(	O
metastatic	O
/	O
locally	O
advanced	O
)	O
.	O
Irrespective	O
of	O
their	O
randomised	O
allocation	O
,	O
participants	O
should	O
commence	O
therapy	O
within	O
14	O
days	O
of	O
randomisation	O
.	O

Participants	O
who	O
have	O
undergone	O
any	O
prior	O
systemic	O
anti	O
-	O
cancer	O
treatment	O
,	O
including	O
with	O
an	O
anti	O
-	O
PD-1	O
,	O
anti	O
-	O
PD	O
-	O
L1	O
,	O
anti	O
-	O
PD	O
-	O
L2	O
,	O
anti	O
-	O
CTLA-4	O
antibody	O
,	O
or	O
any	O
other	O
antibody	O
or	O
drug	O
specifically	O
targeting	O
T	O
-	O
cell	O
co	O
-	O
stimulation	O
or	O
immune	O
checkpoint	O
pathways	O
(	O
previous	O
participation	O
in	O
adjuvant	O
studies	O
allowed	O
,	O
providing	O
the	O
patient	O
was	O
on	O
the	O
observation	O
/	O
placebo	O
armthis	O
may	O
require	O
unblinding	O
of	O
the	O
patient	O
)	O
Patients	O
should	O
be	O
excluded	O
if	O
they	O
have	O
a	O
condition	O
requiring	O
systemic	O
treatment	O
with	O
either	O
corticosteroids	O
(	O
>	O
10	O
mg	O
daily	O
prednisone	O
or	O
equivalent	O
)	O
or	O
other	O
immunosuppressive	O
medications	O
within	O
14	O
days	O
of	O
study	O
drug	O
administration	O
.	O
(	O
Inhaled	O
or	O
topical	O
steroids	O
and	O
adrenal	O
replacement	O
doses	O
>	O
10	O
mg	O
daily	O
prednisone	O
equivalents	O
are	O
permitted	O
in	O
the	O
absence	O
of	O
active	O
autoimmune	O
disease	O
)	O
.	O

Analyses	O
will	O
be	O
conducted	O
following	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
principles	O
(	O
unless	O
otherwise	O
stated	O
a	O
priori	O
)	O
meaning	O
participants	O
will	O
be	O
analysed	O
in	O
the	O
group	O
to	O
which	O
they	O
were	O
randomised	O
regardless	O
of	O
compliance	O
or	O
cross	O
-	O
over	O
.	O
Participants	O
will	O
be	O
included	O
in	O
the	O
primary	O
and	O
key	O
secondary	O
analyses	O
provided	O
they	O
have	O
received	O
at	O
least	O
one	O
dose	O
of	O
trial	O
treatment	O
and	O
have	O
provided	O
the	O
relevant	O
outcome	O
data	O
.	O

Concordance	O
of	O
real	O
-	O
world	O
versus	O
conventional	O
progression	O
-	O
free	O
survival	O
from	O
a	O
phase	B-study_type
3	I-study_type
trial	I-study_type
of	O
endocrine	O
therapy	O
as	O
first	O
-	O
line	O
treatment	O
for	O
metastatic	O
breast	O
cancer	O
CynthiaHuang	B-authors

cynthia.huang@pfizer.com	O
CynthiaHuang	B-authors
Cynthia	B-authors
Huang	I-authors
cynthia.huang@pfizer.com	O
Bartlett1	B-authors
☯	O
Bartlett1	B-authors
☯	O
Bartlett	B-authors
1	O
☯	O
JackMardekian1	B-authors
☯	O
JackMardekian1	B-authors
☯	O
Jack	B-authors
Mardekian	I-authors
1	O
☯	O
MatthewJamesCotter	B-authors
MatthewJamesCotter	B-authors
Matthew	B-authors
James	I-authors
Cotter	I-authors
XinHuang	B-authors
XinHuang	B-authors
Xin	B-authors
Huang	I-authors
ZheZhang1	B-authors
☯	O
ZheZhang1	B-authors
☯	O
Zhe	B-authors
Zhang	I-authors
1	O
☯	O
ChristinaMParrinello	B-authors
Flatiron	O
Health	O
New	O
York	O
NY	O

0000	O
-	O
0002	O
-	O
9838	O
-	O
0544	O
ArielBulua	B-authors
Ariel	B-authors
Bulua	I-authors
0000	O
-	O
0002	O
-	O
9838	O
-	O
0544	O
2	O
☯	O
1	O
Pfizer	O
Inc	O
New	O
York	O
NY	O

Funding	O
:	O
These	O
analyses	O
and	O
the	O
studies	O
included	O
in	O
these	O
analyses	O
(	O
NCT01740427	O
)	O
were	O
sponsored	O
by	O
Pfizer	O
Inc.	O
The	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
data	O
used	O
are	O
derived	O
from	O
the	O
Flatiron	O
Health	O
Analytic	O
electronic	O
health	O
record	O
database	O
as	O
reported	O
in	O
the	O
manuscript	O
and	O
were	O
purchased	O
by	O
Pfizer	O
from	O
Flatiron	O
Health	O
Inc.	O
,	O
an	O
independent	O
subsidiary	O
of	O
the	O
Roche	O
Group	O
.	O
Editorial	O
and	O
medical	O
writing	O
support	O
was	O
provided	O
by	O
Catherine	O
Grillo	O
,	O
of	O
Complete	O
Healthcare	O
Communications	O
,	O
LLC	O
(	O
North	O
Wales	O
,	O
PA	O
)	O
,	O
a	O
CHC	O
Group	O
company	O
,	O
and	O
was	O
funded	O
by	O
Pfizer	O
.	O
The	O
authors	O
also	O
wish	O
to	O
thank	O
Amy	O
P.	O
Abernethy	O
,	O
MD	O
,	O
PhD	O
,	O
for	O
her	O
work	O
on	O
developing	O
this	O
manuscript	O
while	O
at	O
Flatiron	O
Health	O
Inc.	O
;	O
Dr.	O
Abernethy	O
's	O
participation	O
in	O
the	O
development	O
of	O
this	O
manuscript	O
occurred	O
prior	O
to	O
her	O
appointment	O
as	O
Principal	O
Deputy	O
Commissioner	O
of	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
.	O
Cynthia	B-authors
Huang	I-authors
Bartlett	I-authors
is	O
a	O
former	O
employee	O
of	O
Pfizer	O
Inc.	O
Jack	B-authors
Mardekian	I-authors
,	O
Matthew	B-authors
James	I-authors
Cotter	I-authors
,	O
Xin	B-authors
Huang	I-authors
and	O
Zhe	B-authors
Zhang	I-authors
are	O
employed	O
by	O
Pfizer	O
Inc.	O
Pfizer	O
Inc	O
provided	O
support	O
in	O
the	O
form	O
of	O
salaries	O
for	O
authors	O
CHB	O
,	O
JM	O
,	O
MJC	O
,	O
XH	O
and	O
ZZ	O
,	O
study	O
design	O
,	O
data	O
collection	O
,	O
and	O
data	O
analysis	O
.	O
The	O
interpretation	O
of	O
the	O
data	O
,	O
the	O
content	O
of	O
the	O
manuscript	O
,	O
and	O
the	O
decision	O
to	O
publish	O
were	O
at	O
the	O
discretion	O
of	O
the	O
authors	O
.	O
Christina	B-authors
M.	I-authors
Parrinello	I-authors
and	O
Ariel	B-authors
Bulua	I-authors
Bourla	I-authors
are	O
employed	O
by	O
Flatiron	O
Health	O
.	O
Flatiron	O
Health	O
provided	O
support	O
in	O
the	O
form	O
of	O
study	O
design	O
,	O
data	O
collection	O
and	O
management	O
,	O
and	O
salaries	O
for	O
authors	O
CMP	O
and	O
ABB	O
,	O
but	O
did	O
not	O
have	O
any	O
additional	O
role	O
in	O
the	O
data	O
analysis	O
,	O
decision	O
to	O
publish	O
,	O
or	O
preparation	O
of	O
the	O
manuscript	O
.	O

The	O
Flatiron	O
real	O
-	O
world	O
dataset	O
is	O
covered	O
under	O
the	O
Health	O
Insurance	O
Portability	O
and	O
Accountability	O
Act	O
of	O
1996	O
(	O
HIPAA	O
)	O
through	O
Business	O
Associate	O
Agreements	O
with	O
every	O
provider	O
in	O
the	O
Flatiron	O
network	O
.	O
These	O
agreements	O
authorize	O
Flatiron	O
to	O
collect	O
and	O
de	O
-	O
identify	O
patient	O
-	O
level	O
structured	O
and	O
unstructured	O
data	O
to	O
create	O
de	O
-	O
identified	O
data	O
sets	O
for	O
research	O
purposes	O
.	O
Processed	O
data	O
are	O
de	O
-	O
identified	O
according	O
to	O
either	O
the	O
Safe	O
Harbor	O
or	O
Expert	O
Determination	O
method	O
as	O
outlined	O
in	O
HIPAA	O
Section	O
164.514(b	O
)	O
.	O
When	O
using	O
the	O
Expert	O
Determination	O
method	O
,	O
Flatiron	O
employs	O
a	O
third	O
-	O
party	O
expert	O
to	O
design	O
the	O
de	O
-	O
identification	O
methodology	O
and	O
certify	O
that	O
the	O
dataset	O
is	O
de	O
-	O
identified	O
.	O
Only	O
de	O
-	O
identified	O
data	O
is	O
delivered	O
to	O
clients	O
.	O
Institutional	O
Review	O
Board	O
(	O
IRB	O
)	O
approval	O
was	O
obtained	O
for	O
this	O
study	O
;	O
informed	O
consent	O
was	O
waived	O
by	O
the	O
IRB	O
as	O
the	O
study	O
was	O
retrospective	O
and	O
non	O
-	O
interventional	O
,	O
using	O
routinely	O
collected	O
data	O
.	O
Details	O
on	O
the	O
IRB	O
are	O
available	O
in	O
S1	O
Appendix	O
.	O

Propensity	O
scores	O
were	O
generated	O
using	O
a	O
multivariable	O
logistic	O
model	O
executed	O
on	O
data	O
from	O
107	O
real	O
-	O
world	O
patients	O
and	O
222	O
PALOMA-2	O
patients	O
.	O
Study	O
origin	O
(	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
or	O
PALOMA-2	O
)	O
was	O
used	O
as	O
an	O
outcome	O
and	O
potential	O
baseline	O
confounders	O
were	O
included	O
as	O
covariates	O
,	O
having	O
been	O
selected	O
based	O
on	O
the	O
authors	O
'	O
clinical	O
judgment	O
.	O
Covariates	O
included	O
were	O
age	O
,	O
race	O
,	O
disease	O
stage	O
at	O
diagnosis	O
(	O
I	O
-	O
IV	O
or	O
unrecorded	O
/	O
unknown	O
)	O
,	O
ECOG	O
PS	O
score	O
,	O
number	O
of	O
disease	O
sites	O
at	O
diagnosis	O
(	O
1	O
,	O
2	O
,	O
�	O
3	O
)	O
,	O
and	O
bone	O
-	O
only	O
metastases	O
.	O
In	O
order	O
to	O
balance	O
the	O
2	O
study	O
cohorts	O
for	O
duration	O
of	O
follow	O
-	O
up	O
,	O
the	O
propensity	O
score	O
model	O
also	O
included	O
potential	O
follow	O
-	O
up	O
,	O
a	O
baseline	O
measure	O
defined	O
as	O
the	O
number	O
of	O
months	O
from	O
a	O
patient	O
's	O
start	O
of	O
treatment	O
date	O
to	O
the	O
study	O
cutoff	O
:	O
September	O
30	O
,	O
2016	O
for	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
and	O
February	O
26	O
,	O
2016	O
for	O
PALOMA-2	O
.	O

odds	O
ratio	O
:	O
0.92	O
[	O
95	O
%	O
CI	O
,	O
0.56	O
-	O
1.53	O
]	O
;	O
2-sided	O
P	O
=	O
.83	O
)	O
.	O
No	O
significant	O
difference	O
was	O
observed	O
between	O
rwRR	O
and	O
ORR	O
in	O
IPTW	O
adjusted	O
comparisons	O
:	O
41.8	O
%	O
and	O
39.4	O
%	O
,	O
respectively	O
(	O
odds	O
https://doi.org/10.1371/journal.pone.0227256.g002	O

In	O
addition	O
,	O
in	O
contrast	O
to	O
the	O
global	O
PALOMA-2	B-arm_description
study	O
,	O
patients	O
in	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
are	O
all	O
from	O
the	O
US	O
and	O
receive	O
care	O
in	O
routine	O
clinical	O
settings	O
,	O
which	O
may	O
have	O
contributed	O
to	O
the	O
observed	O
differences	O
in	O
the	O
frequency	O
of	O
tumor	O
assessments	O
.	O
The	O
PALOMA-2	B-arm_description
protocol	O
specified	O
that	O
tumor	O
assessments	O
be	O
conducted	O
every	O
12	O
weeks	O
,	O
while	O
in	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
scans	O
were	O
ordered	O
at	O
the	O
discretion	O
of	O
the	O
treating	O
physician	O
.	O
It	O
is	O
noteworthy	O
that	O
12	O
of	O
the	O
patients	O
without	O
tumor	O
assessments	O
had	O
durations	O
of	O
treatment	O
longer	O
than	O
12	O
weeks	O
.	O

Survival	O
benefits	O
of	O
dose	O
-	O
dense	O
early	O
postoperative	O
intraperitoneal	O
chemotherapy	O
in	O
front	O
-	O
line	O
therapy	O
for	O
advanced	O
ovarian	O
cancer	O
:	O
a	O
randomised	B-study_type
controlled	I-study_type
study	I-study_type
6	O
August	O
2019	O

The	O
comparisons	O
and	O
distributions	O
of	O
characteristics	O
between	O
the	O
two	O
groups	O
and	O
subgroups	O
were	O
conducted	O
with	O
the	O
Chisquare	O
or	O
Student	O
's	O
or	O
Mann	O
-	O
Whitney	O
U	O
tests	O
.	O
Median	O
survival	O
was	O
evaluated	O
using	O
the	O
Kaplan	O
-	O
Meier	O
method	O
,	O
and	O
a	O
log	O
-	O
rank	O
test	O
was	O
used	O
to	O
compare	O
survival	O
between	O
two	O
randomised	O
groups	O
.	O
Treatment	O
effects	O
were	O
estimated	O
by	O
using	O
the	O
Cox	O
regression	O
model	O
when	O
proportional	O
hazards	O
could	O
be	O
assumed	O
.	O
Because	O
there	O
was	O
no	O
prespecified	O
plan	O
to	O
stratify	O
or	O
adjust	O
for	O
multiple	O
comparisons	O
,	O
a	O
multivariable	O
analysis	O
was	O
performed	O
to	O
evaluate	O
efficacy	O
outcomes	O
with	O
the	O
adjustment	O
for	O
the	O
important	O
baseline	O
confounders	O
,	O
such	O
as	O
FIGO	O
stage	O
,	O
neoadjuvant	O
chemotherapy	O
and	O
residual	O
diseases	O
.	O
The	O
previous	O
analysis	O
of	O
12-month	O
nonprogression	O
rate	O
has	O
been	O
conducted	O
(	O
two	O
-	O
sided	O
α	O
=	O
0.05	O
)	O
.	O
5	O
Here	O
,	O
prespecified	O
PFS	B-arm_efficacy_metric
and	O
OS	O
analyses	O
were	O
performed	O
after	O
sufficient	O
follow	O
-	O
up	O
for	O
the	O
observation	O
of	O
160	O
(	O
80	O
%	O
)	O
events	O
of	O
disease	O
progression	O
,	O
or	O
death	O
from	O
ovarian	O
cancer	O
,	O
using	O
a	O
two	O
-	O
sided	O
α	O
of	O
0.05	O
.	O

Censored	O
on	O
September	O
10	O
,	O
2018	O
(	O
3	O
years	O
after	O
the	O
last	O
patient	O
enrolled	O
)	O
,	O
the	O
median	O
follow	O
-	O
up	O
time	O
was	O
69.1	O
months	O
(	O
interquartile	O
range	O
,	O
53.1	O
-	O
83.9	O
)	O
.	O
The	O
median	O
time	O
to	O
the	O
first	O
cycle	O
of	O
standard	O
IV	O
chemotherapy	O
since	O
primary	O
surgery	O
were	O
49	O
days	O
and	O
15	O
days	O
in	O
the	O
DD	B-arm_description
-	I-arm_description
EPIC	I-arm_description
and	O
IV	B-arm_description
group	I-arm_description
,	O
respectively	O
(	O
Student	O
's	O
t	O
test	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
the	O
period	O
of	O
front	O
-	O
line	O
chemotherapy	O
was	O
similar	O
between	O
the	O
two	O
groups	O
,	O
with	O
only	O
a	O
0.2-month	O
increase	O
in	O
the	O
DD	B-arm_description
-	I-arm_description
EPIC	I-arm_description
group	O
.	O

Assessment	O
of	O
precision	O
irradiation	O
in	O
early	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
interstitial	O
lung	O
disease	O
(	O
ASPIRE	O
-	O
ILD	O
)	O
:	O
study	B-study_type
protocol	I-study_type
for	I-study_type
a	I-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type
Assessment	O
of	O
precision	O
irradiation	O
in	O
early	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
interstitial	O
lung	O
disease	O
(	O
ASPIRE	O
-	O
ILD	O
)	O
:	O
study	B-study_type
protocol	I-study_type
for	I-study_type
a	I-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type
DavidAPalma	B-authors

Department	O
of	O
Radiation	O
Oncology	O
,	O
Centre	O
Hospitalier	O
de	O
l'Université	O
de	O
Montréal	O
1051	O
Sanguinet	O
Street	O
H2X	O
3E4	O
Montreal	O
Quebec	O
Canada	O
StewartGaede	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
StephenHarrow	B-authors

1053	O
Great	O
Western	O
Road	O
G12	O
0YN	O
Glasgow	O
UK	O
JoannaMLaba	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
XMelody	B-authors
Qu	I-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
GeorgeBRodrigues	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
BrianPYaremko	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
EdwardYu	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
AlexanderVLouie	B-authors

Therefore	O
,	O
the	O
true	O
rates	O
of	O
toxicity	O
of	O
SABR	O
in	O
fibrotic	O
ILD	O
patients	O
are	O
likely	O
higher	O
than	O
in	O
the	O
general	O
population	O
,	O
but	O
the	O
precise	O
extent	O
of	O
toxicity	O
remains	O
unknown	O
.	O

For	O
patients	O
with	O
ILD	O
and	O
concurrent	O
early	O
-	O
stage	O
lung	O
cancer	O
who	O
are	O
not	O
candidates	O
for	O
surgery	O
,	O
these	O
data	O
showing	O
high	O
rates	O
of	O
toxicity	O
have	O
led	O
to	O
a	O
difficult	O
clinical	O
dilemma	O
,	O
since	O
there	O
are	O
few	O
alternate	O
treatment	O
options	O
.	O
The	O
option	O
of	O
delivering	O
no	O
treatment	O
whatsoever	O
,	O
which	O
avoids	O
any	O
risk	O
of	O
treatment	O
-	O
related	O
toxicity	O
,	O
is	O
associated	O
with	O
a	O
high	O
risk	O
of	O
death	O
due	O
to	O
the	O
lung	O
cancer	O
itself	O
.	O
The	O
median	O
survival	O
for	O
untreated	O
stage	O
I	O
NSCLC	O
is	O
only	O
6	O
-	O
8	O
months	O
,	O
with	O
1-year	O
mortality	O
of	O
60	O
-	O
70	O
%	O
[	O
12	O
]	O
,	O
much	O
higher	O
than	O
the	O
risks	O
associated	O
with	O
SABR	O
treatment	O
.	O
For	O
example	O
,	O
in	O
one	O
study	O
of	O
untreated	O
patients	O
with	O
NSCLC	O
in	O
the	O
U.S.	O
National	O
Cancer	O
Database	O
,	O
the	O
median	O
survival	O
for	O
patients	O
with	O
stage	O
I	O
NSCLC	O
who	O
were	O
unfit	O
for	O
an	O
operation	O
was	O
7.6	O
months	O
[	O
13	O
]	O
.	O
This	O
suggests	O
that	O
even	O
in	O
patients	O
with	O
an	O
ILD	O
-	O
GAP	O
score	O
>	O
5	O
,	O
the	O
risk	O
of	O
death	O
due	O
to	O
lung	O
cancer	O
within	O
1	O
year	O
exceeds	O
the	O
risk	O
of	O
death	O
due	O
to	O
ILD	O
or	O
complications	O
of	O
SABR	O
.	O

Alternatively	O
,	O
it	O
may	O
be	O
necessary	O
to	O
reduce	O
the	O
dose	O
of	O
SABR	O
,	O
at	O
the	O
risk	O
of	O
compromising	O
tumor	O
control	O
.	O
Adjustments	O
to	O
the	O
SABR	O
fractionation	O
schedule	O
may	O
reduce	O
the	O
risk	O
of	O
toxicity	O
,	O
while	O
still	O
maintaining	O
some	O
benefit	O
.	O
Radiation	O
dose	O
is	O
expressed	O
in	O
Gray	O
(	O
Gy	O
)	O
,	O
with	O
most	O
SABR	O
treatments	O
delivering	O
approximately	O
a	O
total	O
dose	O
50	O
-	O
60	O
Gy	O
.	O
This	O
total	O
dose	O
is	O
divided	O
up	O
into	O
smaller	O
individual	O
fractions	O
of	O
radiation	O
.	O
Conventional	O
radiotherapy	O
employs	O
fraction	O
sizes	O
of	O
approximately	O
2	O
Gy	O
per	O
day	O
,	O
5	O
days	O
per	O
week	O
,	O
and	O
would	O
require	O
30	O
fractions	O
to	O
deliver	O
60	O
Gy	O
.	O
This	O
prolonged	O
treatment	O
time	O
(	O
i.e.	O
6	O
weeks	O
of	O
treatment	O
)	O
may	O
allow	O
for	O
tumor	O
repopulation	O
,	O
compromising	O
treatment	O
outcomes	O
.	O
With	O
SABR	O
,	O
common	O
fractionations	O
include	O
54	O
Gy	O
in	O
3	O
fractions	O
(	O
i.e.	O
18	O
Gy	O
per	O
fraction	O
)	O
,	O
48	O
Gy	O
in	O
4	O
fractions	O
(	O
i.e.	O
12	O
Gy	O
per	O
fraction	O
)	O
and	O
60	O
Gy	O
in	O
8	O
fractions	O
(	O
i.e.	O
7.5	O
Gy	O
per	O
day	O
)	O
.	O
SABR	O
fractions	O
are	O
often	O
given	O
every	O
second	O
day	O
(	O
or	O
even	O
more	O
widely	O
spaced	O
)	O
to	O
maximize	O
the	O
time	O
for	O
normal	O
tissue	O
repair	O
between	O
fractions	O
.	O

To	O
compare	O
the	O
potency	O
of	O
these	O
different	O
radiation	O
dose	O
fractionations	O
,	O
a	O
formula	O
called	O
the	O
biologically	O
effective	O
dose	O
(	O
BED	O
)	O
is	O
used	O
.	O
BED	O
takes	O
into	O
account	O
the	O
total	O
number	O
of	O
fractions	O
,	O
the	O
dose	O
per	O
fraction	O
,	O
and	O
the	O
intrinsic	O
radiation	O
response	O
curve	O
of	O
the	O
individual	O
tissues	O
treated	O
.	O
BED	O
is	O
calculated	O
according	O
to	O
the	O
formula	O

During	O
the	O
design	O
of	O
this	O
trial	B-study_type
in	O
2016	O
-	O
17	O
,	O
several	O
options	O
were	O
considered	O
and	O
ultimately	O
discussed	O
at	O
a	O
meeting	O
of	O
the	O
Canadian	O
Pulmonary	O
Radiotherapy	O
Investigators	O
'	O
(	O
CAPRI	O
)	O
Group	O
at	O
the	O
September	O
2017	O
Canadian	O
Association	O
of	O
Radiation	O
Oncology	O
Annual	O
Meeting	O
.	O
Two	O
main	O
alternative	O
approaches	O
were	O
considered	O
:	O

There	O
is	O
precedent	O
for	O
this	O
approach	O
,	O
as	O
two	O
other	O
phase	O
I	O
trials	O
of	O
SABR	O
have	O
started	O
at	O
therapeutic	O
doses	O
:	O
RTOG	O
0813	O
for	O
central	O
tumors	O
(	O
started	O
at	O
50	O
Gy	O
in	O
5	O
fractions	O
before	O
escalating	O
to	O
60	O
Gy	O
in	O
5	O
fractions	O
)	O
and	O
SUNSET	O
for	O
ultra	O
-	O
central	O
tumors	O
(	O
starting	O
at	O
60	O
Gy	O
in	O
8	O
fractions	O
,	O
currently	O
underway	O
)	O
[	O
15	O
]	O
.	O

The	O
Study	O
Schema	O
can	O
be	O
found	O
in	O
Fig	O
.	O
1	O
.	O
The	O
required	O
sample	O
size	O
is	O
39	O
.	O
Patients	O
who	O
meet	O
eligibility	O
criteria	O
but	O
decline	O
to	O
pursue	O
radiation	O
and	O
patients	O
for	O
whom	O
SABR	O
can	O
not	O
be	O
delivered	O
at	O
the	O
recommended	O
doses	O
due	O
to	O
inacceptable	O
doses	O
to	O
normal	O
tissues	O
at	O
risk	O
will	O
be	O
asked	O
to	O
consent	O
to	O
limited	O
ongoing	O
follow	O
-	O
up	O
only	O
.	O

Overall	O
survival	O
:	O
defined	O
as	O
time	O
from	O
enrollment	O
to	O
death	O
from	O
any	O
cause	O
Changes	O
in	O
pulmonary	O
function	O
tests	O
,	O
including	O
diffusing	O
capacity	O
of	O
the	O
lungs	O
for	O
carbon	O
monoxide	O
(	O
DLCO	O
)	O
,	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(	O
FEV	O
1	O
)	O
,	O
and	O
forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
.	O
Exploratory	O
quantitative	O
analysis	O
of	O
HRCT	O
features	O
(	O
i.e.	O
radiomics	O
)	O
Analysis	O
of	O
outcomes	O
for	O
patients	O
who	O
otherwise	O
meet	O
the	O
study	O
enrollment	O
criteria	O
but	O
decline	O
radiotherapy	O
.	O

History	O
/	O
physical	O
examination	O
within	O
4	O
weeks	O
prior	O
to	O
registration	O
,	O
including	O
documentation	O
of	O
current	O
medications	O
and	O
home	O
oxygen	O
use	O
.	O
HRCT	O
scan	O
of	O
the	O
thorax	O
(	O
with	O
contrast	O
unless	O
medically	O
contraindicated	O
)	O
within	O
12	O
weeks	O
of	O
registration	O
.	O
Slice	O
thickness	O
must	O
be	O
1.5	O
mm	O
or	O
less	O
with	O
continuous	O
(	O
i.e.	O
non	O
-	O
gapped	O
)	O
images	O
.	O
Each	O
centre	O
must	O
communicate	O
with	O
their	O
radiologists	O
to	O
ensure	O
that	O
CT	O
scans	O
are	O
done	O
using	O
protocols	O
adequate	O
for	O
ILD	O
.	O
The	O
primary	O
tumor	O
dimensions	O
will	O
be	O
measured	O
on	O
CT	O
.	O

Positron	O
emission	O
tomography	O
(	O
PET	O
)	O
scan	O
of	O
the	O
entire	O
body	O
within	O
8	O
weeks	O
of	O
registration	O
,	O
using	O
FDG	O
.	O
Pre	O
-	O
bronchodilator	O
spirometry	O
,	O
lung	O
volumes	O
and	O
diffusion	O
capacity	O
within	O
8	O
weeks	O
prior	O
to	O
treatment	O
.	O
Assessment	O
by	O
a	O
respirologist	O
/	O
pulmonologist	O
within	O
4	O
weeks	O
of	O
enrollment	O
,	O
for	O
the	O
following	O
purposes	O
:	O
To	O
optimize	O
pulmonary	O
function	O
and	O
treatment	O
of	O
ILD	O
,	O
if	O
possible	O
.	O

Clinical	O
/	O
Laboratory	O
Data	O
:	O
Including	O
clinical	O
history	O
,	O
symptoms	O
with	O
date	O
of	O
onset	O
,	O
smoking	O
history	O
(	O
including	O
pack	O
years	O
and	O
quit	O
date	O
)	O
,	O
exposures	O
,	O
CTD	O
features	O
,	O
serology	O
(	O
normal	O
and	O
abnormal	O
)	O
,	O
pulmonary	O
function	O
tests	O
,	O
and	O
the	O
subtype	O
of	O
ILD	O
as	O
determined	O
by	O
the	O
treating	O
respirologist	O
.	O
Pathology	O
:	O
slides	O
(	O
to	O
be	O
returned	O
)	O
and	O
pathology	O
reports	O
Radiology	O
:	O
Digital	O
Imaging	O
and	O
Communications	O
in	O
Medicine	O
(	O
DICOM	O
)	O
images	O
of	O
thoracic	O
CT	O
scans	O
(	O
through	O
Quantitative	O
Imaging	O
for	O
Personalized	O
Cancer	O
Medicine	O
(	O
QIPCM	O
)	O
)	O
and	O
radiology	O
reports	O

The	O
total	O
dose	O
will	O
be	O
50	B-arm_dosage
Gy	I-arm_dosage
in	I-arm_dosage
5	I-arm_dosage
fractions	I-arm_dosage
,	I-arm_dosage
given	I-arm_dosage
every	I-arm_dosage
second	I-arm_dosage
day	I-arm_dosage
.	O
In	O
the	O
event	O
that	O
the	O
dose	O
is	O
de	O
-	O
escalated	O
to	O
50	O
Gy	O
in	O
10	O
fractions	O
or	O
45	O
Gy	O
in	O
15	O
fractions	O
,	O
then	O
the	O
same	O
prescribing	O
principles	O
apply	O
(	O
i.e.	O
using	O
a	O
SABR	O
-	O
like	O
technique	O
)	O
but	O
these	O
latter	O
two	O
fractionations	O
are	O
given	O
daily	O
.	O

The	O
lung	O
constraints	O
are	O
critically	O
important	O
for	O
this	O
study	O
.	O
If	O
one	O
or	O
more	O
of	O
the	O
lung	O
constraints	O
can	O
not	O
be	O
met	O
,	O
even	O
after	O
varying	O
the	O
prescription	O
isodose	O
surface	O
percentage	O
between	O
60	O
and	O
90	O
%	O
,	O
PTV	O
coverage	O
must	O
then	O
be	O
compromised	O
.	O
Target	O
coverage	O
may	O
be	O
reduced	O
until	O
95	O
%	O
of	O
the	O
IGTV	O
is	O
receiving	O
the	O
95	O
%	O
of	O
the	O
prescription	O
dose	O
,	O
and	O
90	O
%	O
of	O
the	O
IGTV	O
is	O
receiving	O
99	O
%	O
of	O
the	O
prescription	O
dose	O
,	O
with	O
the	O
PTV	O
covered	O
as	O
well	O
as	O
possible	O
while	O
respecting	O
lung	O
constraints	O
.	O

If	O
the	O
lung	O
dose	O
constraints	O
still	O
can	O
not	O
be	O
met	O
,	O
the	O
patient	O
should	O
be	O
treated	O
with	O
a	O
10	O
or	O
15-fraction	O
regimen	O
.	O
Such	O
patients	O
treated	O
with	O
protracted	O
regimens	O
due	O
to	O
inability	O
to	O
meet	O
dose	O
constraints	O
will	O
not	O
count	O
toward	O
the	O
primary	O
analysis	O
,	O
but	O
should	O
still	O
be	O
followed	O
for	O
toxicity	O
and	O
outcomes	O
.	O
Such	O
patients	O
will	O
be	O
reported	O
as	O
a	O
separate	O
cohort	O
.	O

In	O
order	O
to	O
ensure	O
patient	O
safety	O
and	O
effective	O
treatment	O
delivery	O
,	O
a	O
robust	O
quality	O
assurance	O
protocol	O
is	O
incorporated	O
.	O
The	O
following	O
requirements	O
must	O
be	O
completed	O
for	O
each	O
patient	O
:	O

Definitions	O
Adverse	O
Event	O
(	O
AE	O
)	O
or	O
reaction	O
,	O
as	O
per	O
definitions	O
by	O
the	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
[	O
21	O
]	O
,	O
is	O
any	O
unfavorable	O
and	O
unintended	O
sign	O
(	O
including	O
an	O
abnormal	O
laboratory	O
finding	O
)	O
,	O
symptom	O
,	O
or	O
disease	O
temporally	O
associated	O
with	O
the	O
use	O
of	O
a	O
medical	O
treatment	O
or	O
procedure	O
that	O
may	O
or	O
may	O
not	O
be	O
considered	O
related	O
to	O
the	O
medical	O
treatment	O
or	O
procedure	O
.	O
Serious	O
Adverse	O
Event	O
(	O
SAE	O
)	O
or	O
reaction	O
as	O
defined	O
in	O
the	O
International	O
Council	O
for	O
Harmonisation	O
(	O
ICH	O
)	O
Guideline	O
:	O
Clinical	O
Safety	O
Data	O
Management	O
:	O
Definitions	O
and	O
Standards	O
for	O
Expedited	O
Reporting	O
,	O
Section	O
2B	O
[	O
22	O
]	O
includes	O
any	O
untoward	O
medical	O
occurrence	O
at	O
any	O
dose	O
that	O
:	O

RT	O
delivered	O
in	O
this	O
protocol	O
can	O
adversely	O
affect	O
organs	O
at	O
risk	O
,	O
most	O
notably	O
lungs	O
,	O
airway	O
,	O
esophagus	O
,	O
pulmonary	O
vessels	O
,	O
and	O
heart	O
/	O
pericardium	O
,	O
as	O
these	O
organs	O
may	O
be	O
in	O
close	O
proximity	O
to	O
the	O
intended	O
target	O
(	O
PTV	O
)	O
of	O
RT	O
.	O

Any	O
Grade	O
3	O
-	O
5	O
toxicity	O
listed	O
in	O
Table	O
4	O
will	O
automatically	O
be	O
considered	O
to	O
be	O
possibly	O
,	O
probably	O
or	O
definitely	O
related	O
to	O
treatment	O
,	O
unless	O
there	O
is	O
clear	O
evidence	O
that	O
the	O
adverse	O
event	O
is	O
unrelated	O
or	O
unlikely	O
to	O
be	O
related	O
.	O
The	O
latter	O
instance	O
may	O
occur	O
,	O
for	O
example	O
,	O
in	O
the	O
case	O
of	O
a	O
cardiac	O
event	O
in	O
a	O
patient	O
with	O
an	O
upper	O
lobe	O
tumor	O
and	O
negligible	O
heart	O
dose	O
,	O
or	O
esophageal	O
issues	O
in	O
a	O
patient	O
who	O
received	O
negligible	O
esophageal	O
dose	O
.	O
The	O
final	O
decision	O
will	O
be	O
made	O
by	O
the	O
members	O
of	O
the	O
data	O
safety	O
monitoring	O
committee	O
(	O
DSMC	O
)	O
.	O
See	O
below	O
for	O
causality	O
definitions	O
.	O

Note	O
:	O
The	O
term	O
"	O
severe	O
"	O
is	O
a	O
measure	O
of	O
intensity	O
:	O
thus	O
a	O
severe	O
adverse	O
event	O
is	O
not	O
necessarily	O
serious	O
.	O
For	O
example	O
,	O
nausea	O
of	O
several	O
hours	O
'	O
duration	O
may	O
be	O
rated	O
as	O
severe	O
,	O
but	O
may	O
not	O
be	O
clinically	O
serious	O
.	O

Any	O
grade	O
4	O
or	O
5	O
adverse	O
reaction	O
that	O
is	O
definitely	O
,	O
probably	O
,	O
or	O
possibly	O
the	O
result	O
of	O
experimental	O
treatment	O
(	O
i.e.	O
radiotherapy	O
)	O
must	O
be	O
verbally	O
reported	O
to	O
the	O
Principal	O
Investigator	O
and	O
Coordinating	O
Centre	O
within	O
24	O
h	O
of	O
discovery	O
,	O
and	O
to	O
the	O
approving	O
REB	O
if	O
necessary	O
as	O
per	O
their	O
reporting	O
guidelines	O
.	O

Local	O
and	O
non	O
-	O
local	O
SAEs	O
will	O
be	O
reported	O
to	O
the	O
applicable	O
REB	O
as	O
per	O
their	O
reporting	O
guidelines	O
.	O
All	O
serious	O
,	O
unexpected	O
adverse	O
events	O
or	O
reactions	O
regardless	O
of	O
causality	O
will	O
be	O
reported	O
within	O
7	O
days	O
of	O
discovery	O
to	O
the	O
pertinent	O
REB	O
,	O
or	O
as	O
required	O
as	O
per	O
the	O
REB	O
guidelines	O
.	O

A	O
sample	O
size	O
of	O
39	O
patients	O
provides	O
>	O
80	O
%	O
power	O
to	O
detect	O
an	O
OS	O
improvement	O
of	O
>	O
20	O
%	O
at	O
1	O
year	O
,	O
compared	O
to	O
a	O
historical	O
control	O
of	O
<	O
50	O
%	O
(	O
i.e.	O
70	O
%	O
vs.	O
49	O
%	O
)	O
,	O
using	O
a	O
one	O
-	O
sample	O
,	O
one	O
sided	O
binomial	O
test	O
at	O
the	O
0.05	O
significance	O
level	O
,	O
assuming	O
10	O
%	O
dropout	O
or	O
loss	O
to	O
follow	O
-	O
up	O
before	O
one	O
year	O
.	O
All	O
cohorts	O
will	O
be	O
combined	O
for	O
this	O
primary	O
analysis	O
.	O

The	O
names	O
and	O
personal	O
information	O
of	O
study	O
participants	O
will	O
be	O
held	O
in	O
strict	O
confidence	O
.	O
All	O
study	O
records	O
(	O
case	O
report	O
forms	O
,	O
safety	O
reports	O
,	O
correspondence	O
,	O
etc	O
.	O
)	O
will	O
only	O
identify	O
the	O
subject	O
by	O
initials	O
,	O
month	O
and	O
year	O
of	O
birth	O
,	O
and	O
the	O
assigned	O
study	O
identification	O
number	O
.	O
The	O
investigator	O
will	O
maintain	O
a	O
confidential	O
subject	O
identification	O
list	O
(	O
Master	O
List	O
)	O
during	O
the	O
course	O
of	O
the	O
study	O
.	O
Access	O
to	O
confidential	O
information	O
(	O
i.e.	O
,	O
source	O
documents	O
and	O
patient	O
records	O
)	O
is	O
only	O
permitted	O
for	O
direct	O
subject	O
management	O
and	O
for	O
those	O
involved	O
in	O
monitoring	O
the	O
conduct	O
of	O
the	O
study	O
(	O
i.e.	O
,	O
Sponsors	O
,	O
contract	O
research	O
organizations	O
,	O
representatives	O
of	O
the	O
IRB/	O
REB	O
,	O
and	O
regulatory	O
agencies	O
)	O
.	O
The	O
subject	O
's	O
name	O
will	O
not	O
be	O
used	O
in	O
any	O
public	O
report	O
of	O
the	O
study	O
.	O

Anonymized	O
imaging	O
data	O
will	O
be	O
collected	O
through	O
the	O
Quantitative	O
Imaging	O
for	O
Personalized	O
Cancer	O
Medicine	O
(	O
QIPCM	O
)	O
platform	O
(	O
qipcm.technainstitute.com	O
)	O
.	O
QIPCM	O
provides	O
centralized	O
storage	O
and	O
data	O
analysis	O
tools	O
for	O
medical	O
imaging	O
,	O
and	O
is	O
compliant	O
with	O
national	O
and	O
international	O
privacy	O
regulations	O
.	O
A	O
flowchart	O
of	O
enrollment	O
and	O
central	O
review	O
can	O
be	O
found	O
in	O
Additional	O
file	O
5	O
.	O

6	O
-	O
5	O
-	O
1	O
Kashiwanoha	O
277	O
-	O
8577	O
Kashiwa	O
Chiba	O
Japan	O
•HirokiHara	B-authors
Department	O
of	O
Gastroenterology	O
Saitama	O
Cancer	O
Center	O
780	O
Komuro	O
362	O
-	O
0806	O
Ina	O
Saitama	O
Japan	O
•TakakiYoshikawa	B-authors

Pertuzumab	B-arm_description
plus	I-arm_description
trastuzumab	I-arm_description
and	I-arm_description
chemotherapy	I-arm_description
for	O
Japanese	O
patients	O
with	O
HER2-positive	O
metastatic	O
gastric	O
or	O
gastroesophageal	O
junction	O
cancer	O
:	O
a	O
subgroup	B-study_type
analysis	I-study_type
of	O
the	O
JACOB	O
trial	O
KoheiShitara	B-authors
kshitara@east.ncc.go.jp	O

The	O
primary	O
objective	O
of	O
the	O
JACOB	O
trial	O
was	O
to	O
compare	O
OS	O
in	O
patients	O
treated	O
with	O
pertuzumab	B-arm_description
plus	I-arm_description
trastuzumab	I-arm_description
and	I-arm_description
chemotherapy	I-arm_description
with	O
those	O
treated	O
with	O
placebo	B-arm_description
plus	I-arm_description
trastuzumab	I-arm_description
and	I-arm_description
chemotherapy	I-arm_description
.	O
Key	O
secondary	O
objectives	O
included	O
comparison	O
of	O
PFS	B-arm_efficacy_metric
,	O
ORR	O
,	O
duration	O
of	O
response	O
,	O
patient	O
-	O
reported	O
outcomes	O
(	O
PROs	O
)	O
,	O
and	O
safety	O
between	O
the	O
two	O
arms	O
.	O

The	O
Kaplan	O
-	O
Meier	O
method	O
was	O
used	O
to	O
estimate	O
the	O
distributions	O
of	O
OS	O
,	O
PFS	B-arm_efficacy_metric
,	O
and	O
duration	O
of	O
response	O
,	O
including	O
estimates	O
of	O
the	O
medians	O
,	O
with	O
95	O
%	O
CIs	O
calculated	O
using	O
the	O
Brookmeyer	O
and	O
Crowley	O
method	O
.	O
Cox	O
proportional	O
hazards	O
regression	O
models	O
were	O
used	O
to	O
estimate	O
the	O
HR	O
for	O
OS	O
and	O
PFS	B-arm_efficacy_metric
with	O
95	O
%	O
CIs	O
between	O
treatment	O
arms	O
.	O
For	O
ORR	O
and	O
clinical	O
benefit	O
rate	O
,	O
the	O
proportion	O
of	O
patients	O
achieving	O
an	O
overall	O
response	O
per	O
the	O
Response	O
Evaluation	O
Criteria	O
In	O
Solid	O
Tumors	O
(	O
RECIST	O
)	O
version	O
1.1	O
was	O
summarized	O
and	O
95	O
%	O
CIs	O
were	O
calculated	O
using	O
the	O
Clopper	O
-	O
Pearson	O
method	O
.	O
Adverse	O
events	O
(	O
AEs	O
)	O
were	O
graded	O
per	O
the	O
National	O
Cancer	O
Institute	O
-Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
(	O
NCI	O
-	O
CTCAE	O
)	O
,	O
version	O
4.03	O
.	O
PRO	O
assessments	O
included	O
health	O
-	O
related	O
quality	O
of	O
life	O
and	O
time	O
to	O
deterioration	O
(	O
TTD	O
)	O
in	O
gastric	O
cancer	O
-	O
related	O
symptoms	O
,	O
which	O
were	O
assessed	O
using	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(	O
EORTC	O
)	O
Quality	O
of	O
Life	O
Questionnaire	O
of	O
cancer	O
patients	O
(	O
QLQ	O
-	O
C30	O
v3.0	O
)	O
,	O
gastric	O
cancer	O
module	O
(	O
QLQ	O
-	O
STO22	O
)	O
,	O
and	O
EuroQol	O
five	O
-	O
dimensional	O
questionnaire	O
(	O
EQ-5D-3L	O
)	O
.	O
TTD	O
assessments	O
included	O
the	O
time	O
from	O
baseline	O
to	O
≥	O
10-point	O
increase	O
in	O
abdominal	O
pain	O
,	O
eating	O
restriction	O
,	O
appetite	O
loss	O
,	O
and	O
fatigue	O
(	O
TTD1	O
)	O
,	O
and	O
the	O
TTD	O
from	O
initiation	O
of	O
therapy	O
with	O
pertuzumab	B-arm_description
/	O
placebo	B-arm_description
plus	I-arm_description
trastuzumab	I-arm_description
alone	O
following	O
cessation	O
of	O
chemotherapy	O
(	O
TTD2	O
)	O
.	O
The	O
distribution	O
of	O
TTD	O
,	O
including	O
an	O
estimate	O
of	O
the	O
median	O
,	O
was	O
assessed	O
using	O
the	O
Kaplan	O
-	O
Meier	O
method	O
.	O

All	O
patients	O
included	O
in	O
the	O
study	O
experienced	O
AEs	O
.	O
AEs	O
were	O
decreased	O
ejection	O
fraction	O
and	O
muscle	O
weakness	O
(	O
n	O
=	O
1	O
each	O
)	O
in	O
the	O
pertuzumab	B-arm_description
arm	I-arm_description
and	O
decreased	O
ejection	O
fraction	O
,	O
multiple	O
organ	O
dysfunction	O
syndrome	O
,	O
gastrointestinal	O
anastomotic	O
leak	O
,	O
and	O
renal	O
dysfunction	O
(	O
n	O
=	O
1	O
each	O
)	O
in	O
the	O
placebo	B-arm_description
arm	I-arm_description
.	O
The	O
total	O
number	O
of	O
deaths	O
was	O
24	O
(	O
60.0	O
%	O
)	O
in	O
the	O
pertuzumab	B-arm_description
arm	I-arm_description
and	O
30	O
(	O
75.0	O
%	O
)	O
in	O
the	O
placebo	B-arm_description
arm	I-arm_description
,	O
of	O
which	O
one	O
in	O
each	O
arm	O
was	O
AE	O
-	O
related	O
.	O
Fatal	O
AEs	O
were	O
myocardial	O
infarction	O
(	O
n	O
=	O
1	O
)	O
in	O
the	O
pertuzumab	B-arm_description
arm	I-arm_description
and	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
n	O
=	O
1	O
)	O
in	O
the	O
placebo	B-arm_description
arm	I-arm_description
.	O
A	O
summary	O
of	O
cardiac	O
AEs	O
is	O
provided	O
in	O
Table	O
4	O
.	O

Overall	O
health	O
-	O
related	O
quality	O
of	O
life	O
was	O
similar	O
between	O
arms	O
for	O
the	O
greater	O
part	O
of	O
the	O
study	O
,	O
with	O
no	O
clinically	O
meaningful	O
differences	O
detected	O
(	O
Fig	O
.	O
5	O
)	O
.	O
The	O
TTD1	O
and	O
TTD2	O
for	O
abdominal	O
pain	O
,	O
appetite	O
loss	O
,	O
eating	O
restrictions	O
,	O
and	O
fatigue	O
are	O
summarized	O
in	O
Table	O
5	O
.	O
A	O
consistent	O
trend	O
of	O
improved	O
TTD	O
was	O
observed	O
for	O
each	O
symptom	O
in	O
the	O
pertuzumab	O
arm	O
compared	O
with	O
the	O
placebo	B-arm_description
arm	I-arm_description
.	O

The	O
conflicting	O
effects	O
of	O
quality	O
of	O
life	O
and	O
survival	O
benefits	O
disrupt	O
proper	O
assessment	O
of	O
the	O
added	O
value	O
of	O
acalabrutinib	O
,	O
which	O
might	O
lead	O
to	O
delays	O
in	O
patient	O
access	O
.	O

To	O
get	O
novel	O
haematological	O
agents	O
to	O
patients	O
effectively	O
and	O
in	O
a	O
timely	O
manner	O
,	O
development	O
should	O
include	O
an	O
early	O
assessment	O
of	O
added	O
value	O
such	O
as	O
that	O
presented	O
here	O
.	O
makers	O
and	O
manufacturers	O
to	O
streamline	O
clinical	O
development	O
and	O
reimbursement	O
processes	O
[	O
15][16][17][18	O
]	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
construct	O
,	O
based	O
on	O
published	O
phase	B-study_type
I	I-study_type
/	I-study_type
II	I-study_type
data	I-study_type
,	I-study_type
an	I-study_type
early	I-study_type
cost	I-study_type
-	I-study_type
utility	I-study_type
analysis	I-study_type
comparing	O
acalabrutinib	B-arm_description
and	O
ibrutinib	B-arm_description
for	O
chronic	O
lymphocytic	O
leukaemia	O
to	O
assist	O
early	O
reimbursement	O
decision	O
making	O
.	O
Sensitivity	O
analyses	O
were	O
performed	O
,	O
and	O
possible	O
development	O
scenarios	O
were	O
assessed	O
,	O
identifying	O
critical	O
parameters	O
and	O
quantifying	O
their	O
relative	O
impact	O
on	O
incremental	O
costs	O
and	O
QALYs	O
.	O

Costs	O
of	O
grade	O
3	O
and	O
4	O
adverse	O
events	O
(	O
AEs	O
)	O
were	O
included	O
according	O
to	O
the	O
UK	O
national	O
schedule	O
of	O
reference	O
costs	O
2015	O
-	O
2016	O
[	O
26	O
]	O
.	O
Incidences	O
were	O
implemented	O
from	O
clinical	O
trials	O
for	O
acalabrutinib	B-arm_description
and	O
from	O
the	O
NICE	O
ibrutinib	B-arm_description
assessment	O
[	O
13,14	O
]	O
.	O
AE	O
costs	O
were	O
inflicted	O
once	O
,	O
in	O
the	O
first	O
cycle	O
.	O
This	O
matched	O
the	O
approach	O
used	O
in	O
the	O
NICE	O
ibrutinib	B-arm_description
submission	O
and	O
is	O
supported	O
by	O
the	O
fact	O
that	O
onset	O
of	O
side	O
effects	O
was	O
generally	O
within	O
the	O
first	O
half	O
year	O
and	O
the	O
duration	O
of	O
side	O
effects	O
was	O
short	O
[	O
2,14	O
]	O
.	O

Annual	O
healthcare	O
resource	O
use	O
such	O
as	O
hospital	O
visits	O
or	O
blood	O
tests	O
associated	O
with	O
routine	O
follow	O
-	O
up	O
care	O
was	O
included	O
.	O
Resource	O
use	O
is	O
based	O
on	O
expert	O
elicitation	O
reported	O
by	O
the	O
manufacturer	O
in	O
the	O
ibrutinib	B-arm_description
submission	O
and	O
differs	O
per	O
model	O
state	O
(	O
PFS	B-arm_efficacy_metric
,	O
PPS	O
-	O
ST	O
,	O
PPS	O
-	O
BSC	O
)	O
and	O
whether	O
the	O
patient	O
in	O
the	O
PFS	B-arm_efficacy_metric
state	O
was	O
a	O
complete	O
responder	O
(	O
CR	O
)	O
,	O
partial	O
responder	O
(	O
PR	O
)	O
or	O
non	O
-	O
responder	O
(	O
NR	O
,	O
including	O
stable	O
disease	O
and	O
progressive	O
disease	O
)	O
.	O
Treatment	O
responses	O
for	O
ibrutinib	B-arm_description
were	O
reported	O
to	O
be	O
84	O
%	O
PR	O
,	O
6	O
%	O
CR	O
and	O
10	O
%	O
NR	O
.	O
For	O
acalabrutinib	B-arm_description
,	O
95	O
%	O
were	O
PR	O
and	O
5	O
%	O
were	O
NR	O
[	O
13,14	O
]	O
.	O
Full	O
calculations	O
of	O
AE	O
costs	O
and	O
resource	O
use	O
per	O
treatment	O
are	O
provided	O
in	O
ESM	O
3	O
.	O

Baseline	O
characteristics	O
of	O
all	O
30	O
patients	O
are	O
listed	O
in	O
Table	O
1	O
.	O
The	O
median	O
age	O
was	O
68.5	O
years	O
.	O
80	O
%	O
of	O
patients	O
were	O
male	O
.	O
All	O
treated	O
patients	O
had	O
an	O
ECOG	O
of	O
0	O
or	O
1	O
.	O
Median	O
tumor	O
length	O
was	O
5.0	O
cm	O
(	O
range	O
,	O
1	O
-	O
11	O
cm	O
)	O
.	O
29	O
patients	O
completed	O
the	O
radiotherapy	B-arm_description
with	O
median	B-arm_dosage
dose	I-arm_dosage
was	I-arm_dosage
60	I-arm_dosage
Gy	I-arm_dosage
,	O
1	O
patients	O
had	O
interruption	O
of	O
treatment	O
when	O
received	O
36	O
Gy	O
due	O
to	O
esophageal	O
fistula	O
.	O
26	O
patients	O
completed	O
the	O
chemotherapy	O
as	O
planned	O
.	O
The	O
second	O
nedaplatin	B-arm_description
dose	O
was	O
reduced	O
by	O
25	O
%	O
in	O
two	O
patient	O
due	O
to	O
grade	O
4	O
myelotoxicity	O
occurred	O
.	O
2	O
patients	O
received	O
1	O
cycle	O
of	O

All	O
patients	O
were	O
evaluated	O
for	O
treatment	O
response	O
6	O
weeks	O
after	O
completion	O
of	O
treatment	O
.	O
Notable	O
,	O
ORR	O
was	O
up	O
to	O
90	O
%	O
.	O
For	O
surviving	O
patients	O
,	O
the	O
median	O
follow	O
-	O
up	O
time	O
was	O
24	O
months	O
(	O
range	O
,	O
19	O
-	O
29.5	O
m	O
)	O
.	O
Total	O
median	O
OS	O
was	O
30	O
months	O
and	O
the	O
1and	O
2-year	O
OS	O
rates	O
in	O
all	O
patients	O
were	O
70.4	O
%	O
and	O
55.7	O
%	O
.	O
The	O
median	O
PFS	B-arm_efficacy_metric
was	O
20	B-arm_efficacy_results
months	I-arm_efficacy_results
,	O
with	O
the	O
1-and	O
2-year	O
PFS	B-arm_efficacy_metric
rates	I-arm_efficacy_metric
were	O
74.8	B-arm_efficacy_results
%	I-arm_efficacy_results
and	I-arm_efficacy_results
43.3	I-arm_efficacy_results
%	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
major	O
toxicities	O
were	O
leukopenia	O
and	O
thrombopenia	O
.	O
At	O
least	O
III	O
°	O
leukopenia	O
and	O
thrombopenia	O
were	O
seen	O
in	O
50	O
%	O
and	O
30	O
%	O
of	O
patients	O
.	O
Other	O
toxicities	O
of	O
grade	O
≥3	O
included	O
oesophagitis	O
(	O
one	O
patient	O
)	O
and	O
pain	O
in	O
upper	O
limb	O
(	O
one	O
patient	O
)	O
.	O
No	O
grade	O
≥3	O
anaemia	O
and	O
cardiotoxicity	O
were	O
observed	O
.	O
One	O
patients	O
developed	O
esophageal	O
fistula	O
at	O
a	O
radiation	B-arm_description
dose	O
of	O
36	O
Gy	O
with	O
1	O
cycle	O
concurrent	O
raltitrexed	B-arm_description
/	O
nedaplatin	B-arm_description
chemotherapy	O
.	O
There	O
was	O
no	O
treatment	O
-	O
related	O
death	O
and	O
radiation	O
-	O
induced	O
lung	O
injury	O
.	O

Male	O
/	O
female	O
24	O
(	O
80%)/6(20	O
%	O
)	O
Age	O
(	O
mean	O
±	O
SD	O
)	O
68.5	O
(	O
68.5	O
±	O
8.4	O
)	O
Tumor	O
locations	O
:	O
Cervical	O
/	O
Ut	O
/	O
Mt	O
/	O
Lt	O
6	O
(	O
20%)/6(20%)/9(30%)/9(30	O
%	O
)	O
chemotherapy	O
(	O
27	O
patients	O
with	O
NDP	O
/	O
S-1	O
regimen	O
,	O
30	O
patients	O
with	O
NDP	O
/	O
docetaxel	O
regimen	O
,	O
and	O
13	O
patients	O
with	O
NDP	O
alone	O
regimen	O
)	O
.	O
The	O
overall	O
response	O
rate	O
was	O
81.4	O
%	O
.	O
The	O
1-year	O
and	O
2-year	O
OS	O
rate	O
was	O
82.9	O
%	O
and	O
53.9	O
%	O
,	O
respectively	O
,	O
with	O
a	O
median	O
survival	O
time	O
of	O
25	O
months	O
.	O
Compared	O
with	O
this	O
result	O
,	O
the	O
overall	O
response	O
rate	O
and	O
median	O
survival	O
time	O
in	O
our	O
study	O
was	O
better	O
,	O
while	O
the	O
1-year	O
OS	O
was	O
much	O
lower	O
(	O
70.4	O
%	O
vs	O
82.9	O
%	O
)	O
.	O
A	O
possible	O
explanation	O
was	O
the	O
differences	O
in	O
radiation	B-arm_description
dose	O
,	O
radiation	O
volume	O
and	O
chemotherapy	O
regimens	O
.	O
The	O
radiation	B-arm_description
dose	O
of	O
our	O
study	O
was	O
lower	O
than	O
that	O
of	O
Zhu	O
's	O
study	O
,	O
with	O
a	O
median	B-arm_dosage
dose	I-arm_dosage
of	I-arm_dosage
60	I-arm_dosage
Gy	I-arm_dosage
vs	I-arm_dosage
64	I-arm_dosage
Gy	I-arm_dosage
(	O
range	O
,	O
60	O
-	O
66	O
Gy	O
)	O
.	O

Phase	B-study_type
II	I-study_type
study	I-study_type
of	O
R	O
-	O
CVP	O
followed	O
by	O
rituximab	B-arm_description
maintenance	I-arm_description
therapy	I-arm_description
for	O
patients	O
with	O
advanced	O
marginal	O
zone	O
lymphoma	O
:	O
consortium	O
for	O
improving	O
survival	O
of	O
lymphoma	O
(	O
CISL	O
)	O
study	O

In	O
B	O
-	O
cell	O
malignancies	O
,	O
rituximab	O
(	O
Mabthera	O
®	O
;	O
Roche	O
,	O
Basel	O
,	O
Switzerland	O
)	O
was	O
the	O
first	O
targeted	O
therapy	O
drug	O
which	O
caused	O
a	O
paradigm	O
shift	O
in	O
disease	O
treatment	O
[	O
11	O
]	O
.	O
Rituximab	O
is	O
a	O
chimeric	O
,	O
monoclonal	O
antibody	O
targeting	O
CD20	O
,	O
a	O
cell	O
surface	O
antigen	O
expressed	O
during	O
most	O
stages	O
of	O
B	O
-	O
cell	O
development	O
[	O
12	O
]	O
,	O
and	O
is	O
found	O
on	O
95	O
%	O
of	O
B	O
-	O
cell	O
lymphoma	O
cells	O
[	O
13	O
]	O
.	O
The	O
clinical	O
efficacy	O
of	O
rituximab	O
was	O
first	O
demonstrated	O
in	O
follicular	O
lymphoma	O
(	O
FL	O
)	O
[	O
14,15	O
]	O
and	O
it	O
has	O
since	O
been	O
prescribed	O
for	O
other	O
subtypes	O
of	O
NHL	O
,	O
including	O
MZL	O
,	O
with	O
promising	O
results	O
[	O
16][17][18][19][20][21][22][23][24	O
]	O
.	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
rituximab	B-arm_description
as	O
a	O
candidate	O
maintenance	O
therapy	O
in	O
patients	O
with	O
advanced	O
MZL	O
.	O

Patients	O
who	O
had	O
received	O
prior	O
chemotherapy	O
or	O
radiotherapy	O
for	O
MZL	O
were	O
excluded	O
from	O
the	O
study	O
,	O
as	O
were	O
those	O
with	O
a	O
large	O
cell	O
component	O
>	O
10	O
%	O
,	O
central	O
nervous	O
system	O
involvement	O
,	O
or	O
previous	O
malignancy	O
in	O
the	O
past	O
5	O
years	O
with	O
the	O
exceptions	O
of	O
curatively	O
treated	O
non	O
-	O
melanoma	O
skin	O
cancer	O
,	O
in	O
situ	O
carcinoma	O
of	O
the	O
cervix	O
uteri	O
,	O
or	O
thyroid	O
cancer	O
with	O
completed	O
active	O
treatment	O
and	O
no	O
evidence	O
of	O
recurrence	O
over	O
a	O
period	O
of	O
1	O
year	O
.	O
Informed	O
consent	O
was	O
obtained	O
from	O
all	O
patients	O
for	O
their	O
participation	O
in	O
the	O
study	O
.	O
Informed	O
consent	O
and	O
patients	O
'	O
enrolment	O
were	O
acquired	O
after	O
the	O
first	O
line	O
R	O
-	O
CVP	O
treatment	O
.	O
Investigators	O
clearly	O
discussed	O
with	O
the	O
patients	O
for	O
their	O
treatment	O
option	O
including	O
"	O
watchful	O
wait	O
"	O
.	O
This	O
clinical	O
trial	O
obtained	O
informed	O
consents	O
for	O
R	O
-	O
maintenance	O
treatment	O
.	O
This	O
study	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
International	O
Conference	O
on	O
Harmonisation	O
Good	O
Clinical	O
Practice	O
guidelines	O
.	O
The	O
study	O
design	O
was	O
reviewed	O
and	O
approved	O
by	O
the	O
relevant	O
independent	O
ethics	O
committees	O
for	O
each	O
investigational	O
site	O
.	O
All	O
authors	O
had	O
access	O
to	O
primary	O
clinical	O
trial	O
data	O
.	O

This	O
trial	O
was	O
designed	O
according	O
to	O
the	O
Simon	O
"	O
optimal	O
"	O
design	O
for	O
phase	O
II	O
trials	O
and	O
aimed	O
to	O
determine	O
whether	O
rituximab	B-arm_description
-	I-arm_description
maintenance	I-arm_description
following	O
R	O
-	O
CVP	O
could	O
improve	O
PFS	B-arm_efficacy_metric
[	O
33	O
]	O
.	O
Based	O
on	O
literature	O
analyses	O
[	O
7,24	O
]	O
,	O
the	O
baseline	O
3-year	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
rate	I-arm_efficacy_metric
was	O
expected	O
to	O
be	O
50	O
%	O
,	O
with	O
an	O
anticipated	O
treatment	O
difference	O
of	O
20	O
%	O
.	O
Assuming	O
a	O
drop	O
-	O
out	O
rate	O
of	O
10	O
%	O
,	O
a	O
total	O
of	O
47	O
patients	O
were	O
required	O
to	O
achieve	O
a	O
power	O
of	O
80	O
%	O
to	O
detect	O
a	O
20	O
%	O
treatment	O
difference	O
with	O
an	O
alpha	O
of	O
0.05	O
.	O
PFS	B-arm_efficacy_metric
was	O
defined	O
as	O
the	O
time	O
R	O
-	O
CVP	O
treatment	O
started	O
to	O
the	O
first	O
recorded	O
incidence	O
of	O
relapse	O
,	O
disease	O
progression	O
,	O
death	O
due	O
to	O
any	O
cause	O
,	O
or	O
last	O
date	O
of	O
follow	O
up	O
for	O
the	O
enrolled	O
patients	O
who	O
did	O
not	O
progress	O
.	O

Portal	O
vein	O
invasion	O
(	O
PVI	O
)	O
frequently	O
develops	O
in	O
patients	O
with	O
advanced	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
,	O
and	O
has	O
an	O
estimated	O
incidence	O
rate	O
of	O
34	O
to	O
80	O
%	O
[	O
1,2	O
]	O
.	O
Without	O
treatment	O
,	O
PVI	O
prognosticates	O
extremely	O
poor	O
prognosis	O
with	O
a	O
median	O
survival	O
of	O
only	O
2.7	O
months	O
[	O
3	O
]	O
.	O
Sorafenib	O
is	O
currently	O
regarded	O
as	O
the	O
standard	O
systemic	O
therapy	O
for	O
HCC	O
with	O
PVI	O
,	O
but	O
the	O
survival	O
gain	O
is	O
only	O
2	O
-	O
3	O
months	O
[	O
4][5][6][7	O
]	O
.	O

Stereotactic	O
ablative	O
radiotherapy	O
(	O
SABR	O
)	O
is	O
an	O
emerging	O
technique	O
,	O
and	O
can	O
achieve	O
tumorcidal	O
doses	O
in	O
limited	O
fractions	O
,	O
with	O
significant	O
normal	O
tissue	O
sparing	O
.	O
Several	O
studies	O
have	O
reported	O
favorable	O
results	O
with	O
SABR	O
for	O
treating	O
different	O
cancers	O
[	O
13,14	O
]	O
.	O
We	O
hypothesized	O
that	O
SABR	O
would	O
provide	O
more	O
benefit	O
than	O
would	O
CFRT	O
in	O
HCC	O
patients	O
with	O
PVI	O
.	O

Univariable	O
analysis	O
revealed	O
that	O
the	O
presence	O
of	O
SABR	B-arm_description
,	O
ECOG	O
0	O
-	O
1	O
,	O
CP	O
class	O
A	O
,	O
single	O
tumor	O
,	O
tumor	O
size	O
≤8	O
cm	O
,	O
Vp3	O
,	O
AFP	O
≤200	O
ng	O
/	O
ml	O
,	O
prior	O
treatment	O
,	O
and	O
BED	O
≥65	O
Gy	O
were	O
predictors	O
of	O
superior	O
OS	O
.	O
No	O
survival	O
difference	O
was	O
noted	O
between	O
patients	O
treated	O
before	O
December	O
31	O
,	O
2011	O
versus	O
after	O
December	O
31	O
,	O
2011	O
.	O
Given	O
the	O
presence	O
of	O
the	O
high	O
correlation	O
between	O
BED	O
and	O
the	O
RT	O
Fig	O
.	O
3	O
Overall	O
survival	O
(	O
a	O
)	O
and	O
in	B-arm_efficacy_metric
-	I-arm_efficacy_metric
field	I-arm_efficacy_metric
progression	I-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
(	O
b	O
)	O
in	O
the	O
entire	O
cohort	O
using	O
Kaplan	O
Meier	O
method	O
technique	O
(	O
p	O
<	O
0.001	O
)	O
,	O
these	O
variables	O
were	O
analyzed	O
by	O
two	O
different	O
Cox	O
models	O
to	O
avoid	O
collinearity	O
.	O
The	O
presence	O
of	O
SABR	B-arm_description
and	O
BED	O
≥65	O
Gy	O
correlated	O
significantly	O
with	O
superior	O
OS	O
in	O
separate	O
multivariable	O
analysis	O
models	O
(	O
Table	O
3	O
)	O
.	O
Furthermore	O
,	O
we	O
identified	O
that	O
the	O
SABR	B-arm_description
group	O
with	O
BED	O
≥65Gy	O
showed	O
a	O
higher	O
survival	O
rate	O
than	O
the	O
CFRT	B-arm_description
group	O
with	O
BED	O
<	O
65Gy	O
(	O
p	O
=	O
0.005	O
)	O
(	O
Fig	O
.	O
5	O
)	O
.	O

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O
OutiLahdenperä	B-authors
PiaVihinen	B-authors
ArjaJukkola	B-authors
PeeterKarihtala	B-authors
SonjaAho	O
Department	O
of	O
Oncology	O

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O
EmiliaAKorhonen	B-authors

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O

Blood	O
samples	O
were	O
obtained	O
from	O
the	O
patients	O
during	O
treatment	O
.	O
EDTA	O
samples	O
for	O
plasma	O
analysis	O
were	O
obtained	O
at	O
the	O
baseline	O
,	O
every	O
6	O
weeks	O
during	O
the	O
bevacizumab	B-arm_description
-	I-arm_description
taxane	I-arm_description
combination	I-arm_description
,	O
at	O
the	O
discontinuation	O
of	O
taxane	B-arm_description
treatment	O
,	O
during	O
the	O
bevacizumab	B-arm_description
maintenance	O
therapy	O
,	O
first	O
every	O
three	O
weeks	O
for	O
the	O
first	O
two	O
months	O
and	O
thereafter	O
every	O
12	O
weeks	O
,	O
and	O
at	O
the	O
final	O
study	O
visit	O
.	O

The	O
patient	O
population	O
and	O
the	O
analyzed	O
plasma	O
samples	O
were	O
identical	O
to	O
our	O
previous	O
paper	O
focusing	O
on	O
plasma	O
interleukin-8	O
levels	O
as	O
a	O
prognostic	O
marker	O
[	O
27	O
]	O
.	O
At	O
the	O
baseline	O
,	O
plasma	O
samples	O
were	O
available	O
from	O
53	O
patients	O
(	O
82	O
%	O
)	O
.	O
Overall	O
,	O
plasma	O
samples	O
were	O
available	O
from	O
58	O
(	O
89	O
%	O
)	O
of	O
the	O
65	O
patients	O
treated	O
in	O
the	O
study	O
.	O
Key	O
characteristics	O
of	O
the	O
study	O
population	O
and	O
the	O
main	O
efficacy	O
outcomes	O
are	O
presented	O
in	O
Table	O
1	O
.	O
Plasma	O
samples	O
for	O
Tie1	B-arm_description
and	O
Ang2	B-arm_description
were	O
analyzed	O
at	O
four	O
time	O
points	O
:	O
at	O
the	O
baseline	O
,	O
six	O
weeks	O
after	O
the	O
treatment	O
initiation	O
,	O
six	O
months	O
after	O
the	O
treatment	O
initiation	O
and	O
at	O
the	O
final	O
visit	O
.	O
The	O
number	O
of	O
patients	O
that	O
had	O
plasma	O
samples	O
analyzed	O
and	O
the	O
reasons	O
for	O
exclusions	O
are	O
presented	O
in	O
a	O
flow	O
chart	O
(	O
Fig	O
.	O
1	O
)	O
.	O
Six	O
weeks	O
'	O
and	O
six	O
months	O
'	O
samples	O
were	O
available	O
only	O
for	O
those	O
patients	O
that	O
were	O
still	O
on	O
study	O
treatment	O
at	O
that	O
time	O
point	O
.	O

The	O
statistical	O
plan	O
for	O
the	O
biomarker	O
analysis	O
was	O
exploratory	O
.	O
Tie1	B-arm_description
and	O
Ang2	B-arm_description
were	O
dichotomized	O
as	O
low	O
or	O
high	O
for	O
each	O
patient	O
using	O
the	O
median	O
value	O
as	O
the	O
cutoff	O
.	O
Sensitivity	O
,	O
specificity	O
and	O
area	O
under	O
curve	O
(	O
AUC	O
)	O
for	O
plasma	O
Tie1	O
concentration	O
were	O
determined	O
using	O
receiver	O
operator	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
.	O
Baseline	O
Tie1	B-arm_description
or	O
Ang2	B-arm_description
levels	O
as	O
independent	O
prognostic	O
factors	O
(	O
below	O
/	O
above	O
median	O
)	O
were	O
evaluated	O
using	O
Cox	O
proportional	O
hazard	O
regression	O
analysis	O
.	O
Multivariate	O
analysis	O
was	O
performed	O
using	O
the	O
Cox	O
model	O
,	O
and	O
it	O
was	O
adjusted	O
by	O
age	O
(	O
continuous	O
)	O
,	O
menopausal	O
status	O
(	O
yes	O
/	O
no	O
)	O
,	O
hormone	O
receptor	O
status	O
(	O
negative	O
/	O
positive	O
)	O
,	O
presence	O
of	O
visceral	O
metastasis	O
(	O
yes	O
/	O
no	O
)	O
,	O
number	O
of	O
metastatic	O
lesions	O
(	O
cut	O
-	O
off	O
of	O
three	O
metastatic	O
lesions	O
)	O
and	O
extent	O
of	O
the	O
disease	O
(	O
cutoff	O
of	O
three	O
metastatic	O
sites	O
)	O
.	O
The	O
Mann	O
-	O
Whitney	O
U	O
test	O

Median	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
was	O
longer	O
for	O
patients	O
in	O
the	O
low	O
baseline	O
Tie1	O
level	O
group	O
than	O
for	O
the	O
patients	O
in	O
the	O
high	O
baseline	O
Tie1	B-arm_description
group	O
(	O
Fig	O
.	O
3a	O
,	O
Table	O
2	O
)	O
.	O
No	O
difference	O
was	O
observed	O
in	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
in	O
relation	O
to	O
baseline	O
Ang2	B-arm_description
levels	O
(	O
Fig	O
.	O
3b	O
,	O
Table	O
2	O
)	O
.	O

Japan	O
Department	O
of	O
Medical	O
Oncology	O
Faculty	O
of	O
Medicine	O
,	O
Osakasayam	O
Kindai	O
University	O
Japan	O
Japan	O
Multicentre	B-study_type
,	I-study_type
phase	I-study_type
II	I-study_type
study	I-study_type
of	O
eribulin	B-arm_description
in	O
combination	O
with	O
S-1	B-arm_description
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
10.1186	O
/	O
s12885	O
-	O
019	O
-	O
6200	O
-	O
5	O
Received	O
:	O
25	O
January	O
2019	O
Accepted	O
:	O
24	O
September	O
2019	O

We	O
previously	O
reported	O
the	O
identification	O
of	O
a	O
synergistic	O
effect	O
ofS-1	O
and	O
eribulin	O
in	O
preclinical	O
models	O
[	O
17	O
]	O
,	O
and	O
recommended	O
using	O
the	O
phase	O
II	O
dose	O
of	O
the	O
combination	O
in	O
the	O
patients	O
with	O
ABC	O
who	O
had	O
been	O
previously	O
treated	O
with	O
anthracycline	O
and	O
taxane	O
[	O
18	O
]	O
.	O
Here	O
,	O
we	O
report	O
results	O
of	O
this	O
phase	B-study_type
II	I-study_type
study	I-study_type
of	O
the	O
administration	O
of	O
eribulin	B-arm_description
in	O
combination	O
with	O
S-1	B-arm_description
in	O
patients	O
with	O
ABC	O
and	O
poor	O
prognosis	O
.	O

Patients	O
were	O
intravenously	O
administered	O
eribulin	B-arm_description
mesylate	O
at	O
a	O
dose	O
of	O
1.4	B-arm_dosage
mg	I-arm_dosage
per	I-arm_dosage
square	I-arm_dosage
meter	I-arm_dosage
of	I-arm_dosage
body	I-arm_dosage
surface	I-arm_dosage
area	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
and	I-arm_dosage
8	I-arm_dosage
,	I-arm_dosage
with	I-arm_dosage
administrations	I-arm_dosage
repeated	I-arm_dosage
every	I-arm_dosage
21	I-arm_dosage
days	I-arm_dosage
.	O
S-1	B-arm_description
was	O
administered	O
orally	B-arm_dosage
on	I-arm_dosage
a	I-arm_dosage
daily	I-arm_dosage
basis	I-arm_dosage
at	I-arm_dosage
a	I-arm_dosage
dose	I-arm_dosage
of	I-arm_dosage
65	I-arm_dosage
mg	I-arm_dosage
per	I-arm_dosage
square	I-arm_dosage
meter	I-arm_dosage
of	I-arm_dosage
body	I-arm_dosage
surface	I-arm_dosage
area	I-arm_dosage
(	I-arm_dosage
divided	I-arm_dosage
into	I-arm_dosage
two	I-arm_dosage
doses	I-arm_dosage
)	I-arm_dosage
for	I-arm_dosage
14	I-arm_dosage
days	I-arm_dosage
,	I-arm_dosage
and	I-arm_dosage
repeated	I-arm_dosage
every	I-arm_dosage
21	I-arm_dosage
days	I-arm_dosage
.	O
The	O
assigned	O
treatment	O
was	O
continued	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxic	O
effects	O
occurred	O
.	O

The	O
median	O
OS	O
was	O
not	O
reached	O
as	O
of	O
May	O
2017	O
(	O
Fig	O
.	O
4	O
)	O
.	O
The	O
DOR	O
was	O
7.8	O
months	O
(	O
95	O
%	O
CI	O
:	O
1.9	O
to	O
−	O
22.5	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O
Disease	O
progression	O
due	O
to	O
new	O
metastases	O
occurred	O
in	O
nine	O
patients	O
(	O
27.2	O
%	O
)	O
.	O
An	O
increase	O
in	O
the	O
size	O
of	O
the	O
pre	O
-	O
existing	O
lesions	O
occurred	O
in	O
five	O
(	O
15.2	O
%	O
)	O
patients	O
.	O
The	O
new	O
metastasis	O
-	O
free	O
survival	O
after	O
eribulin	B-arm_description
and	O
S-1	B-arm_description
combination	O
therapy	O
was	O
9.2	O
months	O
(	O
95	O
%	O
CI	O
:	O
5.1	O
to	O
14.8	O
)	O
(	O
Fig	O
.	O
5	O
)	O
.	O

Prognostic	O
impact	O
of	O
pathological	O
complete	O
remission	O
after	O
preoperative	O
irradiation	O
in	O
patients	O
with	O
locally	O
advanced	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
:	O
re	O
-	O
analysis	O
of	O
a	O
phase	B-study_type
3	I-study_type
clinical	I-study_type
study	I-study_type
Prognostic	O
impact	O
of	O
pathological	O
complete	O
remission	O
after	O
preoperative	O
irradiation	O
in	O
patients	O
with	O
locally	O
advanced	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
:	O
re	O
-	O
analysis	O
of	O
a	O
phase	B-study_type
3	I-study_type
clinical	I-study_type
study	I-study_type
05	O
Mar	O
,	O
2014	O
05	O
Mar	O
,	O
2014	O
KaiWang	B-authors

Department	O
of	O
Radiation	O
Oncology	O
,	O
National	O
Cancer	O
Center	O
/	O
Cancer	O
Hospital	O
,	O
Chinese	O
Academy	O
of	O
Medical	O
Sciences	O
and	O
Peking	O
Union	O
Medical	O
College	O
Beijing	O
China	O
JingweiLuo	B-authors

Department	O
of	O
Radiation	O
Oncology	O
,	O
National	O
Cancer	O
Center	O
/	O
Cancer	O
Hospital	O
,	O
Chinese	O
Academy	O
of	O
Medical	O
Sciences	O
and	O
Peking	O
Union	O
Medical	O
College	O
Beijing	O
China	O
LiGao	B-authors

Department	O
of	O
Radiation	O
Oncology	O
,	O
National	O
Cancer	O
Center	O
/	O
Cancer	O
Hospital	O
,	O
Chinese	O
Academy	O
of	O
Medical	O
Sciences	O
and	O
Peking	O
Union	O
Medical	O
College	O
Beijing	O
China	O
JunlinYi	B-authors
yijunlin1969@163.com	O

Department	O
of	O
Radiation	O
Oncology	O
,	O
National	O
Cancer	O
Center	O
/	O
Cancer	O
Hospital	O
,	O
Chinese	O
Academy	O
of	O
Medical	O
Sciences	O
and	O
Peking	O
Union	O
Medical	O
College	O
Beijing	O
China	O
YuanQu	B-authors

Department	O
of	O
Radiation	O
Oncology	O
,	O
National	O
Cancer	O
Center	O
/	O
Cancer	O
Hospital	O
,	O
Chinese	O
Academy	O
of	O
Medical	O
Sciences	O
and	O
Peking	O
Union	O
Medical	O
College	O
Beijing	O
China	O
YuanTang	B-authors

Department	O
of	O
Radiation	O
Oncology	O
,	O
National	O
Cancer	O
Center	O
/	O
Cancer	O
Hospital	O
,	O
Chinese	O
Academy	O
of	O
Medical	O
Sciences	O
and	O
Peking	O
Union	O
Medical	O
College	O
Beijing	O
China	O
WeixinLiu	B-authors

China	O
Beijing	O
China	O
Department	O
of	O
Radiation	O
Oncology	O
,	O
National	O
Cancer	O
Center	O
/	O
Cancer	O
Hospital	O
,	O
Chinese	O
Academy	O
of	O
Medical	O
Sciences	O
and	O
Peking	O
Union	O
Medical	O
College	O
Beijing	O

China	O
Beijing	O
China	O
Department	O
of	O
Radiation	O
Oncology	O
,	O
National	O
Cancer	O
Center	O
/	O
Cancer	O
Hospital	O
,	O
Chinese	O
Academy	O
of	O
Medical	O
Sciences	O
and	O
Peking	O
Union	O
Medical	O
College	O
Beijing	O

China	O
Beijing	O
China	O
Department	O
of	O
Radiation	O
Oncology	O
,	O
National	O
Cancer	O
Center	O
/	O
Cancer	O
Hospital	O
,	O
Chinese	O
Academy	O
of	O
Medical	O
Sciences	O
and	O
Peking	O
Union	O
Medical	O
College	O
Beijing	O

China	O
Beijing	O
China	O
Prognostic	O
impact	O
of	O
pathological	O
complete	O
remission	O
after	O
preoperative	O
irradiation	O
in	O
patients	O
with	O
locally	O
advanced	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
:	O
re	O
-	O
analysis	O
of	O
a	O
phase	B-study_type
3	I-study_type
clinical	I-study_type
study	I-study_type
05	O
Mar	O
,	O
2014	O
05	O
Mar	O
,	O
2014	O
05	O
Mar	O
,	O
2014	O
10.1186	O
/	O
s13014	O
-	O
019	O
-	O
1428	O
-	O
4	O

In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
relationships	O
between	O
pathological	O
complete	O
remission	O
(	O
pCR	O
)	O
and	O
clinical	O
outcomes	O
in	O
these	O
72	O
non	O
-	O
responder	O
patients	O
.	O

Effects	O
of	O
the	O
MAML2	O
genetic	O
variants	O
in	O
glioma	O
susceptibility	O
and	O
prognosis	O
Effects	O
of	O
the	O
MAML2	O
genetic	O
variants	O
in	O
glioma	O
susceptibility	O
and	O
prognosis	O
29	O
September	O
2020	O
29	O
September	O
2020	O
MingZhang	B-authors

Mastermind	O
-	O
like	O
transcriptional	O
co	O
-	O
activator	O
2	O
(	O
MAML2	O
)	O
is	O
a	O
member	O
of	O
the	O
mastermind	O
-	O
like	O
family	O
of	O
proteins	O
,	O
which	O
is	O
a	O
co	O
-	O
activator	O
of	O
the	O
oncogenic	O
NOTCH	O
signaling	O
pathway	O
[	O
8	O
]	O
.	O
NOTCH	O
signaling	O
activation	O
has	O
been	O
demonstrated	O
to	O
be	O
involved	O
in	O
carcinogenesis	O
,	O
which	O
plays	O
a	O
critical	O
role	O
in	O
cell	O
proliferation	O
,	O
metastasis	O
and	O
epithelial	O
-	O
mesenchymal	O
transition	O
in	O
many	O
diverse	O
solid	O
tumors	O
including	O
glioma	O
[	O
9,10	O
]	O
.	O
Several	O
studies	O
have	O
demonstrated	O
MAML2	O
abnormal	O
expression	O
in	O
various	O
cancers	O
,	O
such	O
as	O
mucoepidermoid	O
carcinoma	O
,	O
hidradenoma	O
and	O
breast	O
cancer	O
[	O
11][12][13	O
]	O
.	O
These	O
studies	O
have	O
suggested	O
that	O
MAML2	O
might	O
be	O
involved	O
in	O
the	O
tumorigenesis	O
and	O
progression	O
of	O
cancers	O
.	O
Based	O
on	O
microarray	O
data	O
of	O
glioma	O
,	O
MAML2	O
as	O
a	O
novel	O
gene	O
related	O
to	O
glioma	O
was	O
identified	O
[	O
14	O
]	O
.	O
Additionally	O
,	O
epidemiological	O
studies	O
have	O
confirmed	O
that	O
polymorphisms	O
in	O
MAML2	O
,	O
a	O
NOTCH	O
pathway	O
gene	O
,	O
were	O
related	O
to	O
cancer	O
susceptibility	O
and	O
prognosis	O
[	O
15,16	O
]	O
.	O
However	O
,	O
no	O
previous	O
study	O
has	O
investigated	O
the	O
contribution	O
of	O
MAML2	O
variants	O
to	O
glioma	O
risk	O
and	O
prognosis	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
EDTA	O
anticoagulated	O
peripheral	O
blood	O
samples	O
from	O
each	O
subject	O
using	O
a	O
Qiagen	O
DNA	O
Isolation	O
Kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
U.S.A.	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
,	O
and	O
stored	O
at	O
−20	O
•	O
C	O
until	O
additional	O
analysis	O
.	O
MAML2	O
mRNA	O
expression	O
analysis	O
in	O
glioma	O
was	O
performed	O
using	O
GEPIA	O
(	O
http	O
:	O
//gepia.cancer	O
-	O
pku.cn/	O
)	O
datasets	O
.	O
Seven	O
MAML2	O
SNPs	O
(	O
rs7107785	O
,	O
rs479825	O
,	O
rs7938889	O
,	O
rs11021499	O
,	O
rs7115578	O
,	O
rs4598633	O
and	O
rs485842	O
)	O
were	O
selected	O
as	O
candidate	O
SNPs	O
for	O
genotyping	O
in	O
the	O
current	O
study	O
.	O
These	O
SNPs	O
were	O
selected	O
based	O
on	O
a	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
of	O
>	O
5	O
%	O
in	O
Chinese	O
populations	O
and	O
with	O
a	O
pairwise	O
r	O
2	O
≥	O
0.80	O
,	O
from	O
the	O
NCBI	O
dbSNP	O
database	O
(	O
http://www.ncbi.nlm.nih.gov/projects/SNP	O
)	O
and	O
the	O
1000	O
Genomes	O
Project	O
data	O
(	O
http://www.internationalgenome.org/	O
)	O
.	O
To	O
evaluate	O
the	O
potential	O
function	O
of	O
the	O
selected	O
SNPs	O
,	O
we	O
conducted	O
in	O
silico	O
analysis	O
using	O
HaploReg	O
v4.1	O
(	O
https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php	O
)	O
and	O
SNPinfo	O
Web	O
Server	O
(	O
https://snpinfo.niehs.nih.gov/	O
)	O
.	O
MAML2	O
SNPs	O
genotyping	O
was	O
performed	O
Agena	O
MassARRAY	O
system	O
(	O
Agena	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
U.S.A.	O
)	O
in	O
double	O
-	O
blinded	O
[	O
17,18	O
]	O
.	O
The	O
primers	O
used	O
in	O
amplification	O
and	O
single	O
base	O
extension	O
were	O
shown	O
in	O
Supplementary	O
Table	O
S1	O
,	O
which	O
was	O
designed	O
by	O
the	O
MassARRAY	O
Assay	O
Design	O
3.0	O
software	O
.	O
For	O
quality	O
control	O
,	O
the	O
call	O
rate	O
of	O
genotyping	O
>	O
95	O
%	O
,	O
and	O
approximately	O
10	O
%	O
of	O
the	O
samples	O
were	O
randomly	O
selected	O
for	O
repeated	O
analysis	O
,	O
of	O
which	O
the	O
reproducibility	O
was	O
100	O
%	O
.	O

Detailed	O
information	O
about	O
the	O
seven	O
selected	O
SNPs	O
is	O
displayed	O
in	O
Supplementary	O
Table	O
S2	O
.	O
Genotype	O
distribution	O
of	O
all	O
SNPs	O
among	O
controls	B-arm_description
was	O
in	O
agreement	O
with	O
HWE	O
(	O
P>0.05	O
)	O
.	O
In	O
silico	O
analysis	O
using	O
HaploReg	O
v4.1	O
and	O
SNPinfo	O
Web	O
Server	O
,	O
the	O
function	O
of	O
the	O
selected	O
SNPs	O
was	O
successfully	O
predicted	O
to	O
have	O
biological	O
functions	O
(	O
Supplementary	O
Table	O
S2	O
)	O
.	O
Furthermore	O
,	O
we	O
extracted	O
MAML2	O
expression	O
data	O
between	O
glioma	B-arm_description
patients	I-arm_description
and	O
healthy	B-arm_description
controls	I-arm_description
from	O
GEPIA	O
database	O
.	O
Supplementary	O
Figure	O
S1	O
showed	O
that	O
there	O
were	O
significant	O
differences	O
of	O
MAML2	O
expression	O
in	O
glioblastoma	O
multiforme	O
and	O
brain	O
lower	O
grade	O
glioma	O
compared	O
with	O
normal	O
tissue	O
(	O
P<0.01	O
)	O
.	O
Moreover	O
,	O
the	O
expression	O
of	O
MAMAL2	O
was	O
particularly	O
associated	O
with	O
the	O
prognosis	O
of	O
lower	O
grade	O
glioma	O
(	O
log	O
-	O
rank	O
P=0.0094	O
,	O
Supplementary	O
Figure	O
S2	O
)	O
.	O

Germany	O
Darmstadt	O
Germany	O
Survival	O
Analysis	B-study_type
in	O
Patients	O
with	O
Metastatic	O
Merkel	O
Cell	O
Carcinoma	O
Treated	O
with	O
Avelumab	B-arm_description
July	O
26	O
,	O
2019	O
July	O
26	O
,	O
2019	O
July	O
26	O
,	O
2019	O
10.1007	O
/	O
s12325	O
-	O
019	O
-	O
01034	O
-	O
0	O
Received	O
:	O
May	O
20	O
,	O
2019	O

In	O
recent	O
years	O
this	O
trend	O
appears	O
to	O
be	O
shifting	O
[	O
7][8][9	O
]	O
,	O
likely	O
because	O
of	O
an	O
increasing	O
number	O
of	O
oncology	O
therapies	O
with	O
novel	O
mechanisms	O
of	O
action	O
receiving	O
regulatory	O
approvals	O
based	O
on	O
short	O
-	O
term	O
data	O
and/or	O
surrogate	O
endpoints	O
[	O
10,11	O
]	O
.	O
Specifically	O
,	O
the	O
novel	O
patterns	O
of	O
response	O
observed	O
with	O
immunooncology	O
(	O
IO	O
)	O
treatments	O
,	O
including	O
durable	O
response	O
for	O
a	O
fraction	O
of	O
patients	O
and	O
a	O
plateau	O
in	O
survival	O
curves	O
[	O
12][13][14	O
]	O
,	O
have	O
led	O
to	O
'	O
'	O
unconventional	O
'	O
'	O
survival	O
curves	O
,	O
inadequately	O
captured	O
with	O
standard	O
parametric	O
approaches	O
[	O
7][8][9][15][16][17][18	O
]	O
.	O

The	O
estimated	O
mean	O
OS	O
(	O
beyond	O
the	O
landmark	O
point	O
)	O
from	O
the	O
log	O
-	O
normal	O
model	O
for	O
patients	O
who	O
did	O
not	O
achieve	O
response	O
was	O
1.2	O
years	O
(	O
Fig	O
.	O
2a	O
)	O
(	O
see	O
ESM	O
Table	O
2	O
)	O
.	O

The	O
Efficacy	O
and	O
Safety	O
of	O
Modified	O
Docetaxel	B-arm_description
,	O
Cisplatin	B-arm_description
,	O
and	O
5-Fluorouracil	B-arm_description
Vs	O
.	O
Epirubicin	B-arm_description
,	O
Oxaliplatin	B-arm_description
,	O
and	O
Capecitabine	B-arm_description
Regimen	O
in	O
the	O
Advanced	O
Gastric	O
Cancer	O
:	O
A	O
Randomized	B-study_type
Controlled	I-study_type
Clinical	I-study_type
Trial	I-study_type

Although	O
different	O
studies	O
have	O
been	O
conducted	O
on	O
the	O
efficacy	O
,	O
safety	O
,	O
and	O
tolerability	O
of	O
m	O
-	O
DCF	O
and	O
EOX	O
regimens	O
,	O
few	O
studies	O
have	O
compared	O
these	O
two	O
regimens	O
.	O
Therefore	O
,	O
we	O
designed	O
and	O
performed	O
this	O
trial	O
to	O
determine	O
the	O
optimal	O
chemotherapy	O
regimen	O
for	O
patients	O
with	O
stage	O
IV	O
gastric	O
cancer	O
.	O

The	O
treatment	O
cycle	O
for	O
both	O
m	B-arm_description
-	I-arm_description
DCF	I-arm_description
and	O
EOX	B-arm_description
treatment	I-arm_description
regimens	O
was	O
repeated	O
every	O
three	O
weeks	O
for	O
a	O
maximum	O
of	O
eight	O
cycles	O
,	O
except	O
for	O
samples	O
with	O
disease	O
progression	O
,	O
unacceptable	O
toxicity	O
,	O
withdrawal	O
from	O
the	O
study	O
,	O
or	O
death	O
.	O
Researchers	O
graded	O
all	O
side	O
effects	O
and	O
toxic	O
effects	O
in	O
patients	O
according	O
to	O
the	O
criteria	O
of	O
the	O
National	O
Cancer	O
Institute	O
(	O
version	O
2.0	O
)	O
in	O
each	O
visit	O
.	O

Effects	O
of	O
dose	O
modifications	O
on	O
the	O
safety	O
and	O
efficacy	O
of	O
dacomitinib	O
for	O
EGFR	O
mutation	O
-	O
positive	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
17	O
July	O
2019	O

For	O
patients	O
with	O
dacomitinib	B-arm_description
DRs	O
,	O
frequency	O
and	O
severity	O
of	O
AEs	O
of	O
interest	O
(	O
diarrhea	O
,	O
dermatitis	O
acneiform	O
,	O
stomatitis	O
and	O
paronychia	O
)	O
before	O
and	O
after	O
DR	B-arm_dosage
from	I-arm_dosage
45	I-arm_dosage
mg	I-arm_dosage
QD	I-arm_dosage
were	O
analyzed	O
by	O
NCI	O
-	O
CTCAE	O
grade	O
.	O
Plasma	O
steady	O
-	O
state	O
trough	O
concentrations	O
(	O
C	O
trough	O
,	O
ss	O
)	O
of	O
dacomitinib	B-arm_description
were	O
collected	O
at	O
day	O
1	O
of	O
cycle	O
2	O
,	O
after	O
at	O
least	O
14	O
days	O
of	O
consecutive	O
dacomitinib	O
45	O
mg	O
QD	O
dosing	O
.	O
These	O
measurements	O
were	O
used	O
to	O
compare	O
the	O
initial	O
plasma	O
exposure	O
in	O
patients	O
who	O
remained	O
at	O
45	O
mg	O
QD	O
for	O
the	O
duration	O
of	O
treatment	O
,	O
patients	O
whose	O
dose	O
was	O
reduced	O
to	O
30	O
mg	O
QD	O
as	O
the	O
lowest	O
dose	O
and	O
patients	O
whose	O
dose	O
was	O
reduced	O
to	O
15	O
mg	O
QD	O
as	O
the	O
lowest	O
dose	O
.	O
Kaplan	O
-	O
Meier	O
estimates	O
were	O
used	O
to	O
construct	O
survival	O
curves	O
and	O
calculate	O
median	O
(	O
with	O
95	O
%	O
CIs	O
)	O
PFS	B-arm_efficacy_metric
and	O
OS	O
for	O
all	O
patients	O
in	O
the	O
dacomitinib	B-arm_description
arm	I-arm_description
,	O
all	O
patients	O
in	O
the	O
dacomitinib	B-arm_description
arm	I-arm_description
who	O
underwent	O
DR	O
(	O
to	O
either	O
30	O
mg	O
QD	O
or	O
15	O
mg	O
QD	O
as	O
lowest	O
dose	O
)	O
,	O
patients	O
in	O
the	O
dacomitinib	B-arm_description
arm	I-arm_description
who	O
remained	O
at	O
45	O
mg	O
QD	O
for	O
the	O
duration	O
of	O
treatment	O
,	O
patients	O
in	O
the	O
dacomitinib	B-arm_description
arm	I-arm_description
who	O
dose	O
reduced	O
to	O
30	O
mg	O
QD	O
as	O
lowest	O
dose	O
and	O
patients	O
who	O
dose	O
reduced	O
to	O
15	O
mg	O
QD	O
as	O
lowest	O
dose	O
.	O

Among	O
all	O
patients	O
starting	O
on	O
the	O
45-mg	B-arm_dosage
QD	I-arm_dosage
dose	I-arm_dosage
of	O
dacomitinib	B-arm_description
(	O
n	O
=	O
227	O
)	O
,	O
DRs	O
due	O
to	O
AEs	O
occurred	O
in	O
150	O
(	O
66.1	O
%	O
)	O
patients	O
,	O
while	O
77	O
(	O
33.9	O
%	O
)	O
patients	O
stayed	O
at	O
45	O
mg	O
QD	O
for	O
the	O
duration	O
of	O
treatment	O
.	O
In	O
total	O
87	O
patients	O
(	O
38.3	O
%	O
of	O
all	O
patients	O
randomized	O
to	O
the	O
dacomitinib	B-arm_description
arm	I-arm_description
)	O
reduced	O
to	O
30	O
mg	O
QD	O
as	O
the	O
lowest	O
dose	O
and	O
63	O
patients	O
(	O
27.8	O
%	O
of	O
all	O
patients	O
randomized	O
to	O
the	O
dacomitinib	O
arm	O
)	O
further	O
dose	O
reduced	O
to	O
15	O
mg	O
QD	O
as	O
the	O
lowest	O
dose	O
.	O
Median	O
time	O
to	O
DR	O
was	O
12.9	O
weeks	O
for	O
the	O
87	O
patients	O
with	O
30	O
mg	O
QD	O
as	O
the	O
lowest	O
dose	O
received	O
.	O
For	O
the	O
63	O
patients	O
who	O
received	O
15	O
mg	O
as	O
the	O
lowest	O
dose	O
,	O
median	O
time	O
to	O
the	O
first	O
DR	O
(	O
to	O
30	O
mg	O
QD	O
)	O
was	O
8.4	O
weeks	O
and	O
median	O
time	O
to	O
subsequent	O
DR	O
to	O
15	O
mg	O
QD	O
(	O
from	O
30	O
mg	O
QD	O
)	O
was	O
12.4	O
weeks	O
.	O
There	O
were	O
no	O
baseline	O
clinical	O
characteristics	O
that	O
were	O
predictive	O
of	O
which	O
patients	O
received	O
DRs	O
.	O
However	O
,	O
DRs	O
generally	O
occurred	O
more	O
frequently	O
in	O
females	O
.	O
Additionally	O
,	O
median	O
weights	O
,	O
as	O
well	O
as	O
the	O
lower	O
-	O
and	O
upper	O
-	O
range	O
bounds	O
for	O
weight	O
,	O
were	O
lower	O
in	O
patients	O
in	O
both	O
DR	O
groups	O
than	O
in	O
those	O
remaining	O
at	O
45	O
mg	O
QD	O
for	O
the	O
duration	O
of	O
treatment	O
(	O
Supplementary	O
Table	O
1	O
)	O
.	O

Median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
was	O
similar	O
in	O
all	O
dacomitinib	B-arm_description
-	I-arm_description
treated	I-arm_description
patients	I-arm_description
(	O
n	O
=	O
227	O
)	O
and	O
those	B-arm_description
with	I-arm_description
DR	I-arm_description
(	O
n	O
=	O
150	O
)	O
:	O
14.7	B-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
:	I-arm_efficacy_results
11.1	I-arm_efficacy_results
-	I-arm_efficacy_results
16.6	I-arm_efficacy_results
)	I-arm_efficacy_results
months	I-arm_efficacy_results
and	O
16.6	B-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
:	I-arm_efficacy_results
14.6	I-arm_efficacy_results
-	I-arm_efficacy_results
18.6	I-arm_efficacy_results
)	I-arm_efficacy_results
months	I-arm_efficacy_results
,	O
respectively	O
(	O
Figure	O
1A	O
)	O
.	O
Median	B-arm_efficacy_metric
(	I-arm_efficacy_metric
95	I-arm_efficacy_metric
%	I-arm_efficacy_metric
CI	I-arm_efficacy_metric
)	I-arm_efficacy_metric
PFS	B-arm_efficacy_metric
by	O
the	O
lowest	O
dose	O
received	O
was	O
as	O
follows	O
:	O
9.1	B-arm_efficacy_results
(	I-arm_efficacy_results
5.6	I-arm_efficacy_results
-	I-arm_efficacy_results
12.8	I-arm_efficacy_results
)	I-arm_efficacy_results
months	I-arm_efficacy_results
for	O
patients	B-arm_description
(	I-arm_description
n	I-arm_description
=	I-arm_description
77	I-arm_description
)	I-arm_description
who	I-arm_description
remained	I-arm_description
on	I-arm_description
45	I-arm_description
mg	I-arm_description
QD	I-arm_description
and	O
12.9	B-arm_efficacy_results
(	I-arm_efficacy_results
10.8	I-arm_efficacy_results
-	I-arm_efficacy_results
16.7	I-arm_efficacy_results
)	I-arm_efficacy_results
months	I-arm_efficacy_results
for	O
patients	B-arm_description
(	I-arm_description
n	I-arm_description
=	I-arm_description
87	I-arm_description
)	I-arm_description
who	I-arm_description
received	I-arm_description
30	I-arm_description
mg	I-arm_description
QD	I-arm_description
as	I-arm_description
the	I-arm_description
lowest	I-arm_description
dose	I-arm_description
and	O
31.2	B-arm_efficacy_results
(	I-arm_efficacy_results
16.5	I-arm_efficacy_results
-	I-arm_efficacy_results
35.1	I-arm_efficacy_results
)	I-arm_efficacy_results
months	I-arm_efficacy_results
for	O
patients	B-arm_description
(	I-arm_description
n	I-arm_description
=	I-arm_description
63	I-arm_description
)	I-arm_description
who	I-arm_description
received	I-arm_description
15	I-arm_description
mg	I-arm_description
QD	I-arm_description
as	I-arm_description
the	I-arm_description
lowest	I-arm_description
dose	I-arm_description
(	O
Figure	O
1B	O
)	O
.	O
Median	O
(	O
95	O
%	O
CI	O
)	O
OS	O
was	O
also	O
similar	O
in	O
all	O
dacomitinib	B-arm_description
-	I-arm_description
treated	I-arm_description
patients	I-arm_description
(	O
n	O
=	O
227	O
)	O
and	O
those	O
with	O
DR	B-arm_description
(	O
n	O
=	O
151	O
)	O
:	O
34.1	O
(	O
29.5	O
-	O
37.7	O
)	O
months	O
and	O
36.7	O
(	O
32.6	O
-not	O
reached	O
[	O
NR	O
]	O
)	O
months	O
,	O
respectively	O
(	O
Figure	O
2A	O
)	O
.	O
Median	O
(	O
95	O
%	O
CI	O
)	O
OS	O
for	O
each	O
of	O
the	O
lowest	O
dose	O
groups	O
was	O
as	O
follows	O
:	O
22.0	O
(	O
15.6	O
-	O
26.4	O
)	O
months	O
for	O
patients	B-arm_description
(	I-arm_description
n	I-arm_description
=	I-arm_description
76	I-arm_description
)	I-arm_description
who	I-arm_description
remained	I-arm_description
on	I-arm_description
45	I-arm_description
mg	I-arm_description
QD	I-arm_description
and	O
32.6	O
(	O
28.8	O
-	O
37.7	O
)	O
months	O
for	O
patients	B-arm_description
(	I-arm_description
n	I-arm_description
=	I-arm_description
88	I-arm_description
)	I-arm_description
who	I-arm_description
received	I-arm_description
30	I-arm_description
mg	I-arm_description
QD	I-arm_description
as	I-arm_description
the	I-arm_description
lowest	I-arm_description
dose	I-arm_description
and	O
NR	O
(	O
34.7-NR	O
)	O
months	O
for	O
patients	B-arm_description
(	I-arm_description
n	I-arm_description
=	I-arm_description
63	I-arm_description
)	I-arm_description
who	I-arm_description
received	I-arm_description
15	I-arm_description
mg	I-arm_description
QD	I-arm_description
as	I-arm_description
the	I-arm_description
lowest	I-arm_description
dose	I-arm_description
(	O
Figure	O
2B	O
)	O
.	O

•	O
Initial	O
plasma	O
dacomitinib	B-arm_description
exposure	O
at	O
45	O
mg	O
QD	O
was	O
generally	O
lower	O
in	O
patients	B-arm_description
remaining	I-arm_description
at	I-arm_description
45	I-arm_description
mg	I-arm_description
QD	I-arm_description
compared	O
with	O
dose	B-arm_description
-	I-arm_description
reducing	I-arm_description
patients	I-arm_description
.	O

•	O
Tolerability	O
-	O
guided	O
dose	O
modifications	O
enabled	O
patients	O
to	O
manage	O
AEs	O
and	O
continue	O
with	O
dacomitinib	B-arm_description
treatment	O
and	O
benefit	O
from	O
improvement	O
in	O
PFS	B-arm_efficacy_metric
and	O
OS	O
.	O

Novartis	O
,	O
Zimmer	O
Becton	O
Dickinson	O
Baxter	O
,	O
Merck	O
,	O
Pfizer	O
,	O
Stryker	O
,	O
Procter	O
&	O
Gamble	O
,	O
Walgreens	O
Novartis	O
,	O
Zimmer	O
Cardinal	O
Health	O
,	O
Express	O
Scripts	O
Becton	O
Dickinson	O

Clinical	O
response	O
to	O
CRT	O
was	O
evaluated	O
10	O
to	O
16	O
weeks	O
after	O
CRT	O
with	O
a	O
PET	O
/	O
CT	O
and	O
clinical	O
examinations	O
by	O
the	O
treating	O
radiation	O
oncologist	O
and	O
head	O
and	O
neck	O
surgeon	O
.	O
Decisions	O
for	O
surgical	O
intervention	O
(	O
ie	O
,	O
biopsy	O
,	O
neck	O
dissection	O
)	O
were	O
based	O
on	O
the	O
PET	O
/	O
CT	O
and	O
clinical	O
evaluations	O
demonstrating	O
suspicion	O
of	O
residual	O
tumor	O
.	O

Clinician	O
assessments	O
of	O
toxicity	O
(	O
National	O
Cancer	O
Institute	O
's	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
[	O
CTCAE	O
]	O
version	O
4.03	O
)	O
and	O
patient	O
self	O
-	O
reported	O
symptoms	O
(	O
patient	O
-	O
reported	O
outcomes	O
version	O
of	O
the	O
CTCAE	O
[	O
PRO	O
-	O
CTCAE	O
]	O
)	O
were	O
collected	O
before	O
treatment	O
,	O
weekly	O
during	O
treatment	O
,	O
and	O
during	O
subsequent	O
follow	O
-	O
up	O
visits	O
.	O
16,17	O
Thirty	O
head	O
and	O
neck	O
-	O
specific	O
items	O
were	O
selected	O
from	O
the	O
PRO	O
-	O
CTCAE	O
.	O
18	O
Patients	O
also	O
completed	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
EORTC	O
QLQ	O
)	O
C30	O
,	O
EORTC	O
QLQ	O
H&N35	O
,	O
and	O
Eating	O
Assessment	O
Tool	O
10	O
questionnaires	O
before	O
treatment	O
,	O
weekly	O
during	O
treatment	O
,	O
and	O
during	O
subsequent	O
follow	O
-	O
up	O
visits	O
.	O
[	O
19][20][21	O
]	O
Modified	O
barium	O
swallow	O
studies	O
were	O
performed	O
before	O
treatment	O
,	O
6	O
to	O
8	O
weeks	O
after	O
treatment	O
,	O
and	O
6	O
months	O
after	O
treatment	O
.	O
The	O
Rosenbek	O
Penetration	O
Aspiration	O
Scale	O
was	O
used	O
to	O
quantify	O
dysphagia	O
.	O
22	O

The	O
primary	O
end	O
point	O
of	O
this	O
study	O
was	O
2-year	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
.	O
The	O
reported	O
PFS	O
for	O
patients	O
with	O
HPV	O
-	O
associated	O
OPSCC	O
treated	O
with	O
standard	O
-	O
intensity	O
70	O
Gy	O
and	O
cisplatin	O
in	O
RTOG	O
0129	O
was	O
74	O
%	O
(	O
3	O
year	O
)	O
and	O
in	O
RTOG	O
1016	O
was	O
78	O
%	O
(	O
5	O
year	O
)	O
.	O
1	O
PFS	B-arm_efficacy_metric
was	O
defined	O
as	O
the	O
time	O
from	O
the	O
beginning	O
of	O
treatment	O
to	O
cancer	O
progression	O
or	O
death	O
.	O
Power	O
calculations	O
were	O
based	O
on	O
the	O
null	O
hypothesis	O
that	O
the	O
true	O
2-year	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
rate	I-arm_efficacy_metric
was	O
87	B-arm_efficacy_results
%	I-arm_efficacy_results
,	O
with	O
the	O
alternative	O
hypothesis	O
being	O
that	O
the	O
2-year	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
rate	I-arm_efficacy_metric
was	O
0.80	B-arm_efficacy_results
(	O
or	O
less	O
)	O
.	O
For	O
a	O
planned	O
total	O
sample	O
size	O
of	O
90	O
,	O
the	O
null	O
hypothesis	O
would	O
have	O
been	O
rejected	O
if	O
18	O
or	O
more	O
patients	O
had	O
a	O
tumor	O
recurrence	O
or	O
death	O
,	O
with	O
a	O
type	O
1	O
error	O
of	O
less	O
than	O
0.05	O
.	O
A	O
pathologically	O
positive	O
lymph	O
node	O
that	O
was	O
found	O
on	O
a	O
neck	O
dissection	O
that	O
was	O
performed	O
because	O
of	O
the	O
results	O
of	O
the	O
3-month	O
post	O
-	O
treatment	O
PET	O
/	O
CT	O
was	O
not	O
classified	O
as	O
a	O
regional	O
failure	O
.	O
This	O
neck	O
dissection	O
was	O
prespecified	O
in	O
the	O
protocol	O
design	O
,	O
outside	O
of	O
the	O
trial	O
is	O
standard	O
of	O
care	O
,	O
and	O
was	O
considered	O
a	O
planned	O
part	O
of	O
the	O
treatment	O
.	O
Kaplan	O
Meier	O
estimates	O
of	O
local	O
control	O
,	O
regional	O
control	O
,	O
local	O
-	O
regional	O
control	O
(	O
LRC	O
)	O
,	O
distant	O
metastasis	O
-	O
free	O
survival	O
(	O
DMFS	O
)	O
,	O
PFS	B-arm_efficacy_metric
,	O
causespecific	O
survival	O
,	O
and	O
OS	O
were	O
calculated	O
.	O

Pertinent	O
patient	O
-	O
reported	O
acute	O
nonhematologic	O
toxicity	O
is	O
listed	O
in	O
Table	O
3	O
.	O
Complete	O
EORTC	O
QLQ	O
C30	O
and	O
EORTC	O
QLQ	O
H&N-35	O
and	O
Eating	O
Assessment	O
Tool	O
10	O
results	O
are	O
listed	O
in	O
Appendix	O
Table	O
A1	O
(	O
online	O
only	O
)	O
.	O
Selected	O
domains	O
and	O
symptoms	O
from	O
these	O
QLQs	O
are	O
shown	O
in	O
Fig	O
2	O
.	O
As	O
expected	O
,	O
we	O
observed	O
declines	O
in	O
global	O
QOL	O
and	O
an	O
increase	O
in	O
symptom	O
scores	O
soon	O
after	O
the	O
completion	O
of	O
treatment	O
.	O
All	O
QOL	O
items	O
,	O
domains	O
,	O
and	O
symptom	O
scores	O
had	O
returned	O
to	O
baseline	O
by	O
6	O
months	O
,	O
with	O
the	O
exception	O
of	O
dry	O
mouth	O
and	O
sticky	O
saliva	O
.	O
There	O
was	O
continued	O
improvement	O
in	O
these	O
symptoms	O
beyond	O
1	O
year	O
.	O
Notably	O
,	O
patients	O
reported	O
that	O
their	O
swallowing	O
function	O
returned	O
to	O
baseline	O
.	O

First	O
draft	O
submitted	O
:	O
9	O
October	O
2019	O
;	O
Accepted	O
for	O
publication	O
:	O
1	O
November	O
2019	O
;	O
2618	O
•	O
gastrointestinal	O
stromal	O
tumor	O
•	O
KIT	O
•	O
PDGFRA	O
•	O
Phase	B-study_type
III	I-study_type
trial	I-study_type
•	O
receptor	O
tyrosine	O
kinase	O
•	O
ripretinib	B-arm_description
•	O
sarcoma	O
•	O
targeted	O
therapy	O
•	O
tyrosine	O
kinase	O
inhibitor	O
JohnNemunaitis	B-authors
john.nemunaitis@utoledo.edu	O

Despite	O
significant	O
improvement	O
in	O
outcomes	O
compared	O
with	O
those	O
in	O
the	O
pre	O
-	O
TKI	O
therapy	O
era	O
,	O
response	O
to	O
imatinib	O
is	O
not	O
experienced	O
by	O
all	O
patients	O
,	O
and	O
most	O
patients	O
with	O
GIST	O
will	O
ultimately	O
develop	O
resistance	O
to	O
imatinib	O
,	O
most	O
commonly	O
due	O
to	O
the	O
development	O
of	O
secondary	O
mutations	O
in	O
KIT	O
[	O
33,[39][40][41][42][43	O
]	O
.	O
Secondary	O
resistance	O
mutations	O
usually	O
arise	O
in	O
the	O
catalytic	O
domain	O
of	O
the	O
kinase	O
:	O
at	O
the	O
switch	O
pocket	O
,	O
which	O
typically	O
occur	O
in	O
KIT	O
exons	O
13	O
and	O
14	O
or	O
PDGFRA	O
exons	O
14	O
and	O
15	O
and	O
sterically	O
disrupt	O
drug	O
binding	O
or	O
conformationally	O
activate	O
KIT	O
and	O
in	O
the	O
activation	O
loop	O
switch	O
encoded	O
by	O
KIT	O
exons	O
17	O
and	O
18	O
and	O
PDGFRA	O
exon	O
18	O
[	O
29,44,45	O
]	O
.	O
Activation	O
loop	O
mutations	O
act	O
by	O
shifting	O
the	O
kinase	O
into	O
an	O
activated	O
Type	O
I	O
or	O
on	O
-	O
state	O
conformation	O
that	O
is	O
less	O
amenable	O
to	O
drug	O
binding	O
by	O
any	O
of	O
the	O
approved	O
Type	O
II	O
TKIs	O
[	O
46	O
]	O
.	O
Although	O
uncommon	O
in	O
primary	O
GIST	O
(	O
1	O
-	O
2	O
%	O
of	O
newly	O
diagnosed	O
cases	O
)	O
,	O
mutations	O
in	O
exons	O
13	O
,	O
14	O
and	O
17	O
are	O
often	O
responsible	O
for	O
acquired	O
imatinib	O
resistance	O
[	O
38	O
]	O
,	O
with	O
exon	O
17	O
mutations	O
alone	O
accounting	O
for	O
as	O
many	O
as	O
50	O
%	O
of	O
the	O
acquired	O
resistance	O
cases	O
to	O
imatinib	O
;	O
exon	O
17	O
mutations	O
also	O
result	O
in	O
resistance	O
to	O
sunitinib	O
[	O
38,47	O
]	O
.	O
Figure	O
3	O
depicts	O
the	O
secondary	O
KIT	O
mutations	O
in	O
patients	O
with	O
GIST	O
across	O
exons	O
13	O
,	O
14	O
,	O
17	O
and	O
18	O
.	O

PF-06439535	B-arm_description
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
Bevacizumab	O
(	O
Avastin	O
®	O
)	O
,	O
Both	O
Plus	O
Paclitaxel	B-arm_description
and	I-arm_description
Carboplatin	I-arm_description
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O
A	O
Randomized	B-study_type
,	I-study_type
Double	I-study_type
-	I-study_type
Blind	I-study_type
Study	I-study_type
23	O
July	O
2019	O

National	O
and	O
Kapodistrian	O
University	O
of	O
Athens	O
Sotiria	O
General	O
Hospital	O
Athens	O
Greece	O
VladimirVladimirov	B-authors
Outpatient	O
Department	O
Pyatigorsk	O
Oncology	O
Dispensary	O
Stavropol	O
Region	O
Pyatigorsk	O
Russian	O
Federation	O
Outpatient	O
Department	O
Pyatigorsk	O
Oncology	O
Dispensary	O
Stavropol	O
Region	O
Pyatigorsk	O
Russian	O
Federation	O
ManuelaZereu	B-authors
Nucleo	O
de	O
Oncologia	O
Santa	O
Casa	O
Hospital	O

PF-06439535	B-arm_description
(	O
a	O
Bevacizumab	O
Biosimilar	O
)	O
Compared	O
with	O
Reference	O
Bevacizumab	B-arm_description
(	I-arm_description
Avastin	I-arm_description
®	I-arm_description
)	I-arm_description
,	O
Both	O
Plus	O
Paclitaxel	B-arm_description
and	B-arm_description
Carboplatin	B-arm_description
,	O
as	O
First	O
-	O
Line	O
Treatment	O
for	O
Advanced	O
Non	O
-	O
Squamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O
A	O
Randomized	B-study_type
,	I-study_type
Double	I-study_type
-	I-study_type
Blind	I-study_type
Study	I-study_type
NielsReinmuth	B-authors
n.reinmuth@asklepios.com	O

When	O
PF-06439535	B-arm_description
or	O
bevacizumab	B-arm_description
-	O
EU	O
was	O
combined	O
with	O
paclitaxel	B-arm_description
and	I-arm_description
carboplatin	B-arm_description
in	O
the	O
first	O
-	O
line	O
treatment	O
of	O
advanced	O
non	O
-	O
squamous	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
,	O
we	O
identified	O
no	O
notable	O
differences	O
between	O
the	O
two	O
treatment	O
groups	O
with	O
respect	O
to	O
efficacy	O
,	O
safety	O
,	O
pharmacokinetics	O
,	O
or	O
immunogenicity	O
.	O

After	O
chemotherapy	O
had	O
been	O
discontinued	O
,	O
PF-06439535	B-arm_description
or	O
bevacizumab	B-arm_description
-	I-arm_description
EU	I-arm_description
monotherapy	O
could	O
be	O
administered	O
until	O
disease	O
progression	O
(	O
defined	O
per	O
RECIST	O
1.1	O
)	O
,	O
unacceptable	O
toxicity	O
,	O
discretion	O
of	O
the	O
investigator	O
,	O
death	O
,	O
withdrawal	O
of	O
consent	O
,	O
or	O
the	O
end	O
of	O
the	O
study	O
,	O
whichever	O
came	O
first	O
.	O
The	O
dose	O
and	O
regimen	O
for	O
PF-06439535	B-arm_description
and	O
bevacizumab	B-arm_description
-	I-arm_description
EU	I-arm_description
were	O
chosen	O
to	O
be	O
consistent	O
with	O
the	O
product	O
labeling	O
of	O
bevacizumab	B-arm_description
-	I-arm_description
EU	I-arm_description
.	O
The	O
chemotherapy	O
given	O
and	O
the	O
regimens	O
used	O
were	O
considered	O
standard	O
of	O
care	O
.	O

Tumor	O
assessments	O
included	O
computed	O
tomography	O
(	O
CT	O
)	O
or	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
scans	O
of	O
the	O
head	O
,	O
chest	O
,	O
abdomen	O
(	O
including	O
adrenals	O
)	O
,	O
and	O
other	O
disease	O
sites	O
such	O
as	O
the	O
pelvis	O
if	O
clinically	O
indicated	O
.	O
CT	O
scans	O
were	O
performed	O
with	O
contrast	O
media	O
unless	O
contraindicated	O
for	O
medical	O
reasons	O
.	O
MRI	O
was	O
only	O
used	O
when	O
considered	O
more	O
appropriate	O
than	O
CT	O
or	O
when	O
there	O
was	O
a	O
contraindication	O
for	O
use	O
of	O
CT	O
with	O
contrast	O
.	O
For	O
a	O
given	O
patient	O
,	O
the	O
same	O
method	O
of	O
tumor	O
assessment	O
was	O
used	O
throughout	O
the	O
trial	O
.	O
CT	O
or	O
MRI	O
assessments	O
were	O
performed	O
every	O
6	O
weeks	O
(	O
±	O
7	O
days	O
)	O
until	O
week	O
25	O
(	O
based	O
on	O
date	O
of	O
randomization	O
)	O
.	O
After	O
week	O
25	O
,	O
assessments	O
were	O
performed	O
every	O
9	O
weeks	O
(	O
±	O
7	O
days	O
)	O
until	O
1	O
year	O
from	O
randomization	O
.	O
Responses	O
were	O
required	O
to	O
be	O
confirmed	O
by	O
a	O
second	O
set	O
of	O
scans	O
obtained	O
6	O
weeks	O
(	O
±	O
7	O
days	O
)	O
later	O
in	O
accordance	O
with	O
RECIST	O
1.1	O
.	O
Additionally	O
,	O
brain	O
scans	O
were	O
performed	O
as	O
clinically	O
indicated	O
and	O
at	O
the	O
time	O
of	O
a	O
confirmatory	O
scan	O
for	O
CR	O
/	O
PR	O
.	O
Patients	O
who	O
continued	O
to	O
receive	O
study	O
treatment	O
after	O
1	O
year	O
had	O
tumor	O
assessments	O
performed	O
according	O
to	O
local	O
standard	O
of	O
care	O
.	O

Blood	O
samples	O
for	O
assessment	O
of	O
immunogenicity	O
were	O
collected	O
pre	O
-	O
dose	O
at	O
specified	O
study	O
cycles	O
and	O
analyzed	O
for	O
the	O
presence	O
or	O
absence	O
of	O
ADAs	O
(	O
anti	O
-	O
bevacizumab	O
or	O
anti	O
-	O
PF-06439535	O
antibodies	O
)	O
.	O
A	O
single	O
,	O
sensitive	O
,	O
specific	O
,	O
and	O
semi	O
-	O
quantitative	O
electrochemiluminescent	O
immunoassay	O
was	O
used	O
.	O
The	O
ADA	O
assay	O
had	O
been	O
validated	O
and	O
used	O
biotinylated	O
and	O
ruthenium	O
-	O
labeled	O
PF-06439535	O
as	O
reagents	O
.	O
Analysis	O
of	O
ADA	O
samples	O
followed	O
a	O
tiered	O
approach	O
of	O
screening	O
,	O
confirmation	O
,	O
and	O
titer	O
determination	O
.	O
Only	O
those	O
samples	O
confirmed	O
positive	O
for	O
ADAs	O
were	O
further	O
tested	O
for	O
NAbs	O
.	O
The	O
NAb	O
analysis	O
was	O
conducted	O
using	O
a	O
single	O
,	O
validated	O
,	O
quasi	O
-	O
quantitative	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
that	O
utilized	O
PF-06439535	O
as	O
a	O
reagent	O
.	O
Analysis	O
of	O
NAb	O
samples	O
followed	O
a	O
tiered	O
approach	O
of	O
screening	O
and	O
titer	O
determination	O
.	O

The	O
primary	O
efficacy	O
analysis	O
for	O
statistical	O
equivalence	O
was	O
performed	O
when	O
all	O
patients	O
had	O
completed	O
the	O
week	O
25	O
visit	O
to	O
support	O
the	O
primary	O
endpoint	O
analysis	O
or	O
had	O
discontinued	O
from	O
the	O
disease	O
evaluation	O
period	O
earlier	O
.	O
All	O
other	O
analyses	O
presented	O
herein	O
are	O
based	O
on	O
final	O
data	O
after	O
study	O
completion	O
.	O
All	O
statistical	O
analyses	O
were	O
conducted	O
as	O
specified	O
in	O
the	O
statistical	O
analysis	O
plan	O
,	O
which	O
can	O
be	O
accessed	O
at	O
ClinicalTrials.gov	O
.	O

Overall	O
,	O
the	O
disposition	O
of	O
patients	O
between	O
treatment	O
groups	O
was	O
comparable	O
.	O
Among	O
the	O
714	O
patients	O
in	O
the	O
safety	O
population	O
,	O
the	O
primary	O
reason	O
for	O
discontinuation	O
of	O
PF-06439535	B-arm_description
or	O
bevacizumab	B-arm_description
-	I-arm_description
EU	I-arm_description
was	O
objective	O
disease	O
progression	O
or	O
relapse	O
(	O
176	O
[	O
49.4	O
%	O
]	O
patients	O
in	O
the	O
PF-06439535	B-arm_description
group	I-arm_description
and	O
207	O
[	O
57.8	O
%	O
]	O
patients	O
in	O
the	O
bevacizumab	B-arm_description
-	I-arm_description
EU	I-arm_description
group	I-arm_description
)	O
(	O
ESM	O
,	O
Table	O
S2	O
)	O
.	O
Including	O
the	O
survival	O
follow	O
-	O
up	O
period	O
,	O
the	O
most	O
frequent	O
reason	O
for	O
discontinuation	O
from	O
the	O
study	O
was	O
death	O
(	O
136	O
[	O
38.2	O
%	O
]	O
patients	O
in	O
the	O
PF-06439535	B-arm_description
group	I-arm_description
and	O
138	O
[	O
38.5	O
%	O
]	O
patients	O
in	O
the	O
bevacizumab	B-arm_description
-	I-arm_description
EU	I-arm_description
group	I-arm_description
)	O
.	O

As	O
of	O
study	O
completion	O
(	O
22	O
December	O
2017	O
)	O
,	O
the	O
extent	O
of	O
exposure	O
was	O
similar	O
between	O
treatment	O
groups	O
in	O
the	O
safety	O
population	O
.	O
The	O
mean	O
(	O
standard	O
deviation	O
)	O
duration	O
of	O
treatment	O
was	O
35.2	O
(	O
27.19	O
)	O
weeks	O
in	O
the	O
PF-06439535	B-arm_description
group	I-arm_description
and	O
34.9	O
(	O
25.96	O
)	O
weeks	O
in	O
the	O
bevacizumab	B-arm_description
-	I-arm_description
EU	I-arm_description
group	I-arm_description
.	O
In	O
the	O
PF-06439535	B-arm_description
group	I-arm_description
,	O
the	O
median	O
number	O
of	O
cycles	O
of	O
PF-06439535	B-arm_description
treatment	I-arm_description
was	O
11.0	O
(	O
range	O
1	O
-	O
41	O
)	O
,	O
with	O
6.0	O
cycles	O
(	O
range	O
1	O
-	O
6	O
cycles	O
)	O
of	O
paclitaxel	O
treatment	O
and	O
6.0	O
cycles	O
(	O
range	O
1	O
-	O
6	O
cycles	O
)	O
of	O
carboplatin	O
treatment	O
.	O
In	O
the	O
bevacizumab	B-arm_description
-	I-arm_description
EU	I-arm_description
group	I-arm_description
,	O
the	O
median	O
number	O
of	O
cycles	O
of	O
bevacizumab	B-arm_description
-	I-arm_description
EU	I-arm_description
treatment	O
was	O
11.0	O
(	O
range	O
1	O
-	O
38	O
)	O
,	O
with	O
6.0	O
cycles	O
(	O
range	O
1	O
-	O
6	O
cycles	O
)	O
of	O
paclitaxel	O
treatment	O
and	O
6.0	O
cycles	O
(	O
range	O
1	O
-	O
6	O
cycles	O
)	O
of	O
carboplatin	O
treatment	O
.	O
Table	O
2	O
)	O
.	O
The	O
unstratified	O
ORR	O
risk	O
ratio	O
was	O
1.015	O
,	O
with	O
a	O
95	O
%	O
CI	O
of	O
0.863	O
-	O
1.193	O
and	O
a	O
90	O
%	O
CI	O
of	O
0.886	O
-	O
1.163	O
.	O
The	O
unstratified	O
ORR	O
risk	O
difference	O
was	O
0.653	O
%	O
,	O
with	O
a	O
95	O
%	O
CI	O
of	O
−	O
6.608	O
%	O
to	O
7.908	O
%	O
.	O
All	O
three	O
CIs	O
fell	O
entirely	O
within	O
the	O
equivalence	O
margins	O
described	O
earlier	O
(	O
Fig	O
.	O
2	O
)	O
.	O
Thus	O
,	O
similarity	O
between	O
PF-06439535	B-arm_description
and	O
bevacizumab	B-arm_description
-	I-arm_description
EU	I-arm_description
was	O
demonstrated	O
for	O
ORR	O
,	O
based	O
on	O
the	O
pre	O
-	O
specified	O
criteria	O
for	O
each	O
of	O
the	O
three	O
health	O
authorities	O
.	O

Analyses	O
of	O
PFS	B-arm_efficacy_metric
,	O
OS	O
,	O
and	O
DOR	O
were	O
based	O
on	O
final	O
data	O
after	O
study	O
completion	O
on	O
22	O
Fig	O
.	O
1	O
Participant	O
flow	O
diagram	O
.	O
a	O
One	O
patient	O
received	O
paclitaxel	O
and	O
carboplatin	O
but	O
withdrew	O
before	O
receiving	O
PF-06439535	B-arm_description
.	O
b	O
Patient	O
was	O
indicated	O
as	O
"	O
study	O
terminated	O
by	O
sponsor	O
"	O
by	O
the	O
investigator	O
;	O
however	O
,	O
this	O
patient	O
was	O
considered	O
to	O
have	O
met	O
the	O
definition	O
of	O
study	O
completion	O
(	O
i.e.	O
patient	O
was	O
alive	O
and	O
had	O
completed	O
survival	O
followup	O
as	O
defined	O
by	O
the	O
protocol	O
)	O
.	O
c	O
The	O
most	O
frequently	O
reported	O
reason	O
for	O
patients	O
not	O
being	O
included	O
in	O
the	O
PP	O
population	O
was	O
due	O
to	O
being	O
randomized	O
but	O
never	O
dosed	O
with	O
PF-06439535	B-arm_description
or	O
bevacizumab	B-arm_description
-	I-arm_description
EU	I-arm_description
(	O
3	O
[	O
0.8	O
%	O
]	O
patients	O
in	O
the	O
PF-06439535	B-arm_description
group	I-arm_description
and	O
3	O
[	O
0.8	O
%	O
]	O
patients	O
in	O
the	O
bevacizumab	B-arm_description
-	I-arm_description
EU	I-arm_description
group	I-arm_description
)	O
.	O
Bevacizumab	B-arm_description
-	I-arm_description
EU	I-arm_description
reference	I-arm_description
bevacizumab	B-arm_description
sourced	O
from	O
the	O
European	O
Union	O
,	O
COPD	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
ITT	O
intent	O
-	O
to	O
-	O
treat	O
,	O
ORR	O
objective	O
response	O
rate	O
,	O
PK	O
pharmacokinetics	O
,	O
PP	O
per	O
-	O
protocol	O

Enhanced	O
antitumor	O
effect	O
of	O
binimetinib	B-arm_description
in	O
combination	B-arm_description
with	I-arm_description
capecitabine	I-arm_description
for	O
biliary	O
tract	O
cancer	O
patients	O
with	O
mutations	O
in	O
the	O
RAS	O
/	O
RAF	O
/	O
MEK	O
/	O
ERK	O
pathway	O
:	O
phase	B-study_type
Ib	I-study_type
study	I-study_type
Enhanced	O
antitumor	O
effect	O
of	O
binimetinib	B-arm_description
in	O
combination	B-arm_description
with	I-arm_description
capecitabine	I-arm_description
for	O
biliary	O
tract	O
cancer	O
patients	O
with	O
mutations	O
in	O
the	O
RAS	O
/	O
RAF	O
/	O
MEK	O
/	O
ERK	O
pathway	O
:	O
phase	B-study_type
Ib	I-study_type
study	I-study_type
17	O
July	O
2019	O
17	O
July	O
2019	O
JinWonKim	B-authors

Biliary	O
tract	O
cancer	O
(	O
BTC	O
)	O
arises	O
from	O
bile	O
duct	O
epithelial	O
cells	O
,	O
and	O
is	O
a	O
heterogeneous	O
family	O
of	O
malignant	O
diseases	O
that	O
includes	O
intrahepatic	O
cholangiocarcinoma	O
,	O
extrahepatic	O
cholangiocarcinoma	O
,	O
gallbladder	O
cancer	O
and	O
ampulla	O
of	O
Vater	O
cancer	O
.	O
The	O
incidence	O
of	O
BTC	O
is	O
higher	O
in	O
Korea	O
,	O
China	O
and	O
Thailand	O
than	O
the	O
rest	O
of	O
the	O
world	O
.	O
1	O
Currently	O
,	O
gemcitabine	O
-	O
based	O
chemotherapy	O
is	O
globally	O
considered	O
the	O
first	O
-	O
line	O
treatment	O
for	O
recurrent	O
or	O
metastatic	O
BTC	O
.	O
2	O
However	O
,	O
even	O
with	O
chemotherapy	O
,	O
the	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
recurrent	O
or	O
metastatic	O
BTC	O
is~1	O
year	O
.	O
2	O
There	O
is	O
no	O
solid	O
evidence	O
for	O
the	O
role	O
of	O
second	O
-	O
line	O
chemotherapy	O
,	O
although	O
fluoropyrimidine	O
-	O
based	O
chemotherapy	O
is	O
widely	O
used	O
in	O
practice	O
.	O
3	O
ABC-06	O
trial	O
has	O
been	O
evaluating	O
the	O
clinical	O
efficacy	O
of	O
second	O
-	O
line	O
mFOLFOX	O
with	O
active	O
symptom	O
control	O
compared	O
with	O
active	O
symptom	O
control	O
alone	O
in	O
BTC	O
.	O
Furthermore	O
,	O
no	O
targeted	O
therapy	O
has	O
been	O
approved	O
for	O
BTC	O
,	O
although	O
many	O
interesting	O
genetic	O
alterations	O
in	O
BTC	O
have	O
been	O
identified	O
.	O
4	O
There	O
is	O
,	O
therefore	O
,	O
a	O
significant	O
unmet	O
need	O
for	O
new	O
and	O
effective	O
BTC	O
treatment	O
strategies	O
.	O

In	O
BTC	O
,	O
the	O
RAS	O
/	O
RAF	O
/	O
MEK	O
/	O
ERK	O
pathway	O
is	O
known	O
to	O
be	O
activated	O
in	O
up	O
to	O
20	O
-	O
40	O
%	O
of	O
cases	O
,	O
which	O
is	O
mediated	O
by	O
mutations	O
in	O
KRAS	O
,	O
NRAS	O
,	O
BRAF	O
and	O
so	O
on	O
.	O
4,5	O
The	O
RAS	O
/	O
RAF	O
/	O
MEK	O
/	O
ERK	O
pathway	O
is	O
a	O
series	O
of	O
proteins	O
that	O
mediates	O
communication	O
between	O
the	O
cell	O
surface	O
and	O
nucleus	O
,	O
which	O
has	O
been	O
linked	O
to	O
several	O
vital	O
cellular	O
functions	O
,	O
such	O
as	O
proliferation	O
,	O
apoptosis	O
and	O
metabolism	O
.	O
6,7	O
Therefore	O
,	O
this	O
pathway	O
could	O
have	O
a	O
potential	O
to	O
be	O
a	O
good	O
therapeutic	O
target	O
in	O
BTC	O
.	O
Furthermore	O
,	O
mutations	O
in	O
RAS	O
or	O
BRAF	O
have	O
been	O
suggested	O
as	O
predictive	O
biomarkers	O
for	O
MEK	O
inhibition	O
.	O
8,9	O
In	O
previous	O
clinical	O
trials	O
,	O
selumetinib	O
,	O
an	O
inhibitor	O
of	O
MEK1/	O
2	O
,	O
demonstrated	O
interesting	O
activity	O
and	O
acceptable	O
tolerability	O
in	O
patients	O
with	O
metastatic	O
BTC	O
.	O
10,11	O
Similarly	O
,	O
binimetinib	O
is	O
a	O
potent	O
,	O
adenosine	O
triphosphate	O
-	O
uncompetitive	O
,	O
highly	O
selective	O
allosteric	O
inhibitor	O
of	O
MEK1/2	O
with	O
on	O
-	O
target	O
activity	O
that	O
has	O
been	O
demonstrated	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
12	O
Moreover	O
,	O
phase	O
I	O
study	O
of	O
binimetinib	O
showed	O
a	O
manageable	O
safety	O
profile	O
,	O
target	O
inhibition	O
and	O
dose	O
-	O
proportional	O
exposure	O
.	O
13	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
preclinical	O
synergistic	O
activity	O
of	O
binimetinib	B-arm_description
and	O
fluoropyrimidine	O
against	O
BTC	O
cell	O
lines	O
.	O
Supported	O
by	O
the	O
preclinical	O
results	O
,	O
we	O
then	O
conducted	O
a	O
phase	B-study_type
Ib	I-study_type
study	I-study_type
of	O
binimetinib	B-arm_description
and	O
capecitabine	B-arm_description
in	O
gemcitabinepretreated	O
BTC	O
patients	O
to	O
assess	O
the	O
safety	O
and	O
early	O
antitumor	O
activity	O
.	O
Furthermore	O
,	O
we	O
identified	O
genetic	O
alterations	O
to	O
the	O
RAS	O
/	O
RAF	O
/	O
MEK	O
/	O
ERK	O
pathway	O
and	O
determined	O
plasma	O
biomarker	O
concentrations	O
.	O

Nine	O
patients	O
were	O
recruited	O
for	O
the	O
dose	O
-	O
escalation	O
part	O
.	O
None	O
of	O
the	O
patients	O
experienced	O
DLT	O
up	O
to	O
DL3	O
;	O
therefore	O
,	O
the	O
RP2D	O
was	O
determined	O
as	O
DL3	O
(	O
binimetinib	B-arm_description
30	B-arm_dosage
mg	I-arm_dosage
,	O
capecitabine	B-arm_description
1250	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
,	O
twice	B-arm_dosage
daily	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
-	I-arm_dosage
14	I-arm_dosage
,	I-arm_dosage
in	I-arm_dosage
3-week	I-arm_dosage
cycles	I-arm_dosage
)	O
.	O
For	O
the	O
expansion	O
part	O
,	O
25	O
patients	O
were	O
enrolled	O
(	O
Supplementary	O
Fig	O
.	O
S1	O
)	O
.	O
At	O
the	O
data	O
cutoff	O
time	O
,	O
22	O
patients	O
had	O
died	O
,	O
and	O
treatment	O
was	O
ongoing	O
in	O
three	O
patients	O
.	O
The	O
median	O
follow	O
-	O
up	O
duration	O
was	O
6.8	O
months	O
(	O
range	O
,	O
2.0	O
-	O
17.8	O
)	O
and	O
patients	O
received	O
a	O
median	O
of	O
five	O
cycles	O
(	O
range	O
,	O
1	O
-	O
16	O
)	O
.	O

In	O
terms	O
of	O
IL-6	O
plasma	O
concentrations	O
,	O
the	O
mean	O
value	O
(	O
±	O
standard	O
deviation	O
)	O
of	O
baseline	O
plasma	O
IL-6	O
was	O
11.5	O
pg	O
/	O
ml	O
(	O
±	O
12.6	O
)	O
.	O
Patients	O
with	O
higher	O
baseline	O
IL-6	O
showed	O
significantly	O
shorter	O
PFS	B-arm_efficacy_metric
and	O
OS	O
(	O
p	B-arm_efficacy_results
=	I-arm_efficacy_results
0.025	I-arm_efficacy_results
,	O
p	O
=	O
0.033	O
,	O
respectively	O
;	O
Fig	O
.	O
3a	O
,	O
b	O
)	O
.	O
Similarly	O
,	O
the	O
baseline	O
value	O
of	O
IL-6	O
was	O
associated	O
with	O
tumour	O
response	O
,	O
that	O
is	O
,	O
IL-6	O
was	O
higher	O
in	O
PD	O
than	O
PR	O
patients	O
.	O
The	O
mean	O
concentrations	O
were	O
19.9	O
,	O
9.2	O
and	O
7.7	O
pg	O
/	O
ml	O
for	O
PD	O
,	O
SD	O
and	O
PR	O
,	O
respectively	O
(	O
p	O
=	O
0.085	O
)	O
.	O
With	O
regard	O
to	O
changes	O
between	O
baseline	O
and	O
after	O
the	O
second	O
cycle	O
,	O
a	O
greater	O
increase	O
in	O
the	O
IL-6	O
concentration	O
(	O
Δ	O
>	O
14.8	O
pg	O
/	O
ml	O
)	O
was	O
associated	O
with	O
shorter	O
PFS	B-arm_efficacy_metric
and	O
OS	O
(	O
Fig	O
.	O
3c	O
,	O
d	O
)	O
.	O
Furthermore	O
,	O
the	O
plasma	O
concentrations	O
of	O
IL-6	O
when	O
PD	O
was	O
confirmed	O
were	O
also	O
significantly	O
increased	O
relative	O
to	O
baseline	O
(	O
mean	O
±	O
standard	O
deviation	O
:	O
32.0	O
±	O
29.8	O
vs.	O
9.0	O
±	O
5.9	O
pg	O
/	O
ml	O
,	O
respectively	O
;	O
paired	O
t	O
test	O
,	O
p	O
=	O
0.008	O
)	O
.	O

Radiotherapy	O
Oncology	O
Department	O
,	O
IRCCS	O
CROB	O
,	O
Rionero	O
In	O
Vulture	O
,	O
Italy	O
.	O
16	O
Radiotherapy	O
Unit	O
,	O
Ospedale	O
San	O
Camillo	O
de	O
Lellis	O
,	O
Rieti	O
,	O
Italy	O
.	O
17	O
Università	O
Cattolica	O
del	O
Sacro	O
Cuore	O
,	O
Istituto	O
di	O
Radiologia	O
,	O
Roma	O
,	O
Italy	O
.	O
18	O
Radiation	O
Oncology	O
Department	O
,	O
University	O
of	O
Genoa	O
(	O
DISSAL	O
)	O
and	O
IRCCS	O
Ospedale	O
Policlinico	O
San	O
Martino	O
,	O
Genoa	O
Italy	O
MarioSantarelli	B-authors
MariaAntoniettaGambacorta	B-authors

Participants	O
entering	O
the	O
PREST	O
trial	O
are	O
affected	O
by	O
a	O
solid	O
tumor	O
with	O
histologically	O
confirmed	O
diagnosis	O
and	O
associated	O
bone	O
metastases	O
.	O
The	O
estimated	O
prognosis	O
is	O
intermediate	O
or	O
high	O
(	O
i.e.	O
,	O
>	O
6	O
months	O
)	O
according	O
to	O
the	O
Mizumoto	O
prognostic	O
score	O
.	O
Eligibility	O
criteria	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

The	O
PREST	O
trial	O
is	O
promoted	O
by	O
Fondazione	O
Policlinico	O
Gemelli	O
-	O
IRCCS	O
in	O
Rome	O
(	O
Italy	O
)	O
.	O
The	O
local	O
Ethics	O
Committee	O
has	O
approved	O
the	O
protocol	O
.	O
Each	O
interested	O
center	O
will	O
submit	O
the	O
protocol	O
to	O
its	O
ethics	O
committee	O
for	O
approval	O
before	O
accrual	O
.	O
After	O
approval	O
,	O
the	O
center	O
will	O
receive	O
a	O
dedicated	O
electronic	O
case	O
report	O
form	O
(	O
CRF	O
)	O
.	O
Eligible	O
participants	O
who	O
have	O
provided	O
consent	O
and	O
meet	O
the	O
inclusion	O
criteria	O
are	O
anonymously	O
registered	O
on	O
the	O
CRF	O
by	O
assigning	O
a	O
numerical	O
code	O
.	O

Following	O
the	O
assessment	O
for	O
eligibility	O
and	O
after	O
informed	O
consent	O
is	O
signed	O
,	O
eligible	O
participants	O
are	O
randomized	O
by	O
phone	O
to	O
the	O
promoting	O
centre	O
.	O
Participants	O
undergo	O
a	O
blind	B-study_type
randomization	I-study_type
using	O
minimization	O
algorithms	O
based	O
on	O
key	O
prognostic	O
factors	O
,	O
incorporating	O
a	O
random	O
element	O
.	O
Patients	O
are	O
allocated	O
in	O
a	O
1:1	O
ratio	O
to	O
either	O
gold	O
standard	O
radiotherapy	B-arm_description
treatment	I-arm_description
or	O
interventional	O
SIB	O
radiotherapy	O
treatment	O
.	O

CT	O
simulation	O
will	O
be	O
carried	O
out	O
with	O
custom	O
immobilization	O
support	O
for	O
each	O
patient	O
(	O
Aquaplast	O
®	O
head	O
mask	O
and/or	O
vacuum	O
mattresses	O
)	O
.	O
For	O
target	O
delineation	O
,	O
co	O
-	O
registration	O
with	O
MRI	O
will	O
be	O
performed	O
using	O
the	O
Velocity	O
®	O
application	O
.	O
The	O
GTV	O
is	O
defined	O
as	O
the	O
visible	O
lesion	O
on	O
MRI	O
imaging	O
.	O
In	O
the	O
experimental	O
arm	O
,	O
two	O
volumes	O
will	O
be	O
defined	O
:	O
PTV1	O
,	O
including	O
GTV	O
plus	O
a	O
2-mm	O
isotropic	O
margin	O
;	O
and	O
PTV2	O
,	O
including	O
total	O
vertebra	O
plus	O
a	O
2-mm	O
isotropic	O
margin	O
.	O
In	O
the	O
standard	O
arm	O
,	O
a	O
single	O
volume	O
will	O
be	O
contoured	O
:	O
PTV1	O
(	O
total	O
vertebra	O
plus	O
a	O
1	O
cm	O
isotropic	O
margin	O
)	O
.	O

The	O
PREST	O
trial	O
will	O
provide	O
insight	O
on	O
efficacy	O
of	O
a	O
hypofractionated	O
SBRT	O
IMRT	O
-	O
SIB	O
in	O
pain	O
control	O
with	O
respect	O
to	O
gold	O
standard	O
fractionation	O
.	O
Highlights	O
of	O
this	O
study	O
include	O
personalization	O
by	O
prognostic	O
score	O
stratification	O
,	O
selection	O
based	O
on	O
imaging	O
-	O
driven	O
stability	O
scores	O
,	O
ultra	O
-	O
conformed	O
RT	O
planning	O
,	O
and	O
lower	O
number	O
of	O
RT	O
sessions	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
design	O
of	O
its	O
kind	O
.	O
The	O
results	O
will	O
clarify	O
if	O
this	O
highly	O

Myers	O
Squibb	O
,	O
Clovis	O
Oncology	O
,	O
Incyte	O
,	O
Janssen	O
Pharmaceuticals	O
,	O
Pharmacyclics	O
,	O
Seattle	O
Genetics	O
,	O
Urogen	O
Pharma	O
Research	O
Funding	O
:	O
Progenics	O
(	O
Inst	O
)	O
,	O
Sanofi	O
(	O
Inst	O
)	O

Bristol	O
-	O
Myers	O
Squibb	O
(	O
Inst	O
)	O
Myers	O
Squibb	O
,	O
Clovis	O
Oncology	O
,	O
Incyte	O
,	O
Janssen	O
Pharmaceuticals	O
,	O
Pharmacyclics	O
,	O
Seattle	O
Genetics	O
,	O
Urogen	O
Pharma	O
Research	O
Funding	O
:	O
Progenics	O
(	O
Inst	O
)	O
,	O
Sanofi	O
(	O
Inst	O
)	O
Seattle	O
Genetics	O
(	O
Inst	O
)	O
Clovis	O
Oncology	O
(	O
Inst	O
)	O
Ada	O
Cap	O
(	O
Inst	O
)	O
Endocyte	O
(	O
Inst	O
)	O
,	O
Genentech	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
,	O
Astellas	O
Medivation	O
(	O
Inst	O
)	O
,	O
Novartis	O
(	O
Inst	O
)	O
,	O
AstraZeneca	O
(	O
Inst	O
)	O
,	O
Bayer	O
(	O
Inst	O
)	O
,	O
Eli	O
Lilly	O
(	O
Inst	O
)	O
,	O
Innocrin	O
Pharma	O
(	O
Inst	O
)	O
,	O
MedImmune	O
(	O
Inst	O
)	O
,	O
Pfizer	O
(	O
Inst	O
)	O
Roche	O
(	O
Inst	O
)	O

The	O
phase	O
I	O
dose	O
escalation	O
and	O
expansion	O
study	O
EV-101	O
(	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT02091999	O
)	O
demonstrated	O
that	O
enfortumab	O
vedotin	O
,	O
administered	O
on	O
days	O
1	O
,	O
8	O
,	O
and	O
15	O
of	O
every	O
28-day	O
cycle	O
,	O
has	O
antitumor	O
activity	O
in	O
previously	O
treated	O
patients	O
with	O
metastatic	O
urothelial	O
carcinoma	O
,	O
including	O
those	O
who	O
received	O
platinum	O
-	O
based	O
chemotherapy	O
and	O
anti	O
-	O
PD-1	O
/	O
L1	O
therapy	O
.	O
17	O
Pharmacokinetic	O
data	O
from	O
this	O
study	O
demonstrate	O
a	O
half	O
-	O
life	O
of	O
approximately	O
2	O
days	O
,	O
which	O
supports	O
this	O
dosing	O
schedule	O
.	O
18	O
EV-201	O
,	O
a	O
two	B-study_type
-	I-study_type
cohort	I-study_type
,	I-study_type
single	I-study_type
-	I-study_type
arm	I-study_type
,	I-study_type
phase	I-study_type
II	I-study_type
study	I-study_type
,	O
was	O
designed	O
to	O
establish	O
the	O
efficacy	O
and	O
safety	O
of	O
enfortumab	B-arm_description
vedotin	I-arm_description
in	O
patients	O
with	O
locally	O
advanced	O
or	O
metastatic	O
urothelial	O
carcinoma	O
who	O
were	O
previously	O
treated	O
with	O
anti	O
-	O
PD-1	O
/	O
L1	O
therapy	O
.	O
Cohort	O
1	O
enrolled	O
patients	O
who	O
were	O
previously	O
treated	O
with	O
both	O
platinum	O
chemotherapy	O
and	O
an	O
anti	O
-	O
PD-1	O
/	O
L1	O
therapy	O
,	O
whereas	O
Cohort	O
2	O
continues	O
to	O
enroll	O
patients	O
who	O
were	O
previously	O
treated	O
only	O
with	O
an	O
anti	O
-	O
PD-1	O
/	O
L1	O
therapy	O
.	O
Here	O
,	O
we	O
report	O
results	O
from	O
EV-201	O
Cohort	O
1	O
.	O

Patients	O
with	O
locally	O
advanced	O
or	O
metastatic	O
urothelial	O
carcinoma	O
who	O
were	O
previously	O
treated	O
with	O
anti	O
-	O
PD-1/	O
L1	O
therapy	O
and	O
age	O
18	O
years	O
or	O
older	O
were	O
eligible	O
to	O
enroll	O
if	O
they	O
experienced	O
progression	O
during	O
or	O
after	O
their	O
most	O
recent	O
therapy	O
,	O
had	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
score	O
of	O
1	O
or	O
less	O
,	O
and	O
had	O
adequate	O
baseline	O
organ	O
function	O
.	O
Patients	O
with	O
ongoing	O
sensory	O
or	O
motor	O
neuropathy	O
grade	O
2	O
or	O
greater	O
,	O
active	O
CNS	O
metastases	O
,	O
or	O
uncontrolled	O
diabetes	O
were	O
excluded	O
.	O
Uncontrolled	O
diabetes	O
was	O
defined	O
as	O
hemoglobin	O
A1C	O
of	O
8	O
%	O
or	O
greater	O
or	O
hemoglobin	O
A1C	O
of	O
7	O
%	O
to	O
less	O
than	O
8	O
%	O
with	O
associated	O
diabetes	O
symptomspolyuria	O
or	O
polydipsia	O
-	O
that	O
were	O
not	O
otherwise	O
explained	O
.	O
There	O
were	O
no	O
limits	O
for	O
prior	O
lines	O
of	O
therapy	O
,	O
including	O
taxanes	O
.	O
Full	O
eligibility	O
criteria	O
are	O
available	O
in	O
the	O
protocol	O
(	O
Data	O
Supplement	O
)	O
.	O
patients	O
were	O
discontinued	O
from	O
the	O
study	O
before	O
receiving	O
study	O
treatment	O
;	O
1	O
due	O
to	O
clinical	O
deterioration	O
,	O
1	O
per	O
patient	O
decision	O
,	O
and	O
1	O
due	O
to	O
low	O
hemoglobin	O
levels	O
after	O
screening	O
and	O
enrollment	O
.	O
This	O
latter	O
patient	O
met	O
all	O
eligibility	O
criteria	O
,	O
including	O
adequate	O
hemoglobin	O
level	O
and	O
was	O
enrolled	O
in	O
the	O
study	O
;	O
however	O
,	O
the	O
patient	O
's	O
hemoglobin	O
levels	O
were	O
subsequently	O
found	O
to	O
be	O
low	O
and	O
the	O
investigator	O
withdrew	O
the	O
patient	O
from	O
the	O
study	O
as	O
a	O
result	O
.	O

EV-201	O
is	O
a	O
global	B-study_type
,	I-study_type
single	I-study_type
-	I-study_type
arm	I-study_type
,	I-study_type
two	I-study_type
-	I-study_type
cohort	I-study_type
,	I-study_type
phase	I-study_type
II	I-study_type
multicenter	I-study_type
study	I-study_type
that	O
was	O
designed	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
enfortumab	B-arm_description
vedotin	I-arm_description
(	O
Fig	O
1	O
)	O
.	O
Cohort	O
1	O
enrolled	O
platinum	O
-	O
and	O
anti	O
-	O
PD-1	O
/	O
L1-treated	O
patients	O
with	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
scores	O
of	O
1	O
or	O
less	O
.	O
Platinum	O
treatment	O
was	O
defined	O
as	O
platinum	O
-	O
containing	O
chemotherapy	O
in	O
the	O
neoadjuvant	O
and/or	O
adjuvant	O
setting	O
with	O
recurrent	O
or	O
progressive	O
disease	O
within	O
12	O
months	O
of	O
completion	O
,	O
or	O
platinum	O
in	O
the	O
locally	O
advanced	O
or	O
metastatic	O
setting	O
.	O

Long	O
-	O
Term	O
Results	O
from	O
the	O
IDEAL	O
-	O
CRT	O
Phase	B-study_type
1/2	I-study_type
Trial	I-study_type
of	O
Isotoxically	O
Dose	O
-	O
Escalated	O
Radiation	O
Therapy	O
and	O
Concurrent	O
Chemotherapy	O
for	O
Stage	O
II	O
/	O
III	O
Non	O
-	O
small	O
Cell	O
Lung	O
Cancer	O
10.1016	O
/	O
j.ijrobp.2019.11.397	O

Time	O
-	O
to	O
-	O
event	O
endpoints	O
were	O
measured	O
from	O
the	O
start	O
of	O
treatment	O
,	O
censored	O
at	O
the	O
date	O
last	O
seen	O
,	O
and	O
estimated	O
using	O
the	O
Kaplan	O
-	O
Meier	O
method	O
to	O
allow	O
for	O
each	O
patient	O
's	O
length	O
of	O
follow	O
-	O
up	O
.	O
Exploratory	O
univariable	O
and	O
multivariable	O
analyses	O
of	O
associations	O
between	O
these	O
endpoints	O
and	O
patient	O
-	O
and	O
treatment	O
-	O
related	O
factors	O
were	O
performed	O
using	O
Cox	O
proportional	O
hazards	O
regression	O
.	O
Stepwise	O
bidirectional	O
elimination	O
,	O
including	O
all	O
factors	O
with	O
P	O
<	O
.20	O
,	O
was	O
used	O
to	O
find	O
the	O
model	O
with	O
the	O
lowest	O
Akaike	O
Information	O
Criterion	O
score	O
.	O
Reported	O
confidence	O
intervals	O
(	O
CIs	O
)	O
and	O
significance	O
levels	O
are	O
2-sided	O
except	O
where	O
otherwise	O
indicated	O
.	O

Pancreatic	O
cancer	O
is	O
a	O
devastating	O
disease	O
with	O
an	O
overall	O
5year	O
survival	O
of	O
less	O
than	O
5	O
%	O
.	O
1,2	O
The	O
mortality	O
trend	O
is	O
increasing	O
in	O
both	O
genders	O
,	O
3,4	O
and	O
pancreatic	O
cancer	O
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
death	O
from	O
cancer	O
.	O
5	O
Over	O
the	O
past	O
two	O
decades	O
,	O
gemcitabine	O
monotherapy	O
has	O
been	O
a	O
standard	O
treatment	O
for	O
metastatic	O
pancreatic	O
cancer	O
.	O
6	O
In	O
2011	O
,	O
the	O
FOLFIRINOX	O
regimen	O
(	O
fluorouracil	O
,	O
leucovorin	O
,	O
irinotecan	O
,	O
and	O
oxaliplatin	O
)	O
7,8	O
and	O
the	O
combination	O
of	O
gemcitabine	O
with	O
nab	O
-	O
paclitaxel	O
9,10	O
demonstrated	O
an	O
improvement	O
in	O
progression	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
compared	O
with	O
gemcitabine	O
alone	O
.	O
These	O
regimens	O
are	O
thus	O
now	O
considered	O
as	O
the	O
standard	O
first	O
-	O
line	O
treatment	O
options	O
in	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
and	O
good	O
general	O
status	O
without	O
marked	O
cholestasis	O
.	O

Using	O
a	O
minimization	O
technique	O
stratified	O
by	O
center	O
and	O
ECOG	O
performance	O
status	O
,	O
patients	O
were	O
randomly	O
assigned	O
(	O
1:2	O
ratio	O
)	O
to	O
receive	O
nab	B-arm_description
-	I-arm_description
paclitaxel	I-arm_description
plus	I-arm_description
gemcitabine	I-arm_description
(	O
control	B-arm_description
arm	I-arm_description
)	O
or	O
nab	B-arm_description
-	I-arm_description
paclitaxel	I-arm_description
plus	I-arm_description
sLV5FU2	I-arm_description
(	I-arm_description
experimental	I-arm_description
arm	I-arm_description
)	I-arm_description
.	O
Both	O
regimens	O
were	O
administered	O
every	B-arm_dosage
28	I-arm_dosage
days	I-arm_dosage
and	O
details	O
of	O
the	O
regimens	O
have	O
previously	O
been	O
published	O
.	O
12	O
The	O
primary	O
endpoint	O
was	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
at	O
4	O
months	O
in	O
the	O
first	O
72	O
patients	O
in	O
the	O
sLV5FU2	O
group	O
.	O
Secondary	O
endpoints	O
were	O
objective	O
response	O
,	O
progressionfree	B-arm_efficacy_metric
survival	I-arm_efficacy_metric
,	O
overall	O
survival	O
,	O
tolerance	O
and	O
HRQoL.	O

HRQoL	O
deterioration	O
-	O
free	O
survival	O
(	O
QFS	O
)	O
was	O
used	O
as	O
a	O
modality	O
of	O
longitudinal	O
analysis	O
.	O
QFS	O
was	O
defined	O
as	O
the	O
time	O
between	O
randomization	O
and	O
the	O
first	O
HRQoL	O
score	O
deterioration	O
of	O
at	O
least	O
5	O
points	O
,	O
as	O
compared	O
to	O
the	O
baseline	O
score	O
,	O
with	O
no	O
further	O
improvement	O
of	O
at	O
least	O
5	O
points	O
as	O
compared	O
to	O
the	O
baseline	O
score	O
,	O
or	O
death	O
,	O
whichever	O
occurred	O
first	O
.	O
17,18	O
QFS	O
curves	O
were	O
estimated	O
using	O
the	O
Kaplan	O
-	O
Meier	O
estimation	O
method	O
.	O
Univariate	O
Cox	O
models	O
were	O
used	O
to	O
calculate	O
HRs	O
and	O
90	O
%	O
CIs	O
of	O
the	O
treatment	O
effect	O
.	O
All	O
variables	O
collected	O
at	O
baseline	O
were	O
tested	O
by	O
univariate	O
Cox	O
analysis	O
.	O
The	O
impact	O
of	O
time	O
to	O
toxicity	O
grade	O
3	O
-	O
4	O
was	O
also	O
tested	O
by	O
univariate	O
analysis	O
as	O
a	O
timedependent	O
variable	O
.	O

Between	O
December	O
2013	O
and	O
October	O
2014	O
,	O
114	O
patients	O
were	O
randomized	O
:	O
39	O
in	O
the	O
gemcitabine	B-arm_description
group	I-arm_description
and	O
75	O
in	O
the	O
sLV5FU2	B-arm_description
group	I-arm_description
.	O
Sixty	O
-	O
four	O
patients	O
(	O
56.1	O
%	O
)	O
completed	O
the	O
QLQ	O
-	O
C30	O
questionnaire	O
at	O
baseline	O
,	O
22	O
patients	O
(	O
56.4	O
%	O
)	O
in	O
the	O
gemcitabine	B-arm_description
group	I-arm_description
,	O
and	O
42	O
(	O
56.0	O
%	O
)	O
in	O
the	O
sLV5FU2	B-arm_description
group	I-arm_description
(	O
Figure	O
1	O
)	O
.	O
Patients	O
in	O
the	O
sLV5FU2	B-arm_description
group	I-arm_description
completed	O
the	O
questionnaire	O
longer	O
after	O
compared	O
to	O
the	O
gemcitabine	B-arm_description
group	I-arm_description
.	O
Indeed	O
,	O
there	O
were	O
more	O
patients	O
included	O
in	O
this	O
treatment	O
arm	O
due	O
to	O
the	O
ratio	O
1:2	O
and	O
the	O
median	O
overall	O
survival	O
was	O
significantly	O
longer	O
in	O
this	O
treatment	O
arm	O
.	O
The	O
median	O
age	O
was	O
66	O
years	O
(	O
range	O
45	O
-	O
86	O
)	O
and	O
70	O
patients	O
(	O
61.4	O
%	O
)	O
were	O
men	O
.	O
The	O
baseline	O
characteristics	O
of	O
the	O
patients	O
are	O
described	O
according	O
to	O
baseline	O
HRQoL	O
availability	O
in	O
Table	O
1	O
.	O
Baseline	O
HRQoL	O
level	O
was	O
similar	O
between	O
treatment	O
arms	O
(	O
Table	O
S1	O
)	O
.	O

The	O
main	O
limitation	O
of	O
this	O
study	O
was	O
the	O
relatively	O
low	O
proportion	O
(	O
56.1	O
%	O
)	O
of	O
questionnaires	O
completed	O
at	O
baseline	O
.	O
However	O
,	O
the	O
completion	O
rate	O
was	O
similar	O
in	O
both	O
treatment	O
arms	O
.	O
A	O
likely	O
explanation	O
could	O
be	O
that	O
the	O
first	O
two	O
HRQoL	O
assessment	O
times	O
were	O
at	O
very	O
short	O
interval	O
(	O
ie	O
,	O
at	O
randomization	O
and	O
day	O
one	O
of	O
the	O
first	O
chemotherapy	O
cycle	O
)	O
and	O
this	O
may	O
have	O
caused	O
some	O
confusion	O
between	O
these	O
two	O
time	O
points	O
at	O
the	O
time	O
of	O
data	O
collection	O
.	O
The	O
completion	O
rate	O
over	O
time	O
was	O
close	O
to	O
those	O
observed	O
in	O
other	O
clinical	O
trials	O
in	O
pancreatic	O
cancer	O
,	O
such	O
as	O
in	O
a	O
phase	O
II	O
clinical	O
trial	O
in	O
resectable	O
or	O
borderline	O
resectable	O
pancreatic	O
cancer	O
patients	O
using	O
also	O
the	O
QLQ	O
-	O
C30	O
questionnaire	O
to	O
assess	O
HRQoL	O
among	O
other	O
questionnaires	O
.	O
24	O
These	O
missing	O
data	O
also	O
had	O
a	O
direct	O
impact	O
on	O
the	O
population	O
for	O
analysis	O
.	O
It	O
was	O
required	O
to	O
define	O
a	O
modified	O
ITT	O
population	O
including	O
all	O
ITT	O
patients	O
with	O
a	O
baseline	O
HRQoL	O
score	O
available	O
.	O
However	O
,	O
it	O
is	O
recommended	O
that	O
the	O
ITT	O
population	O
be	O
studied	O
in	O
order	O
to	O
best	O
reflect	O
the	O
treatment	O
effect	O
without	O
inducing	O
bias	O
.	O
14	O
It	O
is	O
therefore	O
essential	O
to	O
verify	O
that	O
the	O
modified	O
ITT	O
is	O
representative	O
of	O
the	O
ITT	O
population	O
.	O

0000	O
-	O
0002	O
-	O
7749	O
-	O
7217	O
RahulAggarwal	B-authors
Rahul	B-authors
Aggarwal	I-authors
0000	O
-	O
0002	O
-	O
7749	O
-	O
7217	O
JeremyCetnar	B-authors
JeremyCetnar	B-authors
Jeremy	B-authors
Cetnar	I-authors
CharlesJRyan	B-authors
CharlesJRyan	B-authors
Charles	B-authors
J	I-authors
Ryan	I-authors
ShaadiTabatabaei	B-authors
ShaadiTabatabaei	B-authors
Shaadi	B-authors
Tabatabaei	I-authors
ShawnaBailey	B-authors
ShawnaBailey	B-authors
Shawna	B-authors
Bailey	I-authors
ClaireBTurina	B-authors
ClaireBTurina	B-authors
Claire	B-authors
B	I-authors
Turina	I-authors
DavidAQuigley	B-authors
DavidAQuigley	B-authors
David	B-authors
A	I-authors
Quigley	I-authors
XiangnanGuan	B-authors
XiangnanGuan	B-authors
Xiangnan	B-authors
Guan	I-authors
AdamFoye	B-authors
AdamFoye	B-authors
Adam	B-authors
Foye	I-authors
JackFYoungren	B-authors
JackFYoungren	B-authors
Jack	B-authors
F	I-authors
Youngren	I-authors
JoshuaUrrutia	B-authors

Portland	O
,	O
OR	O
97239	O
a	O
Knight	O
Cancer	O
Institute	O
,	O
Oregon	O
Health	O
&	O
Science	O
University	O
,	O
Portland	O
,	O
OR	O
97239	O
Portland	O
,	O
OR	O
97239	O
b	O
Computational	O
Biology	O
Program	O
,	O
Oregon	O
Health	O
&	O
Science	O
University	O
,	O

Portland	O
,	O
OR	O
97239	O
c	O
Molecular	O
Microbiology	O
and	O
Immunology	O
Department	O
,	O
Oregon	O
Health	O
&	O
Science	O
University	O
,	O
Portland	O
,	O
OR	O
97239	O
Portland	O
,	O
OR	O
97239	O
d	O
Biostatistics	O
Shared	O
Resource	O
,	O
Knight	O
Cancer	O
Institute	O
,	O
Oregon	O
Health	O
&	O
Science	O
University	O
,	O

San	O
Francisco	O
,	O
CA	O
94143	O
f	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
,	O
CA	O
94143	O
San	O
Francisco	O
,	O
CA	O
94143	O
g	O
Division	O
of	O
Hematology	O
,	O
Oncology	O
and	O
Transplantation	O
,	O
University	O
of	O
Minnesota	O
Masonic	O
Cancer	O
Center	O
,	O

Santa	O
Cruz	O
,	O
CA	O
95064	O
j	O
University	O
of	O
California	O
Santa	O
Cruz	O
Genomics	O
Institute	O
,	O
University	O
of	O
California	O
,	O
Santa	O
Cruz	O
,	O
CA	O
95064	O
Santa	O
Cruz	O
,	O
CA	O
95064	O
k	O
Department	O
of	O
Biomolecular	O
Engineering	O
,	O
University	O
of	O
California	O
,	O

Cancer	O
Receiving	O
Enzalutamide	O
Therapy	O
enrolled	O
36	O
patients	O
with	O
metastatic	O
CRPC	O
who	O
had	O
not	O
previously	O
received	O
enzalutamide	O
.	O
Patients	O
with	O
prior	O
use	O
of	O
docetaxel	O
or	O
abiraterone	O
were	O
ineligible	O
for	O
this	O
study	O
.	O
Study	O
enrollment	O
,	O
follow	O
-	O
up	O
,	O
and	O
analyses	O
are	O
depicted	O
in	O
SI	O
Appendix	O
,	O
Fig	O
.	O
S1	O
.	O
The	O
demographic	O
characteristics	O
for	O
all	O
36	O
patients	O
enrolled	O
on	O
the	O
study	O
are	O
shown	O
in	O
SI	O
Appendix	O
,	O
Table	O
S1	O
.	O
Thirty	O
-	O
four	O
patients	O
were	O
evaluable	O
for	O
the	O
primary	O
end	O
point	O
of	O
≥50	O
%	O
PSA	O
decline	O
at	O
12	O
wk	O
,	O
and	O
their	O
demographic	O
features	O
are	O
shown	O
in	O
Table	O
1	O
.	O
There	O
were	O
9	O
nonresponders	O
(	O
<	O
50	O
%	O
PSA	O
decline	O
at	O
12	O
wk	O
)	O
and	O
25	O
responders	O
(	O
≥50	O
%	O
PSA	O
decline	O
at	O
12	O
wk	O
)	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Targeted	O
DNA	O
-	O
Sequencing	O
.	O
For	O
26	O
of	O
36	O
patients	O
,	O
there	O
was	O
sufficient	O
DNA	O
to	O
perform	O
targeted	O
DNA	O
-	O
sequencing	O
(	O
DNA	O
-	O
seq	O
)	O
.	O
Five	O
of	O
these	O
patients	O
were	O
nonresponders	O
,	O
and	O
21	O
were	O
responders	O
.	O
We	O
focused	O
on	O
TP53	O
,	O
RB1	O
,	O
and	O
PTEN	O
as	O
those	O
genes	O
have	O
been	O
linked	O
previously	O
to	O
poor	O
outcomes	O
for	O
men	O
with	O
CRPC	O
or	O
resistance	O
to	O
AR	O
-	O
targeting	O
therapies	O
in	O
preclinical	O
or	O
clinical	O
studies	O
(	O
12,(15)(16)(17)(18	O
)	O
.	O
No	O
statistically	O
significant	O
differences	O
were	O
detected	O
between	O
the	O
two	O
groups	O
for	O
these	O
genes	O
(	O
Fig	O
.	O
3	O
)	O
or	O
other	O
genes	O
examined	O
(	O
SI	O
Appendix	O
,	O
Fig	O
.	O
S2	O
)	O
.	O
However	O
,	O
there	O
was	O
a	O
strong	O
trend	O
toward	O
greater	O
likelihood	O
of	O
TP53	O
alterations	O
in	O
nonresponders	O
(	O
Fisher	O
's	O
exact	O
test	O
P	O
=	O
0.055	O
)	O
.	O

For	O
the	O
primary	O
analysis	O
,	O
we	O
assessed	O
correlations	O
between	O
baseline	O
molecular	O
features	O
and	O
PSA50	O
response	O
defined	O
as	O
a	O
PSA	O
decline	O
of	O
≥50	O
%	O
at	O
12	O
wk	O
compared	O
with	O
baseline	O
.	O
Secondary	O
clinical	O
end	O
points	O
included	O
TOT	O
,	O
PFS	B-arm_efficacy_metric
,	O
and	O
OS	O
,	O
all	O
measured	O
from	O
the	O
date	O
of	O
enzalutamide	O
initiation	O
.	O

Statistical	O
Analysis	O
.	O
Descriptive	O
statistics	O
(	O
median	O
and	O
interquartile	O
range	O
for	O
continuous	O
variables	O
;	O
frequencies	O
and	O
percentages	O
for	O
categorical	O
variables	O
)	O
were	O
used	O
to	O
summarize	O
the	O
demographic	O
and	O
clinical	O
data	O
by	O
response	O
group	O
.	O
Time	O
-	O
to	O
-	O
event	O
analysis	O
was	O
performed	O
using	O
Kaplan	O
-	O
Meier	O
curves	O
and	O
log	O
-	O
rank	O
tests	O
to	O
evaluate	O
the	O
association	O
between	O
response	O
group	O
and	O
TOT	O
,	O
PFS	B-arm_efficacy_metric
,	O
and	O
OS	O
.	O
Cox	O
regression	O
models	O
were	O
used	O
to	O
calculate	O
hazard	O
ratios	O
by	O
response	O
group	O
with	O
95	O
%	O
CIs	O
.	O
All	O
statistical	O
analyses	O
were	O
performed	O
using	O
R	O
:	O
A	O
Language	O
and	O
Environment	O
for	O
Statistical	O
Computing	O
.	O
P	O
<	O
0.05	O
was	O
considered	O
statistically	O
significant	O
.	O

Analysis	O
of	O
Baseline	O
Biopsy	O
Samples	O
and	O
DNA	O
-	O
Seq	O
.	O
At	O
the	O
time	O
of	O
consenting	O
for	O
the	O
Genetic	O
and	O
Molecular	O
Mechanisms	O
in	O
Assessing	O
Response	O
in	O
Patients	O
with	O
Prostate	O
Cancer	O
Receiving	O
Enzalutamide	O
Therapy	O
trial	O
,	O
patients	O
also	O
consented	O
to	O
the	O
IRB	O
-	O
approved	O
West	O
Coast	O
Prostate	O
Cancer	O
Dream	O
Team	O
tissue	O
collection	O
protocol	O
through	O
which	O
their	O
tumor	O
samples	O
were	O
sequenced	O
.	O
Results	O
in	O
Fig	O
.	O
3	O
and	O
SI	O
Appendix	O
,	O
Fig	O
.	O
S2	O
are	O
based	O
on	O
a	O
37-gene	O
targeted	O
DNA	O
-	O
seq	O
panel	O
described	O
previously	O
(	O
48	O
)	O
.	O
AR	O
DNA	O
-	O
seq	O
results	O
in	O
Fig	O
.	O
4A	O
are	O
based	O
on	O
an	O
alternate	O
targeted	O
DNA	O
-	O
seq	O
panel	O
that	O
included	O
the	O
AR	O
or	O
whole	O
-	O
genome	O
-	O
seq	O
that	O
has	O
been	O
described	O
previously	O
(	O
21,49	O
)	O
.	O

Characterization	O
of	O
AR	O
Protein	O
Expression	O
.	O
AR	O
protein	O
expression	O
was	O
analyzed	O
using	O
immunohistochemical	O
analysis	O
.	O
The	O
AR	O
[	O
C6F11	O
]	O
XP	O
rabbit	O
monoclonal	O
antibody	O
was	O
used	O
as	O
previously	O
described	O
,	O
and	O
AR	O
nuclear	O
staining	O
was	O
quantified	O
as	O
described	O
previously	O
:	O
0	O
(	O
absent	O
)	O
,	O
1	O
+	O
(	O
low	O
)	O
,	O
2	O
+	O
(	O
intermediate	O
)	O
,	O
and	O
3	O
+	O
(	O
strong	O
)	O
(	O
21	O
)	O
.	O

A	O
Randomized	B-study_type
Phase	I-study_type
IIa	I-study_type
Trial	I-study_type
with	O
Temsirolimus	B-arm_description
versus	O
Sunitinib	B-arm_description
in	O
Advanced	O
Non	O
-	O
Clear	O
Cell	O
Renal	O
Cell	O
Carcinoma	O
:	O
An	O
Intergroup	O
Study	O
of	O
the	O
CESAR	O
Central	O
European	O
Society	O
for	O
Anticancer	O
Drug	O
Research	O
-	O
EWIV	O
and	O
the	O
Interdisciplinary	O
Working	O
Group	O
on	O
Renal	O
Cell	O
Cancer	O
(	O
IAGN	O
)	O
of	O
the	O
German	O
Cancer	O
Society	O

Germany	O
Theodor	O
-	O
Stern	O
-	O
Kai	O
7	O
DE	O
60590	O
Frankfurt	O
Germany	O
A	O
Randomized	B-study_type
Phase	I-study_type
IIa	I-study_type
Trial	I-study_type
with	O
Temsirolimus	B-arm_description
versus	O
Sunitinib	B-arm_description
in	O
Advanced	O
Non	O
-	O
Clear	O
Cell	O
Renal	O
Cell	O
Carcinoma	O
:	O
An	O
Intergroup	O
Study	O
of	O
the	O
CESAR	O
Central	O
European	O
Society	O
for	O
Anticancer	O
Drug	O
Research	O
-	O
EWIV	O
and	O
the	O
Interdisciplinary	O
Working	O
Group	O
on	O
Renal	O
Cell	O
Cancer	O
(	O
IAGN	O
)	O
of	O
the	O
German	O
Cancer	O
Society	O
June	O
15	O
,	O
2020	O
June	O
15	O
,	O
2020	O
June	O
15	O
,	O
2020	O
10.1159/000508450	O
Received	O
:	O
February	O
27	O
,	O
2020	O
Accepted	O
:	O
May	O
6	O
,	O
2020	O

Direct	O
comparisons	O
between	O
the	O
mammalian	O
targets	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
inhibitors	O
everolimus	O
and	O
SUN	O
have	O
been	O
studied	O
in	O
two	O
small	O
randomized	O
trials	O
showing	O
a	O
tendency	O
towards	O
SUN	O
or	O
no	O
significant	O
difference	O
in	O
efficacy	O
,	O
but	O
still	O
the	O
numbers	O
are	O
rather	O
small	O
to	O
draw	O
final	O
conclusions	O
[	O
6,7	O
]	O
.	O
Regarding	O
the	O
mTOR	O
inhibitor	O
TEM	O
,	O
the	O
subgroup	O
analysis	O
of	O
the	O
"	O
Advanced	O
Renal	O
Cell	O
Carcinoma	O
"	O
(	O
ARCC	O
)	O
study	O
showed	O
a	O
comparable	O
median	O
OS	O
(	O
mOS	O
)	O
for	O
ccRCC	O
and	O
nccRCC	O
patients	O
receiving	O
TEM	O
in	O
comparison	O
to	O
interferon	O
-	O
α	O
[	O
13	O
]	O
.	O
No	O
data	O
are	O
available	O
for	O
the	O
mTOR	O
inhibitor	O
TEM	O
in	O
comparison	O
to	O
SUN	O
[	O
14	O
]	O
.	O

This	O
open	B-study_type
-	I-study_type
label	I-study_type
randomized	I-study_type
trial	I-study_type
was	O
performed	O
in	O
9	O
centers	O
of	O
the	O
Central	O
European	O
Society	O
for	O
Anticancer	O
Drug	O
Research	O
-	O
EWIV	O
(	O
CESAR	O
)	O
study	O
group	O
.	O
It	O
was	O
an	O
investigator	O
-	O
initiated	O
trial	O
.	O
Eligible	O
patients	O
had	O
histologically	O
confirmed	O
nccRCC	O
,	O
including	O
sarcomatoid	O
features	O
,	O
defined	O
as	O
>	O
50	O
%	O
sarcomatoid	O
component	O
as	O
assessed	O
through	O
pathological	O
examination	O
by	O
a	O
local	O
site	O
review	O
.	O
Mixed	O
features	O
were	O
allowed	O
if	O
the	O
nccRCC	O
component	O
was	O
>	O
50	O
%	O
.	O
Additional	O
eligibility	O
criteria	O
included	O
a	O
baseline	O
Karnofsky	O
perfor	O
-	O
mance	O
status	O
of	O
70	O
or	O
higher	O
,	O
life	O
expectancy	O
of	O
at	O
least	O
3	O
months	O
,	O
and	O
the	O
presence	O
of	O
measurable	O
metastatic	O
disease	O
as	O
per	O
RECIST	O
1.1	O
criteria	O
.	O
Patients	O
had	O
to	O
have	O
adequate	O
bone	O
marrow	O
,	O
kidney	O
,	O
and	O
liver	O
function	O
and	O
adequate	O
laboratory	O
parameters	O
(	O
baseline	O
creatinine	O
concentration	O
≤2	O
times	O
the	O
institutional	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
,	O
as	O
well	O
as	O
aspartate	O
aminotransferase	O
and	O
alanine	O
aminotransferase	O
concentrations	O
<	O
2•5	O
times	O
the	O
ULN	O
.	O
The	O
patients	O
could	O
not	O
have	O
received	O
any	O
prior	O
systemic	O
cancer	O
treatment	O
and	O
should	O
not	O
have	O
symptomatic	O
brain	O
metastases	O
.	O
Local	O
irradiation	O
and/or	O
surgical	O
procedures	O
were	O
not	O
allowed	O
within	O
4	O
weeks	O
prior	O
study	O
inclusion	O
.	O
Additional	O
exclusion	O
criteria	O
were	O
severe	O
cardiovascular	O
disorders	O
,	O
poorly	O
controlled	O
hypertension	O
,	O
any	O
cardiovascular	O
event	O
within	O
6	O
months	O
of	O
randomization	O
or	O
prolonged	O
QTc	O
time	O
(	O
>	O
450	O
ms	O
)	O
,	O
abnormal	O
pulmonary	O
function	O
(	O
DCO	O
<	O
50	O
%	O
)	O
,	O
poorly	O
controlled	O
diabetes	O
mellitus	O
,	O
patients	O
taking	O
strong	O
CYP3A	O
inhibitors	O
or	O
inducers	O
,	O
active	O
infections	O
,	O
or	O
second	O
malignancies	O
as	O
well	O
as	O
pregnant	O
or	O
nursing	O
women	O
.	O

In	O
total	O
,	O
22	O
patients	O
were	O
eligible	O
and	O
randomized	O
.	O
Due	O
to	O
low	O
recruitment	O
over	O
2	O
years	O
,	O
the	O
study	O
was	O
prematurely	O
stopped	O
.	O
Twelve	O
patients	O
were	O
randomized	O
to	O
arm	B-arm_description
A	I-arm_description
(	I-arm_description
TEM	I-arm_description
)	I-arm_description
and	O
10	O
patients	O
to	O
arm	B-arm_description
B	I-arm_description
(	I-arm_description
SUN	I-arm_description
)	I-arm_description
.	O
The	O
median	O
age	O
was	O
60.8	O
years	O
.	O
A	O
total	O
of	O
59	O
%	O
of	O
the	O
patients	O
had	O
ECOG	O
and	O
41	O
%	O
ECOG	O
1	O
.	O
Further	O
,	O
86.5	O
%	O
of	O
the	O
patients	O
had	O
a	O
metastatic	O
disease	O
,	O
and	O
13.5	O
%	O
a	O
locally	O
advanced	O
stage	O
.	O
The	O
histological	O
classification	O
was	O
done	O
by	O
the	O
local	O
pathologists	O
.	O
Sixteen	O
patients	O
(	O
73	O
%	O
)	O
had	O
a	O
papillary	O
subtype	O
,	O
2	O
patients	O
a	O
chromophobe	O
,	O
1	O
patient	O
a	O
renal	O
medullary	O
and	O
3	O
patients	O
an	O
unclassified	O
non	O
-	O
clear	O
cell	O
carcinoma	O
(	O
Table	O
1	O
)	O
.	O
The	O
median	O
treatment	O
duration	O
was	O
slightly	O
but	O
not	O
significantly	O
lower	O
in	O
the	O
TEM	B-arm_description
group	I-arm_description
.	O
The	O
reason	O
for	O
treatment	O
stop	O
was	O
predominantly	O
tumor	O
progression	O
or	O
death	O
(	O
Table	O
1	O
)	O
.	O

Safety	O
and	O
activity	O
of	O
ibrutinib	B-arm_description
in	O
combination	O
with	O
durvalumab	B-arm_description
in	O
patients	O
with	O
relapsed	O
or	O
refractory	O
follicular	O
lymphoma	O
or	O
diffuse	O
large	O
B	O
-	O
cell	O
lymphoma	O
10.1002	O
/	O
ajh.25659	O

Safety	O
and	O
activity	O
of	O
ibrutinib	B-arm_description
in	O
combination	B-arm_description
with	I-arm_description
durvalumab	I-arm_description
in	O
patients	O
with	O
relapsed	O
or	O
refractory	O
follicular	O
lymphoma	O
or	O
diffuse	O
large	O
B	O
-	O
cell	O
lymphoma	O
AlexFHerrera	B-authors
aherrera@coh.org	O

Diffuse	O
large	O
B	O
-	O
cell	O
lymphoma	O
(	O
DLBCL	O
)	O
and	O
follicular	O
lymphoma	O
(	O
FL	O
)	O
are	O
the	O
most	O
common	O
subtypes	O
of	O
non	O
-	O
Hodgkin	O
lymphoma	O
in	O
adults	O
.	O
[	O
1][2][3][4	O
]	O
Although	O
most	O
patients	O
respond	O
to	O
first	O
-	O
line	O
chemoimmunotherapy	O
,	O
a	O
substantial	O
proportion	O
of	O
patients	O
with	O
DLBCL	O
and	O
most	O
patients	O
with	O
FL	O
will	O
eventually	O
relapse	O
or	O
have	O
refractory	O
disease	O
.	O
[	O
1][2][3][4][5	O
]	O
The	O
treatment	O
of	O
relapsed	O
/	O
refractory	O
DLBCL	O
and	O
FL	O
remains	O
challenging	O
,	O
with	O
a	O
minority	O
of	O
patients	O
with	O
DLBCL	O
achieving	O
durable	O
remission	O
and	O
patients	O
with	O
FL	O
experiencing	O
decreased	O
duration	O
of	O
remission	O
with	O
successive	O
therapies	O
.	O
[	O
1][2][3][4][5	O
]	O
Effective	O
,	O
well	O
-	O
tolerated	O
therapy	O
for	O
relapsed	O
/	O
refractory	O
DLBCL	O
and	O
FL	O
remains	O
an	O
unmet	O
need	O
.	O

Key	O
eligibility	O
criteria	O
included	O
age	O
≥18	O
years	O
;	O
pathologically	O
confirmed	O
DLBCL	O
,	O
with	O
subtype	O
identified	O
via	O
gene	O
expression	O
or	O
immunohistochemistry	O
tests	O
,	O
or	O
FL	O
(	O
grade	O
1	O
,	O
2	O
,	O
or	O
3A	O
)	O
according	O
to	O
World	O
Health	O
Organization	O
criteria	O
;	O
relapsed	O
/	O
refractory	O
disease	O
to	O
at	O
least	O
one	O
line	O
of	O
therapy	O
;	O
measurable	O
disease	O
(	O
≥1	O
lesion	O
>	O
1.5	O
cm	O
in	O
longest	O
dimension	O
)	O
;	O
adequate	O
hematological	O
function	O
independent	O
of	O
transfusion	O
and	O
growth	O
factor	O
support	O
;	O
adequate	O
hepatic	O
and	O
renal	O
function	O
;	O
prothrombin	O
time	O
<	O
1.5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
and	O
activated	O
partial	O
thromboplastin	O
time	O
<	O
1.5	O
times	O
ULN	O
;	O
and	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
or	O
1	O
.	O
In	O
the	O
phase	O
2	O
portion	O
of	O
the	O
study	O
within	O
the	O
DLBCL	O
cohort	O
,	O
patients	O
with	O
germinal	O
center	O
B	O
-	O
cell	O
(	O
GCB	O
)	O
and	O
non	O
-	O
GCB	O
subtypes	O
were	O
to	O
be	O
enrolled	O
in	O
a	O
1:1	O
ratio	O
.	O

This	O
was	O
an	O
open	B-study_type
-	I-study_type
label	I-study_type
,	I-study_type
multicenter	I-study_type
phase	I-study_type
1b/2	I-study_type
study	I-study_type
conducted	O
at	O
12	O
centers	O
in	O
the	O
United	O
States	O
from	O
May	O
2015	O
to	O
February	O
2018	O
.	O

The	O
primary	O
endpoint	O
of	O
the	O
phase	O
2	O
portion	O
of	O
the	O
study	O
was	O
the	O
ORR	O
;	O
secondary	O
endpoints	O
included	O
duration	O
of	O
response	O
,	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
(	O
PFS	B-arm_efficacy_metric
)	O
,	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
safety	O
,	O
and	O
tolerability	O
.	O

Response	O
evaluations	O
were	O
performed	O
every	O
three	O
cycles	O
until	O
cycle	O
12	O
and	O
every	O
six	O
cycles	O
thereafter	O
.	O
Response	O
was	O
assessed	O
by	O
the	O
investigator	O
according	O
to	O
revised	O
criteria	O
for	O
malignant	O
lymphoma	O
described	O
by	O
the	O
International	O
Working	O
Group	O
for	O
non	O
-	O
Hodgkin	O
Lymphoma	O
.	O
26	O
Adverse	O
events	O
(	O
AEs	O
)	O
were	O
coded	O
using	O
the	O
Medical	O
Dictionary	O
for	O
Regulatory	O
Activities	O
(	O
version	O
20.0	O
)	O
and	O
graded	O
according	O
to	O
the	O
National	O
Cancer	O
Institute	O
Common	O
Terminology	O
Criteria	O
for	O
AEs	O
(	O
CTCAE	O
)	O
,	O
version	O
4.03	O
.	O
Treatment	O
-	O
emergent	O
adverse	O
events	O
(	O
TEAEs	O
)	O
were	O
defined	O
as	O
(	O
1	O
)	O
any	O
AE	O
occurring	O
after	O
the	O
start	O
of	O
study	O
treatment	O
and	O
within	O
30	O
days	O
of	O
the	O
last	O
dose	O
of	O
ibrutinib	B-arm_description
or	O
within	O
90	O
days	O
after	O
the	O
last	O
dose	O
of	O
durvalumab	B-arm_description
,	O
(	O
2	O
)	O
any	O
study	O
drug	O
-	O
related	O
AE	O
regardless	O
of	O
start	O
date	O
,	O
or	O
(	O
3	O
)	O
any	O
AE	O
present	O
at	O
baseline	O
that	O
worsens	O
in	O
severity	O
of	O
frequency	O
after	O
the	O
start	O
of	O
study	O
treatment	O
or	O
is	O
considered	O
by	O
the	O
investigator	O
to	O
be	O
study	O
drug	O
-	O
related	O
.	O
Treatment	O
-	O
related	O
DLTs	O
followed	O
guidelines	O
provided	O
in	O
the	O
CTCAE	O
(	O
version	O
4.03	O
)	O
and	O
were	O
defined	O
as	O
(	O
1	O
)	O
any	O
grade	O
3	O
or	O
higher	O
nonhematologic	O
AE	O
or	O
(	O
2	O
)	O
clinically	O
relevant	O
hematologic	O
AE	O
.	O
and	O
white	O
(	O
90	O
%	O
)	O
(	O
Table	O
1	O
)	O
.	O
The	O
median	O
time	O
from	O
initial	O
diagnosis	O
to	O
the	O
first	O
dose	O
of	O
study	O
treatment	O
was	O
26.1	O
months	O
(	O
range	O
:	O
6.0	O
-	O
362.5	O
)	O
.	O

HRQoL	O
data	O
were	O
analysed	O
in	O
the	O
subset	O
of	O
patients	O
in	O
the	O
intention	O
-	O
totreat	O
population	O
who	O
had	O
an	O
evaluable	O
baseline	O
EORTC	O
QLQ	O
-	O
C30	O
or	O
QLQ	O
-	O
PAN26	O
form	O
[	O
patient	O
-	O
reported	O
outcome	O
(	O
PRO	O
)	O
analysis	O
set	O
]	O
.	O
An	O
evaluable	O
form	O
was	O
defined	O
as	O
one	O
on	O
which	O
at	O
least	O
one	O
subscale	O
baseline	O
score	O
could	O
be	O
determined	O
.	O
For	O
the	O
adjusted	O
mean	O
change	O
from	O
baseline	O
in	O
GHS	O
score	O
analysis	O
,	O
only	O
visits	O
with	O
at	O
least	O
25	O
%	O
non	O
-	O
missing	O
values	O
in	O
each	O
treatment	O
arm	O
were	O
included	O
;	O
study	O
treatment	O
discontinuation	O
and	O
30	O
days	O
following	O
last	O
dose	O
of	O
study	O
treatment	O
visits	O
were	O
excluded	O
.	O
The	O
analysis	O
was	O
carried	O
out	O
using	O
a	O
linear	O
mixed	O
model	O
for	O
repeated	O
measures	O
,	O
adjusted	O
for	O
score	O
at	O
baseline	O
,	O
time	O
,	O
and	O
treatment	O
-	O
by	O
-	O
time	O
interaction	O
to	O
estimate	O
the	O
cumulative	O
effect	O
of	O
olaparib	B-arm_description
versus	O
placebo	B-arm_description
on	O
GHS	O
.	O
Between	O
-	O
group	O
differences	O
were	O
compared	O
using	O
adjusted	O
mean	O
estimates	O
for	O
each	O
treatment	O
group	O
with	O
a	O
between	O
-	O
group	O
difference	O
of	O
!	O
10	O
points	O
defined	O
as	O
clinically	O
meaningful	O
,	O
based	O
on	O
published	O
literature	O
[	O
17][18][19	O
]	O
.	O
A	O
change	O
of	O
!	O
10	O
points	O
from	O
baseline	O
was	O
also	O
predefined	O
as	O
clinically	O
meaningful	O
[	O
17][18][19	O
]	O
.	O
TSCMD	O
was	O
analysed	O
by	O
log	O
-	O
rank	O
test	O
[	O
hazard	O
ratio	O
(	O
HR	O
)	O
<	O
1	O
favours	O
olaparib	B-arm_description
]	O
in	O
all	O
patients	O
with	O
a	O
baseline	O
score	O
!	O
10	O
(	O
GHS	O
and	O
functioning	O
subscale	O
analyses	O
)	O
or	O
90	O
(	O
symptom	O
subscales	O
)	O
.	O
HRQoL	O
improvement	O
rates	O
were	O
analysed	O
using	O
a	O
logistic	O
regression	O
model	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
>	O
1	O
favours	O
olaparib	B-arm_description
]	O
.	O

Of	O
154	O
randomized	O
patients	O
,	O
89	O
of	O
92	O
who	O
received	O
olaparib	B-arm_description
and	O
58	O
of	O
62	O
who	O
received	O
placebo	B-arm_description
were	O
included	O
in	O
the	O
PRO	O
analysis	O
set	O
;	O
the	O
remaining	O
seven	O
patients	O
had	O
missing	O
baseline	O
forms	O
.	O
HRQoL	O
scores	O
were	O
well	O
-	O
balanced	O
between	O
treatment	O
groups	O
at	O
baseline	O
with	O
overall	O
high	O
scores	O
for	O
GHS	O
and	O
physical	O
functioning	O
scales	O
,	O
and	O
low	O
scores	O
for	O
symptom	O
scales	O
(	O
supplementary	O
Figure	O
S1	O
,	O
available	O
at	O
Annals	O
of	O
Oncology	O
online	O
)	O
.	O

The	O
overall	O
compliance	O
rate	O
for	O
EORTC	O
QLQ	O
-	O
C30	O
was	O
high	O
,	O
100	O
%	O
at	O
baseline	O
and	O
96.6	O
%	O
and	O
94.8	O
%	O
overall	O
in	O
the	O
olaparib	B-arm_description
and	O
placebo	B-arm_description
groups	O
,	O
respectively	O
,	O
based	O
on	O
the	O
PRO	O
analysis	O
set	O
(	O
supplementary	O
Figure	O
S2	O
,	O
available	O
at	O
Annals	O
of	O
Oncology	O
online	O
)	O
.	O

HRQoL	O
was	O
preserved	O
with	O
olaparib	O
maintenance	O
therapy	O
in	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
and	O
a	O
gBRCAm	O
whose	O
disease	O
had	O
not	O
progressed	O
during	O
first	O
-	O
line	O
platinum	O
-	O
based	O
chemotherapy	O
,	O
with	O
no	O
meaningful	O
difference	O
observed	O
compared	O
with	O
placebo	B-arm_description
.	O
Results	O
of	O
prespecified	O
end	O
points	O
from	O
the	O
POLO	O
trial	O
show	O
that	O
maintenance	O
olaparib	O
significantly	O
Figure	O
4	O
.	O
Best	O
overall	O
quality	O
of	O
life	O
response	O
for	O
EORTC	O
QLQ	O
-	O
C30	O
Global	O
Health	O
Status	O
,	O
physical	O
functioning	O
and	O
symptom	O
scales	O
.	O
Percentages	O
are	O
calculated	O
based	O
on	O
the	O
86	O
olaparib	B-arm_description
-	O
arm	O
patients	O
and	O
55	O
placebo	B-arm_description
-	O
arm	O
patients	O
(	O
54	O
for	O
the	O
diarrhoea	O
subscale	O
)	O
with	O
available	O
results	O
.	O
Three	O
patients	O
in	O
each	O
arm	O
(	O
4	O
placebo	B-arm_description
arm	O
patients	O
for	O
the	O
diarrhoea	O
subscale	O
)	O
were	O
included	O
in	O
the	O
PRO	O
analysis	O
set	O
,	O
but	O
had	O
no	O
evaluable	O
baseline	O
or	O
post	O
-	O
baseline	O
results	O
and	O
are	O
excluded	O
from	O
this	O
figure	O
.	O
O	O
,	O
olaparib	B-arm_description
;	O
P	O
,	O
placebo	B-arm_description
.	O

Nelfinavir	O
and	O
lenalidomide/	O
dexamethasone	O
in	O
patients	O
with	O
lenalidomide	O
-	O
refractory	O
multiple	O
myeloma	O
.	O
A	O
phase	B-study_type
I	I-study_type
/	I-study_type
II	I-study_type
Trial	I-study_type
(	O
SAKK	O
39/10	O
)	O
Nelfinavir	O
and	O
lenalidomide/	O
dexamethasone	O
in	O
patients	O
with	O
lenalidomide	O
-	O
refractory	O
multiple	O
myeloma	O
.	O
A	O
phase	B-study_type
I	I-study_type
/	I-study_type
II	I-study_type
Trial	I-study_type
(	O
SAKK	O
39/10	O
)	O
FHitz	B-authors

Patient	O
and	O
disease	O
characteristics	O
for	O
the	O
29	O
patients	O
are	O
presented	O
in	O
Table	O
1	O
.	O
Most	O
(	O
93	O
%	O
)	O
had	O
undergone	O
two	O
or	O
more	O
prior	O
lines	O
of	O
therapy	O
,	O
and	O
24	O
(	O
83	O
%	O
)	O
had	O
prior	O
bortezomib	O
exposure	O
,	O
including	O
18	O
(	O
62	O
%	O
)	O
with	O
prior	O
autologous	O
stem	O
cell	O
transplantation	O
and	O
10	O
(	O
34	O
%	O
)	O
who	O
were	O
double	O
-	O
refractory	O
to	O
lenalidomide	O
and	O
bortezomib	O
,	O
based	O
on	O
International	O
Myeloma	O
Working	O
Group	O
(	O
IMWG	O
)	O
criteria	O
14	O
.	O

Fifteen	O
patients	O
completed	O
four	O
cycles	O
of	O
study	O
treatment	O
.	O
Fourteen	O
of	O
29	O
patients	O
discontinued	O
trial	O
treatment	O
due	O
to	O
:	O
progressive	O
disease	O
(	O
PD	O
;	O
n	O
=	O
8)	O
,	O
unacceptable	O
toxicity	O
(	O
4	O
)	O
,	O
or	O
patient	O
refusal	O
(	O
2	O
)	O
.	O

Department	O
of	O
Internal	O
Medicine	O
II	O
,	O
Asklepios	O
Klinik	O
Altona	O
Hamburg	O
Germany	O
MartinaEmde	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Labor	O
für	O
Myelomforschung	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
UtaBertsch	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
Medizinische	O
Klinik	O
V	O
Universitätsklinikum	O
Heidelberg	O
Heidelberg	O
Germany	O
ChristinaKunz	B-authors

Both	O
personalized	O
and	O
risk	O
-	O
adapted	O
treatment	O
strategies	O
prerequisite	O
the	O
feasibility	O
of	O
prospective	O
assessment	O
and	O
reporting	O
of	O
targets	O
and	O
prediction	O
of	O
survival	O
probability	O
in	O
clinical	O
routine	O
in	O
a	O
high	O
enough	O
percentage	O
of	O
patients	O
.	O
For	O
phase	O
III	O
trial	O
strategies	O
,	O
e.g.	O
,	O
selecting	O
an	O
add	O
-	O
on	O
treatment	O
,	O
the	O
necessary	O
threshold	O
based	O
on	O
power	O
calculations	O
and	O
clinical	O
feasibility	O
could	O
be	O
estimated	O
as	O
80	O
%	O
of	O
the	O
actual	O
population	O
of	O
patients	O
included	O
in	O
the	O
trial	O
.	O
It	O
is	O
interesting	O
to	O
denote	O
that	O
,	O
despite	O
of	O
course	O
iFISH	O
and	O
GEP	O
have	O
been	O
used	O
in	O
an	O
academic	O
setting	O
or	O
using	O
commercial	O
providers	O
[	O
8,17,[23][24][25][26][27][28	O
]	O
,	O
the	O
question	O
has	O
yet	O
not	O
been	O
answered	O
if	O
this	O
is	O
possible	O
in	O
terms	O
of	O
a	O
prospective	O
molecular	O
analysis	O
and	O
reporting	O
,	O
as	O
opposed	O
to	O
being	O
conducted	O
in	O
a	O
prospective	O
clinical	O
trial	O
.	O
Our	O
study	O
group	O
sees	O
such	O
a	O
proof	O
as	O
prerequisite	O
for	O
indeed	O
planning	O
a	O
clinical	O
trial	O
based	O
on	O
molecular	O
diagnostics	O
such	O
as	O
GEP	O
or	O
RNA	O
-	O
sequencing	O
.	O

Aims	O
of	O
this	O
study	O
were	O
thus	O
:	O
(	O
i	O
)	O
set	O
up	O
a	O
sampling	O
,	O
experimental	O
and	O
analysis	O
strategy	O
to	O
perform	O
iFISH	B-arm_description
in	O
≥	O
90	O
%	O
and	O
GEP	B-arm_description
in	O
≥	O
80	O
%	O
of	O
patients	O
within	O
the	O
first	O
cycle	O
of	O
induction	O
chemotherapy	O
.	O
(	O
ii	O
)	O
Report	O
to	O
patients	O
and	O
physicians	O
within	O
this	O
time	O
to	O
be	O
able	O
to	O
draw	O
a	O
clinical	O
consequence	O
.	O
(	O
iii	O
)	O
Prospectively	O
validate	O
this	O
strategy	O
in	O
the	O
randomized	O
phase	O
III	O
multicenter	O
GMMG	O
-	O
MM5-trial	O
including	O
assessment	O
of	O
potential	O
targets	O
(	O
based	O
on	O
GEP	B-arm_description
)	O
and	O
multimodal	O
assessment	O
of	O
risk	O
using	O
clinical	O
,	O
cytogenetic	O
,	O
and	O
gene	O
expression	O
-	O
based	O
prognostic	O
factors	O
and	O
their	O
integration	O
into	O
a	O
metascore	O
in	O
clinical	O
routine	O
.	O

Density	O
gradient	O
centrifugation	O
of	O
bone	O
marrow	O
aspirates	O
over	O
Ficoll	O
Hypaque	O
(	O
Biochrom	O
,	O
Berlin	O
,	O
Germany	O
)	O
was	O
performed	O
to	O
separate	O
mononuclear	O
cells	O
by	O
standard	O
protocol	O
.	O
CD138	O
+	O
plasma	O
cells	O
were	O
isolated	O
using	O
anti	O
-	O
CD138	O
immunobeads	O
and	O
an	O
autoMACS	O
Pro	O
Separator	O
(	O
Miltenyi	O
Biotec	O
,	O
Bergisch	O
Gladbach	O
,	O
Germany	O
)	O
as	O
published	O
[	O
13,21,[30][31][32][33][34][35	O
]	O
.	O
Purity	O
was	O
assessed	O
by	O
flow	O
cytometry	O
(	O
Becton	O
Dickinson	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
using	O
antibodies	O
against	O
CD38	O
(	O
clone	O
HB-7	O
,	O
FITClabeled	O
;	O
Becton	O
Dickinson	O
)	O
and	O
CD138	O
(	O
clone	O
B	O
-	O
B4	O
,	O
PElabeled	O
;	O
Miltenyi	O
Biotec	O
)	O
.	O
Aliquots	O
of	O
CD138	O
+	O
malignant	O
plasma	O
cells	O
were	O
subjected	O
to	O
cytospin	O
preparation	O
with	O
5000	O
cells	O
per	O
dot	O
for	O
iFISH	B-arm_description
analysis	O
(	O
n	O
=	O
556	O
patients	O
)	O
and	O
RNA	O
/	O
DNA	O
extraction	O
for	O
gene	O
expression	O
profiling	O
(	O
n	O
=	O
458	O
)	O
.	O

The	O
percentages	O
of	O
patients	O
identified	O
as	O
being	O
of	O
high	O
risk	O
(	O
first	O
column	O
)	O
and	O
the	O
overlap	O
of	O
the	O
respective	O
groups	O
of	O
patients	O
are	O
shown	O
GPI	O
,	O
gene	O
expression	O
-	O
based	O
proliferation	O
index	O
;	O
(	O
r)ISS	O
,	O
(	O
revised	O
)	O
International	O
Staging	O
System	O
aberrantly	O
or	O
differentially	O
expressed	O
in	O
myeloma	O
.	O
In	O
our	O
cohort	O
of	O
456	O
patients	O
from	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
for	O
which	O
a	O
GEP	B-arm_description
-	O
R	O
is	O
available	O
,	O
197	O
were	O
found	O
to	O
express	O
AURKA	O
(	O
43.2	O
%	O
)	O
,	O
151	O
IGF1R	O
(	O
33.1	O
%	O
)	O
,	O
and	O
50	O
FGFR3	O
(	O
11	O
%	O
)	O
,	O
respectively	O
.	O
In	O
the	O
same	O
way	O
,	O
candidates	O
for	O
personalized	O
treatment	O
approaches	O
,	O
given	O
the	O
availability	O
of	O
respective	O
inhibitors	O
,	O
could	O
be	O
addressed	O
.	O

Pemetrexed	B-arm_description
,	O
Bevacizumab	B-arm_description
,	O
or	O
the	O
Combination	B-arm_description
As	O
Maintenance	O
Therapy	O
for	O
Advanced	O
Nonsquamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O
ECOG	O
-	O
ACRIN	O
5508	O
Pemetrexed	O
,	O
Bevacizumab	O
,	O
or	O
the	O
Combination	O
As	O
Maintenance	O
Therapy	O
for	O
Advanced	O
Nonsquamous	O
Non	O
-	O
Small	O
-	O
Cell	O
Lung	O
Cancer	O
:	O
ECOG	O
-	O
ACRIN	O
5508	O
MDSureshSRamalingam	B-authors

Eligible	O
patients	O
received	O
carboplatin	O
(	O
dosed	O
to	O
achieve	O
an	O
area	O
under	O
the	O
concentration	O
versus	O
time	O
curve	O
of	O
6	O
mg	O
/	O
mL	O
per	O
minute	O
)	O
,	O
paclitaxel	O
(	O
200	O
mg	O
/	O
m	O
2	O
)	O
,	O
and	O
bevacizumab	O
(	O
15	O
mg	O
/	O
kg	O
)	O
every	O
3	O
weeks	O
for	O
up	O
to	O
four	O
cycles	O
(	O
induction	O
therapy	O
)	O
.	O
Patients	O
achieving	O
complete	O
response	O
,	O
partial	O
response	O
,	O
or	O
stable	O
disease	O
per	O
RECIST	O
criteria	O
after	O
four	O
cycles	O
were	O
then	O
randomly	O
assigned	O
at	O
a	O
1:1:1	O
ratio	O
to	O
maintenance	O
therapy	O
with	O
bevacizumab	B-arm_description
(	O
15	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
kg	I-arm_dosage
)	O
,	O
pemetrexed	B-arm_description
(	O
500	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	O
,	O
or	O
a	O
combination	O
of	O
the	O
two	O
agents	O
at	O
the	O
same	O
doses	O
as	O
in	O
the	O
monotherapy	O
groups	O
every	B-arm_dosage
3	I-arm_dosage
weeks	I-arm_dosage
.	O
Because	O
of	O
the	O
national	O
shortage	O
of	O
paclitaxel	O
in	O
2011	O
,	O
use	O
of	O
docetaxel	O
at	O
75	O
mg	O
/	O
m	O
2	O
was	O
allowed	O
as	O
a	O
substitution	O
for	O
a	O
short	O
duration	O
of	O
time	O
.	O
Standard	O
premedications	O
,	O
including	O
dexamethasone	O
,	O
diphenhydramine	O
,	O
and	O
cimetidine	O
,	O
or	O
appropriate	O
institutional	O
alternative	O
options	O
were	O
used	O
during	O
the	O
induction	O
chemotherapy	O
phase	O
.	O
For	O
maintenance	O
therapy	O
,	O
premedications	O
included	O
vitamin	O
B12	O
injection	O
,	O
dexamethasone	O
,	O
and	O
folic	O
acid	O
supplements	O
for	O
patients	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
pemetrexed	O
groups	O
.	O
Treatment	O
cycles	O
were	O
repeated	O
every	O
3	O
weeks	O
.	O

In	O
the	O
induction	O
phase	O
,	O
patients	O
who	O
did	O
not	O
make	O
it	O
to	O
the	O
fourth	O
cycle	O
because	O
of	O
toxicity	O
were	O
allowed	O
to	O
proceed	O
to	O
maintenance	O
phase	O
after	O
cycle	O
3	O
if	O
they	O
had	O
achieved	O
favorable	O
response	O
or	O
stable	O
disease	O
.	O
In	O
the	O
maintenance	O
phase	O
,	O
treatment	O
was	O
continued	O
until	O
documentation	O
of	O
disease	O
progression	O
,	O
unacceptable	O
toxicity	O
,	O
or	O
withdrawal	O
of	O
informed	O
consent	O
.	O
Dose	O
modifications	O
were	O
made	O
for	O
patients	O
who	O
experienced	O
treatment	O
-	O
related	O
toxicity	O
.	O
Delay	O
in	O
treatment	O
of	O
up	O
to	O
3	O
weeks	O
was	O
allowed	O
for	O
toxicity	O
,	O
with	O
any	O
delays	O
beyond	O
that	O
resulting	O
in	O
discontinuation	O
of	O
study	O
therapy	O
.	O
All	O
appropriate	O
supportive	O
care	O
measures	O
were	O
instituted	O
for	O
patients	O
who	O
experienced	O
toxicity	O
.	O

The	O
study	O
was	O
conducted	O
by	O
the	O
Thoracic	O
Malignancies	O
Committee	O
of	O
the	O
ECOG	O
-	O
American	O
College	O
of	O
Radiology	O
Imaging	O
Network	O
(	O
ACRIN	O
)	O
Cancer	O
Research	O
Group	O
;	O
monitoring	O
was	O
performed	O
by	O
the	O
ECOG	O
-	O
ACRIN	O
Data	O
Safety	O
Monitoring	O
Committee	O
,	O
which	O
meets	O
twice	O
annually	O
.	O
For	O
each	O
meeting	O
,	O
the	O
study	O
was	O
reviewed	O
for	O
safety	O
and	O
progress	O
toward	O
completion	O
.	O
Interim	O
analyses	O
were	O
conducted	O
on	O
the	O
outcome	O
data	O
at	O
predefined	O
time	O
points	O
.	O
Only	O
the	O
study	O
statistician	O
and	O
members	O
of	O
the	O
Data	O
Safety	O
Monitoring	O
Committee	O
had	O
access	O
to	O
interim	O
analyses	O
of	O
the	O
outcome	O
data	O
.	O
Toxicity	O
reports	O
were	O
available	O
to	O
the	O
study	O
investigators	O
throughout	O
the	O
course	O
of	O
the	O
study	O
.	O
The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
of	O
each	O
participating	O
institution	O
and	O
by	O
the	O
National	O
Cancer	O
Institute	O
Central	O
institutional	O
review	O
board	O
.	O

Fostering	O
efficacy	O
of	O
anti	O
-	O
PD-1-treatment	O
:	O
Nivolumab	B-arm_description
plus	O
radiotherapy	B-arm_description
in	O
advanced	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
-study	O
protocol	O
of	O
the	O
FORCE	O
trial	O
FarastukBozorgmehr	B-authors

However	O
,	O
when	O
radiation	O
is	O
applied	O
as	O
a	O
sole	O
treatment	O
modality	O
,	O
this	O
phenomenon	O
is	O
soon	O
suppressed	O
by	O
regulatory	O
signalling	O
pathways	O
that	O
inhibit	O
auto−/	O
tumor	O
-	O
immune	O
responses	O
within	O
and	O
outside	O
the	O
tumor	O
microenvironment	O
[	O
13,17,18	O
]	O
.	O
Thus	O
,	O
the	O
clinical	O
observation	O
of	O
any	O
abscopal	O
effect	O
with	O
radiation	O
alone	O
has	O
always	O
been	O
a	O
rare	O
finding	O
.	O
With	O
the	O
advent	O
of	O
agents	O
that	O
target	O
PD-1	O
/	O
PD	O
-	O
L1	O
and	O
therefore	O
disinhibit	O
tumor	O
-	O
directed	O
immune	O
responses	O
,	O
the	O
potential	O
of	O
inducing	O
an	O
abscopal	O
effect	O
through	O
combined	O
radio	O
-	O
immunotherapies	O
has	O
gained	O
renewed	O
attention	O
.	O
Interestingly	O
,	O
a	O
secondary	O
analysis	O
of	O
a	O
clinical	O
landmark	O
trial	O
has	O
identified	O
98	O
patients	O
,	O
who	O
had	O
received	O
photon	O
radiotherapy	O
prior	O
to	O
immunotherapy	O
[	O
19	O
]	O
.	O
These	O
patients	O
showed	O
significantly	O
improved	O
PFS	O
and	O
OSirrespective	O
of	O
the	O
expression	O
of	O
PD	O
-	O
L1	O
.	O
This	O
finding	O
hasonce	O
again	O
nourished	O
the	O
hope	O
that	O
the	O
combination	O
of	O
pharmacological	O
disinhibition	O
of	O
the	O
immune	O
system	O
through	O
medical	O
immunotherapies	O
and	O
tumor	O
-	O
antigen	O
-	O
exposing	O
photon	O
radiation	O
may	O
be	O
a	O
beneficial	O
combination	O
.	O
However	O
,	O
to	O
date	O
results	O
from	O
prospective	O
clinical	O
trials	O
investigating	O
this	O
hypothesis	O
in	O
lung	O
cancer	O
patients	O
are	O
not	O
available	O
.	O

This	O
is	O
an	O
interventional	B-study_type
two	I-study_type
-	I-study_type
group	I-study_type
,	I-study_type
non	I-study_type
-	I-study_type
randomized	I-study_type
,	I-study_type
open	I-study_type
-	I-study_type
label	I-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type
(	O
Fig	O
.	O
1	O
)	O
[	O
20	O
]	O
.	O

Furthermore	O
,	O
to	O
address	O
the	O
role	O
of	O
radiotherapy	B-arm_description
in	O
the	O
context	O
of	O
immune	O
modulation	O
,	O
several	O
aspects	O
of	O
radiation	O
planning	O
and	O
treatment	O
will	O
be	O
explored	O
.	O
This	O
includes	O
both	O
the	O
location	O
and	O
composition	O
of	O
radiation	O
targets	O
and	O
the	O
anatomical	O
profile	O
of	O
abscopally	O
responding	O
lesions	O
.	O
Therefore	O
,	O
treatment	O
-	O
related	O
aspects	O
characterizing	O
the	O
irradiated	O
targets	O
and	O
abscopally	O
responding	O
target	O
lesions	O
will	O
be	O
documented	O
by	O
the	O
treating	O
radiation	O
oncologist	O
and	O
radiologist	O
.	O
Documentation	O
of	O
these	O
aspects	O
will	O
help	O
to	O
substantiate	O
the	O
phenomenon	O
of	O
radiation	O
-	O
induced	O
abscopal	O
effects	O
and	O
to	O
improve	O
the	O
option	O
of	O
radiation	O
triggered	O
systemic	O
response	O
through	O
identification	O
and	O
possible	O
prediction	O
of	O
both	O
eligible	O
targets	O
for	O
irradiation	O
and	O
probable	O
lesion	O
of	O
abscopal	O
response	O
.	O

An	O
overview	O
of	O
all	O
study	O
procedures	O
is	O
presented	O
in	O
Table	O
2	O
.	O
For	O
each	O
patient	O
enrolled	O
,	O
an	O
electronic	O
case	O
report	O
form	O
(	O
eCRF	O
)	O
must	O
be	O
completed	O
by	O
the	O
principal	O
investigator	O
or	O
authorized	O
delegate	O
from	O
the	O
study	O
staff	O
.	O
For	O
patients	O
in	O
group	O
A	O
,	O
non	O
-	O
measurable	O
and	O
measurable	O
lesions	O
may	O
be	O
chosen	O
for	O
irradiation	O
.	O
However	O
,	O
in	O
order	O
to	O
allow	O
for	O
evaluation	O
of	O
abscopal	O
effects	O
,	O
patients	O
in	O
group	O
A	O
must	O
have	O
at	O
least	O
one	O
measurable	O
lesion	O
beside	O
the	O
lesion	O
planned	O
to	O
be	O
irradiated	O
.	O
Lesions	O
planned	O
to	O
be	O
irradiated	O
may	O
not	O
be	O
defined	O
as	O
a	O
measurable	O
target	O
lesion	O
.	O
Radiographic	O
tumor	O
assessment	O
must	O
be	O
performed	O
within	O
28	O
days	O
before	O
initiation	O
of	O
study	O
treatment	O
.	O
•	O
Target	O
Lesions	O
may	O
be	O
located	O
in	O
a	O
previously	O
irradiated	O
field	O
if	O
there	O
is	O
documented	O
(	O
radiographic	O
)	O
disease	O
progression	O
in	O
that	O
site	O
.	O

•	O
Adequate	O
blood	O
count	O
,	O
liver	O
-	O
enzymes	O
,	O
and	O
renal	O
function	O
(	O
obtained	O
no	O
later	O
than	O
14	O
days	O
prior	O
to	O
start	O
of	O
treatment	O
)	O
:	O

Nivolumab	B-arm_description
will	O
be	O
given	O
every	B-arm_dosage
two	I-arm_dosage
weeks	I-arm_dosage
at	I-arm_dosage
a	I-arm_dosage
dose	I-arm_dosage
of	I-arm_dosage
240	I-arm_dosage
mg	I-arm_dosage
to	I-arm_dosage
be	I-arm_dosage
administered	I-arm_dosage
as	I-arm_dosage
a	I-arm_dosage
60	I-arm_dosage
min	I-arm_dosage
IV	I-arm_dosage
infusion	I-arm_dosage
.	O
Treatment	O
regimen	O
depends	O
on	O
study	O
group	O
:	O
in	O
study	B-arm_description
group	I-arm_description
A	I-arm_description
,	O
nivolumab	B-arm_description
will	O
be	O
given	O
on	O
day	B-arm_dosage
1	I-arm_dosage
of	I-arm_dosage
the	I-arm_dosage
first	I-arm_dosage
cycle	I-arm_dosage
and	I-arm_dosage
continued	I-arm_dosage
to	I-arm_dosage
be	I-arm_dosage
given	I-arm_dosage
every	I-arm_dosage
two	I-arm_dosage
weeks	I-arm_dosage
.	O
The	O
first	B-arm_dosage
fraction	I-arm_dosage
of	O
radiotherapy	B-arm_description
has	O
to	O
be	O
delivered	B-arm_dosage
within	I-arm_dosage
72	I-arm_dosage
h	I-arm_dosage
after	I-arm_dosage
cycle	I-arm_dosage
1	I-arm_dosage
day	I-arm_dosage
1	I-arm_dosage
.	O

Gross	O
tumor	O
volumes	O
(	O
GTV	O
)	O
are	O
contoured	O
on	O
the	O
planning	O
CT	O
,	O
considering	O
additional	O
co	O
-	O
registered	O
imaging	O
techniques	O
such	O
as	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
or	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
,	O
if	O
available	O
.	O
Derived	O
from	O
the	O
GTV	O
,	O
clinical	O
(	O
CTV	O
)	O
and	O
planning	O
target	O
volumes	O
(	O
PTV	O
)	O
are	O
created	O
using	O
common	O
institutional	O
margins	O
to	O
confidently	O
cover	O
radiation	O
targets	O
and	O
simultaneously	O
spare	O
organs	O
at	O
risk	O
(	O
OAR	O
)	O
.	O
Contouring	O
of	O
relevant	O
OAR	O
is	O
only	O
necessary	O
in	O
cases	O
of	O
close	O
vicinity	O
or	O
anticipated	O
critical	O
radiation	O
exposure	O
.	O
In	O
case	O
of	O
thoracic	O
target	O
volumes	O
,	O
both	O
lungs	O
will	O
be	O
contoured	O
to	O
monitor	O
lung	O
dose	O
exposure	O
,	O
which	O
is	O
required	O
to	O
be	O
as	O
low	O
as	O
reasonably	O
achievable	O
.	O
In	O
cases	O
of	O
subtotal	O
lung	O
registration	O
,	O
the	O
OAR	O
"	O
both	O
partial	O
lungs	O
"	O
will	O
be	O
generated	O
.	O

Routine	O
haematological	O
analysis	O
of	O
red	O
and	O
white	O
blood	O
cells	O
and	O
platelets	O
are	O
part	O
of	O
the	O
scheduled	O
patient	O
assessments	O
under	O
therapy	O
and	O
are	O
not	O
a	O
specific	O
part	O
of	O
the	O
exploratory	O
biomarker	O
program	O
.	O
However	O
,	O
their	O
results	O
are	O
mandatory	O
baseline	O
information	O
as	O
absolute	O
cell	O
counts	O
for	O
further	O
investigations	O
.	O

The	O
study	O
requires	O
n	O
=	O
50	O
subjects	O
(	O
in	O
group	B-arm_description
A	I-arm_description
)	O
to	O
detect	O
whether	O
the	O
responding	O
proportion	O
(	O
ORR	O
)	O
is	O
higher	O
than	O
19	O
%	O
by	O
applying	O
a	O
binomial	O
test	O
at	O
a	O
one	O
-	O
sided	O
significance	O
level	O
of	O
0.05	O
with	O
a	O
probability	O
of	O
1-beta	O
=	O
0.8	O
,	O
assuming	O
an	O
actual	O
response	O
rate	O
of	O
35	O
%	O
.	O

P.R.	O
China	O
Department	O
of	O
Hematology	O
and	O
Oncology	O
Tianjin	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Key	O
Laboratory	O
of	O
Cancer	O
Prevention	O
and	O
Therapy	O
Tianjin	O
Medical	O
University	O
Cancer	O
Institute	O
and	O
Hospital	O
National	O
Clinical	O
Research	O
Center	O
for	O
Cancer	O
Tianjin	O

Diffuse	O
large	O
B	O
-	O
cell	O
lymphoma	O
(	O
DLBCL	O
)	O
is	O
an	O
aggressive	O
non	O
-	O
Hodgkin	O
lymphoma	O
with	O
extreme	O
heterogeneity	O
,	O
accounting	O
for	O
30	O
-	O
40	O
%	O
of	O
newly	O
diagnosed	O
lymphomas	O
[	O
1	O
]	O
.	O
Although	O
the	O
standard	O
R	O
-	O
CHOP	O
regimen	O
has	O
extremely	O
good	O
therapeutic	O
effect	O
on	O
DLBCL	O
patients	O
,	O
approximately	O
30	O
-	O
40	O
%	O
of	O
patients	O
show	O
relapse	O
and	O
10	O
%	O
have	O
refractory	O
disease	O
[	O
2	O
]	O
.	O
In	O
the	O
past	O
decades	O
,	O
accumulating	O
evidences	O
have	O
shown	O
the	O
genetic	O
,	O
microenvironment	O
,	O
autoimmune	O
diseases	O
and	O
occupational	O
exposure	O
participated	O
in	O
the	O
pathogenesis	O
of	O
DLBCL	O
[	O
3][4][5	O
]	O
.	O
With	O
gene	O
-	O
expression	O
profiling	O
and	O
next	O
-	O
generation	O
sequencing	O
,	O
some	O
common	O
genetic	O
loci	O
are	O
found	O
to	O
enmesh	O
in	O
the	O
lymphomagenesis	O
of	O
DLBCL	O
[	O
6	O
]	O
.	O
However	O
,	O
the	O
pathogenesis	O
of	O
DLBCL	O
is	O
still	O
not	O
fully	O
understood	O
.	O

Total	O
RNA	O
was	O
isolated	O
using	O
TRIzol	O
reagent	O
(	O
Invitrogen	O
)	O
.	O
We	O
normalized	O
the	O
levels	O
of	O
expression	O
of	O
CREBBP	O
relative	O
to	O
glyceraldehyde	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
,	O
and	O
2	O
−	O
C	O
t	O
indicated	O
the	O
quantification	O
of	O
gene	O
expression	O
.	O
The	O
primers	O
for	O
CREBBP	O
were	O
:	O
forward	O
5	O
-CGGCTCTAGTATCAACCCAGG-3	O
and	O
reverse	O
5	O
-TTTTGTGCTT	O
GCGGATTCAGT-3	O
.	O
The	O
primers	O
for	O
0	O
:	O
italic	O
GAPDH	O
/0	O
:	O
italic	O
were	O
:	O
forward5	O
-CCACATCGCTCAGACACCAT-3	O
andreverse5	O
-CCAGGCGCCCAATACG-3	O
.	O

CREBBP	O
expression	O
was	O
detected	O
in	O
63	O
patients	O
and	O
32	O
controls	O
.	O
The	O
results	O
showed	O
that	O
the	O
CREBBP	O
expression	O
was	O
remarkably	O
down	O
-	O
regulated	O
in	O
patients	O
as	O
compared	O
with	O
controls	O
(	O
P<0.001	O
,	O
Figure	O
2A	O
)	O
.	O
The	O
CREBBP	O
expression	O
of	O
patients	O
with	O
GG	O
genotype	O
was	O
down	O
-	O
regulated	O
as	O
compared	O
with	O
the	O
patients	O
with	O
GA	O
and	O
AA	O
genotype	O
(	O
P=0.016	O
and	O
0.001	O
,	O
respectively	O
,	O
Figure	O
2B	O
)	O
.	O
However	O
,	O
no	O
significant	O
difference	O
was	O
detected	O
between	O
the	O
GA	O
and	O
AA	O
subgroups	O
(	O
P=0.134	O
,	O
Figure	O
2B	O
)	O
.	O
The	O
CREBBP	O
expression	O
was	O
down	O
-	O
regulated	O
in	O
the	O
GA	O
/	O
AA	O
subgroup	O
as	O
compared	O
with	O
the	O
GG	O
subgroup	O
(	O
P=0.002	O
,	O
Figure	O
2C	O
)	O
.	O

Treatment	O
-	O
related	O
toxicities	O
during	O
PCR	B-arm_description
and	O
alemtuzumab	B-arm_description
were	O
those	O
expected	O
in	O
patients	O
with	O
R	O
/	O
R	O
CLL	O
receiving	O
CIT	O
(	O
Table	O
2	O
)	O
.	O
Anemia	O
,	O
thrombocytopenia	O
and	O
neutropenia	O
were	O
observed	O
in	O
16	O
%	O
,	O
34	O
%	O
and	O
60	O
%	O
,	O
respectively	O
,	O
during	O
PCR	B-arm_description
treatment	I-arm_description
.	O
The	O
worst	O
-	O
degree	O
of	O
non	O
-	O
hematologic	O
treatment	O
-	O
related	O
toxicities	O
during	O
PCR	B-arm_description
treatment	I-arm_description
were	O
grades	O
3	O
-	O
4	O
in	O
47	O
patients	O
(	O
47	O
%	O
)	O
and	O
grade	O
5	O
in	O
5	O
patients	O
(	O
5	O
%	O
)	O
.	O
These	O
included	O
fatigue	O
(	O
9	O
%	O
)	O
,	O
nausea	O
(	O
8	O
%	O
)	O
and	O
vomiting	O
(	O
7	O
%	O
)	O
.	O
Metabolic	O
abnormalities	O
were	O
observed	O
in	O
18(18	O
%	O
)	O
patients	O
but	O
all	O
were	O
less	O
than	O
grade	O
4	O
.	O
Tumor	O
-	O
lysis	O
syndrome	O
was	O
documented	O
in	O
six	O
patients	O
,	O
all	O
grade	O
3	O
.	O
Febrile	O
neutropenia	O
occurred	O
in	O
10	O
patients	O
(	O
10	O
%	O
)	O
.	O
Most	O
infections	O
,	O
either	O
presumed	O
or	O
proven	O
,	O
were	O
grades	O
1	O
-	O
3	O
.	O
These	O
included	O
respiratory	O
tract	O
,	O
urinary	O
tract	O
,	O
skin	O
and	O
ocular	O
site	O
infections	O
.	O
Colitis	O
,	O
unrelated	O
to	O
CMV	O
,	O
occurred	O
in	O
two	O
patients	O
(	O
C.	O
difficile	O
,	O
unknown	O
)	O
.	O
Septicemia	O
was	O
documented	O
in	O
2	O
patients	O
,	O
one	O
of	O
whom	O
died	O
.	O
Pneumonia	O
,	O
attributable	O
to	O
CMV	O
occurred	O
in	O
2	O
patients	O
.	O
There	O
were	O
5	O
treatment	O
-	O
related	O
deaths	O
during	O
the	O
PCR	B-arm_description
therapy	I-arm_description
including	O
multiorgan	O
failure	O
(	O
1	O
)	O
,	O
ARDS	O
,	O
non	O
-	O
CMV	O
(	O
1	O
)	O
,	O
infection	O
(	O
1	O
)	O
,	O
pneumonitis	O
(	O
2	O
)	O
.	O

Greece	O
Athens	O
Greece	O
Adverse	O
event	O
management	O
in	O
the	O
TOURMALINE	B-study_type
-	I-study_type
MM3	I-study_type
study	I-study_type
of	O
post	O
-	O
transplant	O
ixazomib	B-arm_description
maintenance	I-arm_description
in	O
multiple	O
myeloma	O
1	O
July	O
2020	O
1	O
July	O
2020	O
1	O
July	O
2020	O
10.1007	O
/	O
s00277	O
-	O
020	O
-	O
04149	O
-	O
5	O
Received	O
:	O
12	O
May	O
2020	O
/	O
Accepted	O
:	O
14	O
June	O
2020	O
#	O
The	O
Author(s	O
)	O
2020	O

The	O
design	O
of	O
the	O
TOURMALINE	B-study_type
-	I-study_type
MM3	I-study_type
study	I-study_type
has	O
been	O
described	O
previously	O
[	O
14	O
]	O
.	O
Briefly	O
,	O
eligible	O
patients	O
were	O
adults	O
with	O
a	O
confirmed	O
diagnosis	O
of	O
symptomatic	O
MM	O
(	O
by	O
the	O
International	O
Myeloma	O
Working	O
Group	O
criteria	O
)	O
who	O
had	O
achieved	O
at	O
least	O
a	O
partial	O
response	O
after	O
receiving	O
standardof	O
-	O
care	O
induction	O
therapy	O
(	O
including	O
a	O
proteasome	O
inhibitor	O
and/or	O
an	O
immunomodulatory	O
drug	O
)	O
followed	O
by	O
high	O
-	O
dose	O
melphalan	O
conditioning	O
and	O
single	O
ASCT	O
.	O
Following	O
transplant	O
,	O
patients	O
were	O
randomized	O
in	O
a	O
3:2	O
ratio	O
to	O
receive	O
either	O
oral	B-arm_description
ixazomib	I-arm_description
3	B-arm_dosage
mg	I-arm_dosage
(	O
n	O
=	O
395	O
)	O
or	O
matching	O
placebo	B-arm_description
(	O
n	O
=	O
261	O
)	O
on	B-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
,	I-arm_dosage
8	I-arm_dosage
,	I-arm_dosage
and	I-arm_dosage
15	I-arm_dosage
in	I-arm_dosage
28-day	I-arm_dosage
cycles	I-arm_dosage
.	O
Stratification	O
factors	O
were	O
induction	O
regimen	O
,	O
pre	O
-	O
induction	O
disease	O
stage	O
,	O
and	O
posttransplant	O
response	O
.	O
The	O
dose	O
of	O
ixazomib	B-arm_description
was	O
increased	B-arm_dosage
to	I-arm_dosage
4	I-arm_dosage
mg	I-arm_dosage
starting	I-arm_dosage
at	I-arm_dosage
cycle	I-arm_dosage
5	I-arm_dosage
if	O
ixazomib	B-arm_description
was	O
tolerated	O
during	O
the	O
previous	O
4	O
cycles	O
.	O
Treatment	O
was	O
continued	O
for	O
up	O
to	O
26	O
cycles	O
(	O
~2	O
years	O
)	O
or	O
until	O
progressive	O
disease	O
or	O
unacceptable	O
toxicity	O
.	O

Supportive	O
measures	O
consistent	O
with	O
optimal	O
patient	O
care	O
(	O
including	O
myeloid	O
growth	O
factors	O
,	O
erythropoietin	O
,	O
red	O
blood	O
cell	O
and	O
platelet	O
transfusions	O
,	O
prophylaxis	O
for	O
deep	O
vein	O
thrombosis	O
/	O
pulmonary	O
embolism	O
,	O
antibiotics	O
,	O
intravenous	O
immunoglobulin	O
,	O
antiemetics	O
,	O
antidiarrheals	O
,	O
and	O
corticosteroids	O
)	O
could	O
be	O
given	O
throughout	O
the	O
study	O
.	O
Unless	O
there	O
was	O
a	O
clinical	O
contraindication	O
,	O
prophylactic	O
antiviral	O
therapy	O
to	O
prevent	O
reactivation	O
of	O
herpes	O
zoster	O
infection	O
was	O
mandatory	O
following	O
a	O
protocol	O
amendment	O
.	O
Use	O
of	O
concomitant	O
medications	O
(	O
such	O
as	O
prophylaxis	O
or	O
symptomatic	O
treatment	O
)	O
,	O
including	O
blood	O
products	O
and	O
supportive	O
therapies	O
,	O
was	O
recorded	O
from	O
the	O
first	O
dose	O
of	O
the	O
study	O
drug	O
through	O
30	O
days	O
after	O
the	O
final	O
dose	O
.	O
Concomitant	O
medications	O
were	O
classified	O
according	O
to	O
their	O
preferred	O
term	O
in	O
the	O
World	O
Health	O
Organization	O
Drug	O
Dictionary	O
.	O

All	O
safety	O
outcomes	O
are	O
presented	O
using	O
descriptive	O
statistics	O
using	O
SAS	O
version	O
9.2	O
(	O
or	O
higher	O
)	O
.	O
TOURMALINE	B-study_type
-	I-study_type
MM3	I-study_type
was	O
conducted	O
in	O
accordance	O
with	O
the	O
International	O
Conference	O
on	O
Harmonisation	O
Guidelines	O
for	O
Good	O
Clinical	O
Practice	O
and	O
all	O
relevant	O
regulatory	O
requirements	O
.	O
The	O
protocol	B-study_type
was	O
approved	O
by	O
an	O
ethics	O
committee/	O
institutional	O
review	O
board	O
at	O
each	O
center	O
.	O
All	O
patients	O
provided	O
written	O
informed	O
consent	O
.	O

The	O
rate	O
of	O
new	O
-	O
onset	O
nausea	O
was	O
highest	O
during	O
the	O
first	O
3	O
months	O
of	O
treatment	O
and	O
then	O
decreased	O
substantially	O
(	O
Fig	O
.	O
3b	O
)	O
.	O
The	O
incidence	O
rate	O
of	O
vomiting	O
was	O
also	O
highest	O
in	O
cycle	O
1	O
in	O
the	O
ixazomib	B-arm_description
arm	O
and	O
generally	O
higher	O
versus	O
placebo	B-arm_description
(	O
Fig	O
.	O
4a	O
)	O
;	O
new	O
-	O
onset	O
vomiting	O
was	O
most	O
common	O
during	O
the	O
first	O
3	O
months	O
and	O
then	O
decreased	O
(	O
Fig	O
.	O
4b	O
)	O
.	O
The	O
incidence	O
rate	O
of	O
diarrhea	O
was	O
similar	O
between	O
groups	O
in	O
cycles	O
1	O
-	O
2	O
and	O
then	O
higher	O
with	O
ixazomib	B-arm_description
versus	O
placebo	B-arm_description
through	O
cycle	O
9	O
(	O
Fig	O
.	O
5a	O
)	O
;	O
the	O
rate	O
of	O
new	O
-	O
onset	O
diarrhea	O
was	O
low	O
and	O
similar	O
between	O
groups	O
thereafter	O
(	O
Fig	O
.	O
5b	O
)	O
.	O

Thromboprophylaxis	O
was	O
not	O
mandated	O
by	O
the	O
protocol	O
but	O
could	O
have	O
been	O
administered	O
per	O
institutional	O
guidelines	O
,	O
and	O
19	O
%	O
of	O
patients	O
in	O
each	O
arm	O
used	O
an	O
antithrombotic	O
agent	O
.	O
Based	O
on	O
the	O
SMQ	O
for	O
venous	O
embolic	O
and	O
thrombotic	O
events	O
,	O
2	O
patients	O
(	O
<	O
1	O
%	O
)	O
in	O
the	O
ixazomib	B-arm_description
arm	O
had	O
a	O
thrombotic	O
event	O
.	O
One	O
of	O
these	O
patients	O
had	O
a	O
history	O
of	O
port	O
catheter	O
implantation	O
,	O
and	O
the	O
other	O
patient	O
had	O
a	O
history	O
of	O
pulmonary	O
embolism	O
and	O
was	O
receiving	O
antithrombotic	O
medication	O
.	O
Each	O
of	O
these	O
patients	O
had	O
low	O
-	O
grade	O
events	O
.	O
One	O
of	O
these	O
patients	O
experienced	O
thromboembolic	O
events	O
of	O
jugular	O
vein	O
thrombosis	O
and	O
subclavian	O
vein	O
thrombosis	O
that	O
led	O
to	O
hospitalization	O
and	O
resulted	O
in	O
discontinuation	O
of	O
ixazomib	B-arm_description
.	O
In	O
the	O
placebo	B-arm_description
arm	O
,	O
no	O
patient	O
had	O
a	O
venous	O
thromboembolic	O
event	O
.	O
Arterial	O
thromboembolic	O
events	O
,	O
as	O
assessed	O
according	O
to	O
the	O
SMQ	O
for	O
arterial	O
embolic	O
and	O
thrombotic	O
events	O
,	O
were	O
reported	O
infrequently	O
(	O
<	O
1	O
%	O
ixazomib	B-arm_description
,	O
1	O
%	O
placebo	B-arm_description
)	O
.	O

Patients	O
with	O
high	O
-	O
risk	O
solid	O
tumors	O
reported	O
to	O
express	O
one	O
or	O
more	O
target	O
tumor	O
antigens	O
-	O
WT1	O
,	O
PRAME	O
,	O
and/or	O
survivin	O
-	O
on	O
the	O
basis	O
of	O
the	O
published	O
literature	O
[	O
12][13][14][15][16][17][18][19][21][22][23	O
]	O
were	O
eligible	O
for	O
this	O
nonrandomized	O
phase	O
I	O
study	O
.	O
Informed	O
consent	O
was	O
obtained	O
for	O
patients	O
who	O
met	O
standard	O
eligibility	O
requirements	O
,	O
including	O
performance	O
status	O
and	O
organ	O
function	O
parameters	O
,	O
before	O
cell	O
procurement	O
and	O
TAA	O
-	O
T	O
infusion	O
(	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT02789228	O
;	O
Appendix	O
Fig	O
A1	O
,	O
online	O
only	O
)	O
.	O
This	O
study	O
was	O
approved	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
(	O
IND	O
16135	O
)	O
and	O
the	O
Children	O
's	O
National	O
Medical	O
Center	O
(	O
CNMC	O
)	O
institutional	O
review	O
board	O
.	O

We	O
analyzed	O
survival	O
data	O
,	O
including	O
PFS	B-arm_efficacy_metric
,	O
median	O
,	O
and	O
95	O
%	O
CIs	O
,	O
with	O
either	O
log	O
-	O
rank	O
test	O
to	O
compare	O
DLs	O
or	O
sign	O
test	O
to	O
compare	O
the	O
difference	O
between	O
TAA	B-arm_description
-	I-arm_description
T	I-arm_description
DL	I-arm_description
3	I-arm_description
and	O
immediate	O
prior	O
therapy	O
.	O
Results	O
were	O
presented	O
using	O
the	O
Kaplan	O
-	O
Meier	O
method	O
.	O
P	O
values	O
,	O
.05	O
were	O
considered	O
statistically	O
significant	O
(	O
Appendix	O
,	O
online	O
only	O
)	O
.	O

The	O
primary	O
end	O
point	O
was	O
investigator	O
-	O
assessed	O
PFS	O
,	O
with	O
secondary	O
end	O
points	O
including	O
OS	O
,	O
ORR	O
,	O
clinical	O
benefit	O
rate	O
,	O
safety	O
and	O
tolerability	O
[	O
13	O
]	O
.	O
Tumor	O
response	O
was	O
assessed	O
per	O
RECIST	O
,	O
version	O
1.1	O
,	O
at	O
screening	O
,	O
every	O
8	O
weeks	O
after	O
randomization	O
for	O
18	O
months	O
and	O
every	O
12	O
weeks	O
thereafter	O
until	O
disease	O
progression	O
,	O
death	O
,	O
withdrawal	O
of	O
consent	O
or	O
loss	O
to	O
follow	O
-	O
up	O
[	O
13	O
]	O
.	O
ECG	O
assessments	O
were	O
performed	O
at	O
screening	O
,	O
on	O
day	O
15	O
of	O
cycle	O
1	O
,	O
on	O
days	O
1	O
and	O
15	O
of	O
cycle	O
2	O
,	O
on	O
day	O
1	O
of	O
all	O
subsequent	O
cycles	O
up	O
to	O
cycle	O
6	O
,	O
at	O
end	O
of	O
treatment	O
,	O
and	O
as	O
clinically	O
indicated	O
.	O
In	O
patients	O
with	O
a	O
QTcF	O
≥481	O
ms	O
at	O
any	O
time	O
before	O
cycle	O
7	O
,	O
additional	O
ECGs	O
were	O
performed	O
predose	O
on	O
day	O
1	O
of	O
subsequent	O
cycles	O
and	O
post	O
dose	O
every	O
third	O
cycle	O
[	O
13	O
]	O
.	O

Ribociclib	B-arm_description
is	O
now	O
being	O
investigated	O
as	O
a	O
potential	O
adjuvant	O
or	O
neoadjuvant	O
therapy	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O
These	O
trials	O
are	O
randomizing	O
HR+	O
,	O
HER2-breast	O
cancer	O
patients	O
to	O
treatment	O
with	O
ribociclib	O
in	O
combination	O
with	O
ET	O
or	O
to	O
standard	O
of	O
care	O
treatment	O
.	O
In	O
the	O
neoadjuvant	O
setting	O
,	O
the	O
Phase	O
II	O
FELINE	O
trial	O
is	O
comparing	O
ribociclib	B-arm_description
plus	O
letrozole	B-arm_description
versus	O
placebo	O
plus	O
letrozole	O
in	O
postmenopausal	O
women	O
with	O
HR+	O
,	O
HER2early	O
breast	O
cancer	O
(	O
NCTT02712723	O
)	O
[	O
41,42	O
]	O
;	O
the	O
Phase	O
II	O
NEOLBC	O
trial	O
is	O
comparing	O
ribociclib	B-arm_description
plus	O
letrozole	B-arm_description
versus	O
standard	O
chemotherapy	O
as	O
a	O
neoadjuvant	O
therapy	O
in	O
postmenopausal	O
women	O
with	O
HR+	O
,	O
HER2-luminal	O
breast	O
cancer	O
(	O
NCT03283384	O
)	O
[	O
43	O
]	O
;	O
and	O
the	O
CORALLEEN	O
trial	O
is	O
comparing	O
ribociclib	B-arm_description
plus	O
letrozole	B-arm_description
versus	O
standard	O
chemotherapy	O
as	O
a	O
neoadjuvant	O
therapy	O
in	O
postmenopausal	O
women	O
with	O
luminal	O
B	O
,	O
HER2-breast	O
cancer	O
(	O
NCT03248427	O
)	O
[	O
44,45	O
]	O
.	O
In	O
addition	O
,	O
the	O
Phase	O
III	O
NATALEE	O
trial	O
will	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
ribociclib	B-arm_description
plus	O
ET	O
compared	O
with	O
ET	O
alone	O
as	O
an	O
adjuvant	O
treatment	O
in	O
pre	O
/	O
perimenopausal	O
and	O
postmenopausal	O
women	O
with	O
early	O
breast	O
cancer	O
(	O
NCT03701334	O
)	O
[	O
46	O
]	O
.	O

